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Summary 
 
Using existing software and six novel scripts, we developed a pipeline for 
variant calling using exome re-sequencing data of germline blood 
deoxyribonucleic acid (DNA) samples. We observed >99% (6,723/6,739) 
concordance between calls from our pipeline and previous genotyping. We 
identified >93% of single nucleotide variants (SNVs) and >94% of 
insertion/deletions called by a commercial partner using the same sequencing 
reads. Using a subset of genes, we showed that around half of predicted 
pathogenic variants could be validated in vitro. Together, these data showed 
that our pipeline was reliable for variant calling. 
 
Next generation sequencing (NGS) of DNA from formalin-fixed, paraffin-
embedded (FFPE) tumours is technically challenging. We sought to determine 
the sensitivity of NGS to detect known somatic hotspot mutations (n=25) in 19 
FFPE advanced colorectal cancers and to optimise it for the identification of 
novel somatic variants. Analysis using Illumina’s MiSeq software identified 
100% of somatic mutations with 93% specificity, whereas the Genome Analysis 
Tool Kit’s (GATK) HaplotypeCaller identified 80-92% of somatic mutations with 
100% specificity. We investigated the background mutator profile and found that 
normal FFPE DNA had 3-fold more SNVs than matched blood DNA, with an 
excess of FFPE-associated C:G>T:A substitutions (27.1 vs. 5.3%). Uracil DNA 
glycosylase treatment reduced this excess. Only ~5% of variants were 
consistently called in replicate runs and were likely to be genuine somatic 
variants. 
 
We detected potential candidates for genetic biomarkers of cetuximab-
resistance in colorectal cancers that were previously shown to be wild type for 
KRAS, NRAS, BRAF and PIK3CA. We found that 7/21 (33%) of the CRCs 
analysed harboured mutations at either codon 12 or 61, whileother CRCs 
carried truncating KRAS mutations. NRAS also carried a codon 12 mutation in 1 
CRC, and PIK3CA possessed mutations at codons 542 and 545. PTEN was 
found to harbour 5 truncating mutations at codons 71, 140, 155, 178 and 189, 
potentially leading to loss of function. 
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Chapter 1 – General introduction 
 
1.1 DNA sequencing 
Deoxyribonucleic acid (DNA) sequencing can be defined as determining the 
order of bases along a DNA molecule. There are several methods of achieving 
this, and most methods can be classified into one of two groups: traditional 
(Sanger and Maxam-Gilbert) and next generation sequencing (NGS). Many of 
the methods have advantages and disadvantages, making them suitable for 
particular purposes and unsuitable for others. 
 
1.1.1 Sanger sequencing 
Sanger sequencing has been the global staple method for determining the order 
of bases in a DNA molecule since its first publication (Sanger, et al. 1977). 
Sanger sequencing was used to determine the first genome sequence of an 
organism, a bacteriophage known as ϕX174 (Sanger, et al. 1977). At the time, 
sequencing was a labour intensive process with little to no automation, and 
DNA was sequenced at the rate of only a few hundred nucleotides per 
experiment. This practice dominated the sequencing landscape until several 
years later when semi-automated sequencers were made available, with higher 
throughput capabilities (Smith et al. 1986; Swerdlow & Gesteland 1990). Further 
technological advances were achieved upon the arrival of capillary array 
electrophoresis (Kim et al. 1996; Ueno & Yeung 1994; Huang et al. 1992).  
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These developments led to production of the single capillary sequencers such 
as the Applied Biosystems (ABI) Prism 310, which were widely used in the DNA 
sequencing community. In the late nineteen nineties, commercial 96 capillary 
sequencers such as the ABI Prism 3700 DNA Analyzer allowed for higher 
throughput in sequencing experiments.  
 
Sanger sequencing is still commonly used today, and is heavily based on the 
original technique. This required obtaining multiple copies (often many millions) 
of the template DNA molecule to be sequenced, and can be achieved with 
relative ease via cloning or amplification through polymerase chain reaction 
(PCR). Each DNA strand has the complementary strand synthesised using 
short upstream priming oligonucleotides (‘primers’), deoxynucleotide 
triphosphates (dNTPs), dideoxynucleotide triphosphates (ddNTPs) and a DNA 
polymerase. Due to lack of a hydroxyl group, ddNTP incorporation into the 
growing complementary strand causes non-reversible chain-termination during 
strand extension. The result is a multitude of DNA strands of many different 
sizes; after denaturation and washing away of unbound primers and 
nucleotides, the newly synthesised strands can be sorted by their molecular 
weights. This is easily achieved via electrophoresis, and as their weights are 
directly linked to their length, shorter molecules traverse faster than longer 
ones. Originally, this electrophoresis step was performed on gels, using 
radioactively labelled ddNTPs. It was later performed in capillaries (Swerdlow & 
Gesteland 1990; George et al. 1997) using ddNTPs labelled with four different 
fluorophores (Smith et al. 1986). 
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Automation of Sanger sequencing has been attempted, using micro-fluidic 
devices that are capable of performing DNA extraction, in vitro amplification and 
sequencing (Blazej et al. 2006; Mariella 2008; Roper et al. 2007; Emrich et al. 
2002). This automation, however, is not widely used for several reasons. 
Currently, high-throughput Sanger sequencers rely on 384 capillaries, and are 
therefore capable of producing up to 384 parallel sequences (Emrich et al. 
2002; Shibata et al. 2000) with read lengths between 600 - 1,000 base pairs 
(bp) (Shendure et al. 2011; Hert et al. 2008) (Table 1.1). It is possible to obtain 
90 Kilobases (Kb) of sequence data per hour using 384 capillary sequencers 
(Shibata et al. 2000).  
 
Prior to production of the draft human genome (Lander et al. 2001; Venter et al. 
2001), Sanger sequencing could produce a sequence at a per-base cost of 
approximately United States (US) $10 (Shendure et al. 2004). The efforts of 
producing a draft sequence pushed costs of Sanger sequencing down to less 
than US $0.09 per finished base (Collins et al. 2003). Current costs are around 
$500 per Megabase (Mb) (Table 1.1) (Kircher & Kelso 2010). Figure 1.1 shows 
that prior to 2007, the cost of sequencing a human genome was falling steadily. 
With the advent of NGS, however, there was a sharp decline in cost; this further 
decline meant the technique suddenly became a lot more attractive to many 
laboratories. 
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Figure 1.1. Sequencing costs for human genomes since 2001. There is a sharp 
drop from 2007, when the first NGS platforms became readily available on the 
market. Data are taken from the National Human Genome Research Institute 
(http://www.genome.gov/sequencingcosts/, accessed 22/07/2015).
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Table 1.1. Metrics of NGS sequencing platforms vs. Sanger sequencing. Daily data generation, typical read lengths and error sources 
and rates are given for comparison. NGS platforms typically have a higher error rate than Sanger sequencing does, however the 
advantageous amount of data generated and the cost to do so outweigh these increased error rates. 
Technology Data 
generated 
(Mb/day) 
Typical read 
lengths (bp) 
Error source(s) Error rate Cost per 
Mb (US $) 
Sanger sequencing 2 (384 
capillary 
sequencers) 
<1000 (although 
longer reads are 
possible) 
 template amplification 
 sample contamination 
 polymerase slippage 
 low signal intensities 
 reduced electrophoretic 
separation 
10-4 – 10-5 500 
 
NGS platforms 
Pyrosequencing / 
sequencing-by-synthesis 
750 300 - 500  template amplification 
 multiple templates per 
amplification bead 
 problematic signal:noise 
ratios for homopolymers 
 increasing cycle number 
 Signal bleed-over 
 phasing (uni-directional) 
10-3 – 10-4 20 
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Sequencing-by-ligation 5,000 25 - 75  template amplification 
 random bead distribution 
(bleed-over) 
 dust/particle contamination 
 signal decline over longer 
reads 
 fluorescent label retention 
 poor probe hybridisation 
10-2 – 10-3 0.5 
Reversible terminator 
chemistry 
5,000 100 – 200 
(approx) 
 template amplification 
 Closely spaced clusters 
(signal interference) 
 phasing (bi-directional) 
 dust/particle contamination 
 increasing cycle number 
10-2 – 10-3 0.5 
Virtual terminator 
chemistry 
4,150 24 - 70  weak signal emission 
 incorporation errors 
 accidental washing of 
hybridised strands 
 premature termination 
>1% 0.3 
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1.1.2 Next generation sequencing 
The demand for high-throughput, low-cost sequencing has inevitably led to the 
development of many ‘next generation’ sequencing techniques (Bentley et al. 
2008; Clarke et al. 2009; Harris et al. 2008; Margulies et al. 2005; Shendure et 
al. 2005; Korlach et al. 2008). Traditional ‘first-generation’ Sanger sequencing 
has been outperformed by these technologies by a factor of 100 – 1000 fold, 
and the cost of sequencing a Mb of DNA has been reduced to between 0.1 and 
4% of the cost incurred via Sanger sequencing. Current sequencing methods 
are based on several key techniques: capillary sequencing, pyrosequencing or 
sequencing-by-synthesis (SBS), sequencing-by-hybridisation (SBH), 
sequencing-by-ligation (SBL), reversible terminator chemistry and virtual 
terminator chemistry. 
 
1.1.3 Emulsion PCR 
Two major themes in template preparation for NGS are fixation of template 
molecules to a solid surface (i.e. a flow cell) or a bead in an emulsion PCR 
(emPCR) reaction. Both of these allow for millions of reactions to occur at the 
same time (hence the term massively parallel sequencing). In emPCR, a 
fragment library is created (e.g. by shearing the original DNA molecules into 
certain range of lengths) and universal primers are ligated to the ends of the 
fragments. The double stranded DNA is then separated into single strands and 
can be captured by beads expressing adapters complementary to one of the 
primer sequences. Typically, only one DNA molecule is attached to a bead, with 
only a single bead per emulsion reaction bubble. PCR is then performed, 
resulting in beads that contain many copies of their original DNA molecule. Prior 
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to sequencing, the beads can be immobilised in a polyacrylamide gel or on a 
glass surface, or deposited into wells in a picotiter plate (Metzker 2010). 
 
1.1.4 Pyrosequencing 
The first NGS technology available was pyrosequencing (Ronaghi et al. 1996), 
and in 2008 Roche/454 Life Sciences released the GS FLX Titanium sequencer, 
designed to harness the new sequencing technology. In pyrosequencing, single 
stranded DNA templates are complemented base-by-base, and the signal 
emitted is read after each nucleotide incorporation (Figure 1.2). This process is 
often referred to as SBS. The advantage of such a technique is that the 
electrophoresis step required by some other techniques is no longer necessary. 
 
A DNA library is created before pyrosequencing can take place. Each DNA 
template in the library is ligated to two different pre-synthesised sequence 
adapters; one at the 5’ end and another at the 3’ end of the template molecule 
(Margulies et al. 2005). One adapter is complementary to a short DNA molecule 
cross linked to a bead to be used in sequencing, allowing for hybridisation of 
DNA to the sequencing beads. The other adapter is complementary to a DNA 
molecule on a set of capture beads. The capture beads are used to isolate 
template DNA-bead complexes from beads that have no template DNA bound, 
so that only beads with template DNA hybridised are used in the following 
sequencing reaction. 
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Figure 1.2. Pyrosequencing reactions are carried out on beads which are usually dispersed 
in picotiter plate wells. A primer attached to the beads is hybridised to the free end of each 
clonally amplified template strand. In each cycle, a specific dNTP is washed over the wells. 
If the nucleotide is complementary to the next base in the template strand, then the 
nucleotide is incorporated into the extending strand. This is achieved via the action of a 
DNA polymerase. Nucleotide incorporation results in the release of organic phosphate. 
Along with adenylyl sulphate and sulphurylase enzymes attached to additional beads in the 
well, this inorganic phosphate is used to drive production of ATP. The ATP is then used as a 
substrate in a reaction catalysed by bead-bound luciferase, along with luciferin, to generate 
oxyluciferin. The by-product of this final reaction is light emission, which is measured for 
each well using a charge-coupled device camera. The knowledge of which nucleotide is 
added per cycle allows for determination of template sequences on each bead.  
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During pyrosequencing, multiple copies of the sequencing template are 
exposed to specific nucleotides. If the nucleotide is complementary to the next 
available base on the template strand, then a polymerase enzyme incorporates 
the nucleotide into the extending strand. During the incorporation process, a 
pyrophosphate molecule is released and an adenosine triphosphate (ATP) 
sulphurylase converts this to ATP. This ATP is then used in a reaction involving 
luciferases, which ultimately emit a light signal, which can be measured. As the 
deoxyadenosine triphosphate (dATP) normally supplied for the strand extension 
may be used in the reaction with the luciferase, deoxyadenosine-5’-(a-thio) 
triphosphate is supplied instead. Luciferase cannot use this molecule as a 
substrate, but it can still be used in the extension step catalysed by the 
polymerase (Kircher & Kelso 2010). Standard versions of the other dNTPs are 
used as these are not normally luciferase substrates. After the light intensity 
emitted by the luciferase reaction has been measured, any unincorporated 
nucleotides are washed away and the next nucleotide is introduced so that the 
cycle can repeat. Light emission signals are captured in high definition using a 
specialised camera known as a charge-coupled device (CCD). 
 
This reaction has been parallelised on picotiter plates (Margulies et al. 2005); 
these plates are composed of around two million wells, each of them the correct 
size to accommodate a bead 28 micrometre (µm) in diameter. The beads are 
coated with single stranded sequence templates, and smaller beads are also 
added which harbour the luciferase and ATP sulphurylase enzymes. The 
sequencing cycles are carried out as described, with nucleotides being washed 
over the plate to allow for the parallelisation to be effective. 
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Using the GS FLX Titanium sequencer, it is possible to sequence reads from 
around 1.5 million beads, with each read being 300 – 500 bases in length (Table 
1.1). The final length of the sequencing reads is determined by the number of 
sequencing cycles performed, along with the base composition of the template 
molecules. Average read lengths over 400 bp may suffer from higher error rates 
due to decreasing enzyme efficiencies over the course of the experiment. 
Roughly 750 Mb of DNA can be sequenced per day via pyrosequencing (Table 
1.1), incurring costs of approximately $20 per Mb (Table 1.1) (Kircher & Kelso 
2010). 
 
1.1.5 Reversible terminator chemistry 
Illumina have released several next generation sequencers to date, and have 
adopted reversible terminator chemistry. Reversible terminator chemistry is 
similar to SBS used in pyrosequencing in that each sequencing cycle involves 
adding a labelled nucleotide to a growing DNA strand and imaging to determine 
the identity of the newly incorporated nucleotide (Turcatti et al. 2008; Bentley et 
al. 2008). 
 
This type of sequencing relies upon generation of a DNA library, often by 
amplification and immobilisation of template DNA (Fedurco et al. 2006). The 5’ 
and 3’ ends of each DNA molecule have sequencing adapters ligated to them, 
which allow for sequencing primers to recognise and amplify the templates 
(Figure 1.3). The DNA is then denatured into single strands using sodium 
hydroxide (NaOH). 
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Figure 1.3. Bridge amplification and reversible terminator sequencing. (a) To create a DNA 
library for sequencing via reversible chain termination, bridge amplification is employed. Here, a 
single stranded DNA molecule is primed with universal sequencing adapters and hybridised with 
a sequencing adapter immobilised on a flow cell surface (I). The free end of the template 
molecule has the freedom to bend over and stochastically hybridise complementary adapter 
sequences, forming a bridge (II). Amplification is performed to generate the complementary 
strands (III) which is covalently linked to the flow cell in clusters of identical templates. One of 
the strands is cleaved, leaving multiple copies of single stranded templates arranged in clusters 
oriented in a single direction (IV). (b) Reversible termination sequencing relies upon 
incorporation of fluorescently labelled nucleotides in each cycle of sequencing. By using 4 
different fluorophores, all 4 nucleotides can be added per cycle (I). Unincorporated nucleotides 
are washed away (II), imaging is performed, and the fluorophores and terminating groups are 
cleaved from the newly extended strand. (c) Each cluster will give a unique signal depending on 
which nucleotide was used in the extension. Each cluster generates a signal from cycle (I) to 
cycle (II). In paired end sequencing, the strand synthesised during the sequencing reaction is 
washed away, bridge amplification is repeated and this time the opposite strand is cleaved, 
leaving clusters oriented in the reverse direction to the previous round of cluster generation. 
Sequencing is then performed from the opposite end of the templates. 
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On platforms such as Illumina’s Genome Analyzer II, the single stranded DNA is 
then introduced to the channels in a flow cell used by the sequencer. On the 
surface of the flow cell are two populations of short DNA oligonucleotides, which 
are complementary to the sequencing adapters at the ends of the DNA 
templates. Hybridisation occurs between the immobilised oligonucleotides and 
the adapter sequences. A strand complementary to the template is then 
synthesised, starting from the end hybridised to the oligonucleotide; once 
complete, this new strand will be immobilised to the surface of the flow cell. In a 
process known as bridge amplification, the newly synthesised single stranded 
DNA molecules are able to bend over and the adapter sequence on the free 
end (the end not attached directly to the flow cell’s surface) can hybridise to a 
complementary immobilised oligonucleotide. Another new strand is synthesised 
that is identical to the original template DNA that is covalently linked to the flow 
cell at the second adapter’s end. Bridge amplification is repeated multiple times, 
creating clusters of DNA molecules in close proximity that represent thousands 
of forward and reverse copies of the original template (Bentley et al. 2008; 
Fedurco et al. 2006). Before sequencing of these clusters can occur, either the 
forward or reverse strands are selectively cleaved at the immobilised 
oligonucleotides attached to the flow cell. All remaining strands on the flow cell 
then contain copies of the template in the same orientation. Hybridising a 
sequencing primer then allows for the sequencing reaction to begin. 
 
This sequencing method uses a modified DNA polymerase to direct 
incorporation of a single reversible terminator (a 3’-O-azidomethyl 2’-
deoxynucleoside triphosphate) into a growing DNA strand. These nucleotides 
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are labelled with a different fluorophore, which can be removed after imaging. 
All four nucleotides are included in each cycle rather than a single nucleotide at 
a time, thus allowing for incorporation of the optimal nucleotide into each 
growing strand. Nucleotides that are not incorporated are washed away. After 
each incorporation step, imaging is performed to determine the identity of each 
newly inserted base. Imaging is carried out by exciting the fluorophore on each 
base using a laser. Tris(2-carboxyethyl)phosphine is then added to remove the 
fluorescent dye and its side arm that was attached to the incorporated base. 
This step also regenerates the 3’ hydroxyl group necessary for the next cycle. 
These cycles are repeated so that the growing strand’s sequence is determined 
base by base. 
 
In the early days of this technology, millions of reads could be sequenced but 
with only very short read lengths, boasting a modest maximum length of 36 bp. 
Current flow cell densities on the Genome Analyzer allow for more than 200 
million clusters to be sequenced in a single run, with a read length of up to 
around 100 bp. Further improvements to the system allowed the sequencing of 
the DNA strands in both directions; post-sequencing of the first strand, the 
newly synthesised strand is washed away. Bridge amplification is performed for 
a second time to regenerate strands in the opposite orientation before the 
previously sequenced strand is cleaved at the covalently bound oligonucleotide 
adapter. The sequencing adapters on the end of the strand to be sequenced are 
recognised by a sequencing primer, and sequencing is performed. Sequencing 
both ends of a template in such a way is known as paired end sequencing, and 
generates approximately twice the amount of data compared to sequencing in a 
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single direction. Illumina sequencers such as the Genome Analyzer are capable 
of producing more than 5,000 Mb per day (Table 1.1) (Kircher & Kelso 2010) 
 
1.1.6 Sequencing-by-ligation 
The major conceptual difference between SBL and other NGS technologies is 
that SBL relies on ligase enzymes rather than polymerases. Single stranded 
templates in a DNA library are hybridised to sequencing primers and 8-mer 
probes are added, which are competitively ligated to the sequencing primer. 
Each probe contains a fluorescent label, the identity of which encodes the two 
most 3’ nucleotides in the probe. The identity of the probe is revealed in imaging 
and by association so are the 3’ nucleotides. From the 5’ end, three nucleotides 
and the fluorescent label are cleaved from the probe. At this point, the primer 
has been extended by five nucleotides, and further ligation is possible due to 
presence of a free 5’ phosphate. Up to 10 cycles of this are performed typically, 
giving the identity of two nucleotides out of every five in the extended strand. 
The extended strand is then chemically melted and washed away. A new 
sequencing primer, shifted in length by one base in comparison to the previous 
primer, is then annealed to the template. The ligation and imaging cycles are 
repeated, with the ligation points shifted by a single base in the sequence. 
Repetition using a further three sequencing primers (each shifted by a single 
base in comparison to the last), is performed. The fluorescence signals 
detected throughout these cycles can then be converted to a sequence, 
revealing the original template DNA’s sequence (Figure 1.4). One caveat of this 
technique is that the first base of the sequence must be known a priori, and so 
the last base of the library adapter is used. Without a reference sequence, 
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errors in fluorescence interpretation can cause incorrect base calling of the 
downstream sequence. 
 
The Sequencing by Oligonucleotide Ligation and Detection (SOLiD) platform 
enables sequencing parallelisation in a similar fashion to pyrosequencing, in 
that beads are coated with multiple copies of the same template. Instead of 
using a picotiter plate, however, a glass slide is used as a flow cell. After 
modification of the 3’ ends of the sequences on the beads, the sequences can 
be covalently bound to the flow cell.  
 
1.1.7 Virtual terminator chemistry 
Not all NGS platforms require preparation of amplified sequence libraries. The 
HeliScope sequencer (developed by Helicos) has the capability to sequence 
individual molecules without the need for in vitro amplification. This has a major 
advantage over other technologies in that amplification and other library 
preparation induced errors are absent from the resulting data. This platform 
may also be able to detect non-standard nucleotides and modifications in the 
template molecules, which would often be lost during amplification steps. 
 
The technology differs from the other technologies and has been coined 
asynchronous virtual terminator chemistry (Harris et al. 2008). Starting double 
stranded DNA templates are fragmented and melted, and each has a poly-A tail 
synthesised onto the end using a polyadenylate polymerase. The last adenine 
in this homopolymer run is attached to a fluorescent label. 
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Figure 1.4. Sequencing by ligation and decoding of colour-space reads. (a) 
During SBL, sequencing primers are hybridised to immobilised adapters 
covalently linked to the sequencing template. SBL uses five rounds of primer 
binding, and each round has 10 ligation cycles. In each cycle, 8-mer probes are 
hybridised to the template and ligated to the primer (step 1). Imaging of the 
probe’s fluorophore gives details about the two 3’ most nucleotides in the probe 
sequence, and hence the complementary template nucleotides (step 2). The 
final step cleaves the three 5’ nucleotides and the fluorophore from the probe, 
and the next cycle is performed. After all the cycles are complete, the next 
primer binding round is performed. Each consecutive primer round is identical to 
the preceding round, except that the primer sequence is shifted by 1 base. This 
results in a knock-on shift in the imaged sequence. (b) Upon completion, colour-
space reads are decoded to give a base-space sequence. An example template 
sequence (5’-GATGCCCGATATCTT-3’) is demonstrated here using an example 
primer sequence (3’-AACGCCGTTGAGAAC-5’, highlighted in bold). Adapted 
from (Metzker 2010; Kircher & Kelso 2010). 
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Washing the template library over a flow cell containing poly-T oligonucleotide 
probes allows for hybridisation. Probes that have template sequences bound 
are determined using fluorescence imaging, followed by removal of the 
fluorescent label from the 3’ adenine. During the sequencing reaction, a 
polymerase and a specific fluorescently labelled nucleotide are washed over the 
flow cell. Starting from the poly-T probes, the polymerase extends the 
complementary sequence strand. Nucleotide incorporation rate is controlled by 
the fluorescent labelling, with a maximum of one nucleotide incorporation per 
sequencing cycle. After each cycle, the polymerases and free nucleotides are 
washed away, virtually terminating the extension (Zhu & Waggoner 1997; 
Bowers et al. 2009). After this, imaging of the flow cell is performed again to 
detect signal emission from newly incorporated nucleotides (Figure 1.5). This is 
followed by removal of the fluorescent labels, completing the cycle. As not every 
sequence is extended in each cycle, the process is asynchronous and may 
result in read lengths of different sizes. Read lengths achieved via the 
HeliScope range from 24 – 70 bp, with an average around 32 bp (Pushkarev et 
al. 2009). 
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Figure 1.5. Virtual terminator chemistry. A flow cell is prepared, containing 
poly-T probes. Template sequences ligated to poly-A oligonucleotides are 
hybridised to the poly-T probes. (a) A single type of nucleotide (adenine [A], 
cytosine [C], guanine [G] or thymine [T]) is then washed over the flow cell 
(step I) and a polymerase extends the poly-T tail if the nucleotide is 
complementary to the next base in the template. Unused nucleotides are 
washed away, leaving only the hybridised template and the (extended) 
probes (step II). Single-colour imaging is performed, with the fluorescent 
dyes on the recently added nucleotides emitting a light signal (step III). The 
process is then repeated using a different nucleotide (b). Given that the 
nucleotides are added in a known order, the sequence of the templates can 
be determined by reading out the fluorescence signals.  
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1.1.8 Sequencing-by-hybridisation 
Studies have demonstrated that sequencing using an SBH approach (Drmanac 
et al. 1998) can lead to sensitive detection of point mutations in clinically 
relevant genes (e.g. HRAS) (Healey et al. 1997). SBH can be performed in two 
distinct ways. In the first method, an array of DNA targets of unknown sequence 
are bound to a substrate and then short labelled oligonucleotides of known 
sequence are hybridised to the targets. Each round of hybridisation allows for 
detection of complementary DNA sequences on the templates. By using the 
reference sequence as a guide, short oligonucleotides that share overlapping 
sequence can be theoretically assembled to determine the longer template 
sequence (Figure 1.6). The second method of SBH relies on immobilising the 
probes of known sequence to a substrate; the probes are then allowed to 
hybridise to the labelled target DNA whose sequence is to be determined. 
 
Detection of probe-target duplexes can be done with relative ease if the probes 
are labelled with a fluorophore, for example fluroescein isothiocyanate. Using 
this approach, duplexes can be detected using fluorescence imaging equipment 
(Sassolas et al. 2008). 
 
It was theorised (Drmanac et al. 1989) that over 1 Mb of unknown DNA 
sequence could be determined using mixes of 11 bp long oligonucleotide 
probes (known as k-mers, where k is the length of the sequence; in this case 
11-mers). Even in the dawn of NGS, it was recognised that extensive computing 
power would be required for analysis of the data. Fortunately, it was also 
recognised that the inherent parallelism in production of the data would provide 
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worthy advantages over pre-existing methods of DNA sequencing (Drmanac et 
al. 1989).  
 
1.1.9 Error rates 
1.1.9.1 Sanger Sequencing 
Sanger sequencing boasts errors that often arise during in vitro amplification of 
the template DNA, which is much higher than in vivo. Sample contamination is 
another source of sequencing errors, as is polymerase slippage caused by low 
sequence complexity (e.g. short variable number repeats and homopolymers). 
Long sequencing reads suffer from errors towards the end of the sequence, 
caused by lower signal intensities (Kircher & Kelso 2010). It is also known that 
base miscalls (Ewing et al. 1998) and deletions increase in number with read 
length, possibly due to reduced separation during electrophoresis. On average, 
Sanger sequencing has a low error rate, with errors estimated to occur at a rate 
of one per 10,000 – 100,000 bases (Ewing & Green 1998) (Table 1.1). 
 
1.1.9.2 Pyrosequencing 
Single nucleotide substitution error rates for pyrosequencing lie in the range of 
10-3 – 10-4 (Quinlan et al. 2008; Margulies et al. 2005), which means 
pyrosequencing has a higher error rate than Sanger sequencing, but lower than 
for other NGS technologies (Table 1.1). The source of many of these errors may 
be in vitro amplification, although this step is a requirement for pyrosequencing 
on the GS FLX Titanium sequencer. 
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Figure 1.6. SBH is performed by fixing template sequence to a substrate (a). 
Short oligonucleotides of known sequence (8-mers are shown here) are added 
one at a time and hybridisation occurs between complementary sequences (I – 
III). Aligning the oligonucleotides against a reference sequence (b) reveals 
overlapping regions between the oligonucleotides; these can be assembled into 
a contig that represents the sequence of the original template molecule. 
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During amplification using emPCR some sequencing beads may end up 
carrying more than one unique template molecule. During the sequencing 
reaction, this results in extraneous light emission, giving a false sequence as 
nucleotides are incorporated into each template in different cycles. It is 
practically impossible to distinguish which template the signal was generated 
by, although in theory it may be possible to filter out these sequencing reads 
using post-sequencing software (Kircher & Kelso 2010). 
 
Another source of error in pyrosequencing arises from miscalling homopolymer 
runs, and the signal-to-noise ratio which may lead to phantom mutations, 
particularly insertions/deletions (indels) (Quinlan et al. 2008). Using higher 
sequencing coverage, these errors may become insignificant. Longer 
homopolymer runs of over 10 nucleotides, on the other hand, may still be an 
issue at higher coverage (Quinlan et al. 2008; Wicker et al. 2006; Green et al. 
2008). Furthermore, high-intensity signals from one well in the plate may affect 
neighbouring cells (i.e. signal bleed-over), potentially creating phantom 
mutations in the affected wells. Sequence artefacts caused by bleed-over may 
be corrected by downstream computational analyses (Green et al. 2006). 
 
The position in the sequencing read may also affect the error rate, with more 
errors typically appearing towards the end of the read. In pyrosequencing this is 
often due to enzyme efficiency reduction, which ultimately results in inhibition of 
sequence extension (where polymerases are affected) or lower signal 
intensities (in the case of luciferases and sulphurylases). Increased phasing 
may also be encountered; a phenomenon in which not all of the amplified 
24 
 
(clonal) template molecules are extended at the same rate. For example, it is 
possible that the correct nucleotide is not incorporated into the extending strand 
in a given cycle, leading to the preceding base re-emitting a signal. 
 
1.1.9.3 Reversible terminator chemistry 
Average error rates of around 10-2 – 10-3 are observed using reversible 
terminator chemistry (Table 1.1) (Dohm et al. 2008; Kircher et al. 2009), and are 
probably made higher by in vitro amplification steps. Preparation of the flow cell 
may also result in some clusters than are composed of several template 
sequences, interfering with signal intensities during imaging. This may lead to 
incorrect base calls or lower confidence scores in correct calls. Furthermore, 
unclean flow cells may have contamination from dust, lint and other particles 
that could be erroneously recognised as clusters and generate ‘ghost’ 
sequences. These ghost sequences, however are likely to be of low quality due 
to the typical low sequence complexity observed (Kircher & Kelso 2010). Error 
rates increase towards the ends of the reads, mainly due to increased signal 
noise created by phasing. Phasing using reversible terminator chemistry can 
occur in two ways; the first as described for pyrosequencing, and the second by 
incorporation of more than one nucleotide in the same sequencing cycle. It is 
also documented that the signal intensity declines during increasing cycle 
numbers (Kircher et al. 2009; Erlich et al. 2008; Rougemont et al. 2008). 
 
1.1.9.4 Sequencing-by-ligation 
For SBL, higher densities can be achieved by using a glass flow cell instead of 
picotiter plates, although the beads are distributed randomly across the flow cell 
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surface which can lead to problems identifying bead positions. This is especially 
true for unclean flow cells, as similar to flow cells used in reversible terminator 
chemistry, dust and other particles impose problems. Signal bleed-over from 
neighbouring beads can also lead to errors in base calling. 
 
Other errors are caused by in vitro amplification, as with other amplification-
dependent library preparation protocols. Beads that contain multiple template 
sequences also suffer from signal noise, similar to that experienced when 
beads are spaced too near one another. Signal decline along the length of the 
read, and failure to remove fluorescent labels also results in errors. Where 
labels are not removed, there is a possibility for them to be removed in the next 
ligation reaction, creating a sequencing artefact similar to that encountered 
during phasing. Phasing itself, however, is not a major problem for the SOLiD 
platform, as permanent termination is ensured by the act of phosphatases 
efficiently removing the phosphate group from strands that were not extended in 
the previous cycle (Kircher & Kelso 2010). Poor hybridisation of probes to the 
template sequence also leads to signal decline over the course of many cycles. 
Where a reference genome sequence is available, typical error rates fall 
between 10-3 – 10-4; in cases where no reference sequence is available, error 
rates are between 10-2 and 10-3 (Kircher & Kelso 2010). Without a reference 
genome sequence, assembly and consensus base calling can be performed 
based on the fluorescent signals obtained (so called ‘colour space’), before the 
signals are converted to nucleotide sequence (‘base space’). 
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1.1.9.5 Virtual terminator technology 
Disadvantages of virtual terminator technology are that since only single 
molecules are sequenced, fluorescence signals that are emitted are weak, and 
the lack of consensus calls using amplified templates means incorporation 
errors cannot be corrected as easily. The technology also relies on hybridisation 
to the flow cell instead of covalent bonding preferred by other technologies, 
meaning that the HeliScope platform is prone to template molecules being 
accidently removed during washing steps. Premature termination may occur via 
addition of erroneously synthesised nucleotides (Kircher & Kelso 2010). Error 
rates are generally high and appears to be biased towards indels (Pushkarev et 
al. 2009; Kircher & Kelso 2010). At 15x – 20x coverage, around 1% of the 
sequenced bases may be incorrect, and at 30x coverage, around just 0.1% of 
the bases sequenced are thought to be identified incorrectly (Pushkarev et al. 
2009). 
 
1.2 De novo genome assembly 
One of the major challenges facing researchers sequencing the genome of an 
organism for the first time is assembling the data to reconstruct the genome 
accurately. Early software built to do this could handle smaller, relatively simple 
bacterial genomes, but the further development of advanced assembly 
algorithms along with increases in computational power has allowed for more 
complex genomes to be assembled de novo (Imelfort & Edwards 2009; Lin et 
al. 2011; Zhang et al. 2011). A hurdle in de novo assembly is repetitive DNA 
sequences that can cause ambiguity in the data. A way to bypass this hurdle is 
to use increased read lengths; however, this is limited by factors in sequencing 
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chemistry and technology. Alternatively, one can use paired end or mate pair 
sequencing, whereby if the distance between each read is long enough then the 
repeat ambiguity can be resolved (Lee et al. 2012). Several pieces of software 
have been developed that are capable of de novo assembly. 
 
1.2.1 SSAKE, VCAKE and SHARCGS 
SSAKE, published in 2007 (Warren et al. 2007), was one of the first assemblers 
for short reads to be released. The software does not account for paired end 
data, and therefore may struggle with genomes with repetitive regions. SSAKE 
does however possess the ability to collapse multiple repetitive regions into one 
contig when run in non-strict mode. An extension of SSAKE, VCAKE (Jeck et al. 
2007) has been reported to be able to handle erroneous reads (Lee et al. 2012). 
Both of these pieces of software perform at roughly comparable levels on 
simpler genomes, but VCAKE outperforms SSAKE for more complicated 
genomes. However, VCAKE also does not take advantage of paired end data 
and so may still struggle with repetitive regions (Jeck et al. 2007). 
 
SHARCGS (Dohm et al. 2007) further complements the methods employed by 
SSAKE and VCAKE. By default, SHARCGS naive assemblies offer a range of 
filtering levels. Contigs from different rounds of assembly can be merged in 
order to increase accuracy; these merged contigs are supplied with quality 
scores for consideration by end users. SHARCGS does not account for paired 
end data and thus has difficulty creating an unambiguous set of repetitive 
regions (Lee et al. 2012). 
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1.2.2 Velvet 
In 2008, a collection of NGS assembly algorithms was released, named Velvet 
(Zerbino & Birney 2008). Since it was first released, Velvet has undergone 
continuous improvements from the original authors and bioinformatics 
community. Velvet is able to take advantage of error correction algorithms, 
which may help maintain a low memory footprint (Lee et al. 2012; Zerbino & 
Birney 2008). The algorithms utilised by Velvet are able to account for paired 
end data, which are used to merge contigs and return collections of scaffolds to 
the user. These algorithms have been updated (Zerbino et al. 2009) and 
scaffold generation improved. Repetitive region resolution has also been 
increased, along with error correction and general speed and memory 
improvements. Larger genomes, however, reportedly take over 1 terabyte (TB) 
of memory (Lee et al. 2012), making the software unfeasible for standard 
desktop computers. Updates to software have been applied to increase memory 
performance and running times. Velvet remains a highly popular assembler, has 
been used in assembly of commercially important genomes such as wheat 
(Berkman et al. 2011) and has been cited over 300 times (Lee et al. 2012). 
 
1.3 Aligning NGS reads to a reference sequence 
NGS data must be either assembled (for de novo genomes or organisms) or 
aligned against the reference genome. Several NGS read aligners are 
available, such as Bowtie (Langmead et al. 2009), Burrows-Wheeler Aligner 
(BWA, Li & Durbin 2009), Maq (H. Li et al. 2008), the SHort Read Mapping 
Package (SHRiMP, Rumble et al. 2009) and the Short Oligonucleotide 
Alignment Programs (SOAP, SOAP2 and SOAP3, (R. Li et al. 2008; R. Li et al. 
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2009; C.-M. Liu et al. 2012) and each have advantages and disadvantages. 
Bowtie, for example, has a relatively small memory footprint of 1.3 Gigabytes 
(GB) for the whole human genome (Ruffalo et al. 2011). This makes it 
computationally less demanding and so can be run on most modern desktop 
computers. However, this comes at a price; if an exact match between a 
sequencing read and the reference genome is not found, then it is not 
guaranteed to find the best quality mapping coordinates for the read. 
Fortunately, Bowtie offers users the chance to alter usage parameters to 
configure the software to run as they would like. 
 
1.3.1 BLAT 
More traditional alignment tools, such as Basic Local Alignment Search Tool 
(BLAST) (Altschul et al. 1990) and Smith-Waterman (Smith & Waterman 1981) 
algorithms are unable to handle the large amounts of data typically generated 
throughout the course of NGS. The BLAST-like alignment tool (BLAT) (Kent 
2002) has been designed for fast alignment of reads to a reference genome. It 
is commonly used for lookup of genomic locations by sequence similarity; in a 
reference the size of the human genome (>3 Gigabases [Gb]) it takes just 
seconds to locate a region with similar sequence identity. This rapid search 
ability has earned BLAT employment amongst several public genome browsers, 
for example Ensembl (Flicek et al. 2013) and the University of California, Santa 
Cruz (UCSC) Genome Browser Database (Karolchik et al. 2003). BLAT 
maintains a low memory footprint by using indexed genome formats, allowing 
for the entire human genome to be read into <1 GB of memory. BLAT has been 
optimised to search for sequences of ≥40 bp that are 95% identical or greater. 
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For shorter or less similar sequences, BLAST or other algorithms may prove to 
be better suited for alignment. 
 
1.3.2 BFAST 
The BLAT-like Fast Accurate Search Tool (BFAST) (Homer et al. 2009) also 
uses genome indexing to retain a low memory footprint and rapid alignment 
speed. BFAST opts for higher alignment accuracies and sensitivities whilst 
sacrificing alignment speed, although it is generally still faster than BLAT and 
has lower false-mapping rates (Lee et al. 2012). It is, however, slower than 
some other aligners, for example Maq, Bowtie and BWA. The gain of speed 
over BLAT is largely due to the improved use of the reference indexing. Greater 
accuracy may be obtained by using a Smith-Waterman algorithm (Smith & 
Waterman 1981) to align query sequences to possible genomic hits. As Smith-
Waterman is a local gapped alignment algorithm, BFAST is readily able to 
account for both single nucleotide polymorphisms (SNPs) and indels in the NGS 
data. 
 
1.3.3 BWA 
Burrows-Wheeler Aligner was the first Burrows-Wheeler algorithm based tool to 
allow gapped alignments (Li & Durbin 2009). BWA also allows for sequence 
mismatches, and can accommodate alignments in both base-space and colour-
space. The performance of BWA has been shown to be comparable to SOAP2 
(Li et al. 2009) and Bowtie (Li & Durbin 2009; Lee et al. 2012), however run-
time may be increased due to handling of gapped alignments. The advantage to 
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handling gapped alignments is crucial for longer reads that are more likely to 
contain indels. 
 
BWA has an advantage over earlier aligners in that it provides mapping quality 
scores for reads. This allows mapped reads to be judged on these qualities, and 
decisions can be made about whether or not to include specific reads in 
downstream analyses. 
 
1.3.4 Maq 
For mapping of large numbers (>10 million) of short reads, Maq is able to 
perform ungapped alignment to a reference genome accurately and efficiently 
(H. Li et al. 2008). Occasionally ambiguity arises in mapping locations, due to 
repetitive regions, short read lengths or sequencing errors; Maq handles these 
cases by inclusion of mapping quality scores. Maq can also take note of paired 
end data and Phred-scaled base quality to calculate error probabilities, and 
where ambiguous alignments may be present, reports only the alignment with 
the lowest error rate. Where multiple ambiguous reads have equally low error 
probabilities, one of the reads is reported randomly. In such cases, Maq sets the 
mapping quality to 0. 
 
1.3.5 Bowtie 
Bowtie is another aligner based on the Burrows-Wheeler algorithm, allowing 
fast alignment of short reads. For example, Bowtie can align 25 million reads to 
the genome per central processing unit (CPU) hour, and still maintain a memory 
footprint of <2 GB. Parallelisation allows for Bowtie to run on multiple 
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processing cores simultaneously. Bowtie supports sequence mismatches, and 
updates have added support for paired end reads, and alignment of colour-
space reads. Integration and parsing data between Bowtie and other software 
such as SAMtools (Li et al. 2009) is possible, and has influenced other 
alignment software such as Tophat (Trapnell et al. 2009) and Cufflinks (Trapnell 
et al. 2010). 
 
1.3.6 SHRiMP 
SHRiMP has been designed to map shorter sequencing reads against a 
reference, even if there is a large amount of mismatches or polymorphism 
present (Lee et al. 2012). This package has been designed to work primarily 
with colour-space reads from SBL platforms. SHRiMP utilises a Smith-
Waterman algorithm and searches for k-mer matches (where k is a positive 
integer). Identification of SNPs is permitted by allowing adjacent mismatches 
between the reference sequence and the sequencing read (Rumble et al. 
2009). Updates to SHRiMP include SHRiMP2 (David et al. 2011) which allows 
for analysis of broader data formats, including FASTA and FASTQ input, as well 
as base-space reads. The updates also account for paired end data and speed 
improvements are introduced via parallel computing (David et al. 2011). 
 
1.4 Variant calling 
1.4.1 Germline variant calling 
Variant calling from germline samples is a standard technique for many 
research and clinical laboratories. As such, there is a demand for accurate 
variant callers. One such caller is VarScan (Koboldt et al. 2009), which has 
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reported sensitivity rates of ~97% for SNVs. VarScan is capable of handling 
data from multiple NGS platforms such as the Roche/454 sequencer and 
Illumina sequencers. Likewise, the Genome analysis tool kit (GATK; DePristo et 
al. 2011; McKenna et al. 2010) was developed to utilise data from several 
platforms and provide a suite of tools for users to ensure reliable variant calls. 
The UnifiedGenotyper tool in GATK has a reported sensitivity of >99% and 
additionally, GATK also has tools to assess quality of the sequencing data and 
quality of the variant calls. This is therefore a powerful tool for bioinformaticians 
working with NGS data. 
 
1.4.2 Somatic variant calling 
Detection of somatic mutations is technically challenging; they are often at low 
frequency due to presence of normal tissue and the heterogeneous nature of 
tumours, and technical and biological noise makes the identification of genuine 
somatic events difficult. There is however, software available that is capable of 
detecting somatic mutations, including MuTect (Cibulskis et al. 2013), 
SomaticSniper (Larson et al. 2012), JointSNVMix (Roth et al. 2012) and Strelka 
(Saunders et al. 2012). 
 
MuTect requires both a sequenced tumour and normal sample in order to call 
somatic variants; calling variants from both samples allows for distinction 
between variants exclusive to the tumour and those present in the matched 
normal sample. MuTect is capable of detecting mutations in colorectal cancer 
(CRC) at low allele frequencies (<1%) with high sensitivity (>95%) (Cibulskis et 
al. 2013). Furthermore, sensitivity increases with higher depth of coverage. 
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MuTect is therefore ideal for use with samples that may have contamination 
from normal tissue or that are of a subclonal nature. 
 
JointSNVMix also requires a matched normal-tumour pair for reliable somatic 
variant calling. The sensitivity of JointSNVMix is also high (>90%), although this 
may be lower in samples with copy number variation (CNV) (Roth et al. 2012). 
The sensitivity of SomaticSniper, which also relies on a matched tumour-normal 
pair, has a similar sensitivity level (~92%) as revealed when tested on data from 
COSMIC (Larson et al. 2012; Forbes et al. 2008). 
 
 
1.5 Molecular analyses of tumours 
The majority of archived tumours are only available in formalin-fixed, paraffin-
embedded (FFPE) blocks. FFPE is routinely used as a preservation technique 
as it maintains the structural integrity of physiological tissues (von Ahlfen et al. 
2007); however, DNA from FFPE material poses several challenges for NGS. 
One of the earliest effectors of FFPE sample quality is the time spent in 
ischaemic anoxia during and after surgery (Hedegaard et al. 2014). Formalin-
fixation should ideally take place as soon as possible after resection as anoxia 
may alter the transcription pattern of some genes (Srinivasan et al. 2002; 
Bennewith & Dedhar 2011), giving a false representation of the original cancer. 
Extended times to fixation from surgical clamping of blood vessels have also 
been shown to affect the number of mitotic cells in resected samples (Cross et 
al. 1990), where the number after 6 hours dropped to 49% of the number 
observed at 30 minutes.  
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Formalin-fixation is known to reduce the efficiency of DNA extraction (Serth et 
al. 2000). This could be because the formaldehyde in formalin denatures the 
hydrogen bonds between chains and causes bases to un-stack in AT-rich 
regions (Srinivasan et al. 2002). Formaldehyde interacts with DNA in a number 
of ways that could affect downstream processes: apurinic and apyrimidinic sites 
(collectively referred to as AP sites) are formed which leave a free pyrimidine or 
purine residue, respectively. This could be a problem for PCR if the AP sites lie 
in primer-binding regions. Formaldehyde can also react with a free amino group 
to form a methylol derivative of a base; these methylol derivatives are then able 
to react to form methylene bridges between the affected bases. The bridges 
formed may prevent strand denaturation during PCR (Douglas & Rogers 1998). 
 
The temperature of samples during fixation also effects DNA quality. At room 
temperature, (non-FFPE) tissues have been reported to suffer degradation 
upon fixation in buffered formaldehyde. At 4°C however, DNA showed no 
degradation (Tokuda et al. 1990). Fixation in the presence of deoxyribonuclease 
(DNase) may also contribute to degradation (Tokuda et al. 1990). Further 
studies have shown that fixation in buffered formaldehyde in the presence of 
DNAse-neutralising ethylenediaminetetraacetic acid (EDTA) allows for high 
molecular weight DNA to be extracted (Yagi et al. 1996). The authors claim, 
however, that a mechanism other than DNAse may be responsible for most of 
the degradation to the DNA. 
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Studies from ancient DNA have shown that while it is assumed that DNA 
extractions from older samples are likely to give lower yield (which itself is 
expected to contain more DNA damage) than more recent samples, the age of 
the sample is not the sole determinant, and environmental factors such as 
temperature and salt concentration play a role (Hofreiter et al. 2001). Fixation 
time also affects FFPE DNA degradation. Fixation periods of 24 to 48 hours are 
not uncommon (Srinivasan et al. 2002), although the longer time periods have a 
more adverse effect on DNA quality. Storage temperature of FFPE tissues after 
formalin fixation may also determine DNA quality. 
 
Additional steps are required during DNA extraction to remove the paraffin, for 
example with xylene and 100% ethanol (Kokkat et al. 2013), which increases 
processing time and costs. There are several commercially available kits 
capable of extracting DNA from FFPE samples. One study (Okello et al. 2010) 
compared 9 commercially available nucleic acid extraction kits and a phenol-
chloroform based in-house method using 7 FFPE blocks. To avoid sample 
biases, the authors used the same set of 7 samples for each kit tested. All but 
two of the commercial protocols used xylene and 100% ethanol to remove and 
wash away paraffin; the remaining protocols used Q-Solution and d-Limonene. 
The kits showed varying yields, ranging between 0.02 – 5.47 ng/µl. Three of the 
commercial kits and their in-house protocol gave consistently high yield, which 
proved to be readily amplifiable. There was no significant correlation between 
amplification suitability and sample age (range = 5 to 15 years since 
embedment in paraffin) or incubation time during the extraction protocol. There 
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may, however, be a statistically significant link between a protocol’s incubation 
time and final yield of DNA (Okello et al. 2010). 
 
1.5.1 DNA from normal tissue preserved in FFPE is useful in genotyping 
studies 
Tumour FFPE (tFFPE) DNA is often the focus of genetic studies in cancer, while 
the use of normal tissue that is also preserved in FFPE (nFFPE) is less 
commonly reported. Typically genome-wide genotyping of FFPE DNA is poor, 
so it is understandable that nFFPE is often overlooked for whole blood samples. 
Whole blood samples offer greater DNA quality in comparison, but where no 
blood sample is available, nFFPE can be used in lieu. Concordance has been 
shown to be high (>99%) between blood and nFFPE samples (Cannon-Albright 
et al. 2011). Where blood and nFFPE samples are available, comparisons 
between data from both may lead to identification of FFPE-induced artefacts. 
 
1.5.2 FFPE-induced artefacts 
It is a common feature of FFPE samples that they harbour formalin-induced 
artefacts, primarily C:G>T:A substitutions. These C:G>T:A artefacts likely arise 
as a result of deamination of cytosine (Do & Dobrovic 2012). Cytosine is 
deaminated to uracil (U) in ancient DNA (Hofreiter, Serre, et al. 2001; Do & 
Dobrovic 2012; Hofreiter, Jaenicke, et al. 2001); during PCR an adenine will be 
incorporated opposite uracil as opposed to a guanine that would normally have 
been incorporated opposite the cytosine. During the next PCR cycle, a thymine 
will be incorporated opposite the adenine, leading to a C:G>T:A transition in the 
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PCR product. The frequency of these artefacts has been reported at around 1 in 
500 bases in FFPE DNA (Williams et al. 1999). 
 
1.5.3 Suitability of FFPE tissues in NGS. 
Fixation times of 24 – 72 hours were used in one study (Schweiger et al. 2009) 
and stored at -20°C for 6 months before sequencing using a SBS approach. 
The authors also prepared snap frozen samples from the same patient and 
subjected them to the same storage and sequencing conditions; comparisons 
between the two tissue types revealed similar read numbers, read alignments 
and chromosome-wise coverage. In fact, older samples (both snap frozen and 
FFPE) were used in the study that dated back up to 18 years and still 
successfully sequenced using the same methods. Snap frozen and FFPE DNA 
samples again revealed similar coverage distribution.  
 
Further work has shown that FFPE DNA is suitable for use in targeted re-
sequencing experiments (Kerick et al. 2011). This study showed that 0.5 – 3.0 
µg of genomic DNA from FFPE can be used in sequencing of 52 Mb (the whole 
exome) and 3.9 Mb (custom targets), using a Genome Analyzer IIx (Illumina). 
The matched snap frozen samples were also sequenced and compared against 
the FFPE samples. For both tissue types, an average of 75% of the mapped 
reads were on-target for the exome sequencing, and 99% of the exome was 
covered by at least one sequencing read. For the custom target panel, 80% of 
the sequencing reads mapped to the target region, and 98% of the region was 
covered by at least one read. These results are testament to the suitability for 
inclusion of FFPE samples in NGS experiments. 
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1.5.4 Highly accurate variant calls are possible from FFPE DNA 
FFPE samples have been used for whole exome sequencing and shown a 98% 
accuracy level when compared to Affymetrix SNP array data, even at low (10x) 
sequencing depths (Kerick et al. 2011). The same study compared the FFPE 
samples against their matched snap frozen counterparts, and found just 179 
loci (1.2% of the total tested) were discordant at 20x depth. 149 of these 
discrepancies were found in FFPE but not snap frozen samples, suggesting 
they may be false positive artefacts. Indeed, the majority were either C:G>T:A or 
A:T>G:C substitutions (Kerick et al. 2011; Do & Dobrovic 2012). At 40x 
coverage, the number of discordant calls between snap frozen and FFPE 
samples fell to just 12, and decreased to 0 at 80x coverage (Kerick et al. 2011). 
 
1.6 Colorectal cancer 
CRC is the third most common cancer diagnosed globally, and is the fourth 
largest cancer in terms of deaths (Haggar & Boushey 2009). Every year, around 
1.4 million people are diagnosed with CRC, and approximately 700,000 die from 
the disease (Torre et al. 2015). Although the incidence of the disease is low for 
younger persons, it rises with age and the median age of diagnosis is around 70 
years (Brenner et al. 2014). It appears to be more common in North America, 
Europe and Australia than in Asia and Africa, suggesting it may be a disease of 
Western lifestyles. However, in Western countries CRC incidence appears to be 
in decline; this is likely due to increasing preventative measures such as 
colonoscopy (Amaro et al. 2016; Torre et al. 2015). 
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CRCs progress through a number of characterised stages (Dukes’ stages). 
Dukes’ stages can be described as follows; stage A involves CRCs limited to the 
bowel wall; stage B sees carcinomas spreading locally beyond the bowel wall 
but with no nodal involvement; stage C involves spreading beyond the bowel 
wall and has lymph node involvement; stage D sees the carcinoma 
metastasising to other organs (Turnbull et al. 1967). Prognosis depends upon 
the stage of CRC at diagnosis; patients diagnosed at Dukes’ stage A have a 
90% chance of surviving for five years, patients with Dukes’ stage B have a 75-
80% chance (Aslam et al. 2015) whereas those diagnoses at Dukes’ stage D 
have only a 5% chance of surviving five years (de la Chapelle 2004). 
 
1.6.1 The development of CRC 
Sporadic CRC develops, in general, through one of two pathways: the 
microsatellite instability (MSI) and chromosomal instability (CIN) pathways. 
 
CRCs with MSI (~15% of cases, Boland & Goel 2010; Webber et al. 2015) are 
less likely to be associated with KRAS or TP53 mutations. Instead, mismatch 
repair (MMR) genes (e.g. MLH1, MSH2 and MSH6) are likely to be 
epigenetically silenced (Horvat & Stabuc 2011). Tumours with MSI contain 
insertion or deletion mutations in dinucleotide repeats (such as CA) and are 
likely to be located within the proximal colon. MSI can be used as a prognostic 
marker in CRC (Webber et al. 2015), as treatments such as 5-fluorouracil (5-
FU) are not effective (Warusavitarne et al. 2006); the DNA damage induced by 
5-FU which normally encourages apoptosis is not recognised by the cell’s faulty 
MMR machinery (Choudhary et al. 2012; Thibodeau et al. 1993). 
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The CIN pathway is characterised by chromosomal aneuploidy, centromere 
dysfunction, inactivating mutations in tumour suppressor genes and activating 
mutations in oncogenes (Pihan 2013; Fearon & Vogelstein 1990). Around 80 - 
85% of CRC cases have CIN (Cisyk et al. 2015; Kołos et al. 2015). Mutations in 
the tumour suppressor gene adenomatous polyposis coli (APC) are common 
(Kołos et al. 2015) in sporadic tumours (Figure 1.7). Powell et al. (1992) found 
that APC was mutated in 63% of small benign adenomas, and in 60% of 
malignant tumours, and others have found APC is mutated at similar 
frequencies (Dow et al. 2015; Samowitz et al. 2007). These data suggest that 
APC mutations occur very early during CRC development. APC is known to be 
hypermethylated in CRC cases (Ding et al. 2015), leading to silencing of the 
gene and its tumour-supressor activity. Inactivating mutations within tumour 
suppressor genes are consistent with Knudson’s two hit hypothesis (Pannett & 
Thakker 2001; Knudson 1971), in which biallelic mutations are required for 
cellular progression to tumourigenesis. Sporadic tumours often have two APC-
inactivating mutations, the first of which can be inherited. Oncogenes, such as 
KRAS, NRAS and HRAS, are (cumulatively) mutated in between 16% and 40% 
of all CRCs (Van Krieken et al. 2016; Waring et al. 2015) and are found in a 
similar amount of adenomas over 1 centimetre (cm) in diameter (Bos et al. 
1987; Vogelstein et al. 1988). Such mutations are rarer in smaller adenomas, 
suggesting these mutations may drive growth of larger adenomas. The CIN 
pathway is often linked with loss of chromosome 17p, which occurs in over 75% 
of CRCs (Lee et al. 2013), in varying degrees in flat adenomas (Postma et al. 
2005), in around 30% of late adenomas and in 10% or less of early adenomas 
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(Delattre et al. 1989; Vogelstein et al. 1988; Fearon & Vogelstein 1990). This 
genomic region contains the tumour suppressor TP53, and the remaining copy 
of the gene has been shown to carry inactivating mutations (Olivier et al. 2010; 
Nigro et al. 1989). These observations indicate that inactivating TP53 therefore 
allows for progression from adenomas to carcinomas (Figure 1.7). 
 
Figure 1.7. Colorectal carcinoma progression from regular epithelium. 
Progression follows the arrow from the base of the crypt. Mutations in genes 
such as APC allow for benign adenomas or polyps to form. Further mutations, 
such as those in EGFR, KRAS and related Ras genes allow for progression of 
late stage adenomas. Finally, mutations in genes such as SMAD4, PIK3CA and 
TP53, along with increased chromosomal instability allow for progression of 
adenomas to malignant cancers (Fodde et al. 2001; Fearon & Vogelstein 1990; 
Pino & Chung 2010). 
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1.6.2 Germline mutations that predispose to CRC 
Up to ~15% of CRCs are thought to be caused by germline factors, but only a 
proportion of these are known. Germline mutations in APC cause familial 
adenomatous polyposis (FAP), and patients present with hundreds or 
thousands of small colorectal adenomas. These adenomas are usually 
detectable by the patient’s thirties, and if left untreated, some of these will 
progress to CRC (Phelps et al. 2009; Fearnhead et al. 2001). 
 
Hereditary non-polyposis colorectal cancer (HNPCC) or Lynch syndrome is 
caused by germline mutations in MMR genes such as MLH1, PMS2, MSH2 and 
MSH6; these mutations show a penetrance of around 80% (de la Chapelle 
2004). Around 5% of CRC cases are attributed to Lynch syndrome and are 
usually diagnosed based on age of onset and whether there is a family history. 
Tumours from patients with HNPCC display MSI. 
 
MutYH-associated-polyposis (MAP) is associated with a colorectal phenotype 
that is similar to mild forms of FAP. MAP is caused by mutations in the base 
excision repair gene MutYH (Sampson et al. 2005). MutYH is a DNA 
glycosylase responsible for excision of adenines that are accidentally 
incorporated opposite 7,8-dihydro-8-oxoguanine (8-oxoG), which is created 
during oxidative damage (Nakabeppu 2014; Slupska et al. 1999). 
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1.6.3 Treatment of CRC - Surgery and chemotherapy 
One of the front line defences against CRC is surgery. However, even after 
surgical resection, there is still up to a 50% chance that the patient could 
relapse. For the majority of these relapsed patients, further surgery is ineffective 
and increases risk of death (Kelly & Cassidy 2007; Obrand & Gordon 1997). 
Initial chemotherapies introduced for CRC patients included 5- FU. It has 
proven to be a success in combination with other treatments, in that it improves 
overall survival (OS) and progression free survival (PFS) in patients following 
resection of Dukes’ stage C CRCs. However, as a first line treatment it is not as 
effective as typically less than 15% of CRCs show beneficial response 
(Johnston & Kaye 2001). Using 5-FU in combination with treatments such as 
oxaliplatin or irinotecan increase the response rate to around 50% in advanced 
CRC (Giacchetti et al. 2000; Douillard et al. 2000).  
 
The mechanism of action for 5-FU is based on its structural similarity to uracil; 
the difference is that 5-FU has a fluorine atom instead of a hydrogen atom at C-
5. Inside the cell, 5-FU is converted to active metabolites including 
fluorodeoxyuridine monophosphate (FdUMP). These active metabolites are 
able to disrupt ribonucleic acid (RNA) synthesis and the action of thymidylate 
synthase (Longley et al. 2003) as they compete for the active site with the 
normal substrate, deoxyuridine monophosphate (dUMP). Inhibiting thymidylate 
synthase blocks deoxythymidine monophosphate synthesis, subsequently 
leading to depletion of deoxythymidine triphosphate and imbalances in the 
levels of other deoxynucleotides. These imbalances cause lethal DNA damage 
by disrupting DNA repair (Longley et al. 2003). 
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Capecitabine is a precursor of 5-FU. The final step during the conversion to 5-
FU relies on thymidine phosphorylase, which can be found at higher levels in 
tumour cells than normal cells (Kelly & Cassidy 2007). This ensures tumour 
cells effectively receive larger doses of the end product than normal cells. 
Clinical trials of capecitabine have shown that there is a greater tumour 
response with capecitabine than with 5-FU (Hoff et al. 2001; Van Cutsen et al. 
2001). 
 
The topoisomerase I inhibitor irinotecan prevents topoisomerase from 
unwinding the DNA double helix during replication, leading to strand breakage 
and ultimately cell death (Kelly & Cassidy 2007). In a study of patients whose 
CRC progressed after 5-FU treatment, Rothenberg et al. (1999) found that 
giving intra-venous irinotecan improved OS, but patients also reported 
gastrointestinal side effects such as diarrhoea and nausea.  
 
1.6.4 EGFR signalling in colorectal cancer 
The epidermal growth factor receptor (EGFR) pathway (Figure 1.8) is 
responsible for cell migration, adhesion and proliferation (Hynes & Lane 2005; 
Oda et al. 2005; Tian et al. 2013). Expression of EGFR (also known as ERBB1) 
can be seen in many carcinomas, including colon, lung, breast, kidney, head 
and neck and pancreas (Krasinskas 2011). Carcinogenesis, survival and 
response are affected by EGFR expression, gene amplification and mutations. 
The extracellular domain of EGFR is responsible for ligand binding. EGFR also 
contains a trans-membrane domain and a cytoplasmic region that contains a 
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tyrosine kinase domain. EGFR is one of four closely related members of the 
ERBB family (ERBB1-4) that each contain the same structural domains (Tebbutt 
et al. 2013; Hynes & Lane 2005). Each member of the family is able to form a 
hetero- or homo-dimer upon ligand binding (Yarden & Sliwkowski 2001). 
 
EGFR signalling, when not regulated, can lead to transformation of benign to 
malignant tissue and increased cell proliferation, angiogenesis, metastasis and 
cell survival, all of which contribute to tumour progression (Krasinskas 2011; 
Mitsudomi & Yatabe 2010; Spano et al. 2005). Over expression of EGFR has 
been reported in CRCs, with wide ranges in the number of cases showing 
increased levels (Spano et al. 2005; Goldstein & Armin 2001; McKay et al. 
2002; Resnick et al. 2004). Some studies have reported that EGFR over 
expression is associated with reduced survival (Goldstein & Armin 2001; 
Resnick et al. 2004); however, this has not be found by others (Spano et al. 
2005). 
 
1.6.5 Treatments targeting EGFR and predictive biomarkers 
Activation of the EGFR pathway, either by natural ligand binding or by molecular 
alterations, signals the cell to proliferate. Constitutive activation is problematic 
and is likely to negatively affect response to anti-EGFR monoclonal antibody 
(mAB) treatments such as cetuximab. EGFR itself has multiple mutations that 
affect response to cetuximab (so called ‘predictive biomarkers’). One such 
mutation is p.T790M (Pao et al. 2005; Kwak et al. 2005; Kobayashi et al. 2005), 
often seen in lung cancer. p.T790M is capable of activating EGFR by increasing 
its affinity for ATP, the proposed main mechanism by which drug resistance is 
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conferred (Yun et al. 2008). In addition, the acquired mutation p.S492R has 
been shown to prevent binding of cetuximab, leading to cetuximab resistance 
(Montagut et al. 2012). However, EGFR mutations are, in general, rare in CRC; 
in an analysis of 156 metastatic CRC (mCRC) patients treated with cetuximab, 
1.9% (3/156) of tumours carried p.S492R, which was only detectable after 
treatment (Esposito et al. 2013).
 
Figure 1.8. EGFR pathway and related signalling. Ligands are shaded purple, 
receptors are shaded green and intracellular molecules are shaded red. Black 
arrows convey signal transduction while red lines indicate inhibition of signalling 
(Li et al. 2013; Parsons et al. 2005; Avraham & Yarden 2011; Organ & Tsao 
2011; Aloy et al. 2006; Kanno et al. 2000; Griffioen & Molema 2000; Oda et al. 
2005; Holohan et al. 2013; Fruman & Rommel 2014; Luo et al. 2012; Virella & 
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Lopes-Virella 2012; Schmidt et al. 2014; Choi et al. 2013; Fernandez & Torres-
Alemán 2012). 
 
The most well known predictor of clinical response to cetuximab is KRAS 
mutation status. This association was first reported by Lièvre et al. (2006), with 
KRAS mutation leading to lack of cetuximab response (P = 0.0003). Pooling of 
data from two studies (Lièvre et al. 2006; Moroni et al. 2005), showed a 91% 
probability of non-response in the presence of a KRAS mutation (with a 10-fold 
higher relative of risk of cetuximab response from KRAS wild-type compared to 
KRAS mutant tumours). 
 
There are several common somatic mutations in KRAS, and known mutation 
hotspots include codons 12, 13, 61 and 146 (Wicki et al. 2010). Codons 12 and 
13 mutations account for 90% of KRAS mutations (Bazan et al. 2005). It has 
been suggested that some KRAS mutations have different predictive effects for 
cetuximab. For example, patients with a p.G13D mutation exhibited longer OS 
and PFS than those with other mutations (De Roock et al. 2010); however, 
these data require independent validation. Patients with CRCs harbouring 
mutations at codon 61 in KRAS may not benefit from cetuximab, as these 
patients have significantly lower response rates than those with wild type KRAS 
(De Roock, Claes, et al. 2010). There is conflicting evidence to suggest that 
codon 146 mutations may significantly lower response to cetuximab in CRCs 
(De Roock, Claes, et al. 2010; Loupakis et al. 2009). 
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NRAS is mutated in around 2-4% of CRCs (Meriggi et al. 2014; De Roock, 
Claes, et al. 2010), and similarly to KRAS, mutations in codons 12, 13 are the 
most common. In KRAS wild type tumours, mutations in NRAS may cause 
resistance to anti-EGFR therapies (Di Bartolomeo et al. 2014). BRAF mutation 
(in particular p.V600E) has been shown to associate with lack of clinical 
response to cetuximab, as well as reduced OS and PFS (Di Nicolantonio et al. 
2008). However, other studies have not supported this (Moroni et al. 2005). 
 
PIK3CA encodes the p110α subunit of PI3K, the signalling of which is inhibited 
by PTEN. Loss of PTEN (seen in ~30% of sporadic cases) therefore allows 
continuous PI3K signalling and cetuximab-resistance (Frattini et al. 2007). 
Common mutations in PIK3CA occur in exons 9 and 20 (Jhawer et al. 2008; 
Prenen et al. 2009; Sartore-Bianchi et al. 2009). Cetuximab-resistance can be 
conferred by PIK3CA mutations mutually exclusive of KRAS mutations, and 
patients harbouring somatic PIK3CA mutations have worse PFS than those with 
wild-type PIK3CA (Sartore-Bianchi et al. 2009). OS decreases in patients with 
at least one PIK3CA mutation, and appears to be statistically significant when 
combined with loss of PTEN (Sartore-Bianchi et al. 2009). 
 
1.7 Background to this Project and Aims 
Patients with colorectal cancer are often treated with the anti-EGFR drug 
cetuximab. However, many patients show lack of response to cetuximab even 
though they do not exhibit mutations in genes associated with response. Using 
samples from Medical Research Council (MRC) COIN trial (Maughan et al. 
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2011), this project set out to identify potential novel genetic predictors of 
response to cetuximab. 
 
The aims of this project were to: 
(1) Test a bioinformatics pipeline and parameters for germline variant calling 
from NGS data (Chapter 3). 
(2) Develop and optimise protocols for variant calling from NGS of FFPE-
DNA (Chapter 4). 
(3) Identify novel genetic markers of non-response to cetuximab (Chapter 5). 
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Chapter 2 - Materials and Methods 
2.1 Reagents and equipment. 
Table 2.1. Suppliers and reagents used during the course of this PhD. 
Supplier (location) Reagent 
4titude (Surrey, UK) 96-well non skirted PCR plate 
96-well skirted PCR plate 
PCR adhesive plate seal 
Agilent (California, USA) SureSelect All Exon 50 Mb enrichment kit 
SureSelect All Exon V2 enrichment kit 
BDH Laboratory Supplies 
(Poole, UK) 
Gill's haematoxylin 
Beckman Coulter Ltd (High 
Wycombe, UK) 
AMPure XP beads 
Bio-Rad (California, USA) Microseal 'A' adhesive film 
Biotium (California, USA) GelRed Nucleic acid gel stain 
Illumina (California, USA) Assay Control DNA 1 (ACD1) 
Assay control oligonucleotide pool (ACP1) 
Adapter collar 
Custom amplicon oligonucleotides (CAT) 
Elution buffer with Tris (EBT) 
Extension-ligation mix 4 (ELM4) 
Filter plate & lid 
Genome Analyser IIx 
HiSeq 2000 
Hybridisation buffer 1 (HT1) 
i5 primers 
i7 primers 
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Incorporation buffer 
Library normalisation additives 1 (LNA1) 
Library normalisation beads 1 (LNB1) 
Library normalisation storage buffer 2 (LNB2) 
Library normalisation wash 1 (LNW1) 
MiSeq reagent cartridge v2 (300/500 cycle) 
Oligonucleotide hybridisation for sequencing 2 
(OHS2) 
PE MiSeq flow cell 
PCR master mix 2 (PMM2) 
Stringent wash 1 (SW1) 
TruSeq DNA polymerase 1 (TDP1) 
Universal buffer 1 (UB1) 
Mettler Toledo (Ohio, USA) GPS-L10 (0.1 - 20 µl) pipette tips 
GPS-L1000 (20 - 1000 µl) pipette tips 
PR-1000 (100 - 1000 µl) pipette 
PR-2 (0.1 - 2 µl) pipette 
PR-20 (0.5 - 20 µl) pipette 
PR-200 (20 - 200 µl) pipette 
SS-L250 (2 - 20 µl) pipette tips 
Motic (Hong Kong, China) B3 Professional Series Digital Microscope 
New England Biolabs 
(Massachusetts, USA) 
Gel loading dye, orange (6x) 
uracil DNA glycosylase (UDG) 
QIAGEN (Manchester, UK) 2 ml collection tubes 
Buffer AL 
Buffer ATE 
Buffer ATL 
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Buffer AW1 
Buffer AW2 
MinElute column 
Proteinase K 
Roche Nimblegen (Wisconsin, 
USA) 
SeqCap EZ Exome capture kit V2 
Sigma-Aldrich (Missouri, USA) 1.5 ml microcentrifuge tubes 
DPX mountant 
Eosin Y solution 
Ethidium bromide (10 mg/ml diluted to 0.5 µg/ml) 
Ethylenediaminetetraacetic acid 
Thermo Fisher Scientific 
(Massachusetts, USA) 
96-well 0.8 ml MIDI plate 
Adhesive aluminium foil seal 
Agarose 
Dimethyl sulfoxide 
Ethanol 
Mineral oil 
NaOH 
Superfrost glass microscope slides 
Swann-Morton scalpel blades 
Tris base 
Xylene 
VWR International 
(Pennsylvania, USA) 
Acetic acid 
Cover glasses 
 
 54 
 
2.2 Patients and samples 
Patients used in this project had advanced or metastatic colorectal cancer and were 
enrolled within the MRC trials COIN (ISRCTN27286448) or COIN-B 
(ISRCTN38375681). Patients within COIN were randomised 1:1:1 into 3 arms; Arm A 
patients received continuous oxaliplatin and fluoropyrimidine chemotherapy, Arm B 
patients received continuous chemotherapy plus cetuximab, and Arm C patients were 
given chemotherapy intermittently. Patients in the COIN-B trial were given intermittent 
chemotherapy and randomised 1:1 into 2 arms; Arm D patients were also given 
intermittent cetuximab, whereas Arm E patients were also given cetuximab 
continuously. Informed consent was obtained from all patients for their samples to be 
used in bowel cancer research, as approved by REC [04/MRE06/60]. 
 
2.3 Identification of normal and tumour tissue within FFPE sections 
2.3.1 FFPE block sectioning 
Ten 5 µm sections of each normal and each tumour FFPE block were cut using a 
microtome and clean cutting blade. Each section was flattened by floating in warm 
water and then fixed to a microscope slide by air drying overnight.  
 
2.3.2 Haematoxylin and eosin staining of FFPE sections 
One slide per FFPE block was selected for staining. Slides were submerged in xylene 
for 5 minutes, and then in fresh xylene for a further 5 minutes. Slides were then dipped 
in 100% ethanol for 5 minutes, and repeated using fresh 100% ethanol. Slides were 
then submerged in 70% ethanol for 5 minutes, followed by 50% ethanol for a further 5 
minutes. Slides were bathed in Milli-Q treated H2O for 2 minutes, and for a further 2 
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minutes in fresh Milli-Q treated H2O. The slides were then immersed in Gill's 
haematoxylin for 30 seconds, and rinsed using H2O for 3 minutes. The slides were 
dipped in eosin Y solution for 10 seconds, and rinsed with H2O for 3 minutes. The 
stained slides were submerged in 50% ethanol for 1 minute, followed by 70% ethanol 
for 1 minute, 100% ethanol for 1 minute, and fresh 100% ethanol for 1 minute. Finally, 
slides were dipped in xylene for 1 minute, followed by fresh xylene for 1 minute. A 
cover slip was fixed to the slide using DPX mountant and allowed to air dry. 
 
2.3.3 Identification of tumour and normal tissue from FFPE sections 
Using a Motic B3 series digital microscope, tumour tissue in stained FFPE sections 
was identified by Dr. Christopher Smith, and was highlighted with a marker pen. 
Tumour tissue in each unstained slide was identified by overlaying with the stained 
section. Normal FFPE (nFFPE) tissue was confined using a digital microscope. 
 
2.3.4 Macrodissection of tissue from FFPE sections 
Tumour tissue was macrodissected using a scalpel blade and collected in a 1.5 ml 
microcentrifuge tube (1 per FFPE block). Normal tissue was macrodissected into clean 
1.5 ml microcentrifuge tubes. 
  
2.4 DNA extraction from FFPE sections. 
A QIAamp® DNA FFPE tissue kit (QIAGEN) was used for extraction of DNA from FFPE 
tissues. 1 ml xylene was added to each microcentrifuge tube containing FFPE tissue 
and vortexed for 10 seconds. The samples were centrifuged at 13,000 RPM for 2 
minutes and the supernatant discarded. 1 ml 100% ethanol was added to each tube 
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and vortexed. Samples were centrifuged at 13,000 RPM for 2 minutes and the 
supernatant was discarded. 
 
The samples were left at room temperature for 10 minutes or until the residual ethanol 
had evaporated. The pellet in each tube was re-suspended in 180 µl buffer ATL, and 20 
µl proteinase K was added. Samples were vortexed and incubated at 56°C for 1 hour. 
Samples were then incubated at 90°C for a further hour. 
 
The samples were centrifuged briefly and 200µl buffer AL was added, followed by 
vortexing. 200µl 100% ethanol was added to each sample and thoroughly vortexed. 
Each sample was transferred to a QIAamp MinElute column, placed inside 2 ml 
collection tubes, and centrifuged at 6,000 x g for 1 minute. The supernatant was 
discarded and the MinElute columns were placed inside clean 2 ml collection tubes. 
500 µl buffer AW1 was added to the MinElute column, which was centrifuged at 6,000 x 
g for 1 minute. 
 
The supernatant was discarded and the MinElute columns placed inside clean 2 ml 
collection tubes. 500 µl buffer AW2 was added to the columns and centrifuged at 6,000 
x g for 1 minute. The columns were placed inside clean 2 ml collection tubes and 
centrifuged at 20,000 x g for 3 minutes. The MinElute columns were placed inside 
clean 1.5 ml microcentrifuge tubes, 100 µl buffer ATE was added and incubated at 
room temperature for 1 minute. Samples were centrifuged at 20,000 x g for 1 minute 
and DNA was stored at -20°C. 
 57 
 
2.5 PCR and Sanger sequencing 
PCR was performed in 25-50 µl reaction volumes containing AmpliTaq Gold, 10-20 ng 
DNA and 10µM of primers For Sanger sequencing, single stranded DNA and excess 
dNTPs were removed using ExoSAP and reactions were cycle-sequenced using Big 
Dye Mix, purified using Montage sequencing clean-up plates and analysed on an ABI 
Prism 3100. 
 
2.6 Mutation analysis of KRAS, BRAF, NRAS and PIK3CA hotspots 
The mutation status at hotspots found in CRCs (deposited in COSMIC (Forbes et al. 
2008)) was determined in all tumour samples analysed in this project. These hotspots 
included codons 12, 13 and 61 of KRAS, codons 12 and 61 of NRAS, codons 594 and 
600 of BRAF, and codons 542, 545, 546 and 1047 of PIK3CA. Mutation status was 
determined either by pyrosequencing or Sequenom assays as previously described 
(Maughan et al. 2011; Smith, Fisher, et al. 2013). 
 
2.7 UDG treatment 
A minimum of 250 ng of tFFPE derived DNA was treated with 10U of uracil-DNA 
glycosylase (UDG) and 1x UDG buffer at 37°C. UDG was heat inactivated (95°C for 10 
minutes) and after cooling to room temperature, products were used in library 
preparation. 
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2.8 NGS protocols 
2.8.1 Exome sequencing 
Germline DNA samples for patients 1-40 were shipped to Beijing Genomics Institute 
(BGI) (Shenzhen, China) where whole exome sequencing was performed. 30/40 (75%) 
exomes were captured using a SureSelect All Exon V2 enrichment kit (Agilent) and 
sequenced using a HiSeq 2000 (Illumina). These 30 exomes were sequenced to a 
depth of ≥30x. A further 10/40 (25%) of the exomes were captured using a SureSelect 
All Exon 50 Mb enrichment kit (Agilent) and sequenced to ≥50x depth on a HiSeq 
2000. Germline samples for patients 41 - 50 were shipped to the University of North 
Carolina (USA) and their exomes captured using a SeqCap EZ Exome capture kit V2 
(Roche Nimblegen) and sequenced on an Illumina Genome Analyzer IIx (Illumina) to a 
depth of ~30x. 
 
2.8.2 Targeted sequencing 
2.8.2.1 Targeted sequencing panel design 
We designed a TruSeq custom amplicon (TSCA) kit (Illumina) that targeted four genes: 
KRAS, BRAF, NRAS and PIK3CA (panel 1). Amplicons targeting the coding exons of 
the 4 genes were designed using Illumina's DesignStudio software 
(http://bioinformatics.illumina.com/informatics/experimental-design/designstudio.html). 
A second panel, targeting the coding regions of 49 genes (listed in Table 2.2) was also 
designed. All amplicons were designed to average 175 bp in length. 
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2.8.2.2 DNA library preparation 
The TSCA library preparation guide ('revision B' or later) was followed to prepare a 
DNA library for use in NGS. Firstly, 5µl of the positive control sample ACD1 (Illumina), 
and 5µl dH2O were added to an empty well in a 96-well PCR plate (the HYP plate). A 
minimum of 250 ng of DNA from nFFPE and tFFPE, and 50 ng of gDNA was used for 
library preparation according to the manufacturer’s specifications (Illumina). 
 
5 µl of CAT was added to each well containing sample DNA, and 5 µl ACP1 was added 
to the well containing ACD1. 35 µl OSH2 was added to each sample and mixed. The 
plate was sealed with adhesive aluminium foil and centrifuged at 1,000 x g for 1 
minute. The plate was incubated at 95°C for 1 minute in a pre-heated block. With the 
plate still on the block, the temperature was set to 40°C and the plate incubated for a 
further 80 minutes. 
 
The filter plate unit (FPU) was assembled by placing the adapter collar over a clean 96-
well 0.8 ml MIDI plate and then placing a filter plate over the collar. 45 µl of SW1 was 
added to each well in the filter plate and the lid was placed over the FPU, followed by 
centrifugation at 2,400 x g for 10 minutes. After incubation, the HYP plate was 
centrifuged at 1,000 x g for 1 minute. 
 
The contents of each well in the HYP plate were transferred to the corresponding wells 
in the filter plate. The lid was placed on the filter plate and centrifuged at 2,400 x g for 2 
minutes. 45 µl of SW1 was added to each sample and centrifuged at 2,400 x g for 2 
minutes, and the flow through discarded. 45 µl of UB1 was added to each sample in 
the filter plate. The lid was placed back on the filter plate, which was then centrifuged at 
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2,400 x g for 2 minutes. 45 µl ELM3 was added to each well, the plate was sealed 
using an aluminium foil seal and incubated at 37°C for 45 minutes. After incubation, the 
aluminium seal was removed and the filter plate was centrifuged at 2,400 x g.  
 
25 µl of 50 mM NaOH was added to each well and pipette mixed 5 - 6 times. The filter 
plate was incubated at room temperature for 5 minutes, during which time a PCR 
master mix was made using 2.8 ml PMM2 and 56 µl TDP1 for every 96 samples. 4 µl of 
Illumina’s i5 Index primers were added to each column of a new indexed amplification 
(IAP) plate and 4 µl of i7 primers were added to each row of the IAP plate, so that each 
well contained a unique i5/i7 index combination. 22 µl of the master mix was added to 
each well of the IAP plate. 20 µl of each sample eluted from the filter plate were 
transferred to the IAP plate and pipette mixed with the PCR master mix. The IAP plate 
was sealed using microseal ‘A’ and centrifuged at 1,000 x g for 1 minute. 
 
PCR was started at 95°C for 3 minutes, followed by either 24 cycles (germline 
samples) or 29 cycles (FFPE samples) of 95°C for 30 seconds, 66°C for 30 seconds 
and 72°C for 1 minute, after which a final extension step of 72°C for 5 minutes was 
performed. 5 µl of PCR product was visualised on a 4% agarose gel. 
 
The IAP plate was centrifuged at 1,000 x g for 1 minute, and 60 µl of AMPure XP beads 
were added to wells in a new MIDI plate. The entire contents of the wells from the IAP 
plate were transferred to the new plate, which was then sealed and shaken at 1,800 
RPM for 2 minutes.  
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Table 2.2. Targeted gene panels for use in NGS. 
Panel Targeted genes 
1 KRAS, NRAS, BRAF, PIK3CA 
2 AKT1, AKT2, AKT3, ARAF, AREG, AXL, BCL2L11, BRAF, CBL, 
CDH1, DOK2, EGF, EGFR, ERBB2, ERBB3, EREG, FCGR2A, 
FCGR3A, FLT1, GAB1, GRB2, HRAS, IGF1, IGF1R, JAK1, 
JAK2, KDR, KRAS, MAP2K1, MAP2K2, MAPK1, MAPK3, MET, 
NCK1, NRAS, PDK1, PIK3CA, PLCG1, PLCG2, PRKCA, 
PRKCD, PTEN, RAF1, SHC1, SOS1, SRC, STAT1, STAT3, TP53 
 
The plate was stored without shaking at room temperature for 10 minutes, after which it 
was placed on a magnetic stand until the supernatant had cleared. With the plate still 
on the stand, the supernatant was removed using a pipette. Keeping the plate on the 
magnetic stand, an ethanol wash was performed by adding 200 µl 80% fresh ethanol to 
each well and the supernatant allowed to clear. The supernatant was removed and the 
ethanol wash step repeated. The supernatant was removed and excess ethanol 
removed via a pipette. The plate was removed from the stand and air dried for 10 
minutes. 
 
30 µl EBT was added to each well. The plate was sealed and shaken again at 1,800 
RPM for 2 minutes. A two minute incubation at room temperature was performed 
without shaking, and the plate was placed back on the magnetic stand. Once the 
supernatant had cleared, 20 µl from each well was transferred to a library normalisation 
MIDI plate (LNP), which was centrifuged at 1,000 x g for 1 minute. 
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800 µl of LNB1 was re-suspended by pipette mixing and added to 4.4 ml LNA1. 45 µl of 
the LNA1/LNB1 mix was added to each well in the LNP. The plate was sealed and 
shaken at 1,800 RPM for 30 minutes, after which it was placed on a magnetic stand 
until the supernatant cleared. Once clear, the supernatant was removed via pipette and 
the plate removed from the magnetic stand. The remaining beads in each of the wells 
were washed as follows; 45 µl LNW1 was added to each well, the plate was sealed and 
shaken at 1,800 RPM for 5 minutes. The plate was placed on the magnetic stand for 2 
minutes and the supernatant was removed. This was step was then repeated a second 
time. 
 
The plate was removed from the magnetic stand and 30 µl of freshly prepared 0.1 N 
NaOH was added to each well. The plate was sealed and shaken at 1,800 RPM for 5 
minutes. The LNP was placed back on the magnetic stand until the supernatant was 
clear. 30 µl of LNS2 was added to the wells of a new 96-well PCR plate, followed by 
transferral of the contents of the LNP to the new plate. The new plate was sealed and 
stored at -20°C for later use or was used immediately for library pooling (Chapter 2, 
Section 2.8.2.3). 
 
2.8.2.3 Library pooling 
The final plate containing the prepared library (Chapter 2, Section 2.8.2.2) was 
centrifuged at 1,000 x g for 1 minute and if the plate was frozen prior to use, the 
contents of each well were resuspended by pipette mixing. 5 µl of DNA from each well 
to be sequenced was pooled into a 1.5 ml centrifuge tube, which was vortexed briefly. 6 
µl of the pooled library was diluted in 594 µl of HT1, followed by vortexing thoroughly.  
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The diluted library was heated for 2 minutes at 96°C on a heat block, and immediately 
after the tube was placed in an ice-water bath for 5 minutes. 
 
2.8.2.4 Next generation sequencing 
At least five hours prior to loading the library onto the MiSeq, a MiSeq reagent cartridge 
was removed from -20°C storage and thawed in a water bath at room temperature. 
Sequencing was initially carried out by loading the dilute amplicon library (Chapter 2, 
Section 2.8.2.3) into the sample reservoir in a thawed 300- or 500-cycle MiSeq reagent 
cartridge (v2). Cartridges were loaded onto one of two independent Illumina MiSeq 
platforms (Illumina, USA); MiSeq 1 used the 500-cycle cartridge and 175 cycles of 
paired-end sequencing were performed whereas MiSeq 2 used the 300-cycle cartridge 
and 150 cycles of paired-end sequencing. Sequencing reads from MiSeq 1 were 
trimmed using Trimmomatic (Bolger et al. 2014). All subsequent runs were carried out 
using the 300 cycle kit (150 cycles). 
 
2.9 Bioinformatics and data analyses 
A bioinformatics pipeline for variant calling was established using BWA version 0.5.9 (Li 
& Durbin 2009), SAMtools version 0.1.18 (H. Li et al. 2009), GATK version 1.3-145 
(DePristo et al. 2011; McKenna et al. 2010) and SnpEff version 2.04 (Cingolani et al. 
2012). A custom Perl script was written to facilitate data parsing and analysis of 
pipeline output (Custom Script 1). All analysis was performed on a workstation running 
an Ubuntu operating system (version 11.10 or later). All software was run using the 
Unix command line, using default parameters unless specified differently. The data flow 
is shown in Figure 2.1. 
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2.9.1 Genome alignment 
BWA was used to first create an index of release GRCh37 of the human reference 
genome, using the bwa index command. Sequencing reads were then mapped to the 
reference genome using BWA's aln and sampe commands. In this step, each aligned 
read was tagged with the sample ID and the sequencing platform (Illumina). The output 
from this step was in sequence/alignment mapping (SAM) format. 
 
2.9.2 Data reformatting and base quality score recalibration 
SAMtools' view command was used to convert the SAM files to a smaller 
binary/alignment mapping (BAM) format. The BAM files were sorted by read name 
using samtools sort so that read mate coordinates and insert size could be added with 
samtools fixmate. The files were then resorted by genomic coordinates, again using the 
samtools sort command. For whole exome sequencing (Chapter 3), PCR duplicated 
reads were removed via the samtools rmdup command. SAMtools' index command 
was used to create an index for faster downstream access to each BAM file. 
 
Local realignment was performed on the sequencing reads using GATK's 
RealignerTargetCreator and IndelRealigner tools. BAM files generated at this stage 
were used for calculating depth of coverage and data metrics. The following steps were 
taken to recalibrate base quality scores for each of the exomes, as recommended in 
the GATK best practice documentation. GATK's CountCovariates tool was first used to 
generate a table of recalibrated quality scores. This tool suspects all sites which 
mismatch the reference genome are sequencing errors, so a list of known variants from 
dbSNP version 132 was used. Several factors were considered by this tool including 
the sequencing cycle, read group, quality score and dinucleotide covariates. The 
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TableRecalibration tool was then used to recalibrate the original base quality scores in 
the BAM file. 
 
2.9.3 Variant calling and quality score recalibration 
Variant calling was primarily performed using GATK's Unifed Genotyper or 
HaplotypeCallertool. Both single nucleotide variants (SNVs) and insertions/deletions 
(indels) were called. dbSNP version 132 or later was used to supply rsIDs for known 
variants. Variants were output in variant call format (VCF) files. 
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Figure 2.1. Flow of data through our bioinformatics pipeline. The purple arrow indicates 
the flow of data. Green boxes indicate individual steps in the pipeline, whereas red 
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boxes indicate the software used for each step. Blue boxes direct to the results chapter 
that each step was involved in. 
 
As recommended in the GATK best practices, variant quality score recalibration 
(VQSR) was performed. GATK's SelectVariants was used to separate SNPs and indels 
into two separate files. GATK's VariantRecalibrator was employed to recalibrate variant 
scores for SNPs, using training sites from HapMap release 3.3, Illumina's Omni2.5M 
SNP microarray and dbSNP. Prior probability values specified for each of these training 
datasets were 15, 12 and 8, respectively. VariantRecalibrator was used with the mG 4 
and percentBad 0.05 arguments specified as each exome was analysed individually, as 
recommended by GATK's best practices. The SNPs and their recalibrated scores were 
added to new VCF files using GATK's ApplyRecalibration tool, and the recalibrated 
SNPs were recombined with the indels from the original VCF file using 
CombineVariants. 
 
For somatic variant calling, we also used MuTect (Cibulskis et al. 2013). MuTect was 
used with default parameters from the command line, and given the reference human 
genome (GRCh37) and files containing variants in dbSNP and COSMIC. Only variants 
that passed MuTect's variant confidence filters were considered genuine, as 
determined by a ‘PASS’ label in the filter column of the output variant file.  
 
2.9.4 Variant annotation 
SnpEff (version 2.0.4 or later) was utilised, with default parameters and reference data 
from GRCh37.64, to perform variant annotation for variants after VQSR. GATK's 
VariantAnnotator was used to add the resulting annotations into the final VCF file for 
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each exome. Further annotation was performed using Custom Script 2, and allele 
frequencies from dbSNP, 1000 Genomes and COSMIC were added for each variant. 
The number of sequenced samples each variant was detected in was calculated, as 
well as presence in germline and/or tumour tissue. 
 
2.9.5 Depth of coverage calculations 
The exome capture kits used by BGI and University of North Carolina targeted exons 
within CCDS (Pruitt et al., 2006) and RefSeq (Pruitt, Tatusova, & Maglott, 2007). To 
calculate the coverage across a gene, coordinates of coding exons were extracted 
from CCDS release 9 or later (ftp://ftp.ncbi.nlm.nih.gov/pub/CCDS/current_human/, 
data made public 9/7/2011) and RefSeq Genes datasets (http://genome.ucsc.edu/, 
accessed 16/5/2012). Gene coordinates from CCDS were considered if the gene had a 
'public' status. For genes with multiple transcripts, the transcript with the most coding 
bases was chosen. The longest transcript of each gene in RefSeq was also chosen, 
providing a transcript for the gene had not already been obtained from CCDS.  
 
To calculate the average sequencing depth across a gene's open reading frame (ORF), 
a custom perl script (Custom Script 3) was written that integrated SAMtools' mpileup 
command. The script examined BAM files and extracted bases in realigned sequencing 
reads that mapped to an ORF of interest. The '-A', '-E' and '-Q 0' arguments were given 
to SAMtools so that anomalous reads were included, per-base quality scores were 
calculated at run time, and bases were excluded if they had a quality of ≤0. The total 
coverage for each coding base of an ORF was summed and divided by the length of 
the ORF to give the average coverage. The percent of the ORF reaching specified 
coverage depths was also calculated. Average depth across each exome was 
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calculated by summing the average ORF coverage and dividing by the number of 
ORFs. 
 
2.9.6 Bioinformatics pipeline comparison 
Using their own bioinformatics pipeline, BGI supplied variants calls for 10 exomes. For 
the same 10 exomes (using the same set of raw sequencing reads), we compared 
variants called by our pipeline to those called by BGI. A custom script (Custom Script 4) 
was written for this task. 
 
For each comparison, variants were classed as concordant if the genomic coordinates, 
reference allele, variant allele and the allele zygosity agreed between both call sets in 
the comparison. 
 
Variants called by our pipeline were broken down into four different subcategories 
including all SNPs, novel SNPs, all indels and novel indels. Variants were classed as 
novel (‘potentially pathogenic’) if they were not observed in dbSNP version 132. 
Concordance rates between call sets were calculated for each of the four 
subcategories separately. To increase the overlap between our variant call set and 
BGI's call set, we performed the variant calling step using GATK's Unified Genotyper 
with a minimum base quality (MBQ) parameter = 10 and a stand_emit_conf parameter 
= 10. 
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2.9.7 Calculating concordance with prior genotyping data 
Prior genotyping data was previously obtained using the Illumina GoldenGate assay for 
153 SNPs in 47/50 (94%) exomes. The genotypes called by our bioinformatics pipeline 
were used in a comparison against this data. To do this, Custom Script 5 was written. 
The rsID for each prior genotype were used to query dbSNP (version 135) to retrieve 
the genomic coordinates and known variant alleles for each assayed SNP. 
 
GATK's Unified Genotyper was used to call alleles at each of the 153 variant sites in 
the 47 exomes. Three parameter sets were used when running Unified Genotyper, the 
first being the default settings (minimum base quality = 17, variant score = 30). The 
second set of parameters tested used minimum base quality = 10 and variant score = 
10. The final set of tested parameters was identical to the second set, plus a per-base 
alignment quality (BAQ) calculation. 
 
2.9.8 Removal of off-target sequences 
Off-target reads were removed by isolating on target reads to new BAM files using 
Custom Script 6 (Chapter 5). Amplicon targets from the TruSeq Custom Amplicon 
Panel were used to define target regions. For targets that overlapped, a contiguous 
region covering the targets affected was created. Coordinates for the targets or 
contiguous regions were then used to isolate sequencing reads from individual BAM 
files; this was performed using SAMtools view. A sequencing read was designated as 
‘on target’ if one of the terminal (start or end) mapping coordinates matched one of the 
targets’ terminal coordinates. The opposite end of the read had to lie closer to the other 
terminus. Reads matching these criteria were isolated by printing to a new BAM file. 
Any reads that did not match these criteria was labelled as ‘off target’ and ignored.  
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2.9.9 Online resources 
COSMIC data: http://cancer.sanger.ac.uk/cosmic. 
CCDS data:ftp://ftp.ncbi.nlm.nih.gov/pub/CCDS/current_human/, data made public 
9/7/2011). 
RefSeq data obtained from: http://genome.ucsc.edu/, accessed 16/5/2012). 
 
  
Chapter 3 – Developing and testing a pipeline for variant calling from 
germline exome re-sequencing data 
 
3.1 Details of work performed 
In this chapter, exome sequencing was performed by BGI. Bioinformatics 
analyses were performed by myself, and in vitro validation (including PCR and 
Sanger sequencing) were performed by myself and Dr Christopher Smith. 
Genotyping of samples prior to exome sequencing was performed by Dr 
Christopher Smith. 
 
3.2 Introduction 
Sequencing the exome allows for sensitive and specific detection of common 
and rare variants. Ng et al. (2009) showed that in Mendelian disease, exome 
sequencing can identify candidate genes in small numbers of individuals. 
Timmermann et al. (2010) were amongst the first to show that the exome can 
be sequenced in primary colon cancers as well as normal colon tissue from the 
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same patient. Furthermore, they showed that rare (MAF <1%) or novel SNVs 
can be identified via this approach. Previously established methods, such as 
genotyping and Sanger sequencing, have developed to be highly specific, but 
may lack the power required to detect a large number of low frequency alleles 
simultaneously within a sample. NGS overcomes these draw backs, but many 
factors such as bioinformatic parameters may lead to inaccurate variant calls.  
 
Most bioinformatics pipelines follow a simple formula; this usually consists of 
sequencing read alignment, data formatting, variant calling and annotation. The 
HugeSeq pipeline (Lam et al. 2012) follows such a formula, using software such 
as BWA, SAMtools, Picard and GATK. Throughout this pipeline several steps 
are taken to ensure higher variant calling accuracy, including removal of PCR 
duplicates, local alignment around known indels and recalibration of base 
qualities. This pipeline and its underlying software have proven suitable for 
Illumina sequencing data (Lam et al. 2012). 
 
Other efforts have resulted in software suites accessible online such as Galaxy 
(Goecks et al. 2010; Giardine et al. 2005) that enable access to bioinformatics 
tools and high performance computing clusters. These suites enable users to 
upload data files, have it analysed on external hardware and have the output 
files returned. 
 
As our grand aim was to detect low frequency somatic mutations (Chapters 4 
and 5), we designed a workflow to ensure our pipeline parameters and 
protocols were rigourous enough to produce a highly sensitive call set. In this 
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chapter, we sought to adopt a pipeline and adapt parameters for highly accurate 
variant calling using exome re-sequencing data from 50 germline samples from 
patients with CRC. We then designed a series of custom scripts to measure 
metrics from our sequencing efforts. 
 
To ensure the exome re-sequencing data had sufficient coverage for reliable 
variant calling, we developed a script that calculated coverage over the exome. 
To measure the pipeline’s ability to call commonly-predicted and therefore 
genuine variants, we developed a script that compared variant calls to those of 
BGI’s pipeline. To test the accuracy of the predicted genotype for each variant 
call, a script was developed that compared predicted genotypes to previous 
genotyping results obtained on the Illumina GoldenGate platform. We then 
identified a series of potential disease causing variants from genes that were 
likely to play a role in colorectal tumourigenesis and determined whether these 
predicted variants were genuine by laboratory validation. 
 
3.3 Materials and methods 
3.3.1 Samples 
We prepared blood DNA samples from unrelated sporadic patients with aCRC 
from the UK-national, multi-centre, randomised controlled trials (RCTs) COIN 
(Maughan et al. 2011) and COIN-B (Adams et al. 2011) (Chapter 2, Section 
2.2). 
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3.3.2 Exome re-sequencing 
DNA samples from 40 patients were processed using Agilent's SureSelect 
Target Enrichment platform (10 with 50 Mb and 30 with 44 Mb capture kits) and 
sequenced on an Illumina HiSeq2000 (10 at ≥50x coverage and 30 at ≥30x 
coverage) by BGI (Hong Kong) (Chapter 2, Section 2.8.1). DNA samples from a 
further 10 patients were processed using the Roche Nimblegen SeqCap EZ 
Exome capture kit and sequenced on an Illumina Genome Analyser (at ~30x 
coverage) (Chapter 2, Section 2.8.1). 
 
3.3.3 Bioinformatics analyses 
Our default pipeline used the backtrack algorithm in BWA version 0.5.9 (Li & 
Durbin 2009) to align the paired-end reads to the reference genome and 
alignments were outputted in SAM format (Li et al. 2009) (Chapter 2, Section 
2.9.1). SAMtools version 0.1.18 (Li et al. 2009) was used for to sort reads in 
each BAM file by genomic coordinates and to remove PCR duplicated reads 
(Chapter 2, Section 2.9.2). Multiple BAM files  for a single patient were merged 
into a single file. The UnifiedGenotyper tool in the Genome Analysis Toolkit 
(GATK) version 1.3 (McKenna et al. 2010; DePristo et al. 2011) was used for 
with default parameters for variant calling. UnifiedGenotyper’s default 
parameters require bases to have a minimum base quality = 17 for inclusion in 
variant calling, and only outputs variants if they have a quality score ≥ 30. 
Variant quality score re-calibration was performed using GATK’s 
VariantRecalibrator and ApplyRecalibration tools with their default parameters 
(Chapter 2, Section 2.9.3). SnpEff (Cingolani et al. 2012) was used to annotate 
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variants and extra annotation was added with a custom Perl (Chapter 2, Section 
2.9.4). Extra annotation included the allele frequencies from the 1000 Genomes 
Project (1000 Genomes Project Consortium et al. 2015) and Exome 
Sequencing Project (EVS 2014) 
 
We optimised our pipeline parameters by relaxing the strictness of variant 
calling. For this, we lowered the minimum base Phred quality score considered 
by UnifiedGenotyper to 10. We also lowered the standard emitting quality score 
of variants to be included in the output VCF files to 10. 
 
Coverage across each exome (18,441 genes with public status in the CCDS 
(Pruitt et al. 2009) dataset and 4,871 genes in RefSeq (Pruitt et al. 2007)) and 
for the 1,138 genes considered likely to play a role in colorectal tumourigenesis 
was calculated using SAMtools in combination with a custom Perl script 
(Custom Script 3, Chapter 2, Section 2.9.5). 
 
To compare calls made by sequencing to genotypes produced on the 
GoldenGate platform, the UnifiedGenotyper tool was applied to the re-calibrated 
BAM files to emit all 153 analysed SNP sites regardless of genotype (Chapter 2, 
Section 2.9.7). Three parameter sets were tested. The first set used 
UnifiedGenotyper’s default settings and the second set used a minimum base 
quality = 10 and variant score = 10. The final parameters were identical to the 
second set with the addition of a per-base alignment quality calculation. 
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3.3.4 BGI pipeline 
BGI’s pipeline aligns sequencing reads to the reference human genome 
(version hg19) using SOAP/SOAP2 (R. Li et al. 2008; R. Li et al. 2009). A 
maximum of 3 mismatches per read were allowed, and the parameters –a, -b, -
D, -o, -u, -p, -2, -m, -x, -s 40, -l 35 and –v 3 were specified for this step. Reads 
in the resulting BAM files were sorted by genomic coordinates and duplicate 
reads were removed with Picard (http://picard.sourceforge.net). Where multiple 
BAM files were present for a single patient, the BAM files were merged. GATK’s 
RealignerTargetCreator and IndelRealigner tools (McKenna et al. 2010; 
DePristo et al. 2011) were used to realign reads mapping to the exome target 
region. GATK’s UnifiedGenotyper tool was used for variant calling with and 
variant filtering was performed with GATK’s VariantFiltration tool. BGI used 
default parameters for all GATK tools. 
 
3.3.5 PCR and Sanger sequencing 
To validate called variants, PCR and Sanger sequencing was carried out as 
previously described (Chapter 2, Section 2.5). 
 
3.4 Results 
3.4.1 Whole exome sequencing 
We exome re-sequenced blood DNA from 50 unrelated sporadic patients with 
aCRC that had been recruited into the UK-national, multi-centre RCTs COIN 
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and COIN-B (Table 3.1). Exomes were sequenced using two different NGS 
platforms (a GenomeAnalyser IIx and a Hiseq2000) and DNA enrichment kits. 
At 30x coverage, the GenomeAnalyser IIx yielded an average of 78,387,002 
reads per exome, whereas the HiSeq2000 sequenced 26,782,135 reads per 
exome. Exomes sequenced on the GenomeAnalyser IIx were sequenced to an 
average depth of 30.4x, whereas the Hiseq2000 sequenced to an average of 
24.5x and 44.5x using the SureSelect Human All Exon V2 and 50 Mb kits, 
respectively. 
 
On average, 46,179,764 paired-end sequencing reads were obtained per 
exome. From these, an average of 97.3% reads were mapped, of which 95.2% 
reads were successfully mapped as a correct mate pair (Table 3.1). A pipeline 
integrating BWA, SAMtools, GATK and SnpEff was established to produce a 
variant call set. A custom script (Custom Script 1) was written to manage data 
parsing throughout the pipeline. 
 
3.4.2 Sequencing coverage 
Custom Script 3 was written and used in conjunction with SAMtools to calculate 
coverage across each exome. From CCDS and RefSeq, 18,441 and 4,871 
coding genes were identified respectively, giving a total of 23,312 genes used in 
exome coverage calculations. Across all 50 samples sequenced, a mean depth 
of 30.2x (range 22.2–52.5x) was observed in coding regions within these genes. 
Average coverage was calculated across the ORF of each gene at varying 
depths. At 10x depth, 69.6% of each ORF was covered. At depths of 20x and 
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30x, 56.1% and 42.6% of ORFs were covered on average, respectively (Table 
3.1). 
 
 
Table 3.1. Summary of sequencing metrics for each exome. All platforms 
produced paired-end reads that mapped well and in correct pairs. Key: All Exon 
50Mb = SureSelect All Exon 50 Mb capture kit; All Exon V2 = SureSelect All 
Exon V2 capture kit; GAIIx = GenomeAnalyser IIx; SeqCap EZ = SeqCap EZ 
exome V2 capture kit. 
Sample 
ID 
Exon 
capture 
kit 
NGS 
platform Depth 
Sequencing 
reads 
Mapped 
reads 
(%) 
Correct 
mate 
pair (%) 
Average ORF (%) 
covered  
≥10x ≥20x ≥30x 
1 
All Exon 
V2 
Hiseq 
2000 25.3x 25,996,910 98.8 98.1 68.3 51.0 34.8 
2 
All Exon 
V2 
Hiseq 
2000 25.3x 26,018,786 98.9 98.3 69.0 51.7 35.3 
3 
All Exon 
V2 
Hiseq 
2000 25.1x 25,775,084 98.9 98.3 67.8 50.2 34.3 
4 
All Exon 
V2 
Hiseq 
2000 24.9x 29,112,742 98.3 97.4 67.3 49.6 33.9 
5 
All Exon 
V2 
Hiseq 
2000 25.2x 25,654,782 98.9 98.2 68.4 50.9 34.7 
6 
All Exon 
V2 
Hiseq 
2000 27.5x 24,227,224 98.2 97.4 68.6 52.2 36.9 
7 
All Exon 
V2 
Hiseq 
2000 47.7x 52,186,484 98.5 96.4 76.0 69.7 62.5 
8 
All Exon 
V2 
Hiseq 
2000 25.1x 25,567,114 98.8 98.2 67.6 50.0 34.3 
9 
All Exon 
V2 
Hiseq 
2000 25.1x 25,416,220 99.0 98.4 67.9 50.4 34.5 
10 
All Exon 
V2 
Hiseq 
2000 25.6x 24,145,266 97.6 96.6 67.3 49.3 33.7 
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11 
All Exon 
V2 
Hiseq 
2000 25.1x 26,246,846 98.8 98.1 68.5 50.9 34.5 
12 
All Exon 
V2 
Hiseq 
2000 25.3x 26,101,224 99.0 98.4 68.2 50.9 34.9 
13 
All Exon 
V2 
Hiseq 
2000 25.2x 25,945,522 98.9 98.3 68.9 51.6 35.1 
14 
All Exon 
V2 
Hiseq 
2000 25.2x 26,094,882 99.0 98.4 69.1 52.4 35.4 
15 
All Exon 
V2 
Hiseq 
2000 25.1x 25,655,404 99.0 98.5 68.7 51.2 34.7 
16 
All Exon 
V2 
Hiseq 
2000 25.2x 25,394,638 99.0 98.4 69.0 51.7 35.1 
17 
All Exon 
V2 
Hiseq 
2000 25.0x 26,080,956 99.0 98.5 68.9 51.4 34.7 
18 
All Exon 
V2 
Hiseq 
2000 25.0x 24,872,560 99.0 98.4 68.1 50.5 34.4 
19 
All Exon 
V2 
Hiseq 
2000 23.6x 26,679,426 98.0 94.5 67.3 50.8 34.0 
20 
All Exon 
50Mb 
Hiseq 
2000 43.6x 66,221,614 96.6 91.5 79.7 72.2 62.8 
21 
All Exon 
V2 
Hiseq 
2000 22.4x 27,109,810 98.0 94.5 66.1 48.7 31.6 
22 
SeqCap 
EZ GAIIx 22.8x 92,339,526 87.2 85.6 59.8 45.7 32.7 
23 
All Exon 
50Mb 
Hiseq 
2000 47.0x 76,298,952 97.1 93.5 80.6 73.9 65.7 
24 
All Exon 
V2 
Hiseq 
2000 23.2x 27,009,544 98.1 94.6 66.5 50.1 33.5 
25 
All Exon 
50Mb 
Hiseq 
2000 52.5x 88,964,856 97.8 94.5 80.8 75.3 69.4 
26 
All Exon 
50Mb 
Hiseq 
2000 46.4x 74,679,802 98.0 95.1 79.4 73.0 65.4 
27 
All Exon 
50Mb 
Hiseq 
2000 48.7x 79,180,926 97.6 94.4 81.2 75.1 67.7 
28 
All Exon 
V2 
Hiseq 
2000 22.2x 26,069,130 98.0 94.4 65.4 47.4 30.7 
29 
All Exon 
V2 
Hiseq 
2000 25.1x 34,822,078 97.6 93.9 67.7 52.4 36.9 
30 
All Exon 
50Mb 
Hiseq 
2000 38.6x 54,062,870 97.0 92.6 78.6 69.6 57.7 
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31 
All Exon 
V2 
Hiseq 
2000 22.3x 24,955,050 98.2 94.9 66.0 48.6 31.5 
32 
SeqCap 
EZ GAIIx 22.9x 78,608,136 89.9 88.0 62.6 48.8 34.0 
33 
All Exon 
V2 
Hiseq 
2000 23.0x 28,018,264 98.2 94.9 65.4 48.7 32.9 
34 
All Exon 
V2 
Hiseq 
2000 23.6x 29,585,984 98.0 94.5 66.5 50.2 34.1 
35 
All Exon 
V2 
Hiseq 
2000 22.4x 29,853,450 97.6 93.9 65.7 48.3 31.7 
36 
All Exon 
V2 
Hiseq 
2000 24.3x 28,797,442 98.0 94.3 66.8 51.0 35.4 
37 
All Exon 
50Mb 
Hiseq 
2000 47.1x 77,604,370 97.7 94.8 80.0 73.7 66.2 
38 
All Exon 
50Mb 
Hiseq 
2000 39.3x 57,691,734 96.8 92.1 78.6 70.1 58.9 
39 
All Exon 
V2 
Hiseq 
2000 23.4x 25,680,424 98.2 94.9 67.0 50.5 33.8 
40 
SeqCap 
EZ GAIIx 37.5x 83,998,846 95.9 95.4 66.0 59.6 52.2 
41 
All Exon 
50Mb 
Hiseq 
2000 36.6x 51,397,194 96.8 91.9 77.7 68.4 55.6 
42 
SeqCap 
EZ GAIIx 39.8x 93,383,898 96.0 95.4 65.1 58.6 51.9 
43 
SeqCap 
EZ GAIIx 34.1x 75,924,258 93.1 91.9 66.5 59.9 51.4 
44 
SeqCap 
EZ GAIIx 23.5x 64,212,086 94.1 91.7 63.9 49.8 35.0 
45 
SeqCap 
EZ GAIIx 29.4x 63,403,226 98.6 97.9 66.3 56.8 45.3 
46 
SeqCap 
EZ GAIIx 28.7x 62,329,802 98.2 97.3 66.1 56.3 44.3 
47 
All Exon 
50Mb 
Hiseq20
00 45.5x 70,147,450 97.4 93.8 80.2 73.5 65.1 
48 
SeqCap 
EZ GAIIx 26.3x 78,854,006 92.0 90.3 63.9 52.8 40.1 
49 
All Exon 
V2 
Hiseq 
2000 25.1x 29,795,162 98.2 95.1 68.0 52.8 37.1 
50 
SeqCap 
EZ GAIIx 39.0x 90,816,234 95.7 95.0 65.5 59.0 52.2 
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Mean -  -  30.2x 46,179,764 97.3 95.2 69.6 56.1 42.6 
 
 
3.4.3 Pipeline output comparisons 
For ten samples, we compared variant calls made through our pipeline to those 
that had independently been determined using the same raw sequencing reads 
through the pipeline at BGI. Using our pipeline with default parameters, we 
called 3.1-fold more SNPs and 3.2-fold more indels than BGI. Importantly, we 
detected on average 93.4% (45,407/48,636) and 94.1% (2,062/2,192) of BGI's 
SNPs and indels respectively. Of the novel variants, we detected on average 
59% (1,302/2,209) and 87.5% (673/769) of BGI’s SNPs and indels respectively.  
We optimised our pipeline’s parameter settings to increase the detected number 
of variants. The pipeline started with read alignment by BWA’s backtrack 
algorithm (Li & Durbin 2009), sorting reads by genomic coordinates and 
removing PCR duplicates by SAMtools (H. Li et al. 2009) Using optimised 
parameter settings (minimum base quality = 10 and variant quality = 10) we 
detected 1.6 fold more SNPs and 2.7 fold more novel SNPs than when using 
our default parameters. Using these optimised parameters, the overlap with 
BGI's pipeline output increased to 94.3% for SNPs and 94.7% for indels. For 
novel SNPs and indels, the overlap increased to 63.3% and 88.9%, respectively 
(Table 3.2, Figure 3.1).
 82 
 
 Figure 3.1. Venn diagrams showing the overlap between number of variants called by 
our pipeline (larger circles) and BGIs pipeline (smaller circles). Altering the parameters 
slightly reduced the number of variants called exclusively by BGI's pipeline.
 83 
 
Table 3.2. Comparisons between our pipeline’s call set and the call set produced by the BGI pipeline. MBQ, minimum base quality; stand_emit_conf, the confidence 
score used by GATK when emitting variants.  
 
    SNPs Indels 
Parameter set 
Sample 
ID 
All Novel All Novel 
  
Our 
pipeline 
BGI 
pipeline 
Overlap 
(%) 
Our 
pipeline 
BGI 
pipeline 
Overlap 
(%) 
Our 
pipeline 
BGI 
pipeline 
Overlap 
(%) 
Our 
pipeline 
BGI 
pipeline 
Overlap 
(%) 
Default (MBQ 
17, 
stand_emit_conf 
10) 
20 121,449 48,306 92.9 10,359 2,427 56.9 5,577 2,052 93.7 886 692 86.9 
23 154,359 50,640 92.7 12,515 2,415 56.2 7,345 2,221 94.3 1,203 784 88.9 
25 160,078 52,642 91.7 12,251 2,739 49.9 8,346 2,377 94.8 1,372 859 88.4 
26 157,857 44,126 96.4 12,893 1,113 75.6 8,767 2,435 93.9 1,441 895 87.5 
27 152,419 47,323 96.8 41,005 1,585 80.8 8,109 2,315 94.7 1,442 812 89.0 
30 118,135 46,976 92.8 9,374 2,274 54.7 5,103 1,932 93.4 776 649 85.5 
37 157,362 51,326 91.6 13,030 2,604 51.5 8,039 2,252 94.8 1,363 799 88.4 
38 122,453 48,110 92.7 9,053 2,363 54.0 5,626 2,077 93.4 828 723 85.5 
41 114,478 46,799 92.8 8,957 2,239 55.5 5,282 1,987 93.3 767 663 86.4 
47 146,902 50,110 92.5 11,471 2,329 54.5 6,984 2,269 94.2 1,151 811 88.9 
Average 149,874 48,636 93.4 14,091 2,209 59.0 6,918 2,192 94.1 1,123 769 87.5 
Altered (MBQ 20 220,462 48,306 93.9 43,119 2,427 61.4 5,830 2,052 94.4 1,017 692 88.4 
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10, 
stand_emit_conf 
10) 
23 253,853 50,640 93.6 45,554 2,415 60.5 7,736 2,221 95.1 1,418 784 89.9 
25 298,625 52,642 92.6 36,861 2,739 54.3 8,783 2,377 95.3 1,608 859 89.5 
26 269,242 44,126 97.2 36,674 1,113 81.4 9,303 2,435 94.7 1,740 895 89.4 
27 245,668 47,323 97.5 41,005 1,585 80.8 8,109 2,315 94.7 1,442 812 89.0 
30 206,528 46,976 93.9 33,848 2,274 59.9 5,363 1,932 94.0 897 649 87.1 
37 250,756 51,326 92.6 34,624 2,604 56.3 8,469 2,252 95.4 1,606 799 90.0 
38 217,709 48,110 93.8 33,145 2,363 58.7 5,928 2,077 94.1 967 723 86.9 
41 201,095 46,799 93.8 28,616 2,239 60.4 5,568 1,987 94.5 915 663 89.0 
47 265,024 50,110 93.5 47,155 2,329 59.2 7,373 2,269 94.8 1,348 811 90.0 
Average 242,896 48,636 94.3 38,060 2,209 63.3 7,246 2,192 94.7 1,296 769 88.9 
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3.4.4 Genotype concordance 
47/50 (94%) of the aCRC patients had previously been genotyped for 153 
coding region SNPs with MAFs >5%, spanning a total of 97 genes, using the 
Illumina Goldengate platform (San Diego, CA) (our unpublished data). We 
compared the genotypes to the calls made from our exome re-sequencing 
pipeline (after excluding low confidence calls or those with <4x coverage). 
Using our default parameters, 6,739 genotypes were called, of which, 6,723 
(99.76%) were concordant. Using the second set of parameters (minimum base 
quality = 10 and variant quality = 10), 6,739 genotypes were called and from 
these, 6,724 (99.78%) calls were concordant. The final set of parameters tested 
(minimum base quality = 10, variant quality = 10 and enabling a BAQ 
calculation) produced 6,736 genotypes, of which 6,720 (99.76%) were 
concordant (Table 3.3). 
 
Across all 3 parameter settings, there was a total of 17 discrepancies between 
previous genotyping and our sequencing data. The majority (n = 10 
inconsistencies, 59%) of these had a low sequencing depth (≤8x). A further 4 
inconsistencies (23%) were due to variants being incorrectly called by our 
pipeline as heterozygous due to a fraction of reads exhibiting mutant alleles; 
mutant:wild-type allele ratios ranged from 1:7 to 1:11. The final 3 discrepancies 
(18%) had a low quality score (quality by depth <5). 
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3.4.5 In vitro validation of variants predicted in silico 
We studied 1,138 genes that were likely to be involved in colorectal 
tumourigenesis to determine the accuracy of our pipeline's variant calls to 
identify potentially disease-causing mutations, which we defined as rare (minor 
allele frequency [MAF] ≤1%) or novel variants that were predicted to truncate 
the encoded protein. Genes included were from the base excision repair (BER) 
pathway (141 genes), the mismatch repair (MMR) pathway (28 genes), the Wnt 
signalling pathway (82 genes), the bone morphogenetic protein (BMP) 
signalling pathway (79 genes), the Notch signalling pathway (73 genes), and 
other pathways implicated through genome-wide association studies (GWAS, 
220 genes) (Figure 3.2; Smith et al. 2013). From transposon-based screens in 
mice (March et al. 2011) a further 545 genes were identified. Note that some 
genes were found in multiple studies or pathways, so overall 1,138 genes in 
total were included in our analyses. 
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Table 3.3. The concordances between genotyping carried out using Illumina’s 
GoldenGate assay and variant calls from our pipeline. When calling variants, we 
used 3 different sets of parameters. 
Pipeline 
parameters 
Default 
MBQ = 10, emitting 
threshold = 10 
MBQ = 10, emitting 
threshold = 10, BAQ 
calculation on 
Sample ID 
Concordant 
calls 
% 
Concordant 
calls 
% 
Concordant 
calls 
% 
1 143/143 100.0 143/143 100.0 143/143 100.0 
2 143/143 100.0 143/143 100.0 142/142 100.0 
3 145/146 99.3 145/146 99.3 145/146 99.3 
4 142/142 100.0 142/142 100.0 142/142 100.0 
5 146/147 99.0 146/147 99.3 146/147 99.3 
6 139/139 100.0 139/139 100.0 139/139 100.0 
7 146/146 100.0 146/146 100.0 146/146 100.0 
8 138/138 100.0 138/138 100.0 138/138 100.0 
9 143/143 100.0 143/143 100.0 143/143 100.0 
10 143/144 99.3 143/144 99.3 142/143 99.3 
11 143/144 99.3 143/144 99.3 143/145 98.6 
12 138/139 99.0 138/139 99.3 138/139 99.3 
13 148/148 100.0 148/148 100.0 147/147 100.0 
14 146/148 98.7 145/147 98.6 145/147 98.6 
15 145/145 100.0 145/145 100.0 145/145 100.0 
16 147/147 100.0 147/147 100.0 147/147 100.0 
17 142/144 99.0 142/144 98.6 142/144 98.6 
18 145/145 100.0 145/145 100.0 145/145 100.0 
19 145/145 100.0 145/145 100.0 144/144 100.0 
20 0/0 - 0/0 - 0/0 - 
21 141/141 100.0 141/141 100.0 141/141 100.0 
22 130/130 100.0 131/131 100.0 130/130 100.0 
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23 152/152 100.0 152/152 100.0 152/152 100.0 
24 143/143 100.0 143/143 100.0 143/143 100.0 
25 151/151 100.0 151/151 100.0 151/151 100.0 
26 152/152 100.0 152/152 100.0 152/152 100.0 
27 152/152 100.0 152/152 100.0 152/152 100.0 
28 147/147 100.0 147/147 100.0 147/147 100.0 
29 144/144 100.0 144/144 100.0 144/144 100.0 
30 150/151 99.3 150/151 99.3 150/151 99.3 
31 145/146 99.3 145/146 99.3 145/146 99.3 
32 136/136 100.0 136/136 100.0 136/136 100.0 
33 139/140 99.3 139/140 99.3 139/140 99.3 
34 143/143 100.0 143/143 100.0 143/143 100.0 
35 145/145 100.0 145/145 100.0 145/145 100.0 
36 0/0 - 0/0 - 0/0 - 
37 152/152 100.0 152/152 100.0 152/152 100.0 
38 149/149 100.0 149/149 100.0 149/149 100.0 
39 142/142 100.0 142/142 100.0 142/142 100.0 
40 136/137 99.0 136/136 100.0 135/135 100.0 
41 150/150 100.0 150/150 100.0 150/150 100.0 
42 136/136 100.0 136/136 100.0 136/136 100.0 
43 135/135 100.0 135/135 100.0 135/135 100.0 
44 133/133 100.0 133/133 100.0 134/134 100.0 
45 136/136 100.0 136/136 100.0 136/136 100.0 
46 131/131 100.0 131/131 100.0 131/131 100.0 
47 152/152 100.0 152/152 100.0 152/152 100.0 
48 131/134 97.8 131/134 97.8 132/135 97.8 
49 143/143 100.0 144/144 100.0 144/144 100.0 
50 0/0 - 0/0 - 0/0 - 
Total 6723/6739 99.8 6724/6739 99.8 6720/6736 99.8 
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Figure 3.2. The 1,138 genes likely to play a role in colorectal tumourigenesis 
(Smith, Naven, et al. 2013), distributed by pathway or study. The shaded circle 
indicates a gene common to both the BMP signalling and GWAS related 
groups. Reproduced with permission; data were gathered and the figure was 
produced by Dr Christopher Smith. 
 
The average depth of coverage across the 1,138 colorectal tumourigenesis 
genes was 35x. The percent of coding bases in the ORFs covered to ≥10x was 
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83.3%, and at ≥20x was 67.7%. Figure 3.3 (Smith, Naven, et al. 2013) 
graphically represents coverage statistics at ≥20x depth for the entire subset, 
with genes grouped by pathway or study. Average coverage of the ORFs at 
≥20x depth was similar between groups. 
 
From the 1,138 genes, and using our optimised parameters, 23 novel or rare 
nonsense mutations, 16 splice site mutations and 30 indels were predicted 
(Table 3.4). Sanger sequencing confirmed that 12 (52.2%) of the nonsense 
variants were present in the germline DNA. Examples of confirmed variants are 
shown in Figure 3.4. The remaining 11 (47.8%) nonsense variants could not be 
validated, and 8 of these were of low quality with quality by depth scores < 10. 
Figure 3.5 shows examples of variants that could not be validated. 
 
Of the splice site mutations, 5 (31.3%) of these variants were true positives (3 
were at splice acceptor sites and the other 2 were at splice donor sites), and all 
were likely to affect function as they were predicted to cause truncation of or 
skipping of substantial portions of the ORF. From the remaining splice site 
variants, eight (50%) could not be validated, 7 of which had low quality by depth 
scores <10 (one had a quality by depth score of 11.2). The final 3 (18.8%) splice 
site variants failed amplification and so could not be validated experimentally. Of 
the 30 rare or novel indels, 20 were validated. The remaining 10 (33.4%) were 
situated at loci with low sequence complexity; these loci often contained short 
repeats of 2-3 bases or homopolymer runs (>3 bases). 
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Figure 3.3. Percentages of the open reading frame covered to a depth of ≥20x 
of 1,138 genes likely to play a role in CRC tumourigenesis (Smith, Naven, et al. 
2013). Genes are grouped by pathway or type of study. The average percent of 
the ORFs sequenced at ≥20x coverage, along with the average coverage, is 
shown for each group of genes. Reproduced with permission, with minor 
modification; data were generated by myself and the figure was produced by 
myself.  
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Table 3.4. Rare or novel truncating variants identified in 1,138 genes likely to 
play a role in colorectal tumourigenesis were predicted by our pipeline. The 
original DNA samples were then assayed via Sanger sequencing in order to 
validate the predictions.  
 
Variant type 
Total 
Nonsense Splice site Indel 
Predicted 23 16 30 69 
Validated 12  5  20  37  
Validated 
(%) 
52.2% 31.3% 66.7% 53.6% 
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b 
a 
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Figure 3.4. Sanger sequencing confirmed the presence of a g.32561313C>T 
and a g.32561316G>T nonsense mutation carried by the same patient (a). The 
presence of a g.58386929_58386932dupTAAT insertion was also confirmed in 
a separate patient (b). The insertion site is marked in the chromatogram by a 
black arrow and vertical line, and in the NGS reads as a series of purple 
indicators. 
 
Figure 3.5. An NC_000014.8:g.105612306C>T mutation could not be validated by 
Sanger sequencing (a). Visual inspection of the NGS reads revealed the locus had low 
sequencing depth. A separate NC_000012.11:g.124838727G>T variant (b) could also 
not be detected via Sanger sequencing, and again the NGS data revealed low depth. 
a 
b 
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3.5 Discussion 
To obtain a highly specific, reliable variant call set a bioinformatics pipeline was 
adopted and sets of parameters rigourously tested. Our pipeline utilised the 
publicly available BWA, SAMtools, GATK and SnpEff software, along with 
several in-house Perl scripts used for data parsing and custom analysis. For 
sensitive detection of germline variants, we recommend mapping reads using 
BWA’s backtrack algorithm (Li & Durbin 2009). Mapping of the sequencing 
reads with BWA worked well, with 97.3% of all reads mapped to release 
GRCh37 of the human genome (96.2% of reads were mapped in the correct 
mate pair).  
 
Due to the wide array of tools available, major differences in variant calling 
pipelines are usually found at the alignment phase. Each tool generally works in 
a unique way; SOAP, as used for BGI for example, can trim the 3-‘ end of reads 
in order to avoid the problem of decreasing quality towards the end of the read 
(Fonseca et al. 2012). We aligned reads with BWA, which doesn’t trim reads, 
and have shown that calling variants from bases with lower quality scores 
results in >3 fold more variants than called by BGI. Mapping tools used are 
therefore a good candidate for the observed differences in number of variants 
predicted. 
 
For exome sequencing data, removing PCR duplicates using SAMtools is 
advised prior to realignment of reads around known indels. Removal of 
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duplicates will help to lower false positive variant calls that arise due to PCR 
artefacts. Local realignment of reads around know indels is advantageous as is 
base quality score recalibration, performed with GATK, and so these steps are 
also recommended (Li 2014; DePristo et al. 2011).  
 
For germline variant calling, we found that lowering the minimum base quality 
required to include a base in variant calling allowed for much more overlap with 
BGI’s pipeline. However, many more variants were called that were not in BGI’s 
call set. Using the lower base quality score parameter we only increased our 
concordance with known genotypes by 1 call out of >6,000. The effort required 
to filter false positives therefore outweighs the benefit of obtaining a very 
minimal increase in true positive rate.  
 
The combined average depth of coverage across our exomes averaged 30.2x, 
which provided enough data for reliable variant calling. This was proven by our 
comparisons with previously obtained genotyping data, which showed a 99.8% 
concordance rate and was consistent across parameter settings. The majority 
of the differences were primarily due to a sequencing depth of ≤8x. These 
factors suggest our pipeline has excellent capabilities of calling variants 
accurately across samples sequenced on multiple sequencers, and processed 
using different enrichment kits.  
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The comparisons between data from our pipeline and BGI's pipeline show that 
we were able to call the majority of variants called by BGI. We successfully 
found 93.4% and 94.1% of BGI's SNPs and indels, respectively, using the 
default parameters. However, when looking at the rare, potentially pathogenic 
variants, we only found 59.0% and 87.5% of their SNPs and indels respectively. 
We therefore modified parameters of our variant calling step and increased the 
overlap with BGI's novel SNPs and novel indels to 63.3% and 88.9%, 
respectively. While this also increased the average number of variants we called 
per exome by around 93,000, we anticipated many of these extra calls being 
false positives and so allowed variants with low quality scores to be marked for 
later filtering. The false positive rates were considered when attempting to 
validate predicted variants in vitro. 
 
From the analysis of 1,138 genes likely to be involved in colorectal 
tumourigenesis, we identified 69 variants which were novel or had a MAF ≤1% 
and we were able to validate 37 (53.6%) of these by experimentally re-assaying 
the original gDNA used for exome sequencing. Interestingly, we were able to 
validate 66.7% of predicted indels, which are notoriously difficult to call 
accurately. Other studies have attempted to validate variants called from NGS 
data using Sanger sequencing and shown that multiple factors affect validation 
rates. Park et al. (2014) conclude that around 66% of variants called by GATK 
could be validated, and variants are more likely to be validated if they have both 
high read depth and high quality scores. Other factors, such as higher mapping 
quality and performing read realignment positively impacted upon validation 
rates (Park et al. 2014). Other work (Zhang et al. 2015) has shown that 
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sequencing platform and analysis pipeline effect validation rates; calling SNPs 
using GATK from paired-end exome data after mapping with BWA’s paired-end 
or single-end mode gave respective validation rates of 90% and 86.6%. Exome 
capture methods and sequencer have also been considered; exomes 
sequenced using Agilent’s SureSelect Human All Exon kit and Illumina’s HiSeq 
2000 gave an 88.3% SNP validation rate, whereas capturing exomes using the 
Ion TargetSeq and sequencing on the Ion Proton sequencer gave a 60% 
validation rate. 89.6% and 15.8% of indels called from HiSeq and Ion Proton 
data were validated, respectively (Zhang et al. 2015).  
 
Together, our work shows that our approach using NGS and bioinformatic 
analyses are acceptable for detecting common polymorphisms as well as rare 
or novel potentially disease causing alleles.  
 
Chapter 4 - Development of next generation sequencing protocols to 
identify somatic mutations in formalin-fixed paraffin-embedded tumours 
 
4.1 Details of work performed 
Sectioning of FFPE blocks, slide staining and DNA extraction was performed by 
myself and Dr Christopher Smith. Library preparation and sequencing of all 
samples was performed by myself, Dr Christopher Smith and Shelley Rundle. 
Bioinformatics and downstream analyses was performed by myself. 
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4.2 Introduction 
Comprehensive and accurate profiling of a patient’s tumour is essential for 
stratification of targeted therapies. For example, patients carrying KRAS or 
NRAS mutations fail to respond to cetuximab (an anti-EGFR antibody) used in 
the treatment of advanced CRC (aCRC) (Karapetis et al. 2008; De Roock, 
Claes, et al. 2010). Similarly, in non-small-cell lung cancer, response to the 
tyrosine kinase inhibitor gefitinib (which targets EGFR's tyrosine kinase domain) 
is increased in patients harbouring particular somatic EGFR mutations (Lynch et 
al. 2004). Many of these mutations cause single amino acid substitutions or 
small in-frame deletions close to the ATP-binding region of EGFR's tyrosine 
kinase domain; this leads to not only increased sensitivity to gefitinib but also 
increased EGFR signalling (Lynch et al. 2004).  
 
The majority of tumour samples available for molecular analyses are from FFPE 
tissues. Cellular DNA is normally damaged during processing causing it to be 
fragmented (Wong et al. 2013) and contain formaldehyde induced cross-links 
(Fraenkel-Conrat & Olcott 1948), abasic sites (Zsikla et al, 2004) and 
deaminated cytosines (Chen 2014) (Chapter 1, Section 1.5.2). These lesions 
reduce the quality and quantity of DNA available for subsequent amplification. 
Furthermore, contamination with normal stroma is often unavoidable (Gerlinger 
et al. 2012), resulting in low levels of mutant alleles. Therefore, molecular 
profiling of DNA from FFPE tumours is technically challenging. 
 
Mutation analysis of FFPE derived DNA has, until recently, largely depended 
upon the use of technologies that interrogate only a small genomic region or 
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number of ‘hotspot’ mutations (e.g. Sanger sequencing and pyrosequencing). 
However, the advent of high-throughput NGS has seen a paradigm shift with 
researchers taking advantage of the increased genomic coverage and higher 
sensitivity (Voelkerding et al. 2009). This means that NGS work flows and 
variant calling pipelines have to deliver high quality results for routine use in 
patient stratification. 
 
Here, we tested NGS of DNA from FFPE material to identify previously 
characterised somatic mutations in patients with aCRC and to develop robust 
strategies for the identification of novel somatic mutations amongst the 
background of FFPE-associated artefacts. 
 
4.3 Materials and methods 
4.3.1 Patients and samples 
Patients were from the MRC trials COIN and COIN-B for the treatment of aCRC 
(Chapter 2, Section 2.2). The somatic mutation status of KRAS (codons 12, 13 
and 61), BRAF (codons 594 and 600), NRAS (codons 12 and 61) and PIK3CA 
(codons 542, 545, 546 and 1047) was previously determined in tumour samples 
from these patients using pyrosequencing (QIAGEN) and MALDI-TOF MS 
(Sequenom) technologies (Maughan et al. 2011; Smith et al. 2013) (Chapter 2, 
Section 2.6). Here, we analysed germline blood DNA (gDNA), and DNA from 
nFFPE colon and tFFPE CRCs from 19 patients that carried (Table 4.1) and 19 
that did not carry such mutations. 
 
 101 
 
Table 4.1 Previously determined somatic mutations in KRAS, NRAS, BRAF and 
PIK3CA from 19 CRC patients (Smith et al. 2013). 
 
Patient ID 
 
Previously determined mutations 
KRAS BRAF NRAS PIK3CA 
19 WT WT WT p.E545K 
51 p.G12D WT WT WT 
52 p.G12V WT WT WT 
53 WT p.V600E WT WT 
54 p.G13D WT WT WT 
55 p.G12V WT WT p.H1047R 
56 p.G12D WT WT WT 
57 p.G12D WT WT p.E545K, 
58 WT WT p.Q61K p.H1047R 
59 p.G12D WT WT p.E545K 
60 p.G12D WT WT p.E545K 
61 p.G13D WT WT WT 
62 p.G13D WT WT WT 
63 p.G13D WT WT WT 
64 p.G13D WT WT WT 
65 p.G12V WT WT p.E545K 
66 WT p.D594G WT WT 
67 WT WT WT p.H1047R 
68 WT WT WT p.E545K 
 
 
gDNA was extracted from blood samples as previously described (Maughan et 
al. 2011). DNA extraction from tFFPE and nFFPE specimens was carried out as 
described in Chapter 2, Section 2.4. 
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4.3.2 UDG treatment 
A minimum of 250 ng of tFFPE derived DNA was treated with 10U of UDG as 
described (Chapter 2, Section 2.7). 
 
4.3.3 TruSeq Custom Amplicon (TSCA) design, library preparation and 
sequencing 
Custom amplicons spanning the open reading frames of KRAS, BRAF, NRAS 
and PIK3CA were designed using Illumina’s DesignStudio software (Chapter 2, 
Section 2.8.2.1). Where possible, oligonucleotide probes were designed to 
regions free of known common polymorphisms. Library preparation and NGS 
was carried out as described (Chapter 2, Sections 2.8.2.2 – 2.8.2.4). 
 
 
4.3.4 Bioinformatics and variant calling 
Sequencing data were processed through our variant calling pipeline (Chapter 
2, Section 2.9, Smith et al. 2013). Briefly, reads were aligned to the reference 
human genome (GRCh37) using BWA's (Li & Durbin 2009) backtrack algorithm, 
SAMtools (H. Li et al. 2009) was used to convert files to BAM format, to which 
paired end information was added (Chapter 2, Section 2.9.2). SAMtools was 
also used to sort reads by genomic coordinates. GATK's 
RealignerTargetCreator (McKenna et al. 2010) identified reads mapping to 
regions containing known indels and IndelRealigner realigned those reads. 
GATK's BaseRecalibrator recalibrated base quality scores across all reads 
(Chapter 2, Section 2.9.2). Variant calling was performed for each sample using 
GATK's HaplotypeCaller. The MiSeq Somatic Variant Caller software (on board 
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MiSeq 1) was also used to call variants for all samples sequenced on MiSeq 1. 
SnpEff (Cingolani et al. 2012) and GATK's VariantAnnotator were used to 
annotate the variants in the resulting VCF files (Chapter 2, Section 2.4). All 
software up to this point were used with their default parameters. Custom Perl 
scripts were written to facilitate all bespoke analyses and data parsing (Chapter 
2, Section 2.9). 
 
4.4 Results 
We initially analysed blood gDNA from 19 patients with aCRC together with 
DNA from their normal healthy colon and tumour tissue that had undergone 
FFPE treatment (nFFPE and tFFPE, respectively). These patients’ tumours 
carried a total of 25 somatic mutations in KRAS, BRAF, NRAS and PIK3CA, as 
previously determined by Pyrosequencing or Sequenom (Smith et al. 2013). 
Thirteen CRCs had KRAS mutations (5x p.G12D, 3x p.G12V, 5x p.G13D), two 
had BRAF mutations (1x p.D594G, 1x p.V600E), one had an NRAS mutation 
(p.Q61K) and nine had PIK3CA mutations (6x p.E545K, 3x p.H1047R). We 
carried out NGS of these samples on a custom TSCA panel targeting the ORF 
of KRAS, BRAF, NRAS and PIK3CA and analysed the libraries on two MiSeq 
sequencers (with 150 bp [MiSeq 2] and 175 bp [MiSeq 1] read length settings). 
Output metrics for MiSeq 1 and MiSeq 2, respectively, were as follows; 7.5 Mb 
vs. 6.2 Mb of sequencing data produced, average base quality 32.9 vs. 32.1 for 
gDNA, 33.5 vs. 33.1 for nFFPE, and 33.7 vs. 32.8 for tFFPE, and mean 
sequencing depth 4288x vs. 3666.3x for gDNA, 2913.5x vs. 2419.2x for nFFPE, 
and 3174x vs. 2769.8x for tFFPE (Tables 4.2 and 4.3). There was a higher 
mean coverage for gDNA as compared to DNA from FFPE processed samples.  
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4.4.1 Mapping reads 
As expected, average read lengths from MiSeq 1 and MiSeq 2 were different 
(176 bp and 151 bp, respectively; Table 4.2) due to the different cycle settings 
used initially. Although both sequencers produced reads with mapping scores 
>30 (the threshold at which 1 in 1000 reads is likely to be mapped incorrectly; 
Table 4.4), reads mapping to PIK3CA or BRAF had considerably lower mapping 
scores from MiSeq 1 than from MiSeq 2 (Figure 4.1a). In addition, more reads 
from MiSeq 2 mapped in the correct paired-end style than those from MiSeq 1 
(Figure 4.1b, Table 4.5). There were no notable differences between tissues, 
suggesting that the problem was not FFPE related. Using Integrative Genomics 
Viewer (IGV) software (Thorvaldsdóttir et al. 2013; Robinson et al. 2011) we 
found numerous reads sequenced on MiSeq 1 were labelled as incorrectly 
mapped and contained 3' overhangs that did not match the reference sequence 
(Figure 4.2a).
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Table 4.2. Sequencing metrics for runs on two MiSeqs using the same libraries prepared from 19 patients with known somatic mutations. 
* We used 500 (MiSeq1) or 300 (MiSeq2) cycle reagent cartridges. 
Sequencing run   MiSeq 1    MiSeq 2  
Tissue type   gDNA nFFPE tFFPE  gDNA nFFPE tFFPE 
Mb sequenced   3.3 2.2 2.0  2.6 1.7 1.9 
No. reads   18724 12745 11560  17002 11545 12479 
Read length*   176 176 176  151 151 151 
Base quality   32.9 33.5 33.7  32.1 33.1 32.8 
         
Average depth of targets   4288 2913.5 3174  3666.3 2419.2 2769.8  
% ORF at 1000x coverage of         
KRAS   94.0 70.0 80.9  92.6 69.7 68.2 
BRAF  86.5 70.4 80.9  90.5 66.6 78.0 
NRAS  76.2 79.8 79.0  83.5 72.1 79.6 
PIK3CA  95.0 88.2 91.8  94.2 82.2 87.7 
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Table 4.3. Average depth of coverage (by individual sample on MiSeq1). 
FFPE tissues typically had lower depths of coverage than their gDNA 
counterparts. The five samples with high levels of C:G>T:A artefacts 
(shaded) did not show higher than average sequencing depths. 
 
Sample 
gDNA 
average 
nFFPE 
average 
tFFPE average 
67 4,395.2 1,371.6 4,087.5 
51 3,998.5 3,364.0 2,731.1 
68 4,969.7 2,884.9 3,864.5 
52 4,527.0 3,491.5 4,060.9 
53 4,010.2 4,099.9 4,471.9 
54 4,110.2 3,596.0 2,981.0 
55 4,314.3 1,244.6 1,195.7 
56 4,222.3 3,529.6 3,651.7 
19 3,492.4 3,031.7 3,816.7 
57 4,034.5 1,229.8 4,067.4 
58 4,358.5 2,095.9 3,688.0 
59 4,022.7 4,535.6 4,491.9 
60 4,608.8 4,697.0 2,536.9 
61 3,700.3 4,115.3 3,381.8 
62 4,515.4 4,912.6 4,395.2 
63 4,787.1 1,372.6 3,429.4 
64 4,931.9 1,758.3 4,251.9 
65 4,738.1 2,981.9 1,598.6 
66 4,847.3 4,174.5 2,968.3 
Average 4,288.0 2,913.5 3,174.0 
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Table 4.4. Mapping qualities across each of the target genes from MiSeq 1 
and MiSeq 2.  
MiSeq 
(Read 
length) 
Tissue 
Average mapping quality (by gene) 
KRAS NRAS BRAF PIK3CA 
1 
(176bp) 
Blood 58.1 52.9 48.3 41.4 
nFFPE 57.7 52.0 47.0 39.4 
tFFPE 58.3 53.1 47.3 40.0 
Average 58.1 52.7 47.5 40.3 
      
2 
(151bp) 
Blood 59.5 59.6 59.5 57.6 
nFFPE 59.5 59.6 59.5 56.7 
tFFPE 59.5 59.6 59.6 57.5 
Average 59.5 59.6 59.6 57.3 
 
 
Table 4.5. Correct mapping of paired-end reads from MiSeq 1 and MiSeq 2. 
MiSeq 
(Read 
length) 
Tissue 
Reads correctly mapped as a pair (%)  
KRAS NRAS BRAF PIK3CA 
1 
(176bp) 
Blood 93.0 55.6 55.4 26.8 
nFFPE 92.2 54.3 54.7 21.3 
tFFPE 93.8 59.3 51.6 20.3 
Average 93.0 56.4 53.9 22.8 
      
2 
(151bp) 
Blood 99.8 99.7 99.6 99.3 
nFFPE 99.8 99.7 99.6 99.4 
tFFPE 99.8 99.7 99.7 99.5 
Average 99.8 99.7 99.6 99.4 
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Figure 4.1. (a) Mapping qualities for all tissues on MiSeq 1 compared to MiSeq 2. (b) The amount of reads mapping as a correct pair (%) 
on MiSeq 1 in comparison to MiSeq 2. 
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Figure 4.2. (a) Visual inspection using IGV revealed reads from MiSeq 1 
contained adapter sequence at read ends (top panel, red arrow). Trimming the 
adapters was performed in MiSeq 1 data (middle panel). MiSeq 2 data used 
fewer sequencing cycles and no adapters were seen. (b) The amount of 
variants called from MiSeq 1 data pre- (left) and post- (right) trimming.
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These mismatching sequences were common to several amplicons and were 
found to match partial adaptor sequences. Using Trimmomatic (Bolger et al. 
2014), these sequencing adapters were accurately removed (Figure 4.2a) prior 
to further bioinformatic analyses. Removal of adaptors resulted in fewer reads 
with soft-clipped (unaligned) bases and decreased variants (Figures 4.2b). 
 
4.4.2 Identifying known mutations 
We assessed the MiSeq Somatic Variant Caller and GATK's HaplotypeCaller to 
identify the known somatic mutations. MiSeq's Somatic Variant Caller 
successfully identified all 25 (100%) somatic mutations whereas 
HaplotypeCaller identified 20 (80%) of known variants using data from MiSeq 1 
and 23 (92%) from MiSeq 2 (Table 4.6). The variants consistently missed by 
HaplotypeCaller were p.E545K (both mutations missed on MiSeq 2 and 2/5 
missed on MiSeq 1) and p.H1047R in PIK3CA (3/5 mutations missed on MiSeq 
1). In all of these cases, there was >1000 fold depth of coverage. However, 
visual inspection of sequence data using IGV suggested that the frequency of 
the mutant alleles might be too low to be recognised above the background 
noise; the p.E545K mutations were only seen in 2-3% of mapped reads from 
both MiSeqs. We also noted that for p.H1047R, the mutation mapped to a probe 
region, potentially resulting in a strand bias towards templates containing the 
wild type allele (Guo et al. 2012).
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Table 4.6. Identification of somatic mutations (n = 25) using MiSeq Somatic Variant Caller and GATK’s HaplotypeCaller using NGS data 
from 19 patients with aCRC. 
Platform MiSeq 1 MiSeq 1 MiSeq 2 
Caller MiSeq Somatic Variant Caller HaplotypeCaller HaplotypeCaller 
Tissue gDNA nFFPE tFFPE gDNA nFFPE tFFPE gDNA nFFPE tFFPE 
Known 
Mutations 
0/25 0/25 25/25 0/25 0/25 20/25 0/25 0/25 23/25 
Sensitivity - - 100% - - 80% - - 92% 
          
Other Hot-
Spot? 
0 10 18 0 0 0 0 0 0 
Specificity - 95.2% 91.4% - - - - - - 
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Twenty-eight false positives were predicted at the hotspot sites (KRAS codons 
12, 13 and 61, BRAF codons 594 and 600, NRAS codons 12 and 61 and 
PIK3CA codons 542, 545, 546 and 1047) by MiSeq's Somatic Variant Caller (18 
in tFFPE and 10 in nFFPE; 93.3% specificity) (Table 4.6) whereas no false 
positives were found by HaplotypeCaller in data from both MiSeqs (100% 
specificity). 
 
4.4.3 Investigating the background mutation profile 
We investigated the background mutation profile associated with the use of 
DNA from FFPE material by comparing variants called by HaplotypeCaller 
across the entire targeted KRAS, BRAF, NRAS and PIK3CA loci using gDNA 
and matched nFFPE DNA samples (data from MiSeq 1 & 2 combined). A three-
fold increase in SNVs was predicted in nFFPE DNA compared to gDNA (735 vs. 
216), whereas only a small number of indels were predicted (14 vs. 7). In terms 
of type of SNVs, we observed the following for nFFPE DNA vs. gDNA (Figure 
4.3) respectively (expressed as a percent of all nFFPE DNA and gDNA SNV 
calls); A:T>T:A (6.9 vs. 1.5), C:G>A:T (4.2 vs. 2.3), C:G>G:C (9.5 vs. 3.0), and 
A:T>C:G (1.7 vs. 0.0). However, the most notable difference was a significant 
increase in C:G>T:A substitutions in FFPE tissue (27.1 vs. 5.3) and in A:T>G:C 
(27.9 vs. 10.6), with most variants being predicted with high confidence. The 
increase in C:G>T:A’s was primarily noted in five samples (Figure 4.4) and 
these samples had similar sequencing coverage compared to the others (Table 
4.3). 
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Figure 4.3. Background mutation profile associated with the use of DNA from 
FFPE material.  A large increase in A:T>G:C and C:G>T:A transitions was 
observed in nFFPE.  
 
We studied the effect of pre-treating DNA samples with UDG by analysing 
tFFPE DNA from a further 19 patients whose CRCs were wild type at the 
mutation hotspots in KRAS, BRAF, NRAS and PIK3CA. UDG treatment 
reduced the total number of SNVs (treated vs. Untreated; 181 vs. 210) 
predicted across the entire KRAS, BRAF, NRAS and PIK3CA loci in these 
samples. 
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Figure 4.4. The increase in C:G>T:A’s artefacts was particularly noted in five 
samples (arrowheads).  
 
 It had little effect on the predicted numbers of (percent of SNVs called with and 
without treatment) A:T>C:G (0.5 vs. 0.5), A:T>G:C (18.9 vs. 19.9), A:T>T:A (7.7 
vs. 7.4), C:G>A:T (3.3 vs. 2.0) and C:G>G:C (0.5 vs. 0.5) substitutions. In 
contrast, UDG treatment significantly reduced the predicted number of C:G>T:A 
substitutions (15.3 vs. 23.0) (Figure 4.5, Table 4.7). It was again noted that 
seven untreated DNA samples were responsible for the excess of C:G>T:A 
substitutions; these were dramatically reduced after treatment (Figure 4.6). 
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Figure 4.5. UDG treatment of DNA from tFFPE samples (UDG tFFPE), reduced 
the frequency of C:G>T:A substitutions (black arrows). 
 
 
Table 4.7. Breakdown of predicted SNVs and indels across the entire KRAS, 
BRAF, NRAS and PIK3CA loci in 19 patients without hotspot mutations. 
Tissue  gDNA  
tFFPE –
UDG (%) 
 
tFFPE 
+UDG (%) 
 
In Both +/- 
UDG 
 Somatic 
Total SNVs  13  210  181  22  3 
A:T>C:G  0  2 (0.5)  2 (0.5)  0  0 
A:T>G:C  11  78 (19.9)  74 (18.9)  10  0 
A:T>T:A  0  29 (7.4)  30 (7.7)  1  0 
C:G>A:T  0  8 (2.0)  13 (3.3)  0  0 
C:G>G:C  0  3 (0.5)  2 (0.5)  0  0 
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Figure 4.6. Analysis of an independent set of tFFPE DNA samples showed that 
seven had high proportions of C:G>T:A mutations prior to UDG treatment 
(arrowheads). These artefacts were removed or reduced (arrowheads) after 
UDG treatment (UDG tFFPE). 
 
C:G>T:A  2  90 (23.0)  60 (15.3)  11  3 
Total indels  0  18  10  0  0 
Insertions  0  1  2  0  0 
Deletions 0  17  8  0  0  
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Given the large number of variants predicted across all four loci studied, we 
considered strategies to facilitate the identification of genuine somatic variants 
over the background of FFPE-associated artefacts. UDG treatment significantly 
reduced the predicted number of C:G>T:A substitutions. We considered variants 
more likely to be genuine if they were consistently found in both the UDG 
treated and untreated runs (column ‘In Both +/- UDG’). Only 22 such SNVs 
were consistently predicted and, of these, 16 were present in the germline. 
Three SNVs had little or no sequencing coverage in the gDNA and could not be 
confirmed as somatic. The remaining 3 SNVs were proven to be somatic. These 
variants included a p.R357Q and p.E545K in PIK3CA, as well as a p.S430L in 
BRAF. For tFFPE +/- UDG columns, the percent of SNVs in each group are 
shown out of all SNVs detected are shown (Table 4.7). 
 
4.5 Discussion 
4.5.1 Presence of adapter sequences 
We found that 176 bp reads showed lower mapping qualities compared to 151 
bp reads, particularly for the larger genes on our panel (e.g. PIK3CA). We 
attributed this to the introduction of partial adapter sequences in the longer 
reads. The amplicons in our project were designed to be on average 175 bp in 
length; however, for shorter amplicons, when the number of sequencing cycles 
exceeded the amplicon length, partial adapter sequences were introduced at 
the 3' ends of the reads. This explains why only particular amplicons exhibited 
large numbers of incorrectly paired reads. This problem was efficiently resolved 
using Trimmomatic, which successfully removed the adaptors; this resulted in 
fewer unaligned (soft-clipped) bases at the ends of reads, along with fewer 
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variant calls (Figure 4.2b). Using read lengths that are shorter than the intended 
amplicon length bypasses the problem of sequencing into adapters. 
 
4.5.2 Somatic variant calling in FFPE DNA 
Schweiger et al. (2009) were amongst the first to apply NGS to the analysis of 
FFPE DNA, and demonstrated a correlation between fresh frozen and FFPE 
DNA using whole genome and exome-sequencing. They found that longer 
fixation times (>72 hours) or time spent between surgical resection and fixation 
do not negatively affect sequencing efforts; however, this contrasts with other 
researchers findings (Chapter 1 Section 1.5.3). FFPE samples gave sequencing 
yields comparable to fresh-frozen samples. Increased storage time of samples 
(sometimes over 18 years) did not automatically exclude FFPE samples from 
use in NGS experiments. FFPE induced DNA damage may, however, result in 
genomic mismatches, but concordance rates of variant calls from fresh-frozen 
and FFPE samples can still reach 95% (Schweiger et al. 2009). Numerous 
studies have since utilised NGS, and suggest an ability to detect mutations 
down to 1-4% mutant allele levels (Bourgon et al. 2014) with >95% sensitivity 
and specificity (Harismendy et al. 2011; Hadd et al. 2013; Altimari et al. 2013; 
Ihle et al. 2014). Here we carried out NGS using Illumina’s MiSeq platform and 
tested two variant callers for detecting known hotspot mutations: MiSeq's 
Somatic Variant Caller had 100% sensitivity but lower specificity whereas 
HaplotypeCaller had 80-92% sensitivity and 100% specificity. 
 
HaplotypeCaller is designed for use with germline samples and may not detect 
variants at low frequency in a given sample (McKenna et al. 2010). This may 
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explain why the sensitivity to detect known variants was lower than for the 
MiSeq’s Somatic Variant Caller. The Somatic Variant Caller detected all of the 
expected known variants, plus a further eighteen and ten variants at hotspots in 
tumour and normal FFPE samples respectively. While the frequency of these 
additional variants may be too low for detection with germline callers or earlier 
sequencing technologies, we did not expect any to be seen in the normal FFPE. 
It is possible that Somatic Variant Caller is calling sequencing artefacts as 
somatic variants (Qiu et al. 2016), or that there is contamination between 
normal stroma and tumour tissue (Elloumi et al. 2011). A further possibility is 
that erroneous mapping could result in false positive variants, especially if the 
mapper aligns to just the targeted region of the genome (Qiu et al. 2016; Park et 
al. 2016) as is possibly performed by MiSeq software.  
 
4.5.3 Performance of other somatic variant calling pipelines 
The performance of several somatic variant callers have been evaluated 
(Krøigård et al. 2016), including MuTect (Cibulskis et al. 2013), Shimmer 
(Hansen et al. 2013), Somatic Sniper (Larson et al. 2012), VarScan 2 (Koboldt 
et al. 2012) and Strelka (Saunders et al. 2012).  
 
For sequencing regions at great depth, MuTect and Strelka appear more 
agreeable between callers (Krøigård et al. 2016), generating a larger pool of 
common calls. Somatic Sniper appears to generate variant many calls that are 
not detected by other callers, while Shimmer fails to detect variants detected by 
multiple other callers (Krøigård et al. 2016). A middle group may therefore be 
optimal, seeking to maximise the number of true positives without generating 
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too many false negatives. Our study used a somatic variant caller as part of a 
software package, for which we had no control over parameters; using a 
separate somatic caller would allow for control over parameters and therefore 
finetuning. 
 
Other studies have found differences between numbers of mutated genes 
reported by SomaticSniper and MuTect, with MuTect reporting more mutant 
genes and a higher frequency of single nucleotide variants (Bodini et al. 2015) 
including those that are implicated in tumours (Futreal et al. 2004).  
 
Studies looking at somatic variation in CRC have also focused on hotspots in 
genes such as KRAS, NRAS and BRAF using commercially available variant 
callers (Sakai et al. 2015). Other groups have used larger panels of around 50 
genes tot sequence CRCs and reported rare somatic variants in genes such as 
CDH1, APC, MLH1 and NRAS (Chang et al. 2016). Sakai et al. (2015) report 
C:G>A:T false positive calls which if genuine would have lead to a mutation a 
KRAS codon 37 and 175, and NRAS codon 351. In their study, they filtered out 
those particular sites in downstream analyses. They also report detection of the 
p.G12S mutation in KRAS is detectable down to a frequency 2.4% and p.G13D 
is detectable at 3.92% . In NRAS, they detect p.Q61K at 0.58% and BRAF 
p.V600E at 1.85%. Detection of such low frequency variants provides 
confidence in high depth, targeted sequencing approaches such as ours. 
However, it is also possible that artefacts at these frequencies may also be 
erroneously identified as somatic variants. 
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4.5.4 FFPE background mutation profile 
In addition to oxidative DNA damage generated during sample preparation 
(Costello et al. 2013) and errors introduced by the polymerase used (Chen 
2014), DNA derived from FFPE contains pre-existing damage that contributes to 
a background mutation profile. It has previously been suggested that there is an 
FFPE-associated C:G>T:A substitution profile (Do & Dobrovic 2012; Do et al. 
2013; Bourgon et al. 2014) and we also found a significant increase in 
C:G>T:A’s in FFPE tissue as compared to matched blood DNA. We found this 
excess in 5/19 samples from our first cohort and 7/19 samples from our second 
cohort, suggesting that the induced damage was specific to a limited number of 
the FFPE samples (perhaps those treated too long or too harshly). This profile 
is thought to be caused by deamination of cytosine to uracil; adenine is then 
misincorporated opposite and, upon DNA replication, results in the replacement 
of the original cytosine with a thymine (Do & Dobrovic 2012; Do et al. 2013; 
Bourgon et al. 2014). Such artefacts could easily be mistaken for low-level 
clinically important mutations (Lamy et al. 2011).  
 
A:T>G:C transitions also appeared frequently in our FFPE-processed samples. 
Oxidation of thymine's methyl group results in 5-hydroxymethyl uracil (5-hmU) 
and 5-formyluracil (5-foU) (Klungland et al. 2001; Schormann et al. 2014). 
Whilst 5-hmU exhibits normal base pairing (i.e. base pairs with adenine, as 
expected of uracil), 5-foU is capable of pairing with adenine and guanine 
(Klungland et al. 2001; Masaoka et al. 2001; Krokan et al. 2002). When 5-foU is 
present in template DNA, it has been shown that efficiency of opposite 
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incorporation of adenine drops to 25-50% of that when pairing with thymine. 
Incorporation of guanine opposite 5-foU however, increases by as much as 5.6-
fold; this accelerated rate may be promoted by increasing pH (7.2 – 8.6) 
(Masaoka et al. 2001). Masaoka et al. (2001) also showed that template 
extension is possible using DNA polymerase, even when the mismatch appears 
at the terminus of a primer. During replication, 5-foU can induce A:T>G:C 
transitions (Krokan et al. 1997; Kasai et al. 1990; Bjelland et al. 1995). Whether 
formalin-fixation or the extraction process itself is capable of driving the 
oxidation of thymine to 5-foU, and hence A:T>G:C mutations is not clear. 
 
It has been suggested that treating FFPE derived DNA with UDG prior to use in 
NGS reduces the frequency of C:G>T:A transitions (Do & Dobrovic 2012; Do et 
al. 2013) and our data support this. It has been proposed that the abasic sites 
created by UDG’s excision of uracil in FFPE DNA halt the progression of certain 
polymerases, including the polymerase used in Illumina’s TSCA protocol 
(Sikorsky et al. 2007). However, it is not clear why the level of C:G>T:A’s in the 
UDG-treated nFFPE-DNA samples observed herein does not reach that 
observed in gDNA, but this could be explained by the methylation of cytosine at 
CpG islands (Do et al. 2013). At such sites, methylated cytosine is deaminated 
to thymine and is not targeted by UDG. 
 
When using NGS as a screening tool to find novel somatic mutations in FFPE 
DNA, we observed large numbers of SNVs, most of which are likely to be 
artefacts. It has been suggested that the use of replicates sequenced using 
independent NGS runs helps mitigate against the errors encountered (Robasky 
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et al. 2014). We sequenced 19 samples in duplicate to determine the number of 
somatic variants shared between runs. We found that only 5.3% of variants 
were consistently predicted across both runs, and the majority of these were 
present in the germline. Multiple runs of the same samples may therefore help 
to remove artefacts in downstream analyses. 
 
4.5.5 Recommendations for somatic variant calling from FFPE samples 
We therefore recommend taking care to avoid cross contamination of normal 
and tumour tissue during sample preparation, pre-treating FFPE-associated 
DNA with UDG, mapping data to the whole reference genome, performing local 
realignment and base quality score recalibration, and using a somatic variant 
caller such as MuTect (Cibulskis et al. 2013) to accurately detect somatic 
variants. 
 
Chapter 5 – Investigation of potential novel genetic biomarkers of 
cetuximab-resistance 
5.1 Details of work performed 
In this chapter, library preparation and sequencing was performed by myself 
and Dr Christopher Smith. Bioinformatics analyses was performed by myself, 
and assessment of on-target read metrics was cross-checked by Dr Kevin 
Ashelford. 
 
5.2 Introduction 
NGS is increasingly used on a routine basis to interrogate the somatic mutation 
profiles of a range of cancers including CRCs. Precise and thorough mutation 
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profiles are essential to help inform the prognostic outcome of the patient 
(Drmanac et al. 1998; Tian et al. 2013). Furthermore, since therapy is 
increasingly stratified upon the tumours mutation profile, optimal efficacy is 
dependent on accurate high-throughput sequence analysis. For example, 
somatic mutations in KRAS, present in 35-45% of CRCs (Maughan et al. 2011; 
Smith et al. 2013), rendered cetuximab (a monoclonal antibody against EGFR) 
ineffective, by virtue of the tumour cell’s ability to constitutively activate EGFR 
signalling independent of ligand binding (Segal et al. 2015). For those aCRC 
patients with KRAS wild-type tumours, cetuximab was shown to increase 
median survival by 4.7 months compared with best supportive care alone, 
although tumour location can significantly influence patient outcome (Lu et al. 
2016). It is likely that mutations in other EGFR pathway genes confer resistance 
to cetuximab; for example, mutations in NRAS (mutated in 2-4% of CRCs) 
cause resistance (De Roock, Claes, et al. 2010). BRAF lies immediately 
downstream of KRAS and is mutated in ~8 - 10% of all CRCs (Barras 2015). 
Generally, mutations of BRAF are mutually exclusive of those in KRAS (Smith 
et al. 2013) and it is likely that BRAF mutations also confer cetuximab 
resistance (Barras 2015; De Roock, Claes, et al. 2010; Di Nicolantonio et al. 
2008). 
 
Here, we initially sought novel genes causing resistance to cetuximab by 
carrying out NGS of EGFR pathway genes in CRCs from patients that did not 
respond to treatment. To exclude known mechanisms of resistance, we focused 
on patients that were wild-type for common hot-spot mutations in KRAS, BRAF 
and NRAS. We discovered hospot mutations in a number of patients that were 
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missed by traditional methods, as well as other non-synonymous KRAS and 
EGFR pathway mutations that may lead to cetuximab resistant. The mutation 
profile observed in our samples hints at a possible role of DNA methylation in 
cetuximab response. 
 
5.3 Materials and Methods 
5.3.1 Patient selection criteria and samples 
Patients were enrolled in the MRC trials COIN or COIN-B (Maughan et al. 2011; 
Chapter 2, Section 2.2). Patients were selected for their lack of response to 
cetuximab (from Arm B of COIN and both arms of COIN-B). Response was 
defined according to Response Evaluation Criteria in Solid Tumours (RECIST) 
guidelines. We selected patients that showed either ‘progressive’ or ‘stable’ 
disease at 12 weeks, who’s ‘best response’ over the course of the trial was 
either ‘progressive’ or ‘stable’ disease and that were wild type for KRAS, BRAF 
and NRAS hotspot mutations as determined by Sequenom and Pyrosequencing 
(Maughan et al. 2011; Smith et al. 2013; Chapter 2, Section 2.6).  
 
5.3.2 Germline and FFPE DNA extraction and UDG treatment 
We obtained gDNA from these patients, as well as matched tFFPE DNA from 
their CRCs as previously described (Chapter 2, Section 2.4). Treatment with 
UDG was carried out as described (Chapter 2, Section 2.7). 
 
5.3.3 TruSeq Custom Amplicon Design 
Custom amplicons were designed using Illumina’s DesignStudio software 
targeting the ORFs of 49 genes (including KRAS, BRAF and NRAS) (Chapter 2, 
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Section 2.8.2.1) with a known or suspected role in EGFR signalling or that had 
been implicated in altering response to cetuximab (Chapter 1, Section 1.6.5, 
Figure 1.8). Optimum amplicon length was 175 bp. 
 
TSCA Library Preparation was carried out as described in Chapter 2, Section 
2.8.2.2. Two DNA samples from each FFPE CRC were processed; one was 
treated with UDG (+UDG) to reduce FFPE-associated C:G>T:A artefacts (Do et 
al. 2013; Do & Dobrovic 2012; Hofreiter et al. 2001; Chapter 4, Section 4.3.3), 
and the other remained untreated (-UDG). Pre- and post-PCR phases of work 
were carried out in dedicated laboratories. 
 
5.3.4 MiSeq sequencing 
All sequencing was carried out using an Illumina MiSeq (Chapter 2, Section 
2.8.2.4). To ensure that a minimum sequencing depth of 400x was reached, 
batches of ≤14 samples were sequenced at any one time. For each run, 150 
cycles of paired-end sequencing was performed. 
 
5.3.5 Bioinformatics pipeline and somatic variant calling 
Alignment of sequencing reads was performed using BWA (Li & Durbin 2009) 
as described in Chapter 2, Section 2.9.1. Base quality score recalibration and 
indel realignment were also performed using SAMtools and GATK (Chapter 2, 
Section 2.9.2). Reads not mapping to our target panel were removed using 
Custom Script 6. Dr Kevin Ashelford (Wales Gene Park Bioinformatics Facility 
and co-supervisor) validated the removal of off-target reads. 
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Somatic variants were called using MuTect (Cibulskis et al. 2013) using the 
UDG-treated tumour and the matched germline sample. Parameters used for 
MuTect are described in Chapter 2, Section 2.9.3. 
 
Variant annotation was performed using snpEff (Cingolani et al. 2012) and 
Custom Script 2 (Chapter 2, Section 2.9.4). Nucleotides adjacent to the variant 
site were taken from human reference GRCh37 and included in the the final 
annotation for somatic variants. 
  
5.3.6 Coverage calculations  
Depth of coverage across each sequenced sample was calculated using 
Custom Script 3 (Chapter 2, Section 2.9.5). Average coverage was calculated 
for all 49 genes on our target panel, along with the percent of each ORF 
covered to a depth of ≥500x.  
 
5.3.7 Somatic variant filtering and profiling 
Somatic variants were included for downstream analysis if they were assigned a 
‘PASS’ in the filter field by MuTect. Only variants likely to change the encoded 
protein sequence were included, as determined by an ‘EXON’, 
‘NON_SYNONYMOUS_CODING’, ‘SPLICE_SITE_ACCEPTOR’, 
‘SPLICE_SITE_DONOR’, ‘START_GAINED’, ‘START_LOST’, ‘STOP_GAINED’, 
or ‘STOP_LOST’ tag issued by snpEff (Cingolani et al. 2012). The number of 
specific nucleotide alterations across our gene panel was recorded and the 
reference genome (GRCh37) was consulted to determine whether C:G>T:A 
mutations were in a CpG island or not. 
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5.4 Results 
5.4.1 Patients 
Twenty one aCRC patients were selected for whom we had matching germline 
and tumour DNA, who showed no response to cetuximab, and that were 
believed to be wild-type for the common somatic hotspots in KRAS, BRAF and 
NRAS. 
 
5.4.2 Gene panel 
A total of 1,536 amplicons were generated targeting the ORFs of the 49 
selected genes (including KRAS, BRAF and NRAS) in the EGFR pathway. 
Illumina’s DesignStudio in-built scoring system (that estimates the percentage 
of attempted probes that will successfully enrich the target sequences) 
predicted an average score of 79% (ranging from 60-98%). Average amplicon 
length was 176 bp (ranging from 170-190 bp). The cumulative target size was 
112,427 bp. In total there were 37 gaps in the target sequence covering 1,664 
bp of sequence. However, total ORF coverage was 99%. 
 
5.4.3 Sequencing of prepared libraries 
Four TruSeq Custom Amplicon libraries were prepared and sequenced across 
separate runs on an Illumina MiSeq. Libraries 1 and 3 were each sequenced on 
a single MiSeq run. Libraries 2 and 4 were pooled into two aliquots each and 
each aliquot sequenced on a separate MiSeq run. One hundred and fifty cycles 
of paired end sequencing was performed for each run. 
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5.4.4 Read mapping and removal of off-target reads 
Mapped reads that did not map to our target region were removed. This left a 
total of 108,557,316 mapped reads (An average of 18,092,886 per run; Table 
5.1) and 47,707,903 unmapped reads (average 7,951,317 per run; Table 5.1). 
We had 16.39 Gb mapped data across all six runs for downstream analyses. 
Average mapping quality was 57.81, and an average 97.4% mapped correctly 
as a pair (Table 5.1). 
 
5.4.5 Depth of coverage 
Germline samples consistently achieved better coverage across all 49 ORFs 
than their matched tumour counterparts (Figure 5.1). At ≥500x coverage, 
average ORF coverage was 76.62%, 50.69% and 40.85% in germline, tumour 
and UDG-treated tumour samples respectively (Table 5.2). Average sequencing 
depth over the 49 genes in our targeted panel was 1,159.19x (range 227.02 – 
2,626.57x; Table 5.2). 
 
Table 5.1 Sequencing and mapping metrics for samples sequenced on the 
MiSeq. 
Run ID 
(library) 
Tissue 
Mapping 
status 
Read count 
Mb 
obtained 
Correctly 
mapped 
(%) 
Mapping 
quality 
1 (1) blood mapped 35,657,382 5,384.26 97.69 57.72 
1 (1) blood unmapped 1,859,426 280.77 0.00 0.00 
2 (2) tFFPE mapped 12,769,865 1,928.25 97.31 57.90 
2 (2) tFFPE unmapped 10,089,369 1,523.49 0.00 0.00 
3 (2) tFFPE mapped 20,257,137 3,058.83 98.22 58.06 
3 (2) tFFPE unmapped 3,075,240 464.36 0.00 0.00 
3 (2) 
UDG 
tFFPE 
mapped 957,526 144.59 98.59 58.12 
3 (2) UDG unmapped 806,882 121.84 0.00 0.00 
 130 
 
tFFPE 
4 (3) blood mapped 6,857,241 1,035.44 97.92 57.99 
4 (3) blood unmapped 284,023 42.89 0.00 0.00 
4 (3) 
UDG 
tFFPE 
mapped 10,246,556 1,547.23 98.16 58.12 
4 (3) 
UDG 
tFFPE 
unmapped 7,862,654 1,187.26 0.00 0.00 
5 (4) 
UDG 
tFFPE 
mapped 9,954,674 1,503.16 96.81 57.79 
5 (4) 
UDG 
tFFPE 
unmapped 9,395,083 1,418.66 0.00 0.00 
6 (4) blood mapped 5,965,826 900.84 97.86 57.87 
6 (4) blood unmapped 1,266,559 191.25 0.00 0.00 
6 (4) tFFPE mapped 2,538,989 383.39 95.66 57.17 
6 (4) tFFPE unmapped 3,875,582 585.21 0.00 0.00 
6 (4) 
UDG 
tFFPE 
mapped 3,352,120 506.17 95.75 57.35 
6 (4) 
UDG 
tFFPE 
unmapped 9,193,085 1,388.16 0.00 0.00 
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Figure 5.1 ORF coverage at ≥500x for genes in our target panel. Coverage is shown for germline, tumour FFPE and UDG-treated tumour 
FFPE samples. 
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Table 5.2 Average ORF depth and coverage at ≥500x across our gene panel. 
Coverage calculations for each tissue are shown. 
Gene 
number 
Gene name 
Average depth % ORF covered at ≥500x 
gDNA tumour 
UDG-
tumour 
gDNA tumour 
UDG-
tumour 
1 AKT1 452.17 135.74 91.55 40.76 6.66 3.91 
2 AKT2 715.54 267.02 161.05 44.11 20.65 10.07 
3 AKT3 1,985.98 1,115.48 663.64 90.37 56.16 45.66 
4 ARAF 826.78 481.31 296.51 61.52 31.74 20.07 
5 AREG 1,122.16 741.14 471.80 70.58 45.65 33.70 
6 AXL 1,169.76 525.77 356.74 69.84 30.99 21.27 
7 BCL2L11 1,307.65 1,099.07 732.81 84.17 62.04 48.46 
8 BRAF 1,886.95 1,207.76 731.52 85.63 61.26 51.03 
9 CBL 1,973.15 1,238.06 824.44 81.19 58.84 49.48 
10 CDH1 2,013.22 1,187.93 804.59 89.09 59.87 49.59 
11 DOK2 891.00 376.58 264.64 62.96 23.72 13.98 
12 EGF 2,182.05 1,263.60 801.75 90.94 60.63 49.97 
13 EGFR 1,337.83 1,234.09 776.27 69.39 50.57 40.72 
14 ERBB2 1,075.70 510.52 356.21 59.52 29.09 20.40 
15 ERBB3 2,390.57 1,296.38 911.00 83.50 61.54 52.71 
16 EREG 1,478.31 980.82 668.00 79.85 54.24 38.24 
17 FCGR2A 2,288.46 1,366.12 808.89 86.09 63.77 52.57 
18 FCGR3A 2,279.05 1,261.42 878.01 80.61 52.17 42.99 
19 FLT1 1,727.07 1,274.54 686.17 80.72 57.37 45.50 
20 GAB1 2,418.94 1,651.93 995.58 88.03 62.15 55.83 
21 GRB2 1,506.57 892.22 629.59 71.41 55.14 46.21 
22 HRAS 432.78 235.48 176.51 42.05 15.30 9.25 
23 IGF1 2,130.14 1,393.14 1,022.35 82.96 54.29 43.60 
24 IGF1R 1,716.61 954.72 608.75 82.95 52.99 40.97 
25 JAK1 2,130.36 1,291.00 812.55 86.32 60.35 48.85 
26 JAK2 2,085.23 1,264.44 806.60 88.98 60.16 51.56 
27 KDR 2,080.99 1,098.57 632.05 85.08 57.24 44.54 
28 KRAS 2,018.14 1,297.71 885.97 91.46 70.50 58.92 
29 MAP2K1 1,804.25 1,004.58 660.48 80.12 53.74 47.38 
30 MAP2K2 495.62 135.97 104.02 36.61 8.68 5.36 
31 MAPK1 1,998.77 1,125.84 772.81 83.81 53.89 49.67 
32 MAPK3 1,409.02 656.25 511.38 61.73 41.16 36.14 
33 MET 1,959.49 1,571.36 944.34 88.38 65.53 56.93 
34 NCK1 3,308.38 2,551.07 1,510.19 95.92 78.70 73.07 
35 NRAS 2,229.87 1,449.62 1,015.41 92.41 69.03 64.92 
36 PDK1 1,755.20 1,179.56 769.24 76.23 55.89 48.88 
37 PIK3CA 2,454.70 1,764.31 1,098.53 91.71 71.96 61.13 
38 PLCG1 1,657.75 1,066.96 646.54 76.95 54.08 38.86 
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39 PLCG2 1,463.91 773.15 471.42 80.92 48.04 33.32 
40 PRKCA 1,895.87 1,132.03 755.25 80.68 57.34 47.73 
41 PRKCD 1,022.79 395.57 237.26 65.39 26.84 14.62 
42 PTEN 2,086.68 2,061.92 1,310.66 92.05 76.10 61.37 
43 RAF1 1,887.09 968.52 618.96 87.37 54.60 42.24 
44 SHC1 1,220.03 571.12 381.33 58.55 35.99 24.66 
45 SOS1 2,010.36 1,422.81 905.89 88.47 64.47 56.23 
46 SRC 981.79 615.84 428.24 55.39 34.85 27.29 
47 STAT1 1,685.86 1,126.15 675.99 89.22 61.15 46.28 
48 STAT3 1,812.76 1,159.05 769.54 81.17 55.48 45.35 
49 TP53 1,354.86 690.20 446.63 61.42 41.39 30.01 
Average  1,675.88 1,042.13 671.22 76.62 50.69 40.85 
 
5.4.6 Somatic KRAS analyses 
KRAS hotspot mutations were detected in seven of twenty one (33.3%) UDG-
treated CRCs that were believed to be wild type prior to NGS. Five (23.8%) 
CRCs had multiple hotspot mutations; one (4.8%) CRC had a p.G12D 
(g.25,398,284C>T) and a p.G12C (g.25,398,285C>A) mutation, three (14.3%) 
CRCs had a p.G12V (g.25,398,284C>A) and a p.G12C (g.25,398,285C>A) 
mutation and one CRC had a p.G12V (g.25,398,284C>A) and a p.Q61R 
(g.25,380,276T>C) mutation. Of the remaining two (9.5%) CRCs, one (4.8%) 
CRC had a p.G12V (g.25,398,284C>A) mutation and one (4.8%) had a p.Q61H 
(g.25,380,275T>G) mutation. 
 
 
Twenty five potential protein-altering mutations were predicted outside of known 
hotspot across ten of the twenty one (47.6%) CRCs whose DNA was 
sequenced (Table 5.3). Five (20%) of these mutations were likely to either 
truncate or lengthen the protein. One CRC carried a g.25,398,324G>A start 
gain mutation upstream of codon 1, potentially altering the reading frame of the 
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gene. One CRC carried a truncating p.K5X (g.25,398,306T>A) mutation and a 
g.25,378,709T>C splice site acceptor mutation. A separate CRC carried a 
p.K101X (g.25,378,697T>A) truncating mutation. One CRC carried a p.X190Q 
(g.25,368,377A>G) mutation, resulting in the loss of a stop codon. 
 
Table 5.3 Somatic KRAS mutations detected in CRCs that showed lack of 
response to cetuximab. 
Patient ID 
Variant type 
ORF altering Other non-synonymous 
36  p.K16M (g.25398272T>A) 
71  p.T87S (g.25380198G>C) 
72 p.X190Q 
(g.25368377A>G) 
p.S172R (g.25368429G>C) 
p.E31K (g.25398228C>T) 
 
75 
codon unspecified 
(g.25398324G>A) 
 
77 p.K5X (g.25398306T>A) 
codon unspecified 
(g.25378709T>C) 
p.T127I (g.25378618G>A), 
p.M67I (g.25380257C>T) 
p.A66V (g.25380261G>A) 
p.Y64C (g.25380267T>C) 
 
 
 
79 
 
p.K104R (g.25378687T>C) 
p.L6H (g.25398302A>T) 
 
85 
p.K101X (g.25378697T>A) 
p.Q129R (g.25378612T>C) 
p.V103A (g.25378690A>G) 
 
86 
 
p.K104R (g.25378687T>C) 
p.S89L (g.25380192G>A) 
p.E49G (g.25380312T>C) 
 
 
87 
 
p.K117I (g.25378648T>A) 
p.Y96C (g.25380171T>C) 
 
82 
 
p.P178R (g.25368412G>C) 
p.Q150R (g.25378549T>C) 
p.R68K (g.25380255C>T) 
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5.4.7 Somatic hotspot profiles across BRAF, NRAS, PIK3CA and PTEN 
No CRCs carried any hotspot mutations at codons 600 and 594 in BRAF. One 
CRC, however, carried a BRAF p.F595S (g.140,453,151A>G) mutation. In 
NRAS, one CRC posessed a G13D (g.115,258,744C>T) hotspot mutation. For 
PIK3CA, one CRC carried both a p.E542K (g. 178,936,082G>A) and a p.E545K 
(g.178,936,091G>A) mutation. Three other CRCs also carried a single p.E545K 
mutation. 
 
In PTEN, eight CRCs carried mutations that were likely to alter the ORF. 
Several nonsense mutations were called, including p.C71X, p.R130X, p.Y155X, 
p.Y178X, and p.R189X, each carried by a separate CRC. One CRC carried 
p.K260X, p.K330X and p.R335X. One CRC carried a g.89,725,043G>A splice 
site acceptor, one carried a g.896,53,780A>T splice site acceptor and one CRC 
carried a g.89,690,801A>T splice site acceptor. One CRC possessed a 
p.K289R mutation; mutations at this codon are thought to affect localisation of 
the protein (Song et al. 2012). 
 
5.4.8 Background somatic profile 
A total of 3,054 variants were included for analysis after filtering, equating to a 
mean 63.33 variants (range 7 – 144) per gene across all twenty one UDG-
treated CRCs (Table 5.4). Of these, 2.59% were A:T>C:G, 18.11% were 
A:T>G:C, 17.87% were A:T>T:A, 12.85% were C:G>A:T, 4.49% were C:G>G:C 
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and 44.09% were C:G>T:A variants. A mean 49.41% of the C:G>T:A mutations 
were at CpG islands (range 0 – 91.67%, Figure 5.2).  
 
Table 5.4 Variant profile in DNA from UDG-treated CRCs across a 49 gene 
panel. 
Gene 
Variant 
count 
A:T>C:G 
(%) 
A:T>G:C 
(%) 
A:T>T:A 
(%) 
C:G>A:T 
(%) 
C:G>G:
C (%) 
C:G>T:A 
(%) 
C:G>T:A 
in CpG 
(%) 
AKT1 23 0.00 34.78 8.70 4.35 0.00 52.17 91.67 
AKT2 36 2.78 33.33 13.89 11.11 2.78 36.11 61.54 
AKT3 40 0.00 10.00 22.50 12.50 7.50 47.50 26.32 
ARAF 52 0.00 21.15 17.31 17.31 3.85 40.38 52.38 
AREG 14 0.00 28.57 28.57 7.14 7.14 28.57 0.00 
AXL 67 1.49 10.45 13.43 14.93 2.99 56.72 50.00 
BCL2L11 21 0.00 23.81 9.52 9.52 4.76 52.38 63.64 
BRAF 69 5.80 21.74 26.09 11.59 4.35 30.43 38.10 
CBL 70 4.29 12.86 18.57 12.86 8.57 42.86 53.33 
CDH1 83 2.41 12.05 16.87 9.64 6.02 53.01 59.09 
DOK2 39 0.00 15.38 10.26 2.56 5.13 66.67 69.23 
EGF 111 1.80 20.72 24.32 11.71 1.80 39.64 40.91 
EGFR 144 4.86 23.61 20.14 7.64 5.56 38.19 63.64 
ERBB2 88 1.14 14.77 15.91 10.23 4.55 53.41 48.94 
ERBB3 144 3.47 5.56 18.75 18.06 4.17 50.00 48.61 
EREG 17 0.00 5.88 29.41 17.65 0.00 47.06 37.50 
FCGR2A 23 0.00 17.39 21.74 13.04 13.04 34.78 50.00 
FCGR3A 22 9.09 13.64 22.73 13.64 4.55 36.36 37.50 
FLT1 115 0.87 16.52 20.87 15.65 2.61 43.48 38.00 
GAB1 63 1.59 11.11 11.11 17.46 1.59 57.14 38.89 
GRB2 16 0.00 18.75 18.75 6.25 0.00 56.25 55.56 
HRAS 7 0.00 0.00 0.00 28.57 14.29 57.14 75.00 
IGF1 14 0.00 21.43 14.29 7.14 21.43 35.71 60.00 
IGF1R 117 3.42 22.22 17.09 17.95 5.13 34.19 67.50 
JAK1 90 1.11 17.78 24.44 11.11 3.33 42.22 57.89 
JAK2 90 5.56 18.89 15.56 7.78 3.33 48.89 43.18 
KDR 127 1.57 14.96 19.69 14.96 2.36 46.46 30.51 
KRAS 37 2.70 29.73 13.51 24.32 8.11 21.62 25.00 
MAP2K1 26 0.00 11.54 23.08 15.38 0.00 50.00 53.85 
MAP2K2 24 0.00 25.00 4.17 12.50 0.00 58.33 71.43 
MAPK1 19 5.26 21.05 21.05 15.79 5.26 31.58 33.33 
MAPK3 36 2.78 13.89 13.89 11.11 2.78 55.56 70.00 
MET 113 3.54 10.62 22.12 17.70 4.42 41.59 46.81 
NCK1 31 3.23 9.68 12.90 16.13 3.23 54.84 41.18 
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NRAS 40 12.50 22.50 22.50 7.50 2.50 32.50 38.46 
PDK1 32 6.25 18.75 18.75 6.25 0.00 50.00 37.50 
PIK3CA 113 4.42 18.58 22.12 12.39 2.65 39.82 22.22 
PLCG1 110 3.64 12.73 18.18 13.64 6.36 45.45 54.00 
PLCG2 100 4.00 16.00 16.00 21.00 2.00 41.00 60.98 
PRKCA 43 2.33 11.63 25.58 23.26 2.33 34.88 46.67 
PRKCD 37 0.00 29.73 16.22 2.70 2.70 48.65 88.89 
PTEN 91 6.59 30.77 34.07 5.49 0.00 23.08 28.57 
RAF1 65 0.00 12.31 18.46 23.08 6.15 40.00 53.85 
SHC1 36 0.00 13.89 13.89 5.56 8.33 58.33 52.38 
SOS1 105 4.76 14.29 18.10 17.14 3.81 41.90 29.55 
SRC 47 6.38 21.28 6.38 6.38 2.13 57.45 81.48 
STAT1 63 0.00 26.98 15.87 7.94 6.35 42.86 37.04 
STAT3 68 1.47 26.47 22.06 14.71 1.47 33.82 56.52 
TP53 116 6.03 22.41 16.38 17.24 8.62 29.31 32.35 
Average 62.327 2.59 18.11 17.87 12.85 4.49 44.09 49.41 
 
 
Figure 5.2 Sequence context of C:G>T:A mutations. Sequences involving CpG 
dinucleotides are indicated in red. 
 
Mutations likely to affect the open reading frame, such as truncating nonsense 
mutations, proved less abundant than those that changed only the amino acid 
 138 
 
sequence (labelled by snpEff as ‘NON_SYNONYMOUS’, Figure 5.3). There 
was a marked increase in the frequency of C:G>T:A mutations. 
 
5.5 Discussion 
5.5.1 Read mapping 
We observed that, on average, 18,092,886 reads were mapped on-target per 
MiSeq run across our 49 gene panel. An average of 7,951,317 reads per run 
were unmapped. Over 95% of our on-target mapped reads were mapped 
correctly with their paired read, and had consistently good mapping quality 
scores. This shows that BWA performed adequately across all our sequencing 
data. 
 
Any mapped reads that did not match our target coordinates were discarded, 
whereas unmapped reads could not technically be removed using the same 
methodology. Given that our mapping quality metrics appear good, it is 
surprising to see the numbers of unmapped reads listed in Table 5.1. 
Interestingly, Run 1 (consisting of library 1) had the lowest ratio of on-target 
mapped reads to unmapped reads. This suggests later libraries had a higher 
portion of off-target reads that were discarded after mapping.  
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Figure 5.3 Mutation frequencies arranged by predicted affect on the encoded protein sequence.
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5.5.2 Sequencing coverage 
All of our samples were sequenced to a depth of >200x, with an average depth 
of 1,159.19x. Depth of coverage is an important consideration during NGS as 
increasing depth increases the sensitivity of somatic mutation detection; depths 
of around 1000x may be required to detect low frequency (1%) somatic 
mutations with a low false discovery rate (K. Chen et al. 2015). Lower depth 
may result in more sequencing artefacts being detected and perhaps called as 
somatic mutations if the matched germline sample does not have a similar 
sequencing depth (Alioto et al. 2015). We achieved a suitably high sequencing 
depth of 671.22x in our UDG-treated CRCs used for somatic variant calling. 
Matched germline samples yielded a depth of 1,675.88x, providing confidence 
in comparisons with our somatic samples. 
 
We achieved ≥500x depth in 76.62%, 50.69% and 40.85% of our targeted 
region in germline, tumour and UDG-treated tumour samples, respectively. The 
differences observed between germline and tumour samples could be due the 
properties of FFPE-associated DNA (Carrick et al. 2015; Van Allen et al. 2014). 
The depth achieved across our targets is sufficient for calling of mutation with a 
variant allele frequency >1%, but lower frequency variants may be 
misinterpreted as sequencing artefacts. Higher depth is advised to ensure low 
false discovery rates (K. Chen et al. 2015) 
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5.5.3 Somatic analyses of KRAS, BRAF, NRAS, PIK3CA and PTEN 
We detected multiple somatic hotspot mutations in CRCs that had not been 
detected via earlier methods. It is possible that the earlier methods used to 
determine the mutation status were not sensitive enough to detect low 
frequency mutations, whereas the increased sensitivity of NGS (Fujita et al. 
2016; Chin et al. 2013) was sufficient for mutation detection. 
 
In KRAS, a third (7/21) of CRCs had ≥1 hotspot mutation including p.G12C, 
p.G12D, p.G12V, p.Q61H and p.Q61R. None of these mutations were 
previously detected in the CRCs. Other KRAS mutations were detected that 
could have significantly altered the protein-coding region, including a p.K5X 
mutation. While this mutation is truncating, other mutations at codon 5 have 
been shown to enhance phosphorylation of downstream affectors (Gremer et al. 
2011). A separate truncating mutation was found at codon 101 (p.K101X); it has 
been suggested that this is a potential ligand binding site (away from the active 
site) in HRAS and also probably in KRAS (Buhrman et al. 2011). A p.X190Q 
stop loss mutation is likely to change the structure and therefore overall function 
of the protein. In NRAS, a p.G13D mutation was found. The hotspot mutations 
in RAS genes were likely missed due to lower sensitivity of earlier technologies. 
 
In BRAF, a p.F595S mutation was detected in one CRC; this CRC also 
harboured the KRAS p.K5X mutation along with codon 12 mutations. This 
mutation alters the functionally important motif spanning codons 594-595-596, 
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and mutations specifically at codon 595 have previously been shown to be 
activating (Kordes et al. 2015); this mutation therefore represents a good 
candidate for consideration when treating CRC with EGFR pathway inhibitors. 
 
PIK3CA had potentially activating mutations, including p.E542K, p.E545K, 
p.M1043I and p.A1046T (S. J. Chen et al. 2015; Tian et al. 2013). The CRC 
carrying p.M1043I also carried p.E542K and p.E545K, three truncating 
mutations in PTEN, but did not carry any KRAS, NRAS or BRAF hotspot 
mutations. Mutations at codons 1043 and 1046, along with codons 542, 545 
and 1047 are good candidates for further investigation into their role in 
cetuximab-resistance. 
 
Mutations in PTEN were detected that would have probably resulted in loss of 
function (Molinari & Frattini 2013). These included five truncating mutations at 
codons 71, 130, 155, 178 and 189, three predicted splice site variants and a 
p.K289R mutation that could affect protein localisation (Song et al. 2012). As 
loss of PTEN leads to potential activation of the PI3K pathway (Dillon & Miller 
2014), cetuximab may not be effective at treating CRCs harbouring these 
mutations. 
 
5.5.4 Background somatic profile 
We observed high ratios of transition (A:T>G:C and C:G>T:A) mutations 
compared to transversions mutations, as expected when sequencing coding 
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regions (Q. Liu et al. 2012). The high levels of transitions in our samples are 
generally consistent with colorectal mutation profiles (Alexandrov et al. 2013), 
although we observe higher levels of A:T>T:A transversion mutations. 
Treatment of FFPE-associated CRC has been shown to reduce C:G>T:A 
artefacts in NGS. However, these mutations are still the most common in our 
data; they do however appear less likely to be labelled as ‘EXON’ by snpEff 
(Cingolani et al. 2012) or affect a start or stop codon. This is probably due to the 
fact that the start codon (ATG) and stop codons (TAA, TAG, TGA) have a limited 
GC content, hence less opportunity for C:G>T:A mutation to occur. EXON 
variants are described by snpEff documentation to affect potentially non-coding 
transcripts or untranslated regions, and therefore may not be subject to the 
same processes governing fully coding variants.  
 
Given that almost half (>49%) of the C:G>T:A mutations are in a CpG sequence 
context (Table 5.4, Figure 5.2), the frequency of these variants could be 
explained by deamination of methylated cytosine. CpG islands are known 
hotspots for C>T transitions in the human genome (Gromenko et al. 2009), and 
have been reported at a rate observed in our somatic analyses (Cooper et al. 
2010). Such cytosine modifications have been highlighted as potential 
biomarkers of cell proliferation in colorectal cancer (Uribe-Lewis et al. 2015).  
 
One final observation is that genes with the highest fraction of C:G>T:A 
mutations in a CpG context, specifically AKT1, HRAS, MAP2K2, MAPK3, 
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PRKCD and SRC (gene numbers 1, 22, 30, 32, 41 and 46 respectively), yielded 
poorer ORF coverage as shown in Figure 5.1. Genes with lower fractions of 
C:G>T:A mutations in a CpG context, namely AKT3, KRAS, PIK3CA, PTEN and 
SOS1 (numbers 3, 28, 37, 42, 45), showed better ORF coverage. 
 
Chapter 6 - General Discussion 
6.1 Development of custom Perl scripts 
Throughout the course of this PhD, custom scripts were written in Perl to assist 
with the analyses of the NGS data. Custom script 1 was written to facilitate and 
manage our bioinformatics pipeline; data in FASTQ format was taken from the 
sequencers and Custom Script 1 parsed the data through each step in the 
pipeline. When starting the script, users were given the option to specify 
software parameters for each step (where applicable). Once the script was 
running, no more user input was required until the workflow was completed. 
This semi-automation gave the user free time to focus on other tasks. 
 
Custom Script 2 compiled variants from the NGS data and added annotation to 
a filterable spreadsheet. Annotation fields added for each variant included 
presence in dbSNP, 1000 Genomes and COSMIC (Forbes et al. 2008), and 
their respective allele frequencies. The presence of a variant in each tissue 
(germline, nFFPE and tFFPE) was specified, allowing for filtering to identify 
potential somatic mutations. 
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Custom Script 3 calculated the depth of coverage across the ORFs. ORF 
regions were defined in CCDS (Pruitt et al. 2009) and RefSeq (Pruitt et al. 
2007). This script gave numerical values for the coverage levels of each ORF 
as well as colour coding the results; this allowed for fast and effective 
visualisation of the data. Furthermore, it allowed for the identification of 
contamination or alignment issues by reporting coverage in genes not targeted 
by the designed panels. Identification of samples that failed sequencing could 
easily be identified, indicating problems with the sample DNA or library 
preparation. 
 
Custom Script 4 took variant calls from our pipeline and compared them to calls 
from BGI’s pipeline. The script compared the call sets to determine the variants 
detected by both pipelines, and which variants were unique. Considering data in 
this way allowed us to modify our pipeline parameters to maximise the number 
of variants that were found by both pipelines; doing so reduced the risk that we 
missed genuine variants. 
 
Custom Script 5 compared genotypes inferred from our variant calls to prior 
genotyping data. Both datasets were first converted into the same data format, 
which proved technically challenging. As the cost of NGS falls, genotyping is 
more likely to be performed using this technology and using our custom script, 
we have shown that NGS can accurately predict genotypes with high 
concordance rates.  
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Custom Script 6 isolated reads mapping to target regions from reads mapping 
to off-target regions. We have shown that off-target reads represent 
contamination from other target panels used within our NGS facility. Custom 
Script 6 was able to effectively remove the contaminating reads. This has 
important applications in personalised medicine as patients may ultimately 
receive therapies based on NGS findings; isolation of on-target reads may 
therefore ensure more accurate variant calls. It should be noted that this script 
relied on differences between amplicons within different panels; where multiple 
panels targeted the same amplicons then the script was incapable of 
determining which panel amplicons originate from. 
 
6.2 Key findings from this project 
6.2.1 Key findings from Chapter 3 
We used several pieces of bioinformatics software (BWA, SAMtools, GATK, 
SnpEff) in a bioinformatics pipeline for calling variants from NGS data. Custom 
Perl scripts were written to facilitate data analyses. By comparing against prior 
genotyping data and testing different parameter settings, we were able to show 
that NGS can predict variants with high concordance. Altering the variant calling 
parameters made only slight differences to the concordance rate, but did 
substantially increase the number of probable false positives we encountered. 
There are often discrepancies between variant callers (Krøigård et al. 2016) and 
choosing parameters which optimise the amount of common calls without 
increasing the burden of false positives represents a major challenge in 
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bioinformatics. The few genotype discrepancies we observed were most likely 
due to poor sequencing coverage at the genotyped loci or poor quality score. 
 
When validating SNVs in vitro, we showed that over half of the variants could be 
successfully validated. Variants were more likely to be validated if they were 
predicted with good quality scores. Our parameter settings that allowed calling 
from lower quality bases almost certainly contributed to this observation. We 
were able to validate ~67% of predicted indels, and validation was more 
successful at loci that had reasonable sequence complexity; validation was 
harder at loci that contained short dinucleotide repeats. Quality of indel calls has 
a significant impact upon their validation rate, as indels regarded as low quality 
have an error rate of >50%, whereas good quality indels have been shown to 
have a 7% error rate (Fang et al. 2014). It seems sensible then that filtering of 
variants based on quality scores is performed before effort is spent on further 
investigating interesting candidates. 
 
Comparing our variant calls to those from BGI’s pipeline, we found that we 
called over 3-fold as many variants as BGI. Our pipeline called the majority of 
BGI’s variants, and relaxing our variant calling parameters allowed us to detect 
more of these. Relaxing the parameters, however, may have resulted in more 
potential false positive variants to be called. 
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We compared the ability of two variant callers (GATK’s HaplotypeCaller and 
Illumina’s Somatic Variant Caller) to detect previously determined hotspot 
mutations.  
 
The options available for GATK users therefore make it a more attractive caller; 
for instance, variant calling parameters can be adjusted to fine-tune call sets. 
Furthermore, it is continuously being developed by its creators (McKenna et al. 
2010; DePristo et al. 2011). The software can be readily integrated into 
bioinformatics pipelines whereas this is not as feasible with the MiSeq’s 
Somatic Variant Caller. 
 
6.2.2 Key findings from Chapter 4 
We showed that adapter sequences are introduced into NGS reads when the 
read length extends beyond the amplicon length; this complicates downstream 
analyses. Use of Trimmomatic removed these adaptor sequences and reduced 
erroneous variant calls. 
 
The two callers we used in operate very differently; GATK is capable of 
realigning sequencing reads around indels, recalibrating per-base quality scores 
and variant quality scores to ensure variants are represented as accurately as 
possible. GATK expects reads have been aligned against the full human 
genome sequence. Somatic Variant Caller on the other hand, takes reads that 
have been aligned against a set of target amplicon sequences. It does not offer 
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realignment of reads or recalibration of quality scores. Somatic Variant Caller is 
designed to call variants in a tumour sample with no matched germline sample 
and is therefore very sensitive; as a result it may mistake signal noise for 
genuine variants. We found that Somatic Variant Caller correctly identified all of 
the known hotspot variants, but also erroneously called eighteen false positives. 
GATK’s HaplotypeCaller identified 80-92% of the known hotspot mutations and 
did not call any false positives at hotspots. Accurate somatic profiling therefore 
requires accurate mapping in combination with a caller sensitive enough to 
detect low frequency variants. 
 
FFPE DNA showed a C:G>T:A mutator profile, as described in the literature (Do 
et al. 2013; Do & Dobrovic 2012; Bourgon et al. 2014). These mutations are not 
genuine somatic events and a proportion can be removed with UDG, which 
increases specificity when calling variants in FFPE. By performing duplicate 
runs of FFPE-associated samples, we showed that ~5% of variants were 
consistently called; these variants were more likely to be genuine (Robasky et 
al. 2014). 
 
It is possible that fixation time for FFPE samples affects overall suitability for 
NGS (Schweiger et al. 2009) and could very well be a contributing factor in our 
study, as we saw the amount of FFPE-associated artefacts focused in a subset 
of our samples. Initimate knowledge of the formalin fixation process applied per 
sample could prove useul when investigating false positive rates in NGS of 
FFPE samples (Lamy et al. 2011). 
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We also encountered A:T>G:C artefacts in our FFPE-associated samples. 
These artefacts likely arose due to oxidation of thymine to 5-foU (Klungland et 
al. 2001; Schormann et al. 2014), which is capable of pairing with guanine. 
Removal of A:T>G:A artefacts with UDG was not as effective as it was for 
C:G>T:A artefacts. This may be due to UDG’s substrate specificity; however, 
treatment of FFPE-associated DNA with 5-foU DNA glycosylase (FDG; 
Matsubara et al. 2003) may result in removal of A:T>G:C artefacts. It may be 
beneficial for future NGS work to treat samples with FDG. 
 
6.2.3 Key findings from Chapter 5 
We noticed a high level of off-target reads in our somatic analyses. Mapping 
scores were generally good, and reads were mapping as paired-end reads as 
expected. It is possible that such off-target reads therefore represent 
contamination that occurred during library preparation. As contamination can 
occur during library preparation (Tosar et al. 2014) and sequencing itself 
(Dickins et al. 2014), extreme care must be taken throughout NGS protocols to 
ensure that accurate data are obtained. High levels of contamination (64% of 
the data) are not unheard of in NGS (Schmieder & Edwards 2011). A literature 
documenting non-human contamination is rapidly building, with evidence that 
projects such as the 1000 Genomes can be affected (Langdon 2014). The 
literature, however, provides limited bioinformatic solutions to the problem 
(Dickins et al. 2014; Cibulskis et al. 2011; Leggett et al. 2013). 
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We detected multiple variants in genes that could affect response to cetuximab. 
A third of the CRCs analysed in our study, that were previously believed to be 
wild type for KRAS, were found to carry KRAS mutations at somatic hotspots 
(codons 12 and 61). Furthermore, potentially novel biomarkers were discovered 
including a p.K5X mutation. This truncating mutation would most likely lead to 
loss of function as it occurs early in the ORF, although mutations at this codon 
have previously been associated with enhanced phosphorylation of downstream 
signaling molecules (Gremer et al. 2011). A p.K101X mutation in KRAS was 
found that could affect the ligand binding site and therefore downstream 
signalling (Buhrman et al. 2011), and a p.X190Q KRAS mutation is also likely to 
change the protein’s the structure and function. In NRAS, that was also 
previously believed to be wild type, a p.G13D mutation was discovered. The 
earlier technologies used to profile the CRCs may not have had the sensitivity 
to accurately call these mutations. 
 
A BRAF p.F595S mutation was discovered in the same CRC harbouring the 
p.K5X KRAS mutation. If the KRAS mutation leads to loss of function and hence 
decrease in signalling, then mutations at BRAF codon 595, previously believed 
to be activating (Kordes et al. 2015), may restore signalling and lead to lack of 
response in cetuximab-treatment. 
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Further mutations in PIK3CA may also be good candidates as cetuximab-
resistance biomarkers. Activating mutations including p.E542K, p.E545K, 
p.M1043I and p.A1046T were detected in our samples that have also been 
indicated in the literature (S. J. Chen et al. 2015; Tian et al. 2013). The 
p.M1043I mutation appears in combination with p.E542K, p.E545K and 
truncating mutations in PTEN. KRAS, NRAS and BRAF hotspots were all wild 
type in this CRC, increasing the likelihood that the PIK3CA mutants have a role 
in cetuximab response. 
 
Several candidate mutations were detected in PTEN that could lead to loss of 
function, and hence cetuximab-resistance (Dillon & Miller 2014; Molinari & 
Frattini 2013). Mutations  include nonsense mutations at codon 72, 130, 155, 
178 and 189 and a missense mutation (p.K289R) that may affect localisation of 
the protein (Song et al. 2012). 
 
We also noted numerous mutations in other EGFR pathway genes that warrant 
further investigation for a potential role in causing resistance to cetuximab. 
These variants need to be screened for in CRCs of patients that did respond to 
cetuximab – if they are genuine biomarkers of non-response then one would 
expect their absence or statistical under-representation in a responsive group of 
patients. 
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We observed high levels of C:G>T:A mutations in our UDG-treated CRCs. 
Around half of these DNA lesions appeared in a CpG context, suggested that 
the affected cytosine may be methylated (Gromenko et al. 2009) and their 
frequency is consistent with the literature (Cooper et al. 2010). These mutations 
may be indicators of methylation-associated gene expression or cell 
proliferation in CRC (Uribe-Lewis et al. 2015) and so further investigation may 
yield insights into cetuximab-response. 
 
As well as SNVs, alterations in expression levels of EGFR and other genes 
have been associated with response to cetuximab (Shigeta et al. 2013). 
However, the role of EGFR expression in modulating response remains 
controversial. Beyond the classical Ras-Raf-Mek-Erk signalling cascade, genes 
encoding members of seemingly unrelated pathways (such as E-cadherin) have 
also been suggested to alter response (Nikolova et al. 2009). It has also been 
suggested that mutations in other genes, such as FCGR3A (Pander et al. 
2010), are associated with reduced PFS in patients treated with cetuximab. 
Furthermore, microRNAs have also been suggested to alter response: Saridaki 
et al. (2014)  have recently associated a polymorphism in the let-7 microRNA 
binding site in KRAS with improved response to cetuximab. However, many of 
these alternate mechanisms require independent validation before they can be 
used in patient stratification. 
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Publications resulting from this PhD 
 
Exome Resequencing identifies potential tumor-supressor genes that 
predispose to colorectal cancer 
Smith CG*, Naven M*, Harris R, Colley J, West H, Li N, Liu Y, Adams R, 
Maughan TS, Nichols L, Kaplan R, McLeod HL & Cheadle JP.  
*joint first authors. 
Human Mutation (2013) 34:1026-1034 
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Appendix 
Custom Script 1 
#VarScape: Calling variants from the NGS data landscape 
#Modified version of var_gate.pl, which was originally modified from exomeExpress.pl. 
#Importantly this pipeline can handle exome and targeted resequencing data - with a few minor 
tweaks. To switch to targeted reseq analysis: 
# - obviously change the input/output folders for the dataset. 
# - remove the samtools rmdup step, and use the fixmate_sorted output as input for the 
realignment steps (will have to create an index for fixmate sorted output). 
# - for VQSR, disable VariantRecalibrator and ApplyRecalibration steps and instead 
activate the VariantFiltration tool. 
#Reverse the changes when handling exome data. 
 
#Calls variants with either UnifiedGenotyper or HaplotypeCaller. With HaplotypeCaller, use 
VariantFiltration instead of VariantRecalibrator (and therefore don't use ApplyRecalibration). For 
a list of best practice filters, see the GATK website. 
 
#Although the best practices for VQSR may specify to filter for mapping quality < 40 and 
haplotype score > 13, with the pilot project using Illumina's TruSeq Custom Amplicon kit, we find 
that known variants are labelled as filtered for the majority of samples - with the main culprit 
being haplotype score. 
#Known variants that passed the HS filter failed mainly on mapping quality. To increase 
specifity after VQSR, I therefore suggest removing the HaplotypeScore filter altogether and 
setting the MQ filter = 35. 
 
#Updated steps from exomeExpress.pl (applied after the analysis of the first 50 exomes): 
#The pipeline now uses a variant validation step, GATK's ValidateVariants tool. 
#The CountCovariates walker has been replaced by BaseRecalibrator and output is applied via 
PrintReads instead of TableRecalibration. 
#VQSR is now also applied to indels. 
 
#!/usr/bin/perl 
 
#This module allows you to create directories, useful when creating folders for the pipeline 
output. 
use File::Path; 
 
use Term::ANSIColor; 
 
#sub user definitions - Create output directories. This array must be in the main program as it is 
used by several subroutines. 
my @output_dirs = ( 
 "02_bwa_aln", "03_bwa_sam", "04_SAMtools_view", "05_SAMtools_sort", 
"06_SAMtools_fixmate", 
 "07_SAMtools_rmdup", "08_GATK_realignertargetcreator", "09_GATK_indelrealigner", 
"10_SAMtools_pileup", 
 "11_GATK_countcovariates", "12_GATK_tablerecalibration", 
"13_GATK_unifiedgenotyper", "14_GATK_selectvariants", 
 "15_GATK_variantrecalibrator", "16_GATK_applyrecalibration", 
"17_GATK_combinevariants", "18_snpEff", "19_GATK_variantannotator" 
); 
 
#create a reference of the output_dirs array for passing to subroutines. 
my $output_dirs = \@output_dirs; 
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#Call the subroutine that takes STDIN from the command line. User answers about sequencing 
data (e.g. location of reads, platform used, paired/single ends, whether to add annotation, etc). 
my ($system_calls_input, $exomes, $system_calls) = user_definitions($output_dirs); 
my @system_calls_input = @$system_calls_input; 
my %exomes = %{$exomes}; 
 
#Displays the user defined input to the user, so that he/she can check the chosen parameters 
before running the pipeline. The user enters 'y' to proceed, 'q' to quit or 'n' to re-enter the 
required input. 
while ($proceed ne "y"){ 
 print "Would you like to execute the pipeline using these parameters? Enter 'y' or 'n'. 
Enter 'q' to quit.\n"; 
 
 chomp($proceed = <STDIN>); 
  
 #convert $proceed to lower case. 
 $proceed =~ s/[A-Z]/[a-z]/; 
 
 #stop the script if the user enters "q" 
 exit if $proceed eq "q"; 
 
 #if the user is happy with their input, then go ahead and run the pipeline. 
 if ($proceed eq "y"){system_calls($output_dirs, $system_calls_input, $exomes, 
$system_calls);} 
  
 #if the user enters something other than y or n (or q), tell them to rechoose, 
 if ($proceed ne "y" && $proceed ne "n"){ 
      $proceed = ""; 
      print "Please enter 'y' or 'n'.\n"; 
     } 
      
     #If the user is not happy with their input, get them to re-enter it, 
     if ($proceed eq "n"){ 
      #call &user definitions again and capture the return values. 
      my ($system_calls_input, $exomes, $system_calls) = 
user_definitions($output_dirs); 
 
  #Take the returned references and turn them into proper arrays/hashes. 
  @system_calls_input = @$system_calls_input; 
  %exomes = %{$exomes}; 
  %system_calls = %{$system_calls}; 
 } 
} 
 
############################################################################
########################## 
#subroutine user_defitions 
#User enters the variables needed for the pipeline including: 
# number of processing cores available 
# location of the fastq input files 
# location to create output directories (and a check to confirm)/store output. 
# the reference genome file 
# the GATK.jar file 
# a file of known polymorphic sites (eg. from dbsnp hapmap and Mills & Devine) in '.vcf' 
format 
# the platform used for sequencing 
# the algorithm for alignment 
# paired ends or single ends or bwasw 
# the types of variants to call 
# ... 
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#The subroutine also gathers input fastq file names, names of output files and the read group 
header information. 
# 
############################################################################
########################## 
sub user_definitions{ 
 my $output_dirs = shift @_; 
 my @output_dirs = @$output_dirs; 
  
 #create local variables for each of the user inputs. 
 my ($bed_file, $call_regions, $trim_reads, $trimmomatic_jar, $seq_adapters, 
$create_index, $add_ann, $fastq_reads_dir, $output_dir, $create_dir, $reference_genome, 
$gatk_jar, $snpEff_jar, $dbsnp, $hapmap_vcf, $omni_vcf, $mills_Devine_vcf, $platform, 
$index_algorithm, $bwa_ended, $bigS, $who_ya_gonna_call, $cores,); 
  
 print "Please enter the choices asked for below. Files or directories should be entered 
as: \"/path/to/file/or/directory\" without the quotation marks.\nEntering 'q' or 's' will allow you to 
quit this program or skip a question, respectively.\nIf you do skip the question then one or more 
downstream processes may not work as expected!\n\n"; 
         
 #sub user definitions - fastq input location 
 #fastq dir is entered via command line (or user enters 'Q' to exit) and the existence of 
the dir is checked. 
  
 while ($fastq_reads_dir eq "" && $fastq_reads_dir ne "s"){ 
  print "\nPlease enter filepath to the folder containing your sequencing reads in 
FASTQ format.\n"; 
         $fastq_reads_dir = &ask; 
                   
         unless (-d $fastq_reads_dir){    
   if ($fastq_reads_dir ne "s"){ 
    $fastq_reads_dir = ""; 
    print "Directory $fastq_reads_dir not found. Please try 
again.\n"; 
   } 
  } 
        } 
         
        while ($trim_reads ne "y" && $trim_reads ne "n" && $trim_reads ne "s"){ 
         print"Would you like to trim adapter sequences from the reads? Please enter \"y\" or 
\"n\".\n"; 
          
         $trim_reads = &ask; 
          
         $trim_reads =~ tr/A-Z/a-z/; 
          
         if ($trim_reads ne "y" && $trim_reads ne "n" && $trim_reads ne "s"){ 
          $trim_reads = ""; 
          print "Please enter 'y' or 'n'.\n"; 
         } 
        } 
         
        #sub user definitions - GenomeAnalysisTK.jar location 
 print "\nPlease type the filepath to the GenomeAnalysisToolKit.jar file.\n"; 
 while ($trimmomatic_jar eq "" && $trimmomatic_jar ne "s"){ 
         $trimmomatic_jar = &ask; 
          
         unless (-f $trimmomatic_jar ){ 
          $trimmomatic_jar =~ tr/A-Z/a-z/; 
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   if ($trimmomatic_jar ne "s"){ 
    $trimmomatic_jar = ""; 
     
    print "Trimmomatic.jar not found! Try again or enter 'q' to 
quit\n"; 
   } 
  } 
        } 
         
        while ($seq_adapters eq "" && $seq_adapters ne "s"){ 
         print "\nPlease enter filepath to the sequencing adapter file.\n"; 
         $seq_adapters = &ask; 
          
         unless (-f $seq_adapters){ 
   unless ($seq_adapters eq "s"){ 
    $seq_adapters = ""; 
    print "Sequencing adapter file not found! Try again or enter 'q' 
to quit\n"; 
   } 
  } 
 } 
         
        while ($output_dir eq "" && $output_dir ne "s"){ 
         print "\nPlease enter filepath to the folder you would like your output storing. You may 
type the name of a new folder and it will be made.\n"; 
         $output_dir = &ask; 
          
         if ($output_dir eq "s"){$output_dir = "contamination";} 
         unless ($output_dir eq "s"){ 
   #cheat - enter bgix\d\d or unc to create output directories for BGI or 
North Carolina respectively 
   if ($output_dir eq "bgix10"){$output_dir = 
"/media/marc/Triceratops/Exomes/BGI output"}; 
   if ($output_dir eq "bgix13"){$output_dir = 
"/media/marc/Triceratops/Exomes/BGIx13 output"}; 
   if ($output_dir eq "bgix16"){$output_dir = 
"/media/marc/Triceratops/Exomes/BGIx16 output"}; 
   if ($output_dir eq "bgix18"){$output_dir = 
"/media/marc/Triceratops/Exomes/BGIx18 output"}; 
   if ($output_dir eq "unc"){$output_dir = 
"/media/marc/Triceratops/Exomes/UNC output"}; 
   if ($output_dir eq "nhs"){$output_dir = 
"/media/marc/Triceratops/Exomes/Pilot project output/NHS output"}; 
   if ($output_dir eq "nhs_trim"){$output_dir = 
"/media/marc/Triceratops/Exomes/NHS trimmed output"}; 
   if ($output_dir eq "nhs_repeat"){$output_dir = 
"/media/marc/Triceratops/Exomes/NHS repeat output"}; 
   if ($output_dir eq "wthd"){$output_dir = 
"/media/marc/Triceratops/Exomes/Pilot project output/WT (HD) output"}; 
   if ($output_dir eq "wtld"){$output_dir = 
"/media/marc/Triceratops/Exomes/WT (LD) output"}; 
   if ($output_dir eq "eden"){$output_dir = 
"/media/marc/Triceratops/Exomes/Eden output"}; 
   if ($output_dir eq "ingram"){$output_dir = 
"/media/marc/Triceratops/Exomes/Ingram 14-6697 output"}; 
   if ($output_dir eq "miseq"){$output_dir = 
"/media/marc/Triceratops/Exomes/Miseq output"}; 
   if ($output_dir eq "nr"){$output_dir = 
"/media/marc/Triceratops/Exomes/Non responder output"}; 
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   if ($output_dir eq "contamination"){$output_dir = 
"/media/marc/Triceratops/Exomes/Contamination output"}; 
  } 
   
  my ($output_dir, $create_dir) = let_there_be_output($output_dir, $output_dirs); 
        } 
         
        #sub user definitions - reference genome location 
 print "\nPlease type the filepath to the reference genome.\n"; 
  
 while ($reference_genome eq "" && $reference_genome ne "s"){ 
         $reference_genome = &ask; 
          
         unless (-f $reference_genome ){ 
          $reference_genome =~ tr/A-Z/a-z/; 
   unless ($reference_genome eq "s"){ 
    $reference_genome = ""; 
    print "Reference genome not found! Try again or enter 'q' to 
quit\n"; 
   } 
  } 
        } 
         
        #sub user definitions - GenomeAnalysisTK.jar location 
 print "\nPlease type the filepath to the GenomeAnalysisToolKit.jar file.\n"; 
 while ($gatk_jar eq "" && $gatk_jar ne "s"){ 
         $gatk_jar = &ask; 
          
         unless (-e $gatk_jar ){ 
          $gatk_jar =~ tr/A-Z/a-z/; 
           
   if ($gatk_jar ne "s"){ 
    $gatk_jar = ""; 
     
    print "GenomeAnalysisTK.jar not found! Try again or enter 'q' to 
quit\n"; 
   } 
  } 
        } 
         
        #sub user definitions - snpEff.jar and snpEff.config locations 
 print "\nPlease type the filepath to the snpEff.jar file.\n"; 
 while ($snpEff_jar eq "" && $snpEff_jar ne "s"){ 
  $snpEff_jar = &ask; 
   
  unless (-e $snpEff_jar ){ 
   $snpEff_jar =~ tr/A-Z/a-z/; 
    
   if ($snpEff_jar ne "s"){ 
    $snpEff_jar = ""; 
    print "snpEff.jar not found! Try again or enter 'q' to quit\n"; 
   } 
  } 
   
 } 
  
  ##sub user definitions - Enter the regions for variant calling. 
  while ($call_regions !~ /^[yns]$/i){ 
         print "Would you like to call variants at specific regions? Please enter 'y' or 'n'.\n"; 
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         $call_regions = &ask; 
         $call_regions =~ tr/A-Z/a-z/; 
          
         unless ($call_regions =~ /^[yns]$/){ 
          $call_regions = ""; 
          print "Please enter 'y' or 'n'.\n"; 
         } 
          
         if ($call_regions eq "y" || $call_regions eq "s"){ 
   print "\nEnter BED file containing regions for variant calling.\n"; 
    
   while ($bed_file eq "" && $bed_file ne "s"){ 
    $bed_file = &ask; 
    
    unless (-f $bed_file){ 
     unless ($bed_file eq "s"){ 
      $bed_file = ""; 
       
      print "Please enter the filepath to regions for 
variant calling.\n"; 
     } 
    } 
   } 
  } 
 } 
  
        #option to index reference genome 
        print "\nWould you like to create an index for the reference genome?\n If you have not 
done this before you must do it before the pipeline can proceed.\n"; 
        while ($create_index eq "" && $create_index ne "y" && $create_index ne "n" && 
$create_index ne "s"){ 
         $create_index = &ask; 
         $create_index =~ tr/A-Z/a-z/; 
          
         if ($create_index ne "y" && $create_index ne "n" && $create_index ne "s"){ 
          $create_index = ""; 
          print "Please enter 'y' or 'n'.\n"; 
         } 
        } 
         
        #sub user definitions - annotate variants? 
 print "\nWould you like to add annotations to your variant calls? This step is advised. 
Enter 'y' or 'n'\n"; 
 while ($add_ann eq "" && $add_ann ne "y" && $add_ann ne "n" && $add_ann ne "s"){ 
         $add_ann = &ask; 
         $add_ann =~ tr/A-Z/a-z/; 
          
         if ($add_ann ne "y" && $add_ann ne "n" && $add_ann ne "s"){ 
          $add_ann = ""; 
          print "Please enter 'y' or 'n'.\n"; 
         } 
        } 
 
        #sub user definitions - training dbSNP_Vxxx.vcf location 
 print "\nPlease type the filepath to the known polymorphic sites dbSNP '.vcf' file.\n"; 
 while ($dbsnp eq "" && $dbsnp ne "s"){ 
         $dbsnp = &ask; 
          
         unless (-e $dbsnp ){ 
          $dbsnp =~ tr/A-Z/a-z/; 
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   if ($dbsnp ne "s"){ 
    $dbsnp = ""; 
     
    print "dbSNP '.vcf' file not found! Try again or enter 'q' to quit\n"; 
   } 
  } 
        } 
         
        #sub user definitions - training hapmap vcf location 
        print "\nPlease type the filepath to the known polymorphic sites hapmap '.vcf' file.\n"; 
         
 while ($hapmap_vcf eq "" && $hapmap_vcf ne "s"){ 
         $hapmap_vcf = &ask; 
          
         unless (-e $hapmap_vcf ){ 
          $hapmap_vcf =~ tr/A-Z/a-z/; 
    
   if ($hapmap_vcf ne "s"){ 
    $hapmap_vcf = ""; 
     
    print "hapmap '.vcf' file not found! Try again or enter 'q' to 
quit\n"; 
   } 
  } 
        } 
         
        #sub user definitions - training 1000 genomes omni chip 2.5M vcf location 
        print "\nPlease type the filepath to the known polymorphic sites 1000genomes omni chip 
'.vcf' file.\n"; 
 while ($omni_vcf eq "" && $omni_vcf ne "s"){ 
         $omni_vcf = &ask; 
          
         unless (-e $omni_vcf ){ 
          $omni_vcf =~ tr/A-Z/a-z/; 
    
   if ($omni_vcf ne "s"){ 
    $omni_vcf = ""; 
     
    print "omni '.vcf' file not found! Try again or enter 'q' to quit\n"; 
   } 
  } 
        } 
         
        #sub user definitions - training 1000 genomes omni chip 2.5M vcf location 
        print "\nPlease type the filepath to the 1000g Phase 1 high confidence SNPs '.vcf' file.\n"; 
         
 while ($phase1 eq "" && $phase1 ne "s"){ 
         $phase1 = &ask; 
          
         unless (-e $phase1 ){ 
          $phase1 =~ tr/A-Z/a-z/; 
    
   if ($phase1 ne "s"){ 
    $phase1 = ""; 
     
    print "1000G Phase 1 SNPs file not found! Try again or enter 'q' 
to quit\n"; 
   } 
  } 
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        } 
         
        #sub user definitions - training Mills & Devine vcf location 
        print "\nPlease type the filepath to the known polymorphic sites Mills & Devine '.vcf' file.\n"; 
         
 while ($mills_Devine_vcf eq "" && $mills_Devine_vcf ne "s"){ 
         $mills_Devine_vcf = &ask; 
          
         unless (-e $mills_Devine_vcf ){ 
          $mille_Devine_vcf =~ tr/A-Z/a-z/; 
    
   if ($mills_Devine_vcf ne "s"){ 
    $mills_Devine_vcf = ""; 
     
    print "Mills & Devine '.vcf' file not found! Try again or enter 'q' to 
quit\n"; 
   } 
  } 
        } 
         
        #Sub user definitions - Choose the sequencing platform 
 print "\nPlease enter the sequencing platform; either 'CAPILLARY' 'LS454' 'ILLUMINA' 
'SOLID' 'HELICOS' IOTORRENT' or 'PACBIO'.\n"; 
  
 while ($platform eq "" && $platform ne "S"){ 
         $platform = &ask;          
         $platform =~ tr/[a-z]/[A-Z]/; 
          
         if ( 
   $platform ne "CAPILLARY" && $platform ne "LS454" && $platform ne 
"ILLUMINA" && 
   $platform ne "SOLID" && $platform ne "HELICOS" && $platform ne 
"IOTORRENT" && 
   $platform ne "PACBIO" && $platform ne "s" && $platform ne "Q" && 
$platform ne "S" 
  ){ 
   $platform = ""; 
    
   print "\nError: please select from 'CAPILLARY', 'LS454', 'ILLUMINA', 
'SOLID', 'HELICOS', 'IOTORRENT' or 'PACBIO'.\n"; 
  } 
        } 
 
        ##sub user definitions - Enter the bwa index algorithm 
        print "\nEnter algorithm to use for bwa index either 'is' or 'bwtsw' (recommended).\n"; 
         
 while ($index_algorithm eq "" && $index_algorithm ne "s" && $platform ne "LS454"){ 
         $index_algorithm = &ask; 
          
         $index_algorithm =~ tr/[A-Z]/[a-z]/; 
          
         if ($index_algorithm ne "is" && $index_algorithm ne "bwtsw" && $index_algorithm 
ne "s"){ 
          $index_algorithm = ""; 
          print "Please select either 'is' or 'bwtsw'.\n"; 
         } 
  } 
  
 #sub user definitions - choose samse sampe or bwasw based on platform choice 
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 unless ($platform eq "LS454"){ #LS454 uses bwasw not bwa samse/sampe - colour 
reads not space reads! 
  print "\nAre your reads single- or paired-ended? Enter either 'samse' (single 
ends) or 'sampe' (paired ends).\n"; 
   
  while ($bwa_ended eq "" && $bwa_ended ne "s"){ 
   $bwa_ended = &ask; 
   $bwa_ended =~ tr/[A-Z]/[a-z]/; 
    
   if ($bwa_ended ne "sampe" && $bwa_ended ne "samse" && 
$bwa_ended ne "s"){ 
    $bwa_ended = ""; 
    print "Please select either 'samse' or 'sampe'. Enter 'q' to quit or 
's' to skip.\n"; 
   } 
  } 
   
  #cheat - default setting on panther 
  if ($bwa_ended eq "s"){$bwa_ended = "sampe";} 
        } 
 
        #use bwasw instead of bwa sampe/samse. 
        else{ 
  $bwa_ended = "bwasw"; 
 } 
  
 if ($bwa_ended eq "sampe"){$bigS = "S";} 
        else {$bigS = "s";} 
 
 #Sub user definitions - Choose the variants to call 
 print "\nWould you like to call SNPs indels or both?\n"; 
 while ($who_ya_gonna_call eq "" && $who_ya_gonna_call ne "S"){ 
         $who_ya_gonna_call = &ask; 
         $who_ya_gonna_call =~ tr/[a-z]/[A-Z]/; 
          
         if ($who_ya_gonna_call ne "SNP" && $who_ya_gonna_call ne "INDEL" && 
$who_ya_gonna_call ne "BOTH" && $who_ya_gonna_call ne "S"){ 
   $who_ya_gonna_call = ""; 
   print "Error please select from 'SNP' 'INDEL' or 'BOTH'.\n"; 
  } 
        } 
 
 #Sub user definitions - Choose the variants to call 
 print "\nWould you like to combine samples to call variants? .\n"; 
 while ($pro_multi eq "" && $pro_multi ne "s"){ 
         $pro_multi = &ask; 
         $pro_multi =~ tr/[A-Z]/[a-z]/; 
          
         if ($pro_multi ne "y" && $pro_multi ne "n" && $pro_multi ne "s"){ 
   $pro_multi = ""; 
   print "Error: please select from 'y' or 'n''.\n"; 
  } 
        } 
 
        ##sub user definitions - Enter the number of cores available. 
        print "\nEnter number of processing cores you have available for use.\n"; 
 while ($cores eq "" && $cores ne "s"){ 
         $cores = &ask; 
         $cores =~ tr/A-Z/a-z/; 
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         if ($cores =~ /\D/ && $cores >= 10 && $cores ne "s"){ 
          $cores = ""; 
           
          print "Please select a realistic (<10) numerical value. Note that you should not 
enter more processors than you have!\n"; 
         } 
  } 
  
 #Default settings on Panther.  
 if ($fastq_reads_dir eq "s"){$fastq_reads_dir = "/media/marc/Brachiosaur/NGS 
data/Contamination profile/Fastq files";} 
 if ($reference_genome eq "s"){$reference_genome = 
"/media/marc/Brachiosaur/Exomes/reference genome/human_g1k_v37.fasta";}#NGS data/Pilot 
project (KRAS, NRAS, BRAF & PIK3CA)/NHS Miseq/Misc Miseq generated 
files/Reference/Chris-Pilot.txt.fa";} 
 if ($trimmomatic_jar eq "s"){$trimmomatic_jar = "/home/marc/Documents/bioinformatics 
software/Trimmomatic-0.32/trimmomatic-0.32.jar";} 
 if ($seq_adapters eq "s"){$seq_adapters = "/home/marc/Documents/bioinformatics 
software/Trimmomatic-0.32/adapters/TruSeq3-PE-2.fa";} 
 if ($gatk_jar eq "s"){$gatk_jar = "/home/marc/Documents/bioinformatics 
software/GenomeAnalysisTK-3.3-0/GenomeAnalysisTK.jar";} 
 if ($dbsnp eq "s"){$dbsnp = "/media/marc/Brachiosaur/Exomes/database 
resources/dbSNP_141_b37.vcf";} 
 if ($snpEff_jar eq "s"){$snpEff_jar = "/home/marc/Documents/bioinformatics 
software/snpEff_3_6/snpEff.jar";} 
 if ($hapmap_vcf eq "s"){$hapmap_vcf = "/media/marc/Brachiosaur/Exomes/database 
resources/hapmap_3.3.b37.sites.vcf";} 
 if ($omni_vcf eq "s"){$omni_vcf = "/media/marc/Brachiosaur/Exomes/database 
resources/1000G_omni2.5.b37.sites.vcf";} 
 if ($phase1 eq "s"){$phase1 = "/media/marc/Brachiosaur/Exomes/database 
resources/1000G_phase1_snps_high_confidence_b37.vcf";} 
 if ($mills_Devine_vcf eq "s"){$mills_Devine_vcf = 
"/media/marc/Brachiosaur/Exomes/database resources/Mills_Devine_2hit.indels.b37.sites.vcf";} 
 if ($bed_file eq "s"){$bed_file = "/home/marc/Documents/work/reseq analysis/pilot 
project/Miscellaneous/hotspot codon regions.BED";} 
 if ($call_regions eq "s"){$call_regions = "n";} 
 if ($create_index eq "s"){$create_index = "y";} 
        if ($add_ann eq "s"){$add_ann = "y";} 
        if ($platform eq "S"){$platform = "ILLUMINA";} 
        if ($index_algorithm eq "s"){$index_algorithm = "bwtsw";} 
        if ($who_ya_gonna_call eq "S"){$who_ya_gonna_call = "BOTH";} 
        if ($pro_multi eq "s"){$pro_multi = "n";} 
        if ($cores eq "s"){$cores = 13;} 
         
        #The SNPEff config file is also required. Assuming a standard install of SNPEff, this config 
file should be in the same folder as the snpEff.jar file. 
        $snpEff_config = $snpEff_jar; 
 $snpEff_config =~ s/jar/config/; 
   
 #The neccessary input to read_exomes sub. Although the @output_dirs here is stored 
in @inputs as simple variables, they can be collected back into an array in read_exomes. 
 my @read_exome_inputs = ($fastq_reads_dir, $output_dir, $bwa_ended, $platform, 
$who_ya_gonna_call); 
 my $read_exome_inputs = \@read_exome_inputs; 
  
 #calls &read_exomes sub using @read_exome_inputs as input and traps the returned 
references as scalars, which can then be turned back into arrays or hashes. 
 my $exomes = read_fq($read_exome_inputs, $output_dirs); 
  
 my $system_calls; 
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 # ($exomes, $system_calls) = trim($exomes, $trimmomatic_jar, $seq_adapters, 
$cores); 
  
 #Turn the returned hash references into a proper hash. 
 my %exomes = %{$exomes}; 
  
 #visible checks for varibles which have just been input. 
 print  "\nInput directory:\n$fastq_reads_dir\n\n"; 
 print  "Output directory:\n$output_dir\n\n"; 
 print  "Create dir check:\n$create_dir\n\n"; 
 print "Trimmomatic.jar:\n$trimmomatic_jar\n\n"; 
 print "Sequencing adapter file:\n$seq_adapters\n\n"; 
 print  "Reference genome:\n$reference_genome\n\n"; 
 print  "Index reference?:\n$create_index\n\n"; 
 print  "GATK.jar:\n$gatk_jar\n\n"; 
 print  "dbSNP.vcf:\n$dbsnp\n\n"; 
 print  "Hapmap.vcf:\n$hapmap_vcf\n\n"; 
 print  "Mills & Devine.vcf:\n$mills_Devine_vcf\n\n"; 
 print  "Sequencing platform:\n$platform\n\n"; 
 print  "Index algorithm:\n$index_algorithm\n\n"; 
 print  "Endings:\n$bwa_ended\n\n"; 
 print  "Variants to call:\n$who_ya_gonna_call\n\n"; 
 print "Regions to call (y/n: $call_regions): $bed_file\n\n"; 
 print  "Cores:\n$cores\n\n"; 
  
 my @system_calls_input = ($call_regions, $bed_file, $trimmomatic_jar, $seq_adapters, 
$create_index, $add_ann, $fastq_reads_dir, $output_dir, $reference_genome, $gatk_jar, 
$snpEff_jar, $dbsnp, $hapmap_vcf, $omni_vcf, $phase1, $mills_Devine_vcf, $platform, 
$index_algorithm, $bwa_ended, $bigS, $who_ya_gonna_call, $pro_multi, $cores, $output_dirs); 
 
 return (\@system_calls_input, \%exomes, $system_calls); 
} 
############################################################################
########################## 
#end of user_definitions subroutine. 
############################################################################
########################## 
 
############################################################################
########################## 
#subroutine ask 
#Gets STDIN from the user, and exits the script if the input is 'q'. 
############################################################################
########################## 
sub ask{ 
  my $input; 
          
         # $input = "s"; 
          
         chomp ($input = <STDIN>); 
          
         exit if ($input eq "q" || $input eq "Q"); 
         return $input; 
} 
############################################################################
########################## 
#end of ask subroutine. 
############################################################################
########################## 
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############################################################################
########################## 
#subroutine read_exomes 
#reads in files from the specified exome directory. 
#Returns the name of the output files in a hash: 
#%exomes = ( 
# $sample => { 
#  output_step_1 
#  output_step_2 .. 
#  output_step_n 
# } 
#) 
############################################################################
########################## 
sub read_fq{ 
 #name the local variables passed on from &user_definitions for each of the user inputs. 
 #@output_dirs captures the variables from the previous @output_dirs array, so the 
parameters passed on are essentially identical. 
 my ($read_exome_inputs, $output_dirs) = @_; 
 my @read_exome_inputs = @$read_exome_inputs; 
 my @output_dirs = @$output_dirs; 
  
 my ($fastq_reads_dir, $output_dir, $bwa_ended, $platform, $who_ya_gonna_call) = 
@read_exome_inputs; 
  
 #initialise the %exomes hash but don't populate it yet. Gives lexical scope. 
 #This hash will contain names of input/output files for each sample. 
 my (%exomes, $sample_count); 
  
 #Search the $fastq_reads_dir and its subdirectories for any FASTQ or FQ files. 
 #The sub_dirs scalar returned here is of no further use. 
        my ($fq_reads, $sub_dirs) = subway($fastq_reads_dir); 
        my %fq_reads = %{$fq_reads}; 
         
        ##sub user definitions - loop over the hash of input fastq files for various purposes. 
        for my $coinID (sort {"\L$a" cmp "\L$b"} keys %fq_reads){ 
  foreach my $fq_file (sort {"\L$a" cmp "\L$b"} @{$fq_reads{$coinID}}){ 
   my (%RG_header, $sampleID, $lane, $mate, $dna_type); 
    
   #count how many sample files have been analysed so far 
   $sample_count++; 
    
   if ($coinID =~ /\-[a-z]+/){$dna_type = $&;} 
    
   #set the variables for this sample. 
   $sampleID = $fq_file; 
    
   $sampleID =~ s/\_(trimmed|repeat)//i; 
    
   #remove the file path and file extension, along with "_pe" that some file 
names may have. Also remove the run, COIN ID and tissue type. 
   $sampleID =~ s/^.+\///g; 
   $sampleID =~ s/\..+$//; 
   $sampleID =~ s/^.+\-.+\-[a-z]+\_//i; 
   if ($sampleID =~ /\_pe/i){$sampleID =~ s/$&//;} 
    
   my @sampleID = split (/\_/, $sampleID); 
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   #remove the mate info for 'multi_sample'. 
   if ($sampleID =~ /multiSample/i){$sampleID =~ s/\_\d$//;} 
    
   if ($fq_file =~ /Chapel Hill Data/){ 
    $lane = $sampleID[3]; 
    $mate = $sampleID[4]; 
   } 
    
   elsif ($fq_file =~ /(Non 
responder)|(Contamination)|(PIK3CA\)\/NHS)|(NHS Miseq)|(NHS repeat)|(NHS 
trimmed)|(Eden)|(Ingram)/){ 
    $lane = $sampleID[1]; 
    $lane =~ s/L00//i; 
     
    $mate = $sampleID[2]; 
    $mate =~ s/R//i; 
     
   } 
    
   else{ 
    #set a generic lane for now. You should be able to determine 
lane from fastq files. 
    $lane = 1; 
    $mate = $sampleID[1]; 
   } 
    
   $sampleID = $coinID."\_".$mate; 
    
   %RG_header = ( 
    $sampleID => { 
     ID => $sampleID, 
     SM => $coinID, 
     Mate => $mate, 
     Lane => $lane, 
     PL => $platform 
    } 
   ); 
    
   print "sampleid: $sampleID\n"; 
 
   #Populate the %exomes hash with RG info for this sample. 
   ${$exomes{$sampleID}{RG_headline}} = 
"\@RG\tID:$RG_header{$sampleID}{ID}\tSM:$RG_header{$sampleID}{SM}\tPL:$RG_header{$
sampleID}{PL}"; 
    
   #sub user definitions - make names of input/output files ('.sai' '.sam' 
'.bam'  '.intervals' '.tranches' '.csv' '.vcf', etc) and store in an exome unique hash. 
   #the hash is built so that each element has the required information for 
calling systems later. i.e. bwa aln has info for both mate pairs whereas samtools sort has info for 
just the exome name/ID 
   #this is because bwa sampe will merge mate pairs into a single file for 
the exome. 
   ${$exomes{$sampleID}{aln_sai}} = 
"\"$output_dir/$output_dirs[0]/$sampleID\_aln.sai\"";     
  #step 2 output (2nd mate) bwa aln 
   ${$exomes{$sampleID}{mate_1_file}} = "\"${$fq_reads{$coinID}}[0]\"";
          #original 1st 
mate query filename 
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   ${$exomes{$sampleID}{mate_2_file}} = "\"${$fq_reads{$coinID}}[1]\"";
          #original 2nd 
mate query filename 
    
   ${$exomes{$sampleID}{mate_1_paired}} = 
"\"$fastq_reads_dir\/$coinID\_1\_paired.fq\""; 
   ${$exomes{$sampleID}{mate_1_unpaired}} = 
"\"$fastq_reads_dir\/$coinID\_1\_unpaired.fq\""; 
   ${$exomes{$sampleID}{mate_2_paired}} = 
"\"$fastq_reads_dir\/$coinID\_2\_paired.fq\""; 
   ${$exomes{$sampleID}{mate_2_unpaired}} = 
"\"$fastq_reads_dir\/$coinID\_2\_unpaired.fq\""; 
    
   #list continued under separate array loop so that exome mate pairs are 
not duplicated (step 3 merges mates 1 & 2 into a single file). 
   #finish making names of output files for step 3 (bwa 
sampe/samse/bwasw) onwards. 
   #Will consider the 2nd mate pair only (1st mate pair not important at 
this step). 
   if ($mate == 2){ 
    ${$exomes{$sampleID}{aln_sai_prev}} = 
"${$exomes{\"$coinID\_1\"}{aln_sai}}";       
     #The aln.sai file for mate 1 
     
    ${$exomes{$sampleID}{sam}} = 
"\"$output_dir/$output_dirs[1]/$coinID\_$bwa_ended\.sam\"";    
      #step 3 output bwa sam 
    ${$exomes{$sampleID}{view_bam}} = 
"\"$output_dir/$output_dirs[2]/$coinID\_view.bam\"";     
     #step 4 output samtools view 
    ${$exomes{$sampleID}{sorted_bam}} = 
"\"$output_dir/$output_dirs[3]/$coinID\_sorted";      
     #step 5 output samtools sort. Notice the lack of 
quotation mark at the end. This is added in system_calls. 
    ${$exomes{$sampleID}{fixmate_bam}} = 
"\"$output_dir/$output_dirs[4]/$coinID\_fixmate.bam\"";     
    #step 6 output samtools fixmate 
    ${$exomes{$sampleID}{postfixmate_sorted_bam}} = 
"\"$output_dir/$output_dirs[4]/$coinID\_post_fixmate_sorted";    
  #step 6 output samtools sort (2). Notice the lack of quotation mark at the end. 
This is added in system_calls. 
    ${$exomes{$sampleID}{nodups_bam}} = 
"\"$output_dir/$output_dirs[5]/$coinID\_nodups.bam\"";     
    #step 7 output samtools rmdup 
    ${$exomes{$sampleID}{indels_intervals}} = 
"\"$output_dir/$output_dirs[6]/$coinID\_indels.intervals\"";    
    #step 8 output gatk realigner target creator 
    ${$exomes{$sampleID}{realigned_bam}} = 
"\"$output_dir/$output_dirs[7]/$coinID\_realigned.bam\"";     
   #step 9 output gatk indel realigner 
    ${$exomes{$sampleID}{mpileup_bam}} = 
"\"$output_dir/$output_dirs[8]/$coinID\_mpileup_bam\"";     
    #step 10 output samtools mpileup 
    ${$exomes{$sampleID}{recalibrated_grp}} = 
"\"$output_dir/$output_dirs[9]/$coinID\_recalibrated.grp\"";    
    #step 11 output gatk base recalibrator 
    ${$exomes{$sampleID}{recalibrated_bam}} = 
"\"$output_dir/$output_dirs[10]/$coinID\_recalibrated.bam\"";    
   #step 12 output gatk table recalibrator 
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    ${$exomes{$sampleID}{metrics}} = 
"\"$output_dir/$output_dirs[11]/$coinID\_metrics.txt\"";     
     #step 14 output gatk unified genotyper 
    ${$exomes{$sampleID}{variant_calls}} = 
"\"$output_dir/$output_dirs[11]/$coinID\_$who_ya_gonna_call.vcf\"";   
    #step 14 output gatk unified genotyper 
    ${$exomes{$sampleID}{SNPs_only}} = 
"\"$output_dir/$output_dirs[12]/$coinID\_SNPs_only.vcf\"";    
     #step 14 & 15 output SNPs gatk select variants 
    ${$exomes{$sampleID}{indels_only}} = 
"\"$output_dir/$output_dirs[12]/$coinID\_indels_only.vcf\"";    
     #step 14 & 15 output indels select variants 
    ${$exomes{$sampleID}{SNPs_recal}} = 
"\"$output_dir/$output_dirs[13]/$coinID\_SNPs.csv\"";     
    #step 16 output SNPs gatk variant recalibrator 
    ${$exomes{$sampleID}{indels_recal}} = 
"\"$output_dir/$output_dirs[13]/$coinID\_indels.csv\"";     
    #step 16 output SNPs gatk variant recalibrator 
    ${$exomes{$sampleID}{SNPs_tranches}} = 
"\"$output_dir/$output_dirs[13]/$coinID\_SNPs.tranches\"";    
    #step 16 output SNPs gatk variant recalibrator 
    ${$exomes{$sampleID}{indels_tranches}} = 
"\"$output_dir/$output_dirs[13]/$coinID\_indels.tranches\"";    
    #step 16 output indels gatk variant recalibrator 
    ${$exomes{$sampleID}{SNPs_recalibrated}} = 
"\"$output_dir/$output_dirs[14]/$coinID\_SNPs_recalibrated.vcf\"";   
   #step 17 output SNPs gatk apply recalibration 
    ${$exomes{$sampleID}{indels_recalibrated}} = 
"\"$output_dir/$output_dirs[14]/$coinID\_indels_recalibrated.vcf\"";   
   #step 17 output indels gatk apply recalibration 
    ${$exomes{$sampleID}{recalibrated_variants_combined}} = 
"\"$output_dir/$output_dirs[15]/$coinID\_all_recalibrated_variants.vcf\"";   #step 
18 output gatk combine variants 
    ${$exomes{$sampleID}{snpEff_output}} = 
"\"$output_dir/$output_dirs[16]/$coinID\_snpEff_output.vcf\"";    
    #step 19 output snpEff 
    ${$exomes{$sampleID}{variants_annotated}} = 
"\"$output_dir/$output_dirs[17]/$coinID\_variants_annotated.vcf\"";   
   #step 20 output gatk variant annotator  
   } 
  } 
 
  # for $keys (sort keys %exomes){ 
   # print color ("blue"), "read_exomes (hash generation) keys: $keys\n"; 
   # print color 'reset'; 
  # } 
 } 
  
 return (\%exomes); 
} 
############################################################################
################################################## 
#end of sub read_exomes 
############################################################################
################################################## 
 
############################################################################
################################################## 
#subroutine subway 
#Search subdirectories of a specified directory for FASTQ files. 
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############################################################################
################################################## 
sub subway{ 
 #get the directory. 
 my $dir = shift; 
  
 #open the directory. 
 opendir FQ, "$dir" or die $!; 
 
 #Read in all files from the directory (excluding the "." and ".." files which may be 
present), and store the full filepaths in an array. 
 my @sub_dirs = map{$dir."/".$_} grep {"$dir/$_" && !/^\.{1,2}$/} readdir FQ; 
 
 #foreach file and sub directory within the current directory. 
 foreach $sub_dir (sort {"\L$a" cmp "\L$b"} @sub_dirs){ 
  #If the current file matches a certain criteria ('-f' specifies a file). 
  if (-f "$sub_dir" && $sub_dir =~ /(fastq|fq)$/i){ 
   #Get the sample name (COIN ID) from the full file path. 
   my $coin = $sub_dir; 
   my $multi_sample; 
    
   #remove the file path and file extension, along with "_pe" that some file 
names may have. 
   $coin =~ s/^.+\///g; 
   $coin =~ s/\..+$//; 
   if ($coin =~ /\_pe/i){$coin =~ s/$&//;} 
    
   my @coin = split (/\-/, $coin); 
    
   $coin[2] =~ s/\_.+$//; 
    
   $coin = "$coin[0]-$coin[1]-$coin[2]"; 
    
   next if $coin =~ /001/i;print "$coin\n"; 
   # next unless $coin =~ /NR6/i; 
    
   if ($coin =~ /\-[a-z]+|Undetermined/){$multi_sample = 
"multiSample".$&;} 
   else{$multi_sample = "multiSample";} 
    
   #Captures FASTQ filepaths in a hash of arrays. 
   unless (grep {$sub_dir eq $_} sort {"\L$a" cmp "\L$b"} 
@{$fq_reads{$coin}}){ 
    push @{$fq_reads{$coin}}, $sub_dir; 
   } 
    
   unless (grep {"$multi_sample\_2" eq $_} sort{"\L$a" cmp "\L$b"} 
@{$fq_reads{$multi_sample}}){ 
    push @{$fq_reads{$multi_sample}}, "$multi_sample\_2"; 
   } 
  } 
   
  #if the directory contains sub directories, store them in the array and call this 
sub routine on them. 
  #the result is each sub directory within a directory will be searched before 
moving onto the next directory; 
  #e.g. a/1/i and a/1/ii will be searched before a/2/i, etc. 
  if (-d $sub_dir){push @sub_dirs, subway($sub_dir);} 
 } 
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 return (\%fq_reads, \@sub_dirs); 
} 
############################################################################
################################################## 
#end of sub subway 
############################################################################
################################################## 
 
############################################################################
################################################## 
#subroutine let_there_be_output 
#creates directories is necessary for the output from the pipeline. 
############################################################################
################################################## 
sub let_there_be_output{ 
 my ($output_dir, $output_dirs) = @_; 
 my @output_dirs = @$output_dirs; 
 my $create_dir; 
  
 while ($create_dir ne "Y" && $create_dir ne "n" && $create_dir ne "s"){ 
  print "\nAre you sure you want to create output folders in ".$output_dir."? Enter 
'Y' for yes or 'n' for no.\n"; 
  $create_dir = &ask; 
   
  if ($create_dir eq "Y"){ 
   #Unless it already exists create an output directory for each folder 
name in @output_dir 
   foreach my $sub_dir (sort {"\L$a" cmp "\L$b"} @output_dirs){ 
    unless (-d "$output_dir/$sub_dir"){ 
     mkpath("$output_dir/$sub_dir") or print "could not 
create $output_dir/$sub_dir\n"; 
     print "Creating folder: \"$output_dir/$sub_dir\".\n"; 
    } 
   } 
  } 
 
  #user doesn't want to create dir. 
  if ($create_dir ne "Y" && $create_dir ne "n" && $create_dir ne "s"){ 
   print "$output_dir not created. Please enter either 'Y' or 'n' only.\n"; 
   $create_dir = ""; 
  } 
 } 
  
 return ($output_dir, $create_dir); 
} 
############################################################################
################################################## 
#end of sub read_exomes. 
############################################################################
################################################## 
 
############################################################################
########################################################### 
#subroutine trim. 
#Calls trimmomatic to trim Illumina adapter sequences from the ends of reads. 
############################################################################
########################################################### 
sub trim{ 
 my ($exomes, $trimmomatic_jar, $seq_adapters, $cores) = @_; 
 my %exomes = %{$exomes}; 
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 for my $sampleID (sort keys %exomes){ 
  next if $sampleID =~ /multiSample/; 
  my ($coinID, $mate, $RG_headline, $mate_file); 
   
  #Copies the name of the fastq file and then removes the sequencing/mate 
information fom the copied variable. 
         #It is essential to still retain the mate information for the samples as 'bwa aln' will use 
this. The copied variable will be used for naming output files for steps further in the pipeline. 
  if ($sampleID =~ /(\_.+$)/){ 
   $mate = $&; 
   $coinID = $sampleID; 
    
   $coinID =~ s/$&//; 
   $mate =~ s/\_//; 
  } 
   
  $mate_1_trimmed = ${$exomes{$sampleID}{mate_1_file}}; 
  $mate_2_trimmed = ${$exomes{$sampleID}{mate_2_file}}; 
   
  $mate_1_trimmed =~ s/\.(fq|fastq)/\_trimmed\.fq/i; 
  $mate_2_trimmed =~ s/\.(fq|fastq)/\_trimmed\.fq/i; 
   
  my $trimlog = $mate_2_trimmed; 
  $trimlog =~ s/trimmed\.fq/trimlog/i; 
   
  if ($mate == 2){ 
   unless (-f "$mate_1_trimmed"){ 
    push @{$system_calls{$coinID}}, 
     # "java -jar \"$trimmomatic_jar\" PE -threads $cores -
phred33 -trimlog $trimlog ${$exomes{$sampleID}{mate_1_file}} 
${$exomes{$sampleID}{mate_2_file}} ${$exomes{$sampleID}{mate_1_paired}} 
${$exomes{$sampleID}{mate_1_unpaired}} ${$exomes{$sampleID}{mate_2_paired}} 
${$exomes{$sampleID}{mate_2_unpaired}} ILLUMINACLIP:\"$seq_adapters\":2:30:10:1:true 
MINLEN:2", 
     # "cat ${$exomes{$sampleID}{mate_1_paired}} 
${$exomes{$sampleID}{mate_1_unpaired}} > $mate_1_trimmed", 
     # "rm ${$exomes{$sampleID}{mate_1_paired}} 
${$exomes{$sampleID}{mate_1_unpaired}}", 
     # "cat ${$exomes{$sampleID}{mate_2_paired}} 
${$exomes{$samp=leID}{mate_2_unpaired}} > $mate_2_trimmed", 
     # "rm ${$exomes{$sampleID}{mate_2_paired}} 
${$exomes{$sampleID}{mate_2_unpaired}}"; 
   } 
  } 
   
  ${$exomes{$sampleID}{mate_1_file}} = $mate_1_trimmed; 
  ${$exomes{$sampleID}{mate_2_file}} = $mate_2_trimmed; 
 } 
  
 return (\%exomes, \%system_calls); 
} 
 
############################################################################
################################################## 
#end of sub trim. 
############################################################################
################################################## 
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############################################################################
########################################################### 
#subroutine system_calls 
#Generates a list of commands for each sample, which are then executed sample by sample. 
############################################################################
########################################################### 
sub system_calls{  
 my ($output_dirs, $system_calls_input, $exomes, $system_calls) = @_; 
  
 my $output_dirs = @$output_dirs; 
 my @system_calls_input = @$system_calls_input; 
 my %exomes = %{$exomes}; 
 my %system_calls = %{$system_calls}; 
  
 my ($call_regions, $bed_file, $trimmomatic_jar, $seq_adapters, $create_index, 
$add_ann, $fastq_reads_dir, $output_dir, $reference_genome, $gatk_jar, $snpEff_jar, $dbsnp, 
$hapmap_vcf, $omni_vcf, $phase1, $mills_Devine_vcf, $platform, $index_algorithm, 
$bwa_ended, $bigS, $who_ya_gonna_call, $pro_multi, $cores) = @system_calls_input; 
  
 my @bam; 
  
 my %months = ( 
  Jan => 1,  Feb => 2,  Mar => 3,  Apr => 4, May => 5,  Jun => 6, 
  Jul => 7, Aug => 8, Sep => 9, Oct => 10, Nov => 11, Dec => 12 
 ); 
  
 my @log_time = split (/\s+/, localtime); 
 my ($day, $month, $date, $time, $year) = @log_time; 
  
 $month = $months{$month}; 
  
 my $log_date = "$year\-$month\-$date\_$time"; 
  
 my $log = "$output_dir/command log $log_date.txt"; 
  
  
  
 my @dna_types; 
  
 my $threads = $cores / 2; 
  
 if ($threads =~ /\.\d+$/){ 
  $threads =~ s/$&//; 
  $threads++; 
 } 
 
 ################################################################### 
 #This section of &system_calls calls BWA index to index the reference genome. 
 ################################################################### 
 
        #1.      Create reference genome index and dictionary with bwa index: 
 #a.      -p                              Prefix of the output, same as reference filename inc. file 
extension. 
 #b.      -a                              Algorithm for constructing BWT index.  Available options 
are: 
  #b.i.    is                      For small (<2Gb) genomes. 
  #b.ii.   bwtsw                   For larger (>2Gb) genomes. 
 #c.      <input_Reference_Genome.fasta>  The reference genome. 
 #Time: 87 mins   Size: 7.36GB (inc. Downloaded reference). 
 if ($create_index eq "y"){   
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  if (-f "$reference_genome\.fai"){print "Genome has already been indexed, 
skipping this step.\n";} 
  else{ 
   #BWA first creates the dictionary (.dict), etc. for the genome, then 
SAMtools creates the '.fai. file. Both steps are necessary. 
   print "Now indexing the reference genome $reference_genome. This 
takes a while so put the kettle on and do something productive!\n"; 
   `bwa index -p \"$reference_genome\" -a $index_algorithm 
\"$reference_genome\"`; 
   `samtools faidx \"$reference_genome\"`; 
  }; 
 } 
 ################################################################### 
 
 ################################################################### 
 #This section of &system_calls generates the commands for each step of the pipeline 
 #for each sample. 
 # - The first 2 steps (bwa aln and bwa sampe/samse/bwasw) are 
performed 
 #  for both mates, if you have paired end data. 
 # - The remaining steps are performed only on 2nd mates as the mates 
will be 
 #  merged into a single file from here on. 
 ################################################################### 
 for my $sampleID (sort {"\L$a" cmp "\L$b"} keys %exomes){ 
  next if $sampleID =~ /multiSample/; 
  my ($coinID, $mate, $RG_headline, $mate_file); 
   
  my @sample = split (/\-/, $sampleID); 
   
  my ($run, $coin, $tissue) = @sample; 
   
  $tissue =~ s/\_.+$//; 
   
  $coinID = "$run-$coin-$tissue"; 
   
  #Copies the name of the fastq file and then removes the sequencing/mate 
information fom the copied variable.  
         #Removes from UNC samples (e.g. 042031_02136_s_6_[1|2]_sequence) then from 
BGI samples (e.g. 3018_2) 
         #It is essential to still retain the mate information for the samples as 'bwa aln' will use 
this. The copied variable will be used for naming output files for steps further in the pipeline. 
  if ($sampleID =~ /(\_\d$)/){ 
   $mate = $&; 
   $mate =~ s/\_//; 
  } 
   
  if ($coinID =~ /\-[a-z]+$/){ 
   my $dna_type = $&; 
   $dna_type =~ s/^\-//; 
   #unless (grep {$dna_type eq $_} sort {"\L$a" cmp "\L$b"} 
@dna_types){push @dna_types, "$dna_type";} 
  } 
 
  #the read group information for the sample. 
  $RG_headline = ${$exomes{$sampleID}{RG_headline}}; 
   
  $mate_file = "mate\_".$mate."\_file"; 
   
  #2. With bwa aln find SA coordinates for input reads: 
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  #a. < reference_Genome.fasta>   The reference genome. 
  #b. < query_Reads.fastq>   Raw sequence reads should 
be in fastq format. 
  #c. > <Ouput.sai>   The output from this step. 
  #Note: using the '- t xx' switch allows you to specify the number of threads used 
by BWA, even though it is not documented on their website. 
  push @{$system_calls{$coinID}}, "bwa aln -t $cores \"$reference_genome\" 
${$exomes{$sampleID}{$mate_file}} > ${$exomes{$sampleID}{aln_sai}}"; 
 
  if ($mate == 2){ 
   if ($platform ne "LS454"){     
    #3.      If you have Illimina/Solexa reads: Use bwa sampe (for 
paired end reads, or bwa samse for single ends) to produce alignments into SAM format: 
    #a.      -r "@RG\tID:x\tSM:x\tPL:x"                     Adds read 
group header to output. Replace 'x' withID/sample/platform names. 
    #b.      < reference_Genome.fasta>                      The reference 
genome. 
    #c.      <query_Reads.sai>                              Output from the 
prev. Step, for both mates. 
    #d.      <query_Reads.fastq>                            The raw 
sequencing reads in FASTQ format. For both mates, in same order as input for .sai files.  
    #e.      > <Ouput.sam>                      The output from this step. 
    # push @{$system_calls{$coinID}}, "bwa $bwa_ended -r 
\"$RG_headline\" \"$reference_genome\" ${$exomes{$sampleID}{aln_sai_prev}} 
${$exomes{$sampleID}{aln_sai}} ${$exomes{$sampleID}{mate_1_file}} 
${$exomes{$sampleID}{mate_2_file}} > ${$exomes{$sampleID}{sam}}"; 
   } 
    
   else{ #use bwasw instead of bwa samse/sampe 
    #If you have LifeScience 454 reads: Use bwasw to align reads 
onto reference genome: 
    #a.      <reference_Genome.fasta> 
    #b.      <query_Reads.fastq> 
    # push @{$system_calls{$coinID}}, "bwasw 
$reference_genome $fastq_reads_dir/$fastq_reads.$file_extension"; 
   } 
    
  
 #####################################################################
############################################################### 
   push @{$system_calls{$coinID}}, 
   #All the quoted lines before the next line of hashes (#) will be added to 
the hash of arrays for the sample. 
  
 #####################################################################
############################################################### 
    #4. Convert output of step 3 into BAM format using samtools 
view: 
    #a. -bSh    b outputs to BAM 
format S indicates input is SAM format. h adds header to the .bam file. 
    #b. <query_Reads.sam>   Input 
    #c. > <query_Reads.bam>   A 
"Â .˜bam"Â™ file will be created using the same name as this file. 
    "samtools view -bSh ${$exomes{$sampleID}{sam}} > 
${$exomes{$sampleID}{view_bam}}", 
    # "rm ${$exomes{$sampleID}{sam}}", #Delete the output 
from the previous step for this sample as it is now not needed. These rm steps are not 
necessary but save a LOT of disk space! 
 
    #5.      Sort reads in BAM file by name with samtools sort: 
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    #a.      -n                                             Sort by read name 
instead of chr position (this is necessary at first). 
    #b.      <query_Reads.bam>                              The output file 
from step 4. 
    #c.      <Sorted.bam>                       The output from this step. 
    "samtools sort -n ${$exomes{$sampleID}{view_bam}} 
${$exomes{$sampleID}{sorted_bam}}\"", 
    # "rm ${$exomes{$sampleID}{view_bam}}", #Delete the 
directory containing the output from the previous step as it is now not needed. 
 
    #6.      Use samtools fixmate to fill in read mate details: 
    #a.      <Sorted.bam>                       The output from prev. step. 
    #b.      <Fixmate.bam>                      The output from this step. 
    "samtools fixmate ${$exomes{$sampleID}{sorted_bam}}\.bam\" 
${$exomes{$sampleID}{fixmate_bam}}", 
    # "rm ${$exomes{$sampleID}{sorted_bam}}\.bam\"", 
 
    #Note: if you ran step 5 with the "-n" switch then run step 5 
again without "-n" (using the output from step 6 as the input) 
    #before proceeding to step 7._ 
    "samtools sort ${$exomes{$sampleID}{fixmate_bam}} 
${$exomes{$sampleID}{postfixmate_sorted_bam}}\"", 
 
    #7.      use samtools rmdup to remove duplicate PCR reads: 
    #a.      -s or -S                                       For single/paired end 
reads. 
    #b.      <Fixmate.bam>                      The output from step 6 
(after running step 5 again). 
    #c.      <NoDups.bam>                       The output from this 
step. 
    # "samtools rmdup -$bigS 
${$exomes{$sampleID}{postfixmate_sorted_bam}}\.bam\" 
${$exomes{$sampleID}{nodups_bam}}", 
 
    #8.      Use samtools index to create an index of the latest 
output: 
    #a.      <noDups.bam>                       The output from the prev. 
Step. 
    "samtools index 
${$exomes{$sampleID}{postfixmate_sorted_bam}}\.bam\"", 
 
    #9.      Advised optional step: indel realignment, to ensure 
regions around indels do not contain false SNPs. This is a 2 stage step, which requires first 
creating a file of known indel regions. This file is then used to align reads around these regions. 
Type java -Xmx2g -jar GenomeAnalysisTK.jar with the following switches: 
    #a.      -T RealignerTargetCreator                Name of the 
tool in the GATK package. 
    #b.      -I <NoDups.bam>              Input is the output 
from prev. step. 
    #c.      -R <reference_Genome.fasta>              The reference 
genome. 
    #d.      -o <Indels.intervals>              Output from this step. 
Notice lower case 'o'. 
    #Note: if the fastq files contain Illumina-encoded qualities 
instead of Sanger-encoded qualities, use -fixMisencodedQuals (specify IMMEDIATELY AFTER 
the input file, with just a space inbetween). Hiseq data usually need this switch on, Miseq data 
do not. 
    #Sometimes, if using modified BAM files (i.e. merged from 
multiple samples or selected reads from FASTQ/BAM files) GATK may throw an error regarding 
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a mix of differently encoded quality scores. In these cases, try also specifying -
allowPotentiallyMisencodedQuals next to -fixMisencodedQuals. 
    "java -jar \"$gatk_jar\" -T RealignerTargetCreator -I 
${$exomes{$sampleID}{postfixmate_sorted_bam}}\.bam\" -R \"$reference_genome\" -o 
${$exomes{$sampleID}{indels_intervals}} -nt $threads -filterNoBases", 
 
    #10.     For the second stage in indel realignment, type java -
Xmx4g -jar GenomeAnalysisTK.jar and use the following options: 
    #a.      -T IndelRealigner                                      Tool in the 
GATK package. 
    #b.      -I <NoDups.bam>                            Input is output from 
step 7. 
    #c.      -R <reference_Genome.fasta>                            The 
reference genome. 
    #d.      -targetIntervals <Indels.intervals>  Input is output 
from prev. step. 
    #e.      -o <Realigned.bam>                         Output of this step. 
    #Note: if the fastq files contain Illumina-encoded qualities 
instead of Sanger-encoded qualities, use -fixMisencodedQuals (specify IMMEDIATELY AFTER 
the input file, with just a space inbetween). Hiseq data usually need this switch on, Miseq data 
do not. 
    #Sometimes, if using modified BAM files (i.e. merged from 
multiple samples or selected reads from FASTQ/BAM files) GATK may throw an error regarding 
a mix of differently encoded quality scores. In these cases, try also specifying -
allowPotentiallyMisencodedQuals next to -fixMisencodedQuals. 
    "java -jar \"$gatk_jar\" -T IndelRealigner -I 
${$exomes{$sampleID}{postfixmate_sorted_bam}}\.bam\" -R \"$reference_genome\" -
targetIntervals ${$exomes{$sampleID}{indels_intervals}} -o 
${$exomes{$sampleID}{realigned_bam}} -filterNoBases", 
 
    #11.     Step may not be needed! Using SAMtools again now, 
type samtools mpileup to generate a pileup format file (easier to use for variant calls): 
    #a.      -E               -Uses extended BAQ 
computation. 
    #b.      <Realigned.bam>    Input is output from prev. Step. 
    #c.      > <mPileUp.bam>    Output from this step. 
    "samtools mpileup -E ${$exomes{$sampleID}{realigned_bam}} 
> ${$exomes{$sampleID}{mpileup_bam}}", 
 
    #12. Advised optional step: quality score recalibration, first 
creates a table of scores. Type java -Xmx4g -jar GenomeAnalysisTK.jar and use the following 
switches: 
    #a.      -T BaseRecalibrator                             The tool in the 
GATK package. 
    #b.      -I <Input realigned.bam >                      Input is output 
from step 10. 
    #c.      -R <reference_Genome.fasta>                    The 
reference genome.-R /media/marc/Brachiosaur/Exomes/reference 
genome/human_g1k_v37.fasta 
    #d.      -l INFO                                        Lower case 'L', not a 
capital 'i'. 
    #e.      -recalFile <output file.csv>                   Output (comma 
separated variable .csv file). 
    #f.      -knownSites <dbsnp_132.hg19.vcf>               File of 
known variants from a database (e.g. dbSNP). 
    #g.      --default_platform illumina                    May be needed if 
not given in step 3 '-r' switch. 
    #h.      -cov         Type '-cov', a 
space and 1 of the following options (do this for all 4 options): 
    #h.i.    ReadGroupCovariate 
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    #h.ii.   QualityScoreCovariate 
    #h.iii.  CycleCovariate 
    #h.iv.   DinucCovariate 
    "java -jar \"$gatk_jar\" -T BaseRecalibrator -I 
${$exomes{$sampleID}{realigned_bam}} -R \"$reference_genome\" -l INFO -o 
${$exomes{$sampleID}{recalibrated_grp}} -knownSites \"$dbsnp\" -cov ReadGroupCovariate -
cov QualityScoreCovariate -cov CycleCovariate -cov ContextCovariate -nct $cores -
filterNoBases", 
 
    #13.     Second part of quality score recalibration, merges new 
Q scores into a recalibrated '.bam' file. Use java -Xmxg4 -jar GenomeAnalysisTK.jar: 
    #a.      -T TableRecalibration    The 
tool in the GATK package. 
    #b.      -I <Input '.bam' file>                         Input is the 
output from step 10. 
    #c.      -R <reference genome.fasta>   The 
reference genome. 
    #d.      -l INFO      
 Lower case 'L', not a capital 'i'. 
    #e.      -recalFile <'.csv' file>    Input 
is the '.csv' from prev. Step. 
    #f.      -o <Recalibrated.bam> Name of the new recalibrated 
'.bam' file. 
    #  -baq RECALCULATE    If 
using after GATK version 2.5, include this switch. Introduced to the pipeline for version 2.4-9 but 
caused a bug. 
    "java -jar \"$gatk_jar\" -T PrintReads -I 
${$exomes{$sampleID}{realigned_bam}} -R \"$reference_genome\" -l INFO -BQSR 
${$exomes{$sampleID}{recalibrated_grp}} -o ${$exomes{$sampleID}{recalibrated_bam}} -nct 
$cores -filterNoBases"; 
  
 #####################################################################
############################################################### 
    
   push @bam, ${$exomes{$sampleID}{recalibrated_bam}}; 
  } 
 } 
  
 #At this stage, you may wish to pool the data so far into a single bam file. This will allow 
for higher confidence in rare variants or those with low depth. You can separate the VCF file 
into individual samples after variant calling using SelectVariants. 
 #The GSA recommend analysing all samples separately up to this point. 
  
 # opendir BAM, "$output_dir\/$output_dirs[10]" or die "Cannot open 
$output_dir\/$output_dirs[10].\n"; 
 # my @bam = map {$output_dir."/".$output_dirs[10]."/".$_} grep {-f 
"$output_dir\/$output_dirs[10]/$_" && /\.bam$/i} readdir (BAM); 
  
 #Multi-sample processing, if the DNA is from several tissue sources (e.g. somatic 
FFPE, normal FFPE, germline, etc). 
 if (@dna_types){ 
  foreach my $dna_type (sort {"\L$a" cmp "\L$b"} @dna_types){ 
   # next unless $dna_type eq "f"; 
   my $multi_samples = ""; 
    
   foreach my $bam (sort {"\L$a" cmp "\L$b"} @bam){ 
    next unless $bam =~ /\-$dna_type/; 
     
    $multi_samples .= "\-I \"$bam\" "; 
   } 
 203 
 
    
   my $sampleID = "multiSample\-".$dna_type."\_2"; 
   my $coinID = "multiSample\-".$dna_type; 
    
   # $system_calls = multi_sample_calls(\%exomes, 
\@system_calls_input, \%system_calls, $multi_samples, $sampleID, $coinID, $threads); 
   %system_calls = %{$system_calls}; 
  } 
   
  execute_sub(\%system_calls, $log); 
 } 
  
 #Multi sample processing if the DNA is all from the same tissue source (e.g. all 
germline, etc). 
 elsif ($pro_multi eq "y"){ 
  my $multi_samples = ""; 
    
  foreach $bam (sort {"\L$a" cmp "\L$b"} @bam){$multi_samples .= "\-I \"$bam\" 
";} 
   
  my $sampleID = "multiSample\_2"; 
  my $coinID = "multiSample"; 
    
  my $system_calls = multi_sample_calls(\%exomes, \@system_calls_input, 
\%system_calls, $multi_samples, $sampleID, $coinID, $threads); 
  %system_calls = %{$system_calls}; 
   
  execute_sub(\%system_calls, $log); 
 } 
  
 #currently set up to do single sample processing. Can easily be switched back to do 
multi-sample work - see comments. 
 else{ 
  my $multi_samples = ""; 
  print "multi calling steps\n"; 
  foreach my $bam (sort{"\L$a" cmp "\L$b"} @bam){ 
   $multi_samples = "\-I $bam\""; 
    
   if ($bam =~ /\_recalibrated\.bam/i){ 
    $sampleID = $bam; 
    $sampleID =~ s/$&//i; 
    $sampleID =~ s/\"//g; 
    $sampleID =~ s/.+\///g; 
    $coinID = $sampleID; 
    $sampleID = "$sampleID\_2"; 
   } 
    
   next unless grep {$sampleID eq $_} sort {"\L$a" cmp "\L$b"} keys 
%exomes; 
    
   my $system_calls = multi_sample_calls(\%exomes, 
\@system_calls_input, \%system_calls, $multi_samples, $sampleID, $coinID, $threads); 
   %system_calls = %{$system_calls}; 
  } 
   
  execute_sub(\%system_calls, $log); 
 } 
} 
#end of sub system_calls 
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############################################################################
############################################################################
########## 
 
############################################################################
############################################################################
########## 
#multi_sample_calls 
############################################################################
############################################################################
########## 
sub multi_sample_calls{ 
 my ($exomes, $system_calls_input, $system_calls, $multi_samples, $sampleID, 
$coinID, $threads) = @_; 
 my %exomes = %{$exomes}; 
 my @system_calls_input = @$system_calls_input; 
 my %system_calls = %{$system_calls}; 
  
 chop $multi_samples; 
 $multi_samples =~ s/^\-I //; 
  
 my ($call_regions, $bed_file, $trimmomatic_jar, $seq_adapters, $create_index, 
$add_ann, $fastq_reads_dir, $output_dir, $reference_genome, $gatk_jar, $snpEff_jar, $dbsnp, 
$hapmap_vcf, $omni_vcf, $phase1, $mills_Devine_vcf, $platform, $index_algorithm, 
$bwa_ended, $bigS, $who_ya_gonna_call, $pro_multi, $cores) = @system_calls_input; 
  
 my $region_switch = ""; 
 if ($call_regions eq "y"){$region_switch = "-L \"$bed_file\"";} 
  
 #14.      Use java -jar GenomeAnalysisTK.jar to call variants in the pileup file from 
previous step: 
 #a.      -T UnifiedGenotyper                  The tool in the GATK package. 
 #b.      -R <reference genome.fasta>          The reference genome. 
 #c.      -glm                                  Calls following type of variant: 
   #c.i.    SNP 
  #c.ii.   INDEL 
  #c.iii.  BOTH 
 #d.      -D <dbsnp_xxx.vcf>              Adds rsIDs to output file 
 #e.      -I <input '.bam' file>          Input is the output from step 13. 
 #f.      -o <output.vcf>                       Output file (in VCF format). 
 #g.      -nct x                                 where x is number of cores available. 
 #h. -metrics <metrics.txt>   metrics file on the variant calls 
 # if ($who_ya_gonna_call eq "SNP"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T UnifiedGenotyper -
R \"$reference_genome\" -glm $who_ya_gonna_call $region_switch -mbq 10 -stand_call_conf 
30 -stand_emit_conf 10 -baq CALCULATE_AS_NECESSARY -D \"$dbsnp\" -I $multi_samples -
o ${$exomes{$sampleID}{SNPs_only}} -metrics ${$exomes{$sampleID}{metrics}} -nt $cores -
nct $threads"; 
 # } 
 # elsif ($who_ya_gonna_call eq "INDEL"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T UnifiedGenotyper -
R \"$reference_genome\" -glm $who_ya_gonna_call $region_switch -mbq 10 -stand_call_conf 
30 -stand_emit_conf 10 -baq CALCULATE_AS_NECESSARY -D \"$dbsnp\" -I $multi_samples -
o ${$exomes{$sampleID}{indels_only}} -metrics ${$exomes{$sampleID}{metrics}} -nt $cores -
nct $threads"; 
 # } 
 # else{ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T UnifiedGenotyper -
R \"$reference_genome\" -glm $who_ya_gonna_call $region_switch -mbq 10 -stand_call_conf 
30 -stand_emit_conf 10 -baq CALCULATE_AS_NECESSARY -D \"$dbsnp\" -I $multi_samples -
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o ${$exomes{$sampleID}{variant_calls}} -metrics ${$exomes{$sampleID}{metrics}} -nt $cores -
nct $threads"; 
 # } 
 #use HaplotypeCaller instead of UnifedGenotyper. 
 push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T HaplotypeCaller -R 
\"$reference_genome\" $region_switch -stand_call_conf 30 -stand_emit_conf 10 -D \"$dbsnp\" -I 
$multi_samples -o ${$exomes{$sampleID}{variant_calls}} -nct $cores"; 
  
 #15. Use java -jar GenomeAnalysisTK.jar to validate variants called by the 
UnifiedGenotyper. This step is optional but I'd recommend it. 
 #a. -T ValidateVariants 
 #b. -R <reference genome.fasta> 
 #c. -V <input.vcf> 
 #d. -D <dbSNP_xxx.vcf> 
 if ($who_ya_gonna_call eq "SNP"){ 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ValidateVariants -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{SNPs_only}} -D \"$dbsnp\""; 
 } 
 elsif ($who_ya_gonna_call eq "INDEL"){ 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ValidateVariants -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{indels_only}} -D \"$dbsnp\""; 
 } 
 else{ 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ValidateVariants -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{variant_calls}} -D \"$dbsnp\""; 
 } 
                      
        #16.     Use  java -jar GenomeAnalysisTK.jar to separate out indels from SNPs. Run it 
twice to create 2 files, one for each type of variant: 
 #a.      -T SelectVariants              The tool in the GATK package. 
 #b.      -R <reference genome.fasta>    The reference genome. 
 #c.      -V <input.vcf>                   Input is output from prev. step/step 14. 
 #d.      -selectType 
  #d.i.    SNP 
  #d.ii.   INDEL 
 #e.      -o <output.vcf>                  Output from this step. 
 push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T SelectVariants -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{variant_calls}} -selectType SNP -o 
${$exomes{$sampleID}{SNPs_only}}", 
 "java -jar \"$gatk_jar\" -T SelectVariants -R \"$reference_genome\" -V 
${$exomes{$sampleID}{variant_calls}} -selectType INDEL -o 
${$exomes{$sampleID}{indels_only}}"; 
               
        #17. Use java -jar GenomeAnalysisTK.jar to produce a table for variant recalibration. 
This will need to be run twice, once for SNPs and again for indels: 
 #a. -T VariantRecalibrator   The tool in the GATK package. 
 #b. -R <reference genome.fasta>  The reference genome. 
 #c. -input <input.vcf>   Output from prev. step. 
 #d. -recalFile <output.csv>   Output for use in next step. 
 #e. -tranchesFile <output.tranches>  Output for use in next step. 
 #f. -mode     Enter only SNP or INDEL. 
 # f.i. SNP 
 # f.ii. INDEL 
 #g. -an 
 # g.ii. HaplotypeScore 
 # g.iii. MQRankSum 
 # g.iv. ReadPosRankSum 
 # g.v. MQ 
 # g.vi. DP 
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 #h. -resource:    Training data (first 3 for SNPs, fourth 
for 
 #      indels only?). Leave no space between 
';' and 
 #      the following options (type -'resource:' 
for 
 #      each). 
 # h.i. -resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 
<hapmap_3.3.hg19.vcf> 
 # h.ii. -resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 
<dbsnp_132_vcf> 
 # h.iii -resource:omni,known=false,training=true,truth=false,prior=12.0 
<1000G_omni2.5.b37.sites.vcf> 
 # h.iiv. -resource:mills,VCF,known=true,training=true,truth=true,prior=12.0 
<Mills_Devine_indels.sites.vcf> 
        #i.      -mG 4                                                   Use for small (<30 exomes) datasets. 
 #k.      -nt x       where x is number of threads 
specified to the tool. Note this is not -nct, the number of cores specified. 
 if ($who_ya_gonna_call eq "SNP"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T 
VariantRecalibrator -R \"$reference_genome\" -input ${$exomes{$sampleID}{SNPs_only}} -
recalFile ${$exomes{$sampleID}{SNPs_recal}} -tranchesFile 
${$exomes{$sampleID}{SNPs_tranches}} -mode SNP -an MQRankSum -an ReadPosRankSum 
-an FS -an QD -resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 
\"$hapmap_vcf\" -resource:omni,known=false,training=true,truth=false,prior=12.0 \"$omni_vcf\" -
resource:1000G,known=false,training=true,truth=false,prior=10.0 \"$phase1\" -
resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 \"$dbsnp\" -mG 4"; 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T VariantFiltration -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{SNPs_only}} --filterExpression \"QD < 2.0 || 
FS > 60.0 || MQ < 35.0 || MappingQualityRankSum < -12.5 || ReadPosRankSum < -8.0\" --
filterName \"Filter\"  -o ${$exomes{$sampleID}{SNPs_recalibrated}}"; 
 } 
 elsif ($who_ya_gonna_call eq "INDEL"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T 
VariantRecalibrator -R \"$reference_genome\" -input ${$exomes{$sampleID}{indels_only}} -
recalFile ${$exomes{$sampleID}{indels_recal}} -tranchesFile 
${$exomes{$sampleID}{indels_tranches}} -mode INDEL -an MQRankSum -an 
ReadPosRankSum -an FS -resource:mills,VCF,known=true,training=true,truth=true,prior=12.0 
\"$mills_Devine_vcf\" -mG 4"; 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T VariantFiltration -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{indels_only}}  --filterExpression \"QD < 2.0 || 
FS > 200.0 || ReadPosRankSum < -20.0\" --filterName \"Filter\" -o 
${$exomes{$sampleID}{indels_recalibrated}}"; 
 } 
 else{ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T 
VariantRecalibrator -R \"$reference_genome\" -input ${$exomes{$sampleID}{SNPs_only}} -
recalFile ${$exomes{$sampleID}{SNPs_recal}} -tranchesFile 
${$exomes{$sampleID}{SNPs_tranches}} -mode SNP -an MQRankSum -an ReadPosRankSum 
-an FS -an QD -resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 
\"$hapmap_vcf\" -resource:omni,known=false,training=true,truth=false,prior=12.0 \"$omni_vcf\" -
resource:1000G,known=false,training=true,truth=false,prior=10.0 \"$phase1\" -
resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 \"$dbsnp\" -mG 4", 
  # "java -jar \"$gatk_jar\" -T VariantRecalibrator -R \"$reference_genome\" -input 
${$exomes{$sampleID}{indels_only}} -recalFile ${$exomes{$sampleID}{indels_recal}} -
tranchesFile ${$exomes{$sampleID}{indels_tranches}} -mode INDEL -an MQRankSum -an 
ReadPosRankSum -an FS -resource:mills,VCF,known=true,training=true,truth=true,prior=12.0 
\"$mills_Devine_vcf\" -mG 4"; 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T VariantFiltration -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{SNPs_only}} --filterExpression \"QD < 2.0 || 
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FS > 60.0 || MQ < 35.0 || MappingQualityRankSum < -12.5 || ReadPosRankSum < -8.0\" --
filterName \"Filter\" -o ${$exomes{$sampleID}{SNPs_recalibrated}}"; 
  push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T VariantFiltration -R 
\"$reference_genome\" -V ${$exomes{$sampleID}{indels_only}} --filterExpression \"QD < 2.0 || 
FS > 200.0 || ReadPosRankSum < -20.0\" --filterName \"Filter\" -o 
${$exomes{$sampleID}{indels_recalibrated}}"; 
 } 
         
        #18. Use java -jar GenomeAnalysisTK.jar to apply the tables from the previous step 
to your SNPs and indels (run this twice, once for each): 
 #a. -T ApplyRecalibration   The tool in the GATK package. 
 #b. -R <reference genome.fasta>  The reference genome. 
        #c. -input <input.vcf>   Input is output from step 14. 
 #d. -recalFile <input.csv>   Input is output from prev. step. 
 #e. -tranchesFile <input.tranches>  Input is output from prev. step. 
 #f. -o <ouput_recalibrated.vcf>  Output of this step. 
 # if ($who_ya_gonna_call eq "SNP"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ApplyRecalibration 
-R \"$reference_genome\" -input ${$exomes{$sampleID}{SNPs_only}} -recalFile 
${$exomes{$sampleID}{SNPs_recalibrated}} -tranchesFile 
${$exomes{$sampleID}{SNPs_tranches}} -o ${$exomes{$sampleID}{SNPs_recalibrated}}"; 
 # } 
 # elsif($who_ya_gonna_call eq "INDEL"){ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ApplyRecalibration 
-R \"$reference_genome\" -input ${$exomes{$sampleID}{indels_only}} -recalFile 
${$exomes{$sampleID}{indels_recalibrated}} -tranchesFile 
${$exomes{$sampleID}{indels_tranches}} -o ${$exomes{$sampleID}{indels_recalibrated}}"; 
 # } 
 # else{ 
  # push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T ApplyRecalibration 
-R \"$reference_genome\" -input ${$exomes{$sampleID}{SNPs_only}} -recalFile 
${$exomes{$sampleID}{SNPs_recalibrated}} -tranchesFile 
${$exomes{$sampleID}{SNPs_tranches}} -o ${$exomes{$sampleID}{SNPs_recalibrated}}", 
  # "java -jar \"$gatk_jar\" -T ApplyRecalibration -R \"$reference_genome\" -input 
${$exomes{$sampleID}{indels_only}} -recalFile ${$exomes{$sampleID}{indels_recalibratedre}} -
tranchesFile ${$exomes{$sampleID}{indels_tranches}} -o 
${$exomes{$sampleID}{indels_recalibrated}}"; 
 # } 
  
 #19. Use  java -jar GenomeAnalysisTK.jar to recombine the data for SNPs and 
indels. This can also be used to check the output from this pipeline to that of others: 
        #You can use CombineVariants to combine your SNPs with those from another pipeline or 
lab followed by SelectVariants using -select 'set == "Intersection"Â•' to output a file with just the 
SNPs found in both datasets. 
 #a. -T CombineVariants  The tool in the GATK package. 
 #b. -R <reference genome.fasta> The reference genome. 
 #c. -V    Output from the prev. 
Step."/media/marc/Brachiosaur/Exomes/CHD 
output/09_gatk_indelrealigner/004031_02145_s_1_realigned.bam" 
 # c.i. <input_SNPs.vcf> 
 # c.ii. <input_INDELs.vcf> 
 #d. -genotypeMergeOptions May not have to specify, but if you do you're 
not bothered about genotypes then use 'unsorted'. 
 # d.i. -UNSORTED 
 # d.ii. -PRIORITIZE 
 # d.iii. -UNIQUIFY 
 # d.iv. -REQUIRE_UNIQUE 
 #e. -o <output_recombined.vcf> 
 if ($who_ya_gonna_call eq "BOTH"){push @{$system_calls{$coinID}}, "java -jar 
\"$gatk_jar\" -T CombineVariants -R \"$reference_genome\" -V:SNP 
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${$exomes{$sampleID}{SNPs_recalibrated}} -V:Indel 
${$exomes{$sampleID}{indels_recalibrated}} -genotypeMergeOptions UNSORTED -o 
${$exomes{$sampleID}{recalibrated_variants_combined}}";} 
  
 #20. use snpEff to do some snp effect stuff. 
 #a. snpEff.jar  
 #b eff  
 #c -c path to/snpEff.config 
 #d -i vcf  
 #e -o vcf  
 #f GRCh37.63  
 #g <input vcf>  
 #h > snpEff_output.vcf 
 if ($add_ann eq "y"){push @{$system_calls{$coinID}}, "java -jar \"$snpEff_jar\" eff -c 
\"$snpEff_config\" -i vcf -o gatk GRCh37.75 
${$exomes{$sampleID}{recalibrated_variants_combined}} > 
${$exomes{$sampleID}{snpEff_output}}";} 
   
 #21. Use  java -jar GenomeAnalysisTK.jar to add annotation to the variant file: 
 #a. -T VariantAnnotator  The tool in the GATK package. 
 #b. -R <reference genome.fasta> The reference genome. 
 #c. -A SnpEff   God only knows what this is for. 
 #d. -V <input.vcf>   Input is the output from combine variants step. 
 #e. -snpEffFile <input.vcf>  The file generated by running snpEff. 
 #f. -o <output_annotated.vcf> Annotated output from this step. 
 if ($add_ann eq "y"){push @{$system_calls{$coinID}}, "java -jar \"$gatk_jar\" -T 
VariantAnnotator -R \"$reference_genome\" -A SnpEff -V 
${$exomes{$sampleID}{recalibrated_variants_combined}} -snpEffFile 
${$exomes{$sampleID}{snpEff_output}} -o ${$exomes{$sampleID}{variants_annotated}}";} 
   
 return \%system_calls; 
} 
############################################################################
############################################################################
########## 
#End of sub multi_sample_calls. 
############################################################################
############################################################################
########## 
 
############################################################################
############################################################################
########## 
#subroutine executre 
#Executes the system commands for the pipeline. 
############################################################################
############################################################################
########## 
sub execute_sub{ 
 my ($system_calls, $log) = @_; 
 my %system_calls = %{$system_calls}; 
  
 for my $sample (sort {"\L$a" cmp "\L$b"} keys %system_calls){ 
  my $step_no = 0; 
  my $total_steps = scalar @{$system_calls{$sample}}; 
   
  my ($prev_time, $date, $time_elapsed, $total_hours, $total_minutes, 
$total_seconds) = outta_time($prev_time, time(), $total_hours, $total_minutes, $total_seconds); 
   
  open LOG, ">>$log" or die $!; 
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  foreach my $call (@{$system_calls{$sample}}){ 
   $step_no++; 
    
   $call_print = $call; 
   #$call_print =~ s/\s/\n/g; 
    
   print color ("blue"), "Sample: $sample.\tNow performing step 
$step_no/$total_steps\nDate: $date command line:\n"; 
   print color ("green"), "$call_print\n"; 
   print color 'reset'; 
    
   print LOG "--------------------------------------------------------------------------------
----\n\>>Date: $date\tSample: $sample.\nNow performing step $step_no/$total_steps, command 
as follows:\n------------------------------------------------------------------------------------\n"; 
   print LOG "$call_print\n\n"; 
    
   # system ($call); #Execute the current command 
    
    
   ($prev_time, $date, $time_elapsed, $total_hours, $total_minutes, 
$total_seconds) = outta_time($prev_time, time(), $total_hours, $total_minutes, $total_seconds); 
   print color ("yellow"), "The date and time is now: $date. The previous 
step took $time_elapsed seconds to run.\nTotal run time (hh:mm:ss): 
$total_hours:$total_minutes:$total_seconds\n\n"; 
   print color 'reset'; 
  } 
   
  print "\n\n\n"; 
  print LOG "\n\n"; 
 } 
  
 close LOG; 
} 
############################################################################
############################################################################
########## 
#End of sub execute. 
############################################################################
############################################################################
########## 
 
############################################################################
############################################################################
########## 
#sub outta_time 
#calculates the time taken to perform a step of the pipeline. 
############################################################################
############################################################################
########## 
sub outta_time{ 
 my ($prev_time, $current_time, $total_hours, $total_minutes, $total_seconds) = @_; 
 my ($elapsed_hours, $elapsed_minutes, $elapsed_seconds); 
  
 #get the current time and date and reorder for printing. 
 my $localtime = localtime; 
 my @time = split (/\s+/, $localtime); 
 my ($day, $month, $date, $time, $year) = @time; 
 my $date = "$year\-$month\-$date\-$time"; 
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 #calculate how long has elapsed since the last time this subroutine was called, 
therefore revealing how long the last pipeline step took. 
 if (defined $prev_time){ 
  $elapsed_seconds = $current_time - $prev_time; 
 } 
  
 else{$elapsed_seconds = 0;} 
  
 $elapsed_hours = sprintf("%02d", int($elapsed_seconds/3600)%3600); 
 $elapsed_minutes = sprintf("%02d", int($elapsed_seconds/60)%60); 
 $elapsed_seconds = sprintf("%02d", ($elapsed_seconds%60)); 
  
 $total_hours += $elapsed_hours; 
 $total_minutes += $elapsed_minutes; 
 $total_seconds += $elapsed_seconds; 
  
 $total_hours = sprintf("%02d", int($total_seconds/3600)%3600); 
 $total_minutes = sprintf("%02d", int($total_seconds/60)%60); 
 $total_seconds = sprintf("%02d", ($total_seconds%60)); 
  
 my $time_elapsed = "$elapsed_hours\:$elapsed_minutes\:$elapsed_seconds"; 
  
 return ($current_time, $date, $time_elapsed, $total_hours, $total_minutes, 
$total_seconds); 
} 
############################################################################
############################################################################
########## 
#End of sub outta_time 
############################################################################
############################################################################
########## 
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Custom Script 2 
#filter_tuner.pl 
#This script is designed to read in variant from a VCF file and print them out to a CSV file along 
with their pass/filter status for a number of metrics used in the pipeline. Filters according to the 
best practices for VQSR unclude: 
 #Mapping quality >40 (>35 for the adjusted pilot project parameters). 
 #Quality by depth >2. 
 #Fisher strand bias <60. 
 #Haplotype score <13 (this filter is ignored for the adjusted parameters in the pilot 
project to maximise the number of known variants passing). 
 #Mapping quality rank sum >-12.5. 
 #Read pos rank sum >-8. 
#It can also read in a list of known variants and retrieve just this list from the VCF files along 
with filter status. This script is therefore useful for checking parameter sets used to filter out 
potential false positives/negatives. 
#It also tells which of the other tissues a variant was called in. If given a set of coordinates for 
CCDS, the script can potentially also inform you if a variant lies in an exon or not. 
 
($date, $time) = &delorean; 
 
print "$date\n"; 
 
#The CCDS file. 
$ccds = "/media/marc/Brachiosaur/Exomes/database resources/CCDS_2013_10_24.txt"; 
 
$dbSNP = "/media/marc/Brachiosaur/Exomes/database resources/dbSNP_141_b37.vcf"; 
$kg = "/media/marc/Brachiosaur/Exomes/database 
resources/ALL.wgs.phase1_release_v3.20101123.snps_indels_sv.sites.vcf";  
$esp_dir = "/media/marc/Brachiosaur/Exomes/database resources/Exome sequencing project 
6500SI_V2_SSA137"; 
$cosmic = "/media/marc/Brachiosaur/Exomes/database 
resources/CosmicCompleteExport_v70_100814 sorted.tsv"; 
 
$ref_file = "/media/marc/Brachiosaur/Exomes/reference genome/human_g1k_v37.fasta"; 
 
#The output file that the final list of variants is printed to. 
$out_file = "/home/marc/Documents/work/reseq analysis/non responder project/Output/MuTect 
variants - alien amplicons ($date).csv"; 
$variant_list = "/home/marc/Documents/work/reseq analysis/pilot project/Output/pilot project - 
list of variants ($date).csv"; 
 
#The VCF directories. 
$nr_dir = "/media/marc/Triceratops/Exomes/Non responder output/19_GATK_variantannotator"; 
$mutect_dir = "/media/marc/Triceratops/Exomes/Non responder output/MuTect output/alien 
amplicons"; 
 
#This array will be used to pass the VCF dirs to a dir reader subroutine later. 
@vcf_dirs = ($mutect_dir); 
 
%tissues = ( 
 a => "tFFPE", 
 d => "nFFPE", 
 e => "blood", 
 f => "WGA tFFPE", 
 u => "UDG tFFPE", 
 du => "UDG nFFPE", 
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 Undetermined => "Undetermined" 
); 
 
%tissue_presence = ( 
 "blood" => "N", 
 "nFFPE" => "N", 
 "tFFPE" => "N", 
 "UDG nFFPE" => "N", 
 "UDG tFFPE" => "N", 
 "Undetermined" => "N", 
 "WGA tFFPE" => "N" 
); 
 
($variants, $runs, $final_chr) = get_variants(\@vcf_dirs, \%tissues, $ref_file); 
 
$variants = dbSNP_reader($variants, $final_chr, $dbSNP); 
$variants = kg_reader($variants, $final_chr, $kg); 
$variants = esp_reader($variants, $final_chr, $esp_dir); 
$variants = cosmic_reader($variants, $final_chr, $cosmic); 
 
printer($variants, $out_file, $variant_list, \%tissues, \%tissue_presence, $runs); 
 
######################################################################## 
#subroutine delorean 
#Gets the local time and converts it into a date (format: yyyy-mm-dd) and time (hh:mm:ss). 
#These are then returned, 
######################################################################## 
sub delorean{ 
 my @flux_capacitor = localtime(time); 
  
 #Set the variables for the time and date. Note: year is a count of years after 1900 (e.g. 
2015 = 115), and month is 0-based integer (0 = Jan, 11 = Dec). 
 my ($sec, $min, $hour, $date, $month, $year) = @flux_capacitor; 
  
 $month += 1; 
 $year += 1900; 
  
 $month = sprintf ("%02d", $month); 
 $date = sprintf ("%02d", $date); 
 $day = sprintf ("%02d", $day); 
 $sec = sprintf ("%02d", $sec); 
 $min = sprintf ("%02d", $min); 
 $hour = sprintf ("%02d", $hour); 
  
 my $return_date = "$year-$month-$date"; 
  
 my $return_time = "$hour:$min:$sec"; 
  
 return ($return_date, $return_time); 
} 
######################################################################## 
#End of subroutine delorean. 
######################################################################## 
 
############################################################################
##################### 
#Subroutine get_variants. 
#Opens up a VCF directory, reads in the VCF files and then reads in the variants and returns 
them in a hash. 
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############################################################################
##################### 
sub get_variants{ 
 my ($vcf_dirs, $tissues, $ref_file) = @_; 
  
 my @vcf_dirs = @$vcf_dirs; 
  
 my %tissues = %{$tissues}; 
  
 my (%variants, @runs); 
  
 my $final_chr; 
  
 foreach my $vcf_dir (sort {"\L$a" cmp "\L$b"} @vcf_dirs){ 
  my ($vcf_count, @vcf_files); 
    
  print "Reading variants:\n$vcf_dir\n"; 
   
  opendir VCF_DIR, "$vcf_dir" or die "$vcf_dir not found!\n"; 
   
  if ($vcf_dir =~ /Brachiosaur/){@vcf_files = map {"$vcf_dir/$_"} grep {-f 
"$vcf_dir/$_" && !/genome/i && /\.vcf$/i} readdir VCF_DIR;} 
  else{@vcf_files = map {"$vcf_dir/$_"} grep {-f "$vcf_dir/$_" && 
/(variants\_annotated)?\.vcf$/i} readdir VCF_DIR;} 
   
  closedir VCF_DIR; 
   
  foreach my $vcf (sort {"\L$a" cmp "\L$b"} @vcf_files){ 
   $vcf_count++; 
    
   my $sample = $vcf; 
    
   $sample =~ s/^.+\///g; 
   $sample =~ s/\_.+$//g; 
    
   my @sample = split (/-/, $sample); 
    
   my ($run, $coin, $tissue) = @sample; 
    
   if ($tissue =~ /\s.+/){$tissue =~ s/$&//;}print "$run\t$coin\t$tissue\n"; 
     
   unless (grep {$run eq $_} sort {"\L$a" cmp "\L$b"} @runs){push @runs, 
$run;} 
    
   unless (defined $tissue){$tissue = "Undetermined";} 
    
   $tissue = $tissues{$tissue}; 
    
   # next unless $coin =~ /(14030|62015)/; 
   # next if $run =~ /NR3/; 
    
   print "Sample $vcf_count: $coin\tTissue: $tissue\tRun: $run\n"; 
    
   open VCF, "$vcf" or die $!; 
    
   while (my $line = <VCF>){ 
    chomp $line; 
     
    my ($gene_name, $amino_acid, $transcript, $depth_ref, 
$depth_alt, $preceeding_base, $proceeding_base); 
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    my $allele_i = 0; 
     
    next if $line =~ /^\#/; 
     
    my @fields = split (/\s+/, $line); 
     
    my ($chr, $pos, $rsID, $ref_allele, $alt_allele, $qual, $filter, 
$info, $format_header, $format) = @fields; 
     
    if ($chr =~ /^chr/i){$chr =~ s/$&//;} 
     
    # last if $chr > 1; 
    # next if $filter eq "REJECT"; 
     
    if ($chr > $final_chr){$final_chr = $chr;} 
     
    my $pos_end = ($pos + length $ref_allele) - 1; 
     
    #samtools faidx 
    my $flank_start = $pos - 1; 
    my $flank_end = $pos_end + 1; 
     
    my $region = $chr.":".$flank_start."-".$flank_end; 
     
    my $flank_sequence = `samtools faidx "$ref_file" $region`; 
     
    $flank_sequence =~ s/^\>$region//i; 
    $flank_sequence =~ s/\n//g; 
     
    if ($flank_sequence =~ /^[A-Z]/i){$preceeding_base = $&;} 
    if ($flank_sequence =~ /[A-Z]$/i){$proceeding_base = $&;} 
     
    $flank_sequence = $preceeding_base."_".$proceeding_base; 
     
    if ($info =~ /SNPEFF_GENE_NAME\=[A-Z0-9\-\.]+\;/i){ 
     $gene_name = $&; 
      
     $gene_name =~ s/^.+\=//; 
     $gene_name =~ s/\;$//; 
    } 
     
    else{$gene_name = "Unspecified";} 
     
    # next unless exists $known_variants{$coin}{$gene_name}; 
     
    if ($info =~ /AMINO_ACID_CHANGE\=[A-Z0-9\*]+\;/i){ 
     $amino_acid = $&; 
      
     $amino_acid =~ s/^.+\=//; 
     $amino_acid =~ s/\;$//; 
    } 
     
    else{$amino_acid = "Unspecified";} 
     
    if ($info =~ /SNPEFF_TRANSCRIPT_ID\=[A-Z\d]+\;/i){ 
     $transcript = $&; 
      
     $transcript =~ s/^.+\=//; 
     $transcript =~ s/\;$//; 
    } 
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    else{$transcript = "Unspecified";} 
     
    my @format = split (/\:/, $format); 
    my $allele_depths = $format[1]; 
     
    if ($run =~ /miseq/i){$allele_depths = $format[2];} 
     
    my @allele_depths = split (/,/, $allele_depths); 
     
    my $ref_depth = $allele_depths[0]; 
     
    # next unless (exists 
$known_variants{$coin}{$gene_name}{$amino_acid} && exists 
$known_variants{$coin}{$gene_name}{$amino_acid}{$chr} && exists 
$known_variants{$coin}{$gene_name}{$amino_acid}{$chr}{$pos}); 
     
    my @alt_alleles = split (/,/, $alt_allele); 
     
    foreach my $var_allele (sort {"\L$a" cmp "\L$b"} @alt_alleles){ 
     my ($mq, $qd, $fs, $haplotype_score, $mqrs, 
$read_pos_rank, $snpeff_effect); 
      
     $allele_i++; 
      
     my $allele_depth = $allele_depths[$allele_i]; 
      
     my ($mq_filter, $qd_filter, $fs_filter, 
$haplotype_score_filter, $mqrs_filter, $read_pos_rank_filter) = ("Pass", "Pass", "Pass", "Pass", 
"Pass", "Pass"); 
      
     my $nucleotide_change = $ref_allele.">".$var_allele; 
      
     # next unless 
$known_variants{$coin}{$gene_name}{$amino_acid}{$chr}{$pos} = $nucleotide_change; 
      
     if ($info =~ /MQ\=[0-9\.]+\;/i){ 
      $mq = $&; 
       
      $mq =~ s/^MQ\=//i; 
      $mq =~ s/\;$//; 
     } 
      
     else{$mq = "Unspecified";} 
      
     if ($info =~ /QD\=[0-9\.]+\;/i){ 
      $qd = $&; 
       
      $qd =~ s/^QD\=//i; 
      $qd =~ s/\;$//; 
     } 
      
     else{$qd = "Unspecified";} 
      
     if ($info =~ /FS\=[0-9\.]+\;/i){ 
      $fs = $&; 
       
      $fs =~ s/^FS\=//i; 
      $fs =~ s/\;$//; 
     } 
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     else{$fs = "Unspecified";} 
      
     if ($info =~ /HaplotypeScore\=[0-9\.]+\;/i){ 
      $haplotype_score = $&; 
       
      $haplotype_score =~ s/^HaplotypeScore\=//i; 
      $haplotype_score =~ s/\;$//; 
     } 
      
     else{$haplotype_score = "Unspecified";} 
      
     if ($info =~ /MQRankSum\=[0-9\.]+\;/i){ 
      $mqrs = $&; 
       
      $mqrs =~ s/^MQRankSum\=//i; 
      $mqrs =~ s/\;$//; 
     } 
      
     else{$mqrs = "Unspecified";} 
      
     if ($info =~ /ReadPosRankSum\=[0-9\.]+\;/i){ 
      $read_pos_rank = $&; 
       
      $read_pos_rank =~ s/^ReadPosRankSum\=//i; 
      $read_pos_rank =~ s/\;$//; 
     } 
      
     else{$read_pos_rank = "Unspecified";} 
      
     if ($info =~ /SNPEFF_EFFECT\=[a-z0-9\-\_]+\;/i){ 
      $snpeff_effect = $&; 
       
      $snpeff_effect =~ s/^.+\=//i; 
      $snpeff_effect =~ s/\;$//; 
     } 
      
     else{$snpeff_effect = "Unspecified";} 
      
     #These are the filters used to mark variants as filtered 
or pass. 
     if ($mq < 35){$mq_filter = "Filter";} 
     if ($qd < 2){$qd_filter = "Filter";} 
     if ($fs > 60){$fs_filter = "Filter";} 
     if ($haplotype_score > 13){$haplotype_score_filter = 
"Filter";} 
     if ($mqrs < -12.5){$mqrs_filter = "Filter";} 
     if ($read_pos_rank < -8){$read_pos_rank_filter = 
"Filter";} 
      
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"gene 
name"} = $gene_name; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"transcr
ipt"} = $transcript; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"snpEff 
effect"} = $snpeff_effect; 
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 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"rsID"} 
= $rsID; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"flankin
g sequence"} = $flank_sequence; 
      
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"filter"} 
= $filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"mappi
ng quality"} = $mq; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"quality 
by depth"} = $qd; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"strand 
bias"} = $fs; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"haplot
ype score"} = $haplotype_score; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"map 
quality rank sum"} = $mqrs; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"read 
pos rank sum"} = $read_pos_rank; 
      
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"mappi
ng quality filter"} = $mq_filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"quality 
by depth filter"} = $qd_filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"strand 
bias filter"} = $fs_filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"haplot
ype score filter"} = $haplotype_score_filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"map 
quality rank sum filter"} = $mqrs_filter; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"read 
pos rank sum filter"} = $read_pos_rank_filter; 
      
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ref 
depth"} = $ref_depth; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"var 
depth"} = $allele_depth; 
      
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"dbSNP 
presence"} = "N"; 
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 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG 
presence"} = "N"; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ESP 
presence"} = "N"; 
    
 $variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSM
IC presence"} = "N"; 
    } 
   } 
    
   close VCF; 
  } 
 } 
  
 return (\%variants, \@runs, $final_chr); 
} 
############################################################################
##################### 
#End of subroutine get_variants. 
############################################################################
##################### 
 
############################################################################
############################################################################
####### 
#dbSNP_reader 
#Opens dbSNP and checks whether each dbSNP line is in the %variants hash. 
#If it is in the hash, then it is deleted so that what remains in the hash are novel variants with 
respect to dbSNP. 
############################################################################
############################################################################
####### 
sub dbSNP_reader{ 
 my ($variants, $final_chr, $dbSNP) = @_; 
 my %variants = %{$variants}; 
  
 my $chromosome; 
  
 #open the dbSNP file and read it in line by line. 
 open dbSNP, "$dbSNP" or die "Cannot open dbSNP, did you mount the drive?\n"; 
  
 while ($dbSNP_line = <dbSNP>){ 
  chomp $dbSNP_line; 
  next if $dbSNP_line =~ /^\#/; 
   
  my @dbSNP_line = split (/\t/, $dbSNP_line); 
   
  my $chr = $dbSNP_line[0]; 
  my $pos = $dbSNP_line[1]; 
  my $rsID = $dbSNP_line[2]; 
  my $ref_allele = $dbSNP_line[3]; 
  my $alt_allele = $dbSNP_line[4]; 
  my $info = $dbSNP_line[7]; 
   
  last if $chr > $final_chr; 
   
  unless ($chromosome eq $chr){print "Now searching dbSNP, chromosome 
$chr.\n";} 
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  $chromosome = $chr; 
   
  #set the allele frequencies for each world population for the variant. 
  if ($info =~ /AF=[\d\.]+/i){ 
   $af = $&; 
   $af =~ s/AF\=//i; 
  } 
   
  else{$af = "NA";} 
 
  #although the majority of cases are mono-allelic, some are multi-allelic and so 
must be accounted for. 
  #this will split all alleles for a variant into an array (the array will only contain 1 
allele if mono-allelic) 
  my @alt_alleles = split (/\,/, $alt_allele); 
   
  #foreach alt allele at the site... 
  foreach my $alt_allele (@alt_alleles){ 
   #...make a unique key to identify variants, as one position can have 
many different variants (e.g. 2 SNPs, many indels or a SNP and an indel). 
   my $allele_key = $ref_allele."\>".$alt_allele; 
    
   #if the exomes hash contains the allele_key at the chromosomal 
position, then the variant is not unique and must be marked. 
   #I think it is necessary to have these 3 exist statements as if you just 
have the final 1, you risk creating $exomes{$chr}{$pos} if $exomes{$chr}{$pos}{$allele_key} 
   #doesn't exist. 
   #$variants{$chr}{$pos}{$allele_key}{$sample}} 
   if ((exists $variants{$chr}) && (exists $variants{$chr}{$pos}) && (exists 
$variants{$chr}{$pos}{$allele_key})){ 
    for $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}}){ 
     for $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}}){ 
      for $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}}){ 
       for $coin (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}}){ 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"dbSNP 
presence"} = "Y"; 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"dbSNP AF"} = 
$af; 
       } 
      } 
     } 
    } 
   } 
  } 
 } 
  
 close dbSNP; 
  
 #return %variants with only novel variants (that appear in multiple samples). 
 return \%variants; 
} 
############################################################################
############################################################################
####### 
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#End of dbSNP_reader 
############################################################################
############################################################################
####### 
 
############################################################################
############################################################################
####### 
#kg_reader 
#Opens 1000 genomes and checks whether each 1kg line is in the %variants hash. 
#If it is in the hash, then it is deleted so that what remains in the hash are novel variants with 
respect to 1kg. 
############################################################################
############################################################################
####### 
sub kg_reader{ 
 my ($variants, $final_chr, $kg) = @_; 
 my %variants = %{$variants}; 
  
 my ($af, $asn_af, $afr_af, $eur_af); 
  
 #open the kg file and read it in line by line. 
 open KG, "$kg" or die "Cannot open kg, did you mount the drive?\n"; 
  
 while ($kg_line = <KG>){ 
  chomp $kg_line; 
  next if $kg_line =~ /^\#/; 
   
  my @kg_line = split (/\t/, $kg_line); 
   
  my $chr = $kg_line[0]; 
  my $pos = $kg_line[1]; 
  my $rsID = $kg_line[2]; 
  my $ref_allele = $kg_line[3]; 
  my $alt_allele = $kg_line[4]; 
  my $info = $kg_line[7]; 
   
  last if $chr > $final_chr; 
   
  unless ($chromosome eq $chr){print "Now searching kg, chromosome $chr.\n";} 
  $chromosome = $chr; 
   
  #set the allele frequencies for each world population for the variant. 
  if ($info =~ /AF=[\d\.]+/i){ 
   $af = $&; 
   $af =~ s/AF\=//i; 
  } 
   
  else{$af = "NA";} 
   
  if ($info =~ /ASN_AF=[\d\.]+/i){ 
   $asn_af = $&; 
   $asn_af =~ s/ASN_AF\=//i; 
  } 
   
  else{$asn_af = "NA";} 
   
  if ($info =~ /AMR_AF=[\d\.]+/i){ 
   $amr_af = $&; 
   $amr_af =~s/AMR_AF\=//i; 
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  } 
   
  else{$amr_af = "NA";} 
   
  if ($info =~ /AFR_AF=[\d\.]+/i){ 
   $afr_af = $&; 
   $afr_af =~ s/AFR_AF\=//i; 
  } 
   
  else{$afr_af = "NA";} 
   
  if ($info =~ /EUR_AF=[\d\.]+/i){ 
   $eur_af = $&; 
   $eur_af =~ s/EUR_AF\=//i; 
  } 
   
  else{$eur_af = "NA";} 
   
  #although the majority of cases are mono-allelic, some are multi-allelic and so 
must be accounted for. 
  #this will split all alleles for a variant into an array (the array will only contain 1 
allele if mono-allelic) 
  my @alt_alleles = split (/\,/, $alt_allele); 
   
  #foreach alt allele at the site... 
  foreach my $alt_allele (@alt_alleles){ 
   #...make a unique key to identify variants, as one position can have 
many different variants (e.g. 2 SNPs, many indels or a SNP and an indel). 
   my $allele_key = $ref_allele."\>".$alt_allele; 
    
   if ((exists $variants{$chr}) && (exists $variants{$chr}{$pos}) && (exists 
$variants{$chr}{$pos}{$allele_key})){ 
    for $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}}){ 
     for $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}}){ 
      for $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}}){ 
       for $coin (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}}){ 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG presence"} 
= "Y"; 
         
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG AF"} = $af; 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG AFR AF"} = 
$afr_af; 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG AMR AF"} = 
$amr_af; 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG ASN AF"} = 
$asn_af; 
       
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"KG EUR AF"} = 
$eur_af; 
       } 
      } 
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     } 
    } 
   } 
  } 
 }   
  
 close KG; 
  
 #return %variants with only novel variants. 
 return \%variants; 
} 
############################################################################
############################################################################
####### 
#End of kg_reader 
############################################################################
############################################################################
#######  
 
############################################################################
############################################################################
####### 
#esp_reader 
#Opens esp and checks whether each esp line is in the %variants hash. 
#If it is in the hash, then it is deleted so that what remains in the hash are novel variants with 
respect to esp. 
############################################################################
############################################################################
####### 
sub esp_reader{ 
 my ($variants, $final_chr, $esp_dir) = @_; 
 my %variants = %{$variants}; 
  
 opendir ESP, "$esp_dir" or die "Cannot open $esp_dir.\n"; 
  
 my @esp_files = grep {-f "$esp_dir/$_" && /\.(vcf)$/i} readdir(ESP); 
  
 closedir ESP; 
  
 #open the esp file and read it in line by line. 
 foreach $esp_file (sort {"\L$a" cmp "\L$b"} @esp_files){ 
  open esp_file, "$esp_dir/$esp_file" or die "Cannot open ESP file, did you mount 
the drive?\n"; 
   
  while ($esp_line = <esp_file>){ 
   chomp $esp_line; 
   next if $esp_line =~ /^\#/; 
    
   my @esp_line = split (/\t/, $esp_line); 
    
   my $chr = $esp_line[0]; 
   my $pos = $esp_line[1]; 
   my $rsID = $esp_line[2]; 
   my $ref_allele =$esp_line[3]; 
   my $alt_allele = $esp_line[4]; 
   my $info = $esp_line[7]; 
    
   my @info = split (/\;/, $info); 
    
   my $maf = $info[4]; 
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   $maf =~ s/^MAF\=//; 
    
   my @maf = split (/\,/, $maf); 
    
   my $ea_maf = $maf[0]; 
   my $aa_maf = $maf[1]; 
   my $total_maf = $maf[2]; 
    
   if ($total_maf eq ""){$total_maf = "NA";} 
   if ($ea_maf eq ""){$ea_maf = "NA";} 
   if ($aa_maf eq ""){$aa_maf = "NA";} 
    
   last if $chr > $final_chr; 
    
   unless ($chromosome eq $chr){print "Now searching esp, chromosome 
$chr.\n";} 
   $chromosome = $chr; 
    
   #although the majority of cases are mono-allelic, some are multi-allelic 
and so must be accounted for. 
   #this will split all alleles for a variant into an array (the array will only 
contain 1 allele if mono-allelic) 
   my @alt_alleles = split (/\,/, $alt_allele); 
    
   #foreach alt allele at the site... 
   foreach my $alt_allele (@alt_alleles){ 
    #...make a unique key to identify variants, as one position can 
have many different variants (e.g. 2 SNPs, many indels or a SNP and an indel). 
    my $allele_key = $ref_allele."\>".$alt_allele; 
     
    if ((exists $variants{$chr}) && (exists $variants{$chr}{$pos}) && 
(exists $variants{$chr}{$pos}{$allele_key})){ 
     for $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}}){ 
      for $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}}){ 
       for $tissue (sort {"\L$a" cmp "\L$b"} 
keys %{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}}){ 
        for $coin (sort {"\L$a" cmp 
"\L$b"} keys %{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}}){ 
        
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"ESP presence"} 
= "Y"; 
          
        
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"ESP AF"} = 
$total_maf; 
        
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"ESP AA AF"} = 
$aa_maf; 
        
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"ESP EA AF"} = 
$ea_maf; 
        } 
       } 
      } 
     } 
    } 
   } 
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  } 
   
  close esp_file; 
 } 
  
 #return %variants with only novel variants (that appear in multiple samples). 
 return \%variants; 
} 
############################################################################
############################################################################
####### 
#End of esp_reader 
############################################################################
############################################################################
####### 
 
############################################################################
############################################################################
####### 
#sub cosmic_reader 
#Reads in COSMIC .tsv and extracts info on relevent variants. 
############################################################################
############################################################################
####### 
sub cosmic_reader{ 
 my ($variants, $final_chr, $cosmic_file) = @_; 
  
 my %variants = %{$variants}; 
  
 my %complement = ( 
  A => "T", 
  C => "G", 
  G => "C", 
  T => "A" 
 ); 
  
 my %cosmic_counts; 
  
 my $chromosome; 
  
 print "Now searching COSMIC. Please be patient.\n"; 
  
 open COSMIC, "$cosmic_file" or die $!; 
  
 while (my $cosmic_line = <COSMIC>){ 
  chomp $cosmic_line; 
   
  my ($allele_key, $complementary_key); 
   
  next if $cosmic_line =~ /Gene name/; 
   
  my @fields = split (/\t/, $cosmic_line); 
   
  my $gene = $fields[0]; 
  my $accession_id = $fields[1]; 
  my $primary_site = $fields[7]; 
  my $site_subtype  = $fields[8]; 
  my $mutation_CDS = $fields[13]; 
  my $mutation_AA = $fields[14]; 
  my $mutation_description = $fields[15]; 
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  my $genome_coords = $fields[17]; 
  my $fathmm_prediction = $fields[21]; 
  my $somatic_status = $fields[22]; 
  my $pubmed_id = $fields[23]; 
  my $id_study = $fields[24]; 
  my $sample_source = $fields[25]; 
  my $tumour_origin = $fields[26]; 
   
  my @genome_coords = split (/[\:\-]/, $genome_coords); 
  my $chr = $genome_coords[0]; 
  my $pos = $genome_coords[1]; 
   
  last if $chr > $final_chr; 
   
  unless ($chromosome eq $chr){print "Now searching COSMIC, chromosome 
$chr.\n";} 
  $chromosome = $chr; 
    
  if ($mutation_CDS =~ /([A-Z]+\>[A-Z]+)|([\d\_]+(ins|del)[A-Z]+)/i){ 
   $allele_key = $&; 
  } 
   
  $alllele_key =~ tr/a-z/A-Z/; 
   
  if ($allele_key =~ /\>/){ 
   my @alleles = split (/\>/, $allele_key); 
    
   my $ref_allele = $alleles[0]; 
   my $var_allele = $alleles[1]; 
    
   my $ref_comp = $complement{$ref_allele}; 
   my $var_comp = $complement{$var_allele}; 
    
   $complementary_key = "$ref_comp>$var_comp"; 
    
   if ((exists $variants{$chr}) && (exists $variants{$chr}{$pos}) && (exists 
$variants{$chr}{$pos}{$complementary_key})){$allele_key = $complementary_key;} 
  } 
   
  if ((exists $variants{$chr}) && (exists $variants{$chr}{$pos}) && (exists 
$variants{$chr}{$pos}{$allele_key})){ 
   for $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}}){ 
    for $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}}){ 
     for $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}}){ 
      for $coin (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}}){ 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
presence"} = "Y"; 
        
       $cosmic_counts{"$run $tissue $coin 
$chr:$pos $allele_key"}++; 
        
       my $cosmic_count = 
$cosmic_counts{"$run $tissue $coin $chr:$pos $allele_key"}; 
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       #Due to limits imposed by MS excel 
and LibreOffice Calc, you cannot have too many characters per cell (limit unknown). 
       #COSMIC may contain many entries 
for a given variant, so limiting the number of entries stored in the output file will hopefully not 
overload the end product. 
       next if $cosmic_count >= 10; 
        
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
accession ID"} .= "[$cosmic_count]$accession_id;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
primary site"} .= "[$cosmic_count]$primary_site;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC site 
subtype"} .= "[$cosmic_count]$site_subtype;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC CDS"} 
.= "[$cosmic_count]$mutation_CDS;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC AA"} 
.= "[$cosmic_count]$mutation_AA;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
description"} .= "[$cosmic_count]$mutation_description;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
coords"} .= "[$cosmic_count]$genome_coords;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
FATHMM prediction"} .= "[$cosmic_count]$fathmm_prediction;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
somatic status"} .= "[$cosmic_count]$somatic_status;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
pubmed ID"} .= "[$cosmic_count]$pubmed_id;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC study 
ID"} .= "[$cosmic_count]$id_study;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
sample source"} .= "[$cosmic_count]$sample_source;"; 
      
 $variants{$chr}{$pos}{$allele_key}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
tumour origin"} .= "[$cosmic_count]$tumour_origin;"; 
      } 
     } 
    } 
   } 
  } 
 } 
  
 close COSMIC; 
  
 return \%variants; 
} 
############################################################################
############################################################################
####### 
 227 
 
#End of cosmic_reader 
############################################################################
############################################################################
####### 
 
############################################################################
##################### 
#Subroutine printer. 
#Takes a hash of variants and prints them out to a CSV file. 
############################################################################
##################### 
sub printer{ 
 my ($variants, $out_file, $variant_list, $tissues, $tissue_presence, $runs) = @_; 
  
 my %variants = %{$variants}; 
  
 my %tissues = %{$tissues}; 
  
 my @runs = @$runs; 
  
 my %rev_tissues = reverse %tissues; 
  
 open OUT, ">$out_file" or die $!; 
 
 print OUT "\#Run,Tissue,COIN ID,Gene,Transcript,Chr,Pos,rsID,Nucleotide change,AA 
change,No. samples called in,Ref allele depth,Variant allele depth,snpEff effect,Flanking 
nucleotides,Overall Filter,Map Qual,MQ Filter,Qual by Depth,QD Filter, Fisher Strand Bias,FS 
Filter,Haplotype Score,HS Filter,MQ Rank Sum,MQRS Filter,Read Pos Rank Sum,RPRS 
Filter,"; 
  
 foreach my $run (sort {"\L$a" cmp "\L$b"} @runs){print OUT "Present in $run,"} 
  
 print OUT "Present in germline (any sample),Present in nFFPE (any sample),Present in 
tFFPE (any sample),Present in UDG nFFPE (any sample),Present in UDG tFFPE (any 
sample),Present in undetermined (any sample),Present in WGA tFFPE (any sample),Present in 
germline (by sample),Present in nFFPE (by sample),Present in tFFPE (by sample),Present in 
UDG nFFPE (by sample),Present in UDG tFFPE (by sample),Present in undetermined (by 
sample),Present in WGA tFFPE (by sample),Present in dbSNP,Present in 1000 
Genomes,Present in Exome Sequencing Project,Present in COSMIC,dbSNP allele 
frequency,1KG global allele frequency,1KG AFR frequency,1KG AMR frequency,1KG ASN 
frequency,1KG EUR frequency,ESP total frequency,ESP AA frequency,ESP EA 
frequency,COSMIC accession ID,COSMIC primary site,COSMIC site subtype,COSMIC 
coords,COSMIC CDS,COSMIC AA,COSMIC description,COSMIC FATHMM 
prediction,COSMIC somatic status,COSMIC pubmed ID,COSMIC study ID,COSMIC sample 
source,COSMIC tumour origin\n"; 
 
 for my $chr (sort {"\L$a" cmp "\L$b"} keys %variants){ 
  for my $pos (sort {$a <=> $b} keys %{$variants{$chr}}){ 
   for my $nucleotide_change (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}}){ 
    my $sample_count = 0; 
     
    for my $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}}){ 
     for my $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}}){ 
      for my $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}}){ 
       $sample_count += scalar keys 
%{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}} 
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      } 
     } 
    } 
        
    for my $amino_acid (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}}){ 
     for my $run (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}}){ 
      for my $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}}){ 
       #Use these lines of code if you want to 
look at presence of a variant in a tissue across all samples. 
       my %tissue_presence_overall = 
%{$tissue_presence}; 
        
       for my $other_run (sort {"\L$a" cmp 
"\L$b"} @runs){ 
        for my $other_tissue (sort 
{"\L$a" cmp "\L$b"} keys %rev_tissues){ 
         #Is the variant present 
in any other tissue across all runs? 
         if (exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run} && exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run}{$other_tissue}){ 
         
 $tissue_presence_overall{$other_tissue} = "Y"; 
         } 
        } 
       } 
        
       for my $coin (sort {"\L$a" cmp "\L$b"} 
keys %{$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}}){ 
        #Use this if you want to look at 
presence of a variant in a tissue for a specific sample. 
        my %tissue_presence = 
%{$tissue_presence}; 
         
        my $snpeff_effect = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"snpEff effect"}; 
        my $flanking_sequence = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"flanking 
sequence"}; 
        my $rsID = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"rsID"}; 
         
        my $gene_name = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"gene name"}; 
        my $transcript = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"transcript"}; 
        my $filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"filter"};  
        my $mq = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"mapping 
quality"}; 
        my $qd = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"quality by 
depth"}; 
        my $fs = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"strand bias"}; 
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        my $haplotype_score = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"haplotype 
score"}; 
        my $mqrs = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"map quality 
rank sum"}; 
        my $read_pos_rank = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"read pos rank 
sum"}; 
         
        my $mq_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"mapping 
quality filter"}; 
        my $qd_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"quality by 
depth filter"}; 
        my $fs_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"strand bias 
filter"}; 
        my $haplotype_score_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"haplotype 
score filter"}; 
        my $mqrs_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"map quality 
rank sum filter"}; 
        my $read_pos_rank_filter = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"read pos rank 
sum filter"}; 
         
        my $ref_depth = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ref depth"}; 
        my $var_depth = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"var depth"}; 
         
        my $dbSNP_presence = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"dbSNP 
presence"}; 
        my $kg_presence = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG 
presence"}; 
        my $esp_presence = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ESP 
presence"}; 
        my $cosmic_presence = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
presence"}; 
         
        my $dbSNP_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"dbSNP AF"}; 
        my $kg_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG AF"}; 
        my $kg_afr_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG AFR AF"}; 
        my $kg_amr_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG AMR AF"}; 
        my $kg_asn_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG ASN AF"}; 
        my $kg_eur_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"KG EUR AF"}; 
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        my $esp_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ESP AF"}; 
        my $esp_aa_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ESP AA AF"}; 
        my $esp_ea_af = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"ESP EA AF"}; 
         
        my $accession_id = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
accession ID"}; 
        my $primary_site = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
primary site"}; 
        my $site_subtype = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC site 
subtype"}; 
        my $genome_coords = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
coords"}; 
        my $cosmic_cds = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
CDS"}; 
        my $cosmic_aa = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC AA"}; 
        my $cosmic_decription = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
description"}; 
        my $fathmm_prediction = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
FATHMM prediction"}; 
        my $somatic_status = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
somatic status"}; 
        my $pubmed_id = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
pubmed ID"}; 
        my $study_id = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC study 
ID"}; 
        my $sample_source = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
sample source"}; 
        my $tumour_origin = 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$tissue}{$coin}{"COSMIC 
tumour origin"}; 
         
        print OUT 
"$run,$tissue,$coin,$gene_name,$transcript,$chr,$pos,$rsID,$nucleotide_change,$amino_acid,
$sample_count,$ref_depth,$var_depth,$snpeff_effect,$flanking_sequence,$filter,$mq,$mq_filter
,$qd,$qd_filter,$fs,$fs_filter,$haplotype_score,$haplotype_score_filter,$mqrs,$mqrs_filter,$read
_pos_rank,$read_pos_rank_filter"; 
         
        #Is the variant in this sample 
found in the same sample from another run? 
        for my $other_run (sort {"\L$a" 
cmp "\L$b"} @runs){ 
         if (exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run} && exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run}{$tissue} && exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run}{$tissue}{$coin}){ 
 231 
 
          print OUT 
",Y"; 
         } 
          
         else{print OUT ",N";} 
          
         #Use these lines of 
code if you want to look at variants in a patient that are found across all runs and tissues for that 
patient. 
         for my $other_tissue 
(sort {"\L$a" cmp "\L$b"} keys %tissue_presence){ 
          if (exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run} && exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run}{$other_tissue} && exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$other_run}{$other_tissue}{$coin}){  
          
 $tissue_presence{$other_tissue} = "Y"; 
          } 
         } 
        } 
         
        for my $other_tissue (sort 
{"\L$a" cmp "\L$b"} keys %tissue_presence_overall){ 
         #use this line if you're 
looking at variants in other tissues for this sample only. 
         # if (exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$other_tissue}){$tissue_presen
ce{$other_tissue} = "Y";} 
          
         print OUT 
",$tissue_presence_overall{$other_tissue}"; 
        } 
         
        for my $other_tissue (sort 
{"\L$a" cmp "\L$b"} keys %tissue_presence){ 
         #use this line if you're 
looking at variants in other tissues for this sample only. 
         # if (exists 
$variants{$chr}{$pos}{$nucleotide_change}{$amino_acid}{$run}{$other_tissue}){$tissue_presen
ce{$other_tissue} = "Y";} 
          
         print OUT 
",$tissue_presence{$other_tissue}"; 
        } 
         
        print OUT 
",$dbSNP_presence,$kg_presence,$esp_presence,$cosmic_presence,$dbSNP_af,$kg_af,$kg_
afr_af,$kg_amr_af,$kg_asn_af,$kg_eur_af,$esp_af,$esp_aa_af,$esp_ea_af,$accession_id,$pri
mary_site,$site_subtype,$genome_coords,$cosmic_cds,$cosmic_aa,$cosmic_description,$fath
mm_prediction,$somatic_status,$pubmed_id,$study_id,$sample_source,$tumour_origin\n"; 
       } 
      } 
     } 
    } 
   } 
  } 
 } 
 
 close OUT; 
} 
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############################################################################
##################### 
#End of subroutine printer. 
############################################################################
##################### 
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Custom Script 3 
 
#DOCTOR - Depth Of Coverage In Translated Only Regions. 
#Calculate the percent of each ORF of each gene of interest (GOI) at 4x, 10x, 20x 30x, 40x 
coverage. 
#Also calculate the average coverage for each gene of interest. Two major steps, including: 
#Diagnosis - gathering information about coding regions from a given dataset (in this case 
NCBI's CCDS) 
#and genes of interest from a specified list. A line of code is used to look only at these GOIs or 
every 
#gene in the dataset (the 'exome'). 
 
#Treatment - Using SAMtools mpileup to get the coverage at each nucleotide in the CDS for 
every GOI. 
#Search the output for the coverage at only the coding bases and calculate the coverage across 
the gene 
#(divide by the number of coding bases). Also works out the coverage across the exome. The 
printing subroutines 
#are called from this subroutine, which initialise the output file (&admit) and print the output 
(&discharge). 
 
############################################################################
################# 
 
#use this script to test writing an excel file. 
use Spreadsheet::WriteExcel; 
 
#prints things in pretty colours. 
use Term::ANSIColor; 
 
#Tells perl we're going to be using R. 
use Statistics::R; 
 
($date, $time) = &delorean; 
 
#name of the output table (note the full filepath is given later). 
$doc_table = "contamination profile ($date)"; 
 
@depths = (1, 10, 20, 50, 100, 200, 300, 400, 500, 1000, 2000, 2500, 3000); 
 
#used to convert the BGIx10 samples to their COIN IDs. 
#%bgi_exomes = ( 
 #x => "110926_I174_FCC0343ACXX_L3_HUMvejXAAAAAPEI-9", x => 
#"110930_I810_FCC02KFACXX_L6_HUMvejXABAAAPEI-12", 
 #x => "110926_I174_FCC0343ACXX_L3_HUMvejXACAAAPEI-1", x => 
#"110926_I174_FCC0343ACXX_L3_HUMvejXADAAAPEI-2", 
 #x => "110930_I810_FCC0335ACXX_L5_HUMvejXAEAAAPEI-3", x => 
#"110930_I810_FCC02KFACXX_L6_HUMvejXAFAAAPEI-4", 
 #x => "110930_I810_FCC02KFACXX_L6_HUMvejXAGAAAPEI-5", x => 
#"110930_I810_FCC0335ACXX_L5_HUMvejXAHAAAPEI-7", 
 #x => "110930_I810_FCC0335ACXX_L5_HUMvejXAIAAAPEI-8", x => 
#"110926_I174_FCC0343ACXX_L4_HUMvejXAJAAAPEI-9" 
#); 
   
%rev_bgi = reverse %bgi_exomes; 
 
#load sample names into an array. 
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#look up all files (realigned.bam files) in specified directories and store filepaths for each in an 
array (will contain files from each sequencing set). 
$unc = "/media/marc/Triceratops/Exomes/UNC output/09_GATK_indelrealigner"; 
$bgix10 = "/media/marc/Triceratops/Exomes/BGIx10 output/09_GATK_indelrealigner"; 
$bgix13 = "/media/marc/Triceratops/Exomes/BGIx13 output/09_GATK_indelrealigner"; 
$bgix16 = "/media/marc/Triceratops/Exomes/BGIx16 output/09_GATK_indelrealigner"; 
$bgix18 = "/media/marc/Triceratops/Exomes/BGIx18 output/09_GATK_indelrealigner"; 
$nhs = "/media/marc/Triceratops/Exomes/Pilot project output/NHS 
output/09_GATK_indelrealigner/isolated amplicons"; 
$nhs_repeat = "/media/marc/Triceratops/Exomes/Pilot project output/NHS repeat 
output/09_GATK_indelrealigner"; 
$nhs_trimmed = "/media/marc/Triceratops/Exomes/Pilot project output/NHS trimmed 
output/09_GATK_indelrealigner"; 
$wthd = "/media/marc/Triceratops/Exomes/Pilot project output/WT (HD) 
output/09_GATK_indelrealigner/isolated amplicons"; 
$wtld = "/media/marc/Triceratops/Exomes/Pilot project output/WT (LD) 
output/09_GATK_indelrealigner"; 
$nhs_raw= "/media/marc/Brachiosaur/NGS data/Pilot project (KRAS, NRAS, BRAF & 
PIK3CA)/NHS Miseq/Misc MiSeq generated files"; 
$nr = "/media/marc/Triceratops/Exomes/Non responder output/09_GATK_indelrealigner/alien 
amplicons"; 
$ingram = "/media/marc/Triceratops/Exomes/Ingram 14-5546 output/09_GATK_indelrealigner"; 
$contamination = "/media/marc/Triceratops/Exomes/Contamination 
output/09_GATK_indelrealigner"; 
 
$amplicon_file = "/home/marc/Documents/work/reseq analysis/pilot 
project/Miscellaneous/DesignStudio amplicons.csv"; 
$panel_file = "/home/marc/Documents/work/reseq analysis/non responder 
project/Miscellaneous/NR & NHS panel genes.csv"; 
 
@sample_sets = ($contamination); 
 
foreach my $data_dir (sort {"\L$a" cmp "\L$b"} @sample_sets){ 
 #Read in the 'realigned.bam' file names for each sample, and store them in the 
@data_wave array. 
 opendir DATA, "$data_dir" or die "$data_dir not found. Did you mount the drive, you 
tool?"; 
  
 #@data_wave is a temporary collection of files in the current directory (containing the 
relaigned.bams for the centre). 
 #could just push these straight into @data_pool but this method takes virtually no time 
anyway and is only performed once. 
 my @data_wave = map {$data_dir."/".$_} grep { -f "$data_dir/$_" && 
/(isolated_amplicons_sorted|realigned)\.bam$/i} readdir DATA; 
  
 #for each sample, create the path to its BAM file and store this in a new array, 
@data_pool. 
 foreach my $file (sort {"\L$a" cmp "\L$b"} @data_wave){ 
  my $sample = $file; 
   
  $sample =~ s/.+\///g; 
   
  my @sample = split (/-/, $sample); 
   
  my ($run, $coin, $tissue) = @sample; 
   
  $tissue =~ s/\_.+$//; 
   
  #skip x, it is a re-sequenced copy of x. 
  # next if $run =~ /[^6]run2/i; 
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  # next if $coin =~ /Undetermined/; 
  # next unless $sample =~ /x\-e/i; 
   
  #@data_pool will contain the full filepath. 
  push (@{$data_pool{$run}{$coin}{$tissue}}, $file); 
  @{$data_pool{$run}{$coin}{$tissue}} = sort {"\L$a" cmp "\L$b"} 
@{$data_pool{$run}{$coin}{$tissue}}; 
 } 
  
 closedir DATA; 
} 
 
# $targets = panel_reader($panel_file); 
 
#Call the sub routines. 
$gene_coordinates = diagnosis($targets); 
# $gene_coordinates = second_diagnosis($gene_coordinates, $amplicon_file);  
 
if (%gene_coordinates){$plot = treatment($gene_coordinates, \%rev_bgi, \%data_pool, 
$doc_table, \@depths);} 
 
print "No of bases for resequencing: $seq_target.\n"; 
 
# plot($plot); 
 
 
sub panel_reader{ 
 my $panel_file = shift; 
  
 my %targets; 
  
 open PANEL, "$panel_file" or die $!; 
  
 while (my $line = <PANEL>){ 
  chomp $line; 
   
  next if $line =~ /^#/; 
   
  my @fields = split (/,/, $line); 
   
  my ($gene, $panel) = @fields; 
   
  unless (grep {$panel eq $_} sort @{$targets{$gene}}){push 
@{$targets{$gene}}, $panel;} 
   
  @{$targets{$gene}} = sort {"\L$a" cmp "\L$b"} @{$targets{$gene}};print 
"@{$targets{$gene}}\n"; 
 } 
  
 close PANEL; 
  
 return (\%targets); 
} 
 
############################################################################
############################################################################
######### 
#diagnosis 
#step 1: find exon regions for each gene. open gene list, store gene names in an array 
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# open up the CCDS file and store genes of interest (GOIs) in an array. the exon starts 
and ends can be split into a hash. 
# if a GOI isn't in the CCDS, then the GOI will not be used any further. 
############################################################################
############################################################################
######### 
sub diagnosis{ 
 my $targets = shift; 
  
 my %targets = %{$targets}; 
  
 print "Diagnosis\n"; 
  
 #the files containing the GOIs and the CCDS dataset.  
 my $gene_list = "/home/marc/Documents/work/exome analysis/Miscellaneous/team 
requests/Hannah/coverage_cmt_20x_2013-6-20.csv"; 
 my $ncbi_ccds = "/media/marc/Brachiosaur/Exomes/database 
resources/CCDS_2013_6_16.txt"; 
 my $ref_seq = "/media/marc/Brachiosaur/Exomes/database 
resources/refseq_genes_GRCh37_2013-06-20"; 
  
 #Open them. 
 open GENE_LIST, $gene_list or die "The gene_list file $gene_list is not in the specified 
location"; 
 open CCDS, $ncbi_ccds or die "The NCBI file $ncbi_ccds is not in the specified 
location"; 
 open REFSEQ, $ref_seq or die "The RefSeq file $ref_seq is not in the specified 
location"; 
  
 #read the gene list line by line. split each line into an array, use the first element to find 
the gene name. 
 #store each gene name into an array. 
 while ($gene_line = <GENE_LIST>){ 
  #ignore the first line. 
  next if ($gene_line =~ /^Gene Name/i); 
   
  #remove new line characters from end of line. 
  chomp $gene_line; 
   
  #split the line into an array, by commas. 
  my @gene_line = split (/\,/, $gene_line); 
   
  my $gene = $gene_line[0]; 
  $gene =~ s/\'//g; 
   
  #converts the gene name to upper case. 
  #gene names in CCDS = all caps (and start with a letter). 
  $gene =~ tr/a-z/A-Z/; 
   
  #last if $gene eq ""; 
  #last if $gene eq ""; 
 
  #store the GOIs in an array. 
  push (@GOI, $gene); 
 } 
  
 close GENE_LIST; 
  
 #use this if you want to look at coverage in specified genes. 
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 @GOI = qw(AKT1  AKT2  AKT3  ARAF  AREG  AXL  BCL2L11  BRAF 
 CBL  CDH1  DOK2  EGF  EGFR  ERBB2  ERBB3  EREG  FCGR2A 
 FCGR3A  FLT1  GAB1  GRB2  HRAS  IGF1  IGF1R  JAK1  JAK2  KDR 
 KRAS  MAP2K1  MAP2K2  MAPK1  MAPK3  MET  NCK1 
 NRAS  PDK1  PIK3CA  PLCG1  PLCG2  PRKCA  PRKCD  PTEN 
 RAF1  SHC1  SOS1  SRC  STAT1  STAT3  TP53 DDR2 KIT); 
 # @GOI = qw(KRAS NRAS BRAF PIK3CA); 
  
 #Sort the GOI array alphabetically. 
 @GOI = sort {"\L$a" cmp "\L$b"} @GOI; 
 # @chr = qw(6 22 X); 
 
 #read in from the CCDS file to extract exon regions for the genes of interest. Some 
genes have several transcripts. 
 #Some of these transcripts share the same name but have different coding regions on 
the chromosome. 
 #all transcripts have a unique transcript ID. 
 while (my $ccds_line = <CCDS>){ 
  #reset the number of exons for the gene/transcript. Necessary for hash 
creation. 
  my $no_exons = 0; 
  my $gene_length = 0; 
  my $no_bases = 0; 
  my $holding_gene = 0; 
  my %holding_bases = (); 
   
  # my $gene_panel; 
   
  #ignore the first line 
  next if $ccds_line =~ /^\#chromosome/i; 
   
  #remove any new line characters from the line in the CCDS file. 
  chomp $ccds_line; 
   
  #split the CCDS line into an array (by spaces). 
  @ccds_line = split (/\s/, $ccds_line); 
   
  #the number of elements in the CCDS line array. 
  $ccds_line_size = scalar (@ccds_line); 
   
  #Assign scalars to CCDS line array elements. 
  my $chr = $ccds_line[0]; 
  my $gene = $ccds_line[2]; 
  my $transcript_id = $ccds_line[4]; 
  my $ccds_status = $ccds_line[5]; 
   
  #translate the gene name to upper case. 
  $gene =~ tr/a-z/A-Z/; 
   
  # if (grep {$gene eq $_} sort {"\L$a" cmp "\L$b"} keys %targets){$gene_panel = 
${$targets{$gene}}[0];} 
   
  #store vital information from the CCDS line (chr/gene/transcript name). 
  my $chr_gene = $chr."\_".$gene; 
  my $gene_transcript = $gene."\_".$transcript_id; 
  my $chr_gene_transcript = $chr."\_".$gene_transcript; 
   
  if (@{$holding_lengths{$chr_gene}}){$holding_gene = 1;} 
   
 238 
 
  #ignore CCDS statuses if they are not public (eg. are withdrawn, pending 
withdrawal, etc). 
  #non public genes typically have low coverage or the CCDS line contains 
insufficient data to calculate coverage for the transcript. 
  next unless $ccds_status eq "Public"; 
   
  #number of genes in the CCDS 
  $total_transcripts++; 
   
  #skips the line if the gene is not a GOI. Ensures only GOIs are added to the 
GOI hash. 
  #silence this line to include all genes in CCDS. 
  # next unless (grep {$gene eq $_} sort @GOI); 
  # next unless (grep {$chr eq $_} sort @chr); 
   
  #count the number of GOI transcripts in the CCDS. 
  $goi++; 
   
  #this checks the current transcript against the previous line, to see whether or 
not it is a duplicate 
  $is_duplicate = $chr_gene_transcript;  
  $is_duplicate =~ s/\_[a-z\d\.]+$//i; 
  if ($is_duplicate =~ /^$chr\_$gene$/){$duplicate_transcripts++;} 
  $unique_transcripts = $goi - $duplicate_transcripts; 
   
  #store genes in the CCDS file in an array, to see how many genes (not 
transcripts) there are in CCDS. 
  #unless (grep {$gene eq $_} sort @genes){push (@genes, $gene);} 
   
  #create a hash of hash of arrays for all genes: %gene_coordinates = 
{%chr_gene_transcripts => (@exon_no = (start pos, stop pos))} 
  #for first exon in line to last exon in line, where $i is the (exon number + 8). 
  for $i (9 .. ($ccds_line_size-2)){ 
   #remove the [], characters from the exon positions. 
   $ccds_line[$i] =~ s/[\[\]\,]//g; 
    
   #split the exon into start and stop positions. 
   @exon_start_end = split (/\-/, $ccds_line[$i]); 
    
   #push the start and stop positions into the hash, if the positions are 
numerical (some may have errors in, rendering the CCDS line useless). 
   if ($exon_start_end[0] =~ /^\d+$/ && $exon_start_end[1] =~ /^\d+$/){ 
    #foreach (coding) nucleotide in the exon. 
    for $base ($exon_start_end[0] .. $exon_start_end[1]){ 
     #store each base in an array in a hash. 
     push @{$holding_bases{$chr_gene}}, $base; 
    } 
 
    #the gene length is the total number of coding bases.  
    #Note the +1 at the end is essential, or the length will be (1 * 
number of exons) too short. 
    $gene_length += ($exon_start_end[1] - $exon_start_end[0]) + 
1; 
     
    #count how many exons there are in the line - need to know 
this. 
    $no_exons++; 
   } 
  } 
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  #if the gene has many transcripts, use this to store details for the transcript with 
the most coding bases. 
  #the first time a gene is encountered, store the details. If another transcripts is 
encountered, replace the prev. details with the new ones. 
  if ($holding_gene == 1){ 
   if ($gene_length > ${$holding_lengths{$chr_gene}}[1]){ 
    #this stores the lengths of the transcripts. 
    @{$holding_lengths{$chr_gene}} = ($chr_gene, $gene_length); 
     
    @{$gene_coordinates{$chr}{$chr_gene}{"bases"}} = 
@{$holding_bases{$chr_gene}}; 
    ${$gene_coordinates{$chr}{$chr_gene}{"transcript"}} = 
$ccds_line[4]; 
    ${$gene_coordinates{$chr}{$chr_gene}{"gene_length"}} = 
$gene_length; 
    ${$gene_coordinates{$chr}{$chr_gene}{"no_exons"}} = 
$no_exons; 
    $no_bases = scalar 
@{$gene_coordinates{$chr}{$chr_gene}{"bases"}}; 
    $cds_end = ${$holding_bases{$chr_gene}}[$no_bases - 1]; 
    $cds_start = ${$holding_bases{$chr_gene}}[0]; 
    push @{$gene_coordinates{$chr}{$chr_gene}{"CDS"}}, 
$cds_start, $cds_end; 
     
    $seq_target += $gene_length; 
   } 
  } 
   
  #the first time a gene is encountered 
  else{ 
   #keep a record of every unique gene in CCDS. 
   push @genes, $gene; 
    
   #this stores the lengths of the transcripts. 
   @{$holding_lengths{$chr_gene}} = ($chr_gene, $gene_length); 
    
   #store details of the gene. 
   @{$gene_coordinates{$chr}{$chr_gene}{"bases"}} = 
@{$holding_bases{$chr_gene}}; 
   ${$gene_coordinates{$chr}{$chr_gene}{"transcript"}} = $ccds_line[4]; 
   ${$gene_coordinates{$chr}{$chr_gene}{"gene_length"}} = 
$gene_length; 
   ${$gene_coordinates{$chr}{$chr_gene}{"no_exons"}} = $no_exons; 
   $no_bases = scalar @{$gene_coordinates{$chr}{$chr_gene}{"bases"}}; 
   $cds_end = ${$holding_bases{$chr_gene}}[$no_bases - 1]; 
   $cds_start = ${$holding_bases{$chr_gene}}[0]; 
   push @{$gene_coordinates{$chr}{$chr_gene}{"CDS"}}, $cds_start, 
$cds_end; 
    
   #print BED "$chr  
    
   $seq_target += $gene_length; 
    
   #special cirumstances only: keep a record of genes in CCDS so that 
they can be ignored in the refseq file.  
   #essentially stored the same data as @genes (plus chr data) but in a 
way more efficient for searching. 
   #push @{$refseq_check{$chr}}, $gene; 
  } 
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 } 
  
 close CCDS; 
  
 #sort the genes array. 
 @genes = sort (@genes); 
 
 #Check the number of GOI that aren't in the database file. 
 print "Checking whether GOIs are in the CCDS database\n"; 
 foreach my $gene_of_interest (@GOI){ 
  unless (grep {$gene_of_interest eq $_} sort @genes){ 
   #special circumstances only: used by refseq to look up GOIs that 
appear in refseq but not in CCDS. 
   #stores GOIs that do not appear in CCDS. 
   push (@ref_seek, $gene_of_interest); 
    
   $absent++;  
   print "$absent\t$gene_of_interest is not in the CCDS file\n";} 
 } 
  
 print "reading in missing genes from RefSeq.\n"; 
 #read in from the RefSeq file to get exon boundaries for genes which weren't in the 
CCDS. 
 while ($refseq_line = <REFSEQ>){ 
  #reset the number of exons for the gene/transcript. Necessary for hash 
creation. 
  my $no_exons = 0; 
  my $gene_length = 0; 
  my $no_bases = 0; 
  my $holding_gene = 0; 
  my %holding_bases = (); 
   
  # my $gene_panel; 
   
  #ignore the first line 
  next if $refseq_line =~ /^\#bin/i; 
   
  #remove any new line characters from the line in the CCDS file. 
  chomp $refseq_line; 
   
  #split the CCDS line into an array (by spaces). 
  @refseq_line = split (/\t/, $refseq_line); 
   
  #the number of elements in the CCDS line array. 
  $refseq_line_size = scalar (@refseq_line); 
   
  #Assign scalars to CCDS line array elements. 
  $chr = $refseq_line[2]; 
  $chr =~ s/^chr//i; 
  $gene = $refseq_line[12]; 
  $nm_accession = $refseq_line[1]; 
  $nm_accession =~ s/\_/\-/; 
   
  #only looks at chr 1 - 22, X & Y. 
  next if $chr =~ /\_/; 
   
  #translate the gene name to upper case. 
  $gene =~ tr/a-z/A-Z/; 
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  # if (grep {$gene eq $_} sort {"\L$a" cmp "\L$b"} keys %targets){$gene_panel = 
${$targets{$gene}}[0];} 
   
  #store vital information from the refseq line (chr/gene/transcript name). 
  $chr_gene = $chr."\_".$gene; 
  $gene_accession = $gene."\_".$nm_accession; 
  $chr_gene_transcript = $chr."\_".$gene_accession; 
   
  if (@{$holding_lengths{$chr_gene}}){$holding_gene = 1;} 
   
  #number of genes in the CCDS 
  $total_accessions++; 
   
  #silence this line to include all genes in refseq, otherwise will look at only GOIs. 
  # next unless (grep {$gene eq $_} sort @GOI); 
  # next unless (grep {$chr eq $_} sort @chr); 
 
  #skips genes which have already been added by the CCDS. can ignore unless 
adding to %WET in CCDS. 
  next if (grep {$chr_gene eq $_} sort {"\L$a" cmp "\L$b"} keys 
%{$gene_coordinates{$chr}}); 
   
  #count the number of GOI transcripts in RefSeq. 
  $goi++; 
   
  @exon_starts = split (/\,/, $refseq_line[9]); 
  @exon_ends = split (/\,/, $refseq_line[10]); 
   
  #store base numbers for each exon. 
  for $exon_no (0 .. ((scalar @exon_ends) - 1)){    
   $exon_start = $exon_starts[$exon_no]; 
   $exon_end = $exon_ends[$exon_no]; 
    
   for $base ($exon_start .. $exon_end){push 
@{$holding_bases{$chr_gene}}, $base;} 
    
   $gene_length += ($exon_end - $exon_start) + 1; 
    
   $no_exons++; 
  } 
   
  if ($holding_gene == 1){ 
   if ($gene_length > ${$holding_lengths{$chr_gene}}[1]){ 
    #since the transcript in the refseq line is the longest transcript 
for this gene, update %holding lengths and %WET. 
    @{$holding_lengths{$chr_gene}} = ($chr_gene, $gene_length); 
     
    @{$gene_coordinates{$chr}{$chr_gene}{"bases"}} = 
@{$holding_bases{$chr_gene}}; 
    ${$gene_coordinates{$chr}{$chr_gene}{"transcript"}} = 
$nm_accession; 
    ${$gene_coordinates{$chr}{$chr_gene}{"gene_length"}} = 
$gene_length; 
    ${$gene_coordinates{$chr}{$chr_gene}{"no_exons"}} = 
$no_exons; 
    $no_bases = scalar 
@{$gene_coordinates{$chr}{$chr_gene}{"bases"}}; 
    $cds_end = ${$holding_bases{$chr_gene}}[$no_bases - 1]; 
    $cds_start = ${$holding_bases{$chr_gene}}[0]; 
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    push @{$gene_coordinates{$chr}{$chr_gene}{"CDS"}}, 
$cds_start, $cds_end; 
     
    $seq_target += $gene_length; 
   } 
  } 
   
  else{  
   #since the transcript in the refseq line is the longest transcript for this 
gene, update %holding lengths and %WET. 
   @{$holding_lengths{$chr_gene}} = ($chr_gene, $gene_length); 
    
   @{$gene_coordinates{$chr}{$chr_gene}{"bases"}} = 
@{$holding_bases{$chr_gene}}; 
   ${$gene_coordinates{$chr}{$chr_gene}{"transcript"}} = $nm_accession; 
   ${$gene_coordinates{$chr}{$chr_gene}{"gene_length"}} = 
$gene_length; 
   ${$gene_coordinates{$chr}{$chr_gene}{"no_exons"}} = $no_exons; 
   $no_bases = scalar @{$gene_coordinates{$chr}{$chr_gene}{"bases"}}; 
   $cds_end = ${$holding_bases{$chr_gene}}[$no_bases - 1]; 
   $cds_start = ${$holding_bases{$chr_gene}}[0]; 
   push @{$gene_coordinates{$chr}{$chr_gene}{"CDS"}}, $cds_start, 
$cds_end; 
    
   push @refseq_genes, $gene; 
    
   $seq_target += $gene_length; 
  } 
 } 
  
 close REFSEQ; 
  
 foreach my $gene_of_interest (@ref_seek){ 
  unless (grep {$gene_of_interest eq $_} sort @refseq_genes){ 
   $still_absent++; 
   print "$still_absent\t$gene_of_interest is not in the CCDS or RefSeq 
datasets.\n";} 
 } 
  
  
 #special circumstances: looks only at refseq genes. 
 # for $chr (sort {"\L$a" cmp "\L$b"} keys %refseq_check) 
 # { 
  # foreach $gene (sort @{$refseq_check{$chr}}) 
  # { 
   # $chr_gene = $chr."\_".$gene; 
   # delete ($gene_coordinates{$chr}{$chr_gene}); 
  # } 
 # } 
  
 #count how many genes/transcripts of interest there are. 
 $goi = scalar (@GOI) - $absent; 
 $no_genes = scalar (@genes); 
 for $chr (sort {"\L$a" cmp "\L$b"} keys %gene_coordinates){ 
  $toi += scalar (keys %{$gene_coordinates{$chr}}); 
 } 
 
 #print "There are $ref_genes\:$transcript_count refseq genes:transcripts\n"; 
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 print "There are $goi GOIs ($toi TOIs) present in CCDS, $total_transcripts total 
(\"public\") transcripts ($unique_transcripts unique and $duplicate_transcripts duplicate 
transcripts)\n\n$seq_target\n\n"; 
  
 return \%gene_coordinates; 
} 
 
############################################################################
############################################################################
######### 
#End of Diagnosis 
############################################################################
############################################################################
######### 
 
sub second_diagnosis{ 
 my ($gene_coordinates, $amplicon_file) = @_; 
  
 my %gene_coordinates = %{$gene_coordinates}; 
  
 open AMP, "$amplicon_file" or die $!; 
  
 while (my $line = <AMP>){ 
  chomp $line; 
   
  next if $line =~ /^#/; 
   
  my @bases; 
   
  my @fields = split (/,/, $line); 
   
  my $gene = $fields[0]; 
  my $amplicon = $fields[1]; 
  my $chr = $fields[2]; 
  my $start_coord = $fields[3]; 
  my $end_coord = $fields[4]; 
   
  my $chr_gene_amp = $chr."\_".$gene."\_".$amplicon; 
   
  for (my $pos = $start_coord; $pos <= $end_coord; $pos++){ 
   push @{$gene_coordinates{$chr}{$chr_gene_amp}{"bases"}}, $pos; 
  } 
   
  ${$gene_coordinates{$chr}{$chr_gene_amp}{"transcript"}} = $amplicon; 
  ${$gene_coordinates{$chr}{$chr_gene_amp}{"gene_length"}} = scalar 
@{$gene_coordinates{$chr}{$chr_gene_amp}{"bases"}}; 
  @{$gene_coordinates{$chr}{$chr_gene_amp}{"CDS"}} = ($start_coord, 
$end_coord); 
 } 
  
 return \%gene_coordinates; 
} 
############################################################################
############################################################################
######### 
#treatment 
#step 2:  Calculates the coverage for each transcript in %WET for each sample. 
#  Printing output is performed by a further 2 called subroutines; admit & 
discharge. 
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############################################################################
#####s######################################################################
########## 
sub treatment{ 
 my ($gene_coordinates, $rev_bgi, $data_pool, $doc_table, $depths) = @_; 
 my %gene_coordinates = %{$gene_coordinates}; 
 my %rev_bgi = %{$rev_bgi}; 
 my %data_pool = %{$data_pool}; 
 my @depths = @$depths; 
  
 my $sample_count; 
  
 #used when printing - starts at -1 not 0. It's complicated but works perfectly. 
 my ($row, $column) = (0, 0); 
  
 print "Starting Treatment subroutine\n"; 
  
 #initialise the excel file. $workbook is returned by 'admit' and caught by the code here 
so can be used downstream. 
 my $workbook = admit(\%gene_coordinates, \%rev_bgi, \%data_pool, $doc_table, 
\@depths); 
  
 #foreach sample, calculate the coverage stats for each gene and print to the wookbook 
the stats, gene by gene. 
 #calls &discharge, which does the printing. 
 for my $run (sort {"\L$a" cmp "\L$b"} keys %data_pool){ 
  for my $coin (sort {"\L$a" cmp "\L$b"} keys %{$data_pool{$run}}){ 
   for my $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$data_pool{$run}{$coin}}){ 
    foreach my $filepath (sort {"\L$a" cmp "\L$b"} 
@{$data_pool{$run}{$coin}{$tissue}}){ 
     #count the number of samples covered. 
     $sample_count++; 
      
     #set the necessary variables. 
     $row = 1; 
     $column += 1; 
     $sample_print_count = 1; 
     $gene_count = 0; 
     $col_counter = 0; 
     $no_genes = 0; 
      
     my $index_file = $filepath; 
     $index_file =~ s/bam$/bai/i; 
      
     unless (-f "$index_file"){`samtools index "$filepath"`;} 
      
     if (grep {$coin eq $_} sort {"\L$a" cmp "\L$b"} keys 
%rev_bgi){$coin = $rev_bgi{$coin};} 
      
     #loop over each gene in the hash of hash of arrays 
     for my $chr (sort {"\L$a" cmp "\L$b"} keys 
%gene_coordinates){ 
      #running count of the number of transcripts 
analysed. 
      $no_genes += scalar keys 
%{$gene_coordinates{$chr}}; 
       
      #foreach transcript. 
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      for my $genes (sort {"\L$a" cmp "\L$b"} keys 
%{$gene_coordinates{$chr}}){ 
       #count the number of genes in the 
hash, and reset other variables if necessary. 
       $gene_count++; 
       $row++; 
       $gene_coverage = 0; 
       $base = 0; 
        
       foreach my $depth (sort {$a <=> $b} 
@depths){ 
        my $depth_var = "x".$depth; 
        $$depth_var = 0; 
       } 
        
       %gene_bases = (); 
        
       #get the chromosome number/name 
       if ($genes =~ /\_[^\_]+$/i){$gene = 
$&;$gene =~ s/\_//g;} 
 
       #get some stuff about the CDS. 
       $cds_start = 
${$gene_coordinates{$chr}{$genes}{"CDS"}}[0]; 
       $cds_end = 
${$gene_coordinates{$chr}{$genes}{"CDS"}}[1]; 
       $gene_length = 
${$gene_coordinates{$chr}{$genes}{"gene_length"}};#length = number of bases in exons 
       $no_exons = 
${$gene_coordinates{$chr}{$genes}{"no_exons"}}; 
        
       #call samtools mpileup specifying the 
whole gene region and the sample's realigned BAM file as input. 
       #From the STDOUT, cut the position 
and number of reads covering the position and save it to an array. 
       #For more info on switches, google 
them. 
       (@coverage) = `samtools mpileup -A -
E -Q 0 -r $chr\:$cds_start\-$cds_end "$filepath" | cut -f2,4`; 
        
       # next if scalar @coverage == 0; 
       #loop over the @coverage array and 
store the coverage at each base in a hash. 
       foreach my $site (@coverage) { 
        #split the array element into a 
temporary array containing the position and the coverage at the pos. 
        @pileup = split (/\s/, $site); 
        $base = $pileup[0]; 
        $base_coverage = $pileup[1]; 
         
        #store the coverage at each 
nucleotide in the gene into a hash. 
        #memory usage is minimal as 
this hash is emptied for every gene. 
        ${$gene_bases{$base}} = 
$base_coverage; 
       } 
        
       #loop over the coding bases in the 
gene and look up the coverage from the %gene_bases hash created above. 
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       #count the number of bases with a 
coverage > each depth threshold. 
       foreach my $base (sort {$a <=> $b} 
@{$gene_coordinates{$chr}{$genes}{"bases"}}){ 
        #looks up the coverage at the 
coding base. 
        $base_coverage = 
${$gene_bases{$base}}; 
         
        #keep a count of the total 
coverage across the whole gene. 
        #this will be averaged later. 
        $gene_coverage += 
$base_coverage; 
         
        #counts the number of bases 
with coverage > thresholds. 
        foreach my $depth (sort {$a 
<=> $b} @depths){ 
         if ($base_coverage >= 
$depth){ 
          my 
$depth_var = "x".$depth; 
         
 $$depth_var++; 
         } 
        } 
       } 
        
       #Get the average gene coverage by 
dividing gene coverage by the number of coding bases. 
       $gene_coverage /= $gene_length; 
        
       #turn the counts of bases with 
coverage > thresholds into percent of the ORF. 
       foreach my $depth (sort {$a <=> $b} 
@depths){ 
        my $depth_var = "x".$depth; 
        $$depth_var = ($$depth_var / 
$gene_length) * 100; 
         
        $admissions{$depth} = 
$$depth_var; 
       } 
        
       #keep a running count of the total 
coverage for every gene in the exome, 
       #and average it by dividing by the 
number of genes in the exome. 
       ${$exome_coverage{$exome}} += 
$gene_coverage; 
       $exome_average = 
${$exome_coverage{$exome}}/$gene_count; 
        
       #print some helpful stuff so you can 
see what's occuring. 
       print "\nSample "; 
       print color ("blue"), "$sample_count"; 
       print color ("red"), ": $coin\t"; 
       print color 'reset'; 
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       print "Transcript "; 
       print color ("green"), 
"$gene_count/$toi"; 
       print color 'reset'; 
       print ": "; 
       print color ("blue"), "$genes\n"; 
       print color 'reset'; 
       print "CDS: $cds_start - 
$cds_end\tGene length: ".$gene_length."bp\tExons: $no_exons 
${$gene_coordinates{$chr}{$genes}{$no_exons - 1}}[0]\nAverage gene coverage: 
$gene_coverage\nAverage exome coverage so far: $exome_average\nORF % at"; 
        
       #call discharge from here, passing a 
reference to the workbook. 
       my $workbook = 
discharge(${$workbook}, \%admissions, $row, $column); 
        
       #Plot bar charts to show data per 
sample (or group of samples) extra-graphically. Not at all necessary for the xls file creation but 
is a nice little add on. 
       foreach my $depth (sort {$a <=> $b} 
@depths){ 
        my $depth_key = $depth."x"; 
        my $depth_var = "x".$depth; 
         
        print "\t$depth_key: 
$$depth_var"; 
         
        $$depth_var = ($$depth_var / 
$gene_length) * 100; 
         
        $plot{$tissue}{"ORF 
depths"}{$depth_key}{$genes} = $$depth_var;  
       } 
        
       print "\n\n"; 
        
       #sample group can be a group of 
samples/patients (eg.  germline blood, non-responders, etc) or a single sample. 
       #genes is '$chr\_$gene'. 
       $plot{$tissue}{"average 
coverage"}{$genes} = $gene_coverage;    
      } 
     } 
      
     #the average coverage for the exome 
     ${$exome_coverage{$exome}} /= $gene_count; 
    } 
   } 
  } 
 } 
   
 #set row and column for printing exome averages. 
 $row += 2; 
 $column = 0; 
  
 #write exome averages in a row at the bottom of the .xls file. 
 foreach my $sample (sort {"\L$a" cmp "\L$b"} @samples){ 
  #leave a space so that averages are written underneath the average columns. 
  $column += 1; 
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  #print averages for every exome to every worksheet. 
  foreach $worksheet ($workbook -> sheets()){ 
   $sheet_name = $worksheet -> get_name(); 
   if ($sheet_name eq "averages"){$worksheet -> write ($row, $column, 
${$exome_coverage{$sample}});} 
  } 
 } 
  
 print "Treated $sample_count samples, each with $all_genes_genes genes 
($all_genes_trans transcripts)\n"; 
  
 return \%plot; 
} 
############################################################################
############################################################################
######### 
#End of treatment 
############################################################################
############################################################################
######### 
 
############################################################################
############################################################################
######### 
#discharge 
#print the coverage stats to the output table. 
############################################################################
############################################################################
######### 
sub discharge{ 
 #take the reference from the treatment routine by using shift on the array of args. 
 #(which isn't specified by a line of code but is how perl works). 
 my ($workbook, $admissions, $row, $column) = @_; 
 my %admissions = %{$admissions}; 
  
 #foreach worksheet in the workbook. 
 foreach my $worksheet ($workbook -> sheets()){ 
  #inc. counter for printing to spreadsheet. 
  $col_counter++; 
   
  #get the name of the sheet using Spreadsheet::writeExcel::get_name. 
  $sheet_name = $worksheet -> get_name(); 
   
  #print out blank cells for this gene in this sample as there is no coverage 
  #(eg. the gene lies on chr Y and the patient is female). 
  unless ($sheet_name eq "averages"){ 
   unless ($gene_coverage){ 
    for $col ($column .. ($column)){ 
     $worksheet -> write_blank ($row, $col); 
    } 
   } 
  } 
   
  #get the ORF % covered at $array_index fold coverage. the average coverage 
for the ORF is the i=5 index when you measure 4x, 10, 20x, 30x and 40x. 
  #array index is used to get the number in the sheet name, which is useful as 
each sheet contains coverage at a given threshold. 
  if ($sheet_name =~ /^\d+/){ 
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   #stat is used to point to the ORF percent covered at any depth 
threshold (the threshold being the sheet name with an 'x' in front). 
   $stat = "x$&"; 
    
   #to avoid going over the limit of cell styles in excel, cut the remainders 
of each stat so you have an integer. 
   #(stat therefore being an integer percent between 0 - 100). 
   $rgb = $$stat; 
   if ($rgb =~ /\.\d+$/){$rgb =~ s/$&//;} 
    
   #calculate each of the R and G values used in the colour format. 
   #if the percent is higher than 50, more green should be used and fade 
to yellow 
   if ($rgb >= 50){ 
    #this equation increases the amount of red the lower the 
percent gets 
    #i.e. as % goes down, red goes up. 
    #eg. at 100%, r = ((1 - 1) * 255) * 2 = 0 
    #  50%, r = ((1 - 0.5) * 255) * 2 = 255. 
    $r = ((1-($rgb/100))*255) * 2; 
    $g = 255; 
    $b = 0; 
   } 
    
   #if percent is less than 50, fade from yellow to red. 
   else{ 
    #this equation decreases the amount of green the lower the 
percentage gets 
    #i.e. as % goes down, so does green. 
    $g = (($rgb/100)*255) * 2; 
    $r = 255; 
    $b = 0; 
   } 
   
   #Excel uses a palette of 56 colours, ranging from 8 - 63. What I do here 
is I replace each colour in the palette with a custom colour (based on the RGB values of the 
ORF percent). 
   #Since percents range from 0 - 100, I must scale them to fit into the 56 
colour window. 
   #This is done by dividing the percent by 100/56 (~1.786, any more d.p. 
and it won't work quite right) and then adding 8. 
   #e.g. % = 0, colour = 0 / 1.786 + 8 = 8. % = 100, colour = 100 / 1.786 + 
8 = 63. % = 50, colour = 50 / 1.786 + 8 = 36. 
   $colour = ($rgb / 1.786) + 8; 
   $colour =~ s/\.\d+$//; 
 
   #to stay within the cell style limit, store each of the custom formats in a 
hash. 
   #each colour, 8 - 63 is then associated with a format, giving a 
maximum of 56 cell styles. 
   if (grep {$colour eq $_} sort {"\L$a" cmp "\L$b"} keys %formats){ 
    $format = ${$formats{$colour}}; 
   } 
    
   else{ 
    #if the colour isn't associated with a format yet, make it so. 
    #shade is the RGB settings of the colour. Each There are a 
maximum of 100 possible shades using this % system 
    #which is well below excel's cell style limit yet allows for a good 
looking gradient. 
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    $shade = $workbook -> set_custom_color ($colour, $r, $g, $b); 
     
    #format of the cell. 
    $format = $workbook -> add_format(bg_color => $shade); 
     
    #store the format in a hash, will store up to 100 formats (as 
intended). 
    ${$formats{$colour}} = $format; 
    push @{$gradient{$colour}}, $r, $g, $rgb; 
   } 
    
   #write the percent of the ORF covered, using the value-specific 
formatting 
   $worksheet -> write ($row, $column, $$stat, $format);  
  
  } 
   
  #print out all the average coverages on the final sheet (named 'averages'). 
  else{$worksheet -> write ($row, $column, $gene_coverage);} 
 } 
  
 #return the workbook to treatment sub. 
 return \$workbook; 
} 
############################################################################
############################################################################
######### 
#End of Discharge 
############################################################################
############################################################################
######### 
 
############################################################################
############################################################################
######### 
#admit 
#initialise the .xls output file; print samples across the top and gene/transcript names along the 
side. 
############################################################################
############################################################################
######### 
sub admit{ 
 my ($gene_coordinates, $rev_bgi, $data_pool, $doc_table, $depths) = @_; 
 my %gene_coordinates = %{$gene_coordinates}; 
 my %data_pool = %{$data_pool}; 
 my %rev_bgi = %{$rev_bgi}; 
 my @depths = @$depths; 
  
 #initialise the .xls file. 
 my $workbook = Spreadsheet::WriteExcel-
>new('/home/marc/Documents/work/DOCTOR/ORF coverage/'.$doc_table.'.xls');  
  
 #add worksheets for each of the coverage thresholds. 
 foreach my $depth (sort {$a <=> $b} @depths){ 
  my $sheet = $depth."x"; 
  my $depth = "x".$depth; 
   
  $$depth = $workbook -> add_worksheet($sheet); 
 } 
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 $averages = $workbook -> add_worksheet('averages'); 
  
 #foreach sheet in the workbook. 
 foreach my $worksheet ($workbook -> sheets()){ 
  #reset to row 1 (will be incremented before printing data). 
  my $row = 1; 
   
  #this is the column to print the sample name to, and the column to print the 
column headers (eg. ORF% and seq depth) to. 
  my $sample_print_count = 0; 
  my $header_column = 0; 
   
  #get the sheet name. 
  my $sheet_name = $worksheet -> get_name(); 
   
  #print column/row titles in the top left corner cell and the cell below it. 
  $worksheet->write(0, 0, 'Sample >'); 
  $worksheet->write(1, 0, 'Gene'); 
   
  my $orf_header = "ORF \% at $sheet_name"; 
  my $coverage_header = "Mean ORF depth"; 
   
  #loop over the samples 
  for my $run (sort {"\L$a" cmp "\L$b"} keys %data_pool){ 
   for my $coin (sort {"\L$a" cmp "\L$b"} keys %{$data_pool{$run}}){ 
    for my $tissue (sort {"\L$a" cmp "\L$b"} keys 
%{$data_pool{$run}{$coin}}){ 
     foreach my $filepath (sort {"\L$a" cmp "\L$b"} 
@{$data_pool{$run}{$coin}{$tissue}}){ 
      #count the number of samples printed.  
      #Effectively used as a column count when 
printing sample names. 
      $sample_print_count++; 
       
      if (grep {$coin eq $_} sort {"\L$a" cmp "\L$b"} 
keys %rev_bgi){$coin = $rev_bgi{$coin};} 
       
      #write the sample names to the column heads. 
      $worksheet -> write (0, $sample_print_count, 
"$run-$coin-$tissue"); 
       
      #increment sample count again - leaves a 
column for printing averages across the ORF. 
      #$sample_print_count++; 
      
      #prints out the headers for each column 
(percent of ORF covered at Yx and average coverage across the ORF). 
      if ($sheet_name =~ /\d+x/i){ 
       #starts at 0, but increases twice (2 
elements in @column_headers) for every sample looped over. 
       #So below every sample name is 
'ORF% at Yx Average coverage across ORF'. 
       $header_column++; 
       $worksheet -> 
write(1,$header_column,$orf_header); 
      } 
       
      else{ 
       $header_column++; 
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       $worksheet -> 
write(1,$header_column,$coverage_header); 
      } 
     } 
    } 
   } 
  } 
   
  #print out the genes down the first (0th) column. 
  for my $chr (sort {"\L$a" cmp "\L$b"} keys %gene_coordinates){ 
   for my $gene (sort {"\L$a" cmp "\L$b"} keys 
%{$gene_coordinates{$chr}}){ 
    my $print_transcript = 
$gene."\_".${$gene_coordinates{$chr}{$gene}{"transcript"}}; 
     
    $row++; 
    $worksheet -> write($row, 0, $print_transcript); 
   } 
  } 
 } 
 
 print "Ending 'admit' subroutine\n"; 
 
 #returns the workbook to treatment subroutine so it can be used by the downstream 
script. 
 return \$workbook; 
} 
############################################################################
############################################################################
######### 
#End of Admit 
############################################################################
############################################################################
######### 
 
sub plot{ 
 my $plot = shift; 
 my %plot = %{$plot}; 
  
 my $r_tissue = "/home/marc/Documents/work/DOCTOR/Coverage plots/pilot project 
test 2014-06-02.png"; 
  
 my (@samples, @sample_averages); 
  
 #Used so you know which tissue code is which tissue type. Not essential but nice to see 
the actual type printed. 
 my %tissue = ( 
  a => "tFFPE",  
  d => "nFFPE", 
  e => "Germline", 
  f => "WGA tFFPE", 
  Undetermined => "Undetermined" 
 ); 
  
 #Set $R as a new Statistics::R object and start the R session. 
 my $R = Statistics::R -> new(); 
 $R -> start_sharedR; 
  
 print "Loading ggplot2.\n"; 
 $R -> run(q`library(ggplot2)`); 
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 for my $tissue (sort {"\L$a" cmp "\L$b"} keys %plot){ 
  my $sample_count = scalar keys %plot; 
  my $sample_coverage = 0; 
  my $gene_count = 0; 
  my ($colour, @genes, @gene_averages); 
  my $tissue_code = $tissue{$tissue}; 
   
  my $r_gene = "/home/marc/Documents/work/DOCTOR/Coverage 
plots/Coverage by genes (pilot project test 2014-06-02).png"; 
   
  if ($tissue_code eq "tFFPE"){$colour = "red";} 
  if ($tissue_code eq "nFFPE"){$colour = "darkred";} 
  if ($tissue_code eq "Germline"){$colour = "green";} 
  if ($tissue_code eq "WGA tFFPE"){$colour = "yellow";} 
   
  @colour_genes = ($colour); 
   
  #Loop over the genes sequenced for this sample and sum the average 
coverages. 
  for my $chr_gene (sort {"\L$a" cmp "\L$b"} keys %{$plot{$tissue}{"average 
coverage"}}){ 
   my $gene = $chr_gene; 
   $gene =~ s/^.+\_//g; 
    
   $gene_count++; 
    
   #The averge coverage for this gene in this sample. 
   my $gene_coverage = $plot{$tissue}{"average coverage"}{$chr_gene}; 
    
   #Running total coverage across all genes for this sample. 
   $sample_coverage += $gene_coverage; 
    
   push @genes,  $chr_gene; 
   push @gene_averages, $gene_coverage; 
  } 
   
  $R -> run(qq`png("$r_gene")`); 
   
  $R -> set('genes', \@genes); 
  $R -> set('depths', \@gene_averages); 
   
  $R -> set('plot_colours', \@colour_genes); 
   
  #Plot the data by gene. 
  $R -> run(q`#put the data into a dataframe, sorted by gene name. 
   genes_df <- data.frame(Genes = genes, Depths = depths) 
   genes_df <- genes_df[order(genes_df$Genes),] 
    
   #create an object of the plot. Reordering the data will let you plot by 
ascending/descending frequency. 
   depth_plot <- ggplot( 
    genes_df,  
    aes( 
     x=Genes, 
     y=Depths 
    ) 
    
   #It will be a barplot. 
   ) + geom_bar( 
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    fill=plot_colours, 
    colour="black" 
    
   #Give the plot a title. 
   ) + labs( 
    title = "Average depth for each gene" 
    
   #labels the axis. 
   ) + xlab("Gene" 
    
   #Rearrange the axis text. 
   ) + opts( 
    axis.text.x = theme_text( 
     angle = 45, 
     hjust = 1 
    ) 
    
   ) + ylim(0, 5000) 
       
    
   #Plot the graph. 
   depth_plot`); 
    
  #This is necessary to complete the plot. 
  $R -> run (q`dev.off()`); 
    
  #Calculate the sample's average coverage by dividing by the number of 
samples. 
  my $sample_average = $sample_coverage / $gene_count; 
   
  $stats{$tissue_code}{"average"} = $sample_average; 
  $stats{$tissue_code}{"colour"} = $colour; 
   
  # push @samples, $tissue_code; 
  # push @sample_averages, $sample_average; 
 } 
  
 for my $tissue (sort {"\L$a" cmp "\L$b"} keys %stats){ 
  push @samples, $tissue; 
  push @sample_averages, $stats{$tissue}{"average"}; 
  push @colour_tissues, $stats{$tissue}{"colour"}; 
 } 
  
 print "Creating and plotting graph now\n"; 
 #makes the output file. 
 $R -> run(qq`png("$r_tissue")`); 
  
 $R -> set('samples', \@samples); 
 $R -> set('depths', \@sample_averages); 
 $R -> set('plot_colours', \@colour_tissues); 
  
 #Plot the coverage data by tissue type. 
 #set the genes and frequency data as a dataframe object. 
 $R -> run(q`#put the data into a dataframe, sorted by gene name. 
  tissues_df <- data.frame(Samples = samples, Depths = depths) 
  tissues_df <- tissues_df[order(tissues_df$Samples),] 
   
  #create an object of the plot. Reordering the data will let you plot by 
ascending/descending frequency. 
  depth_plot <- ggplot( 
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   tissues_df,  
   aes( 
    x=Samples, 
    y=Depths 
   ) 
   
  #It will be a barplot. 
  ) + geom_bar( 
   fill=plot_colours, 
   colour="black" 
   
  #Give the plot a title. 
  ) + labs( 
   title = "Average depth in each tissue type" 
   
  #labels the axis.r 
  ) + xlab("Tissue type" 
   
  #Rearrange the axis text. 
  ) + opts( 
   axis.text.x = theme_text( 
    angle = 45, 
    hjust = 1 
   ) 
  ) 
   
  #Plot the graph. 
  depth_plot`); 
   
  
  
 #This is necessary to complete the plot. 
 $R -> run (q`dev.off()`); 
 
 #Stop R. 
 $R -> stopR(); 
} 
 
######################################################################## 
#subroutine delorean 
#Gets the local time and converts it into a date (format: yyyy-mm-dd) and time (hh:mm:ss). 
#These are then returned, 
######################################################################## 
sub delorean{ 
 my @flux_capacitor = localtime(time); 
  
 #Set the variables for the time and date. Note: year is a count of years after 1900 (e.g. 
2015 = 115), and month is 0-based integer (0 = Jan, 11 = Dec). 
 my ($sec, $min, $hour, $date, $month, $year) = @flux_capacitor; 
  
 $month += 1; 
 $year += 1900; 
  
 $month = sprintf ("%02d", $month); 
 $date = sprintf ("%02d", $date); 
 $day = sprintf ("%02d", $day); 
 $sec = sprintf ("%02d", $sec); 
 $min = sprintf ("%02d", $min); 
 $hour = sprintf ("%02d", $hour); 
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 my $return_date = "$year-$month-$date"; 
  
 my $return_time = "$hour:$min:$sec"; 
  
 return ($return_date, $return_time); 
} 
######################################################################## 
#End of subroutine delorean. 
######################################################################## 
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Custom Script 4 
 
#Compare variants in my pipeline with variants from the University of North Carolina (UNC) and 
Beijing Genomics Institute (BGI) pipelines. 
#The percentage of SNPs and InDels between mine and their pipelines are then calculated. 
#This is all done by reading through each of my variant call files (VCFs) and loading each 
variant into a hash. Their respective VCFs can then be read and variants stored in hashes. 
#All the variants are ultimately stored in a hash of hashes of hashes of arrays, as illustrated 
below: 
#%pipeline = (%sample = (%variant_type => {@chromosome_chrPosition = (ref allele, alt 
allele)})) 
#created by pushing ref and alt alleles into 
@{$pipeline{$sample}{$variant_type}{$chromosome_chrPosition}} 
 
#Hash of BGI x10 exomes, where sample name (key) is associated with sequencing reads 
name (value) 
%bgi_exomes = ( x => "110926_I174_FCC0343ACXX_L3_HUMvejXAAAAAPEI-9", x => 
"110930_I810_FCC02KFACXX_L6_HUMvejXABAAAPEI-12", 
  x => "110926_I174_FCC0343ACXX_L3_HUMvejXACAAAPEI-1", x => 
"110926_I174_FCC0343ACXX_L3_HUMvejXADAAAPEI-2", 
  x => "110930_I810_FCC0335ACXX_L5_HUMvejXAEAAAPEI-3", x => 
"110930_I810_FCC02KFACXX_L6_HUMvejXAFAAAPEI-4", 
  x => "110930_I810_FCC02KFACXX_L6_HUMvejXAGAAAPEI-5", x => 
"110930_I810_FCC0335ACXX_L5_HUMvejXAHAAAPEI-7", 
  x => "110930_I810_FCC0335ACXX_L5_HUMvejXAIAAAPEI-8", x => 
"110926_I174_FCC0343ACXX_L4_HUMvejXAJAAAPEI-9"); 
 
#Use the following code for comparing only certain genes. 
$genes_file = "/home/marc/Documents/work/exome analysis/Miscellaneous/genes 1609.csv"; 
 
open GENES, $genes_file or die "gene file $genes_file cannot be opened.\n"; 
 
while ($line = <GENES>) 
{ 
 next if $line =~ /^Gene name/i; 
  
 @lines = split (/,/, $line); 
 $gene_name = $line[0]; 
  
 push (@genes, $gene_name); 
} 
 
$ccds_file = "/media/Brachiosaur/Exomes/database resources/CCDS.current.txt"; 
 
open CCDS, $ccds_file or die "ccds file $ccds_file cannot be opened.\n"; 
while ($line = <CCDS>) 
{ 
 next if $line =~ /^\#/i; 
  
 @lines = split (/\s/, $line); 
  
 $chromosome = $line[0]; 
 $gene_name = $line[2]; 
 $coordinates = $line[7]."\_".$line[8]; 
  
 $gene_coordinates{$chromosome}{$coordinates} = $gene_name; 
} 
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reader(); 
concordance(); 
printer(); 
 
 
############################################################################
############################################################################
############ 
#sub routine to read in all data to hash 
############################################################################
############################################################################
############ 
sub reader{ 
 print "Now reading in variants from variant files.\n"; 
 #hash containing filepaths to all variant directories. 
 %vaDirs = ( BGIx10 => "/media/Brachiosaur/Exomes/sequencing 
data/BGI/HKC11050", 
   BGIx13 => "/media/Brachiosaur/Exomes/sequencing data/BGI 
x13/HK11788/CleanData", 
   BGIx18 => "/media/Brachiosaur/Exomes/sequencing data/BGI 
x18/HK11582", 
   UNC => "/media/Brachiosaur/Exomes/sequencing data/Chapel Hill 
Data/2010"); 
   
 @variant_types = ("snp", "indel"); 
  
 for $centre (sort keys %vaDirs) 
 { 
  print "Centre: $centre.\n"; 
   
  opendir VaDir, $vaDirs{$centre} or die "$centre not found. Did you mount the 
drive?\n"; 
   
  if ($centre eq "BGIx10") 
  { 
   @bgix10_samples = grep {-d "$vaDirs{$centre}/$_" && !/^\.+/} readdir 
VaDir; 
   foreach (@bgix10_samples) 
   { 
    $sample = $_; 
     
    $sample_no++;  
 
    foreach (@variant_types) 
    { 
     print "Sample $sample_no: $sample\tVariants: $_\n"; 
      
     $total_csv = 0; 
      
     $variant_type = $_; 
      
     opendir CSVdir, 
"$vaDirs{$centre}/$sample/result_variation/$variant_type" or die 
"$vaDirs{$centre}/$sample/result_variation/$variant_type could not be opened\n"; 
     @var_files = grep {/\.+csv$/} readdir CSVdir; 
      
     foreach $csv_file (@var_files) 
     { 
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      open CSV, 
"$vaDirs{$centre}/$sample/result_variation/$variant_type/$csv_file" or die 
"$vaDirs{$centre}/$sample/result_variation/$variant_type/$csv_file could not be opened\n"; 
      while ($csv_line = <CSV>) 
      { 
       #increase total variants for each line 
       $total_csv++; 
        
       #ignore header line 
       next if ($csv_line =~ /^Func/i); 
 
       #some lines in these CSV files contain 
commas within quotation marks, so replace these to ensure they are not used to split the line 
later. 
       @csv_line = split(//, $csv_line); 
        
       $new_line = ""; 
        
       foreach (@csv_line) 
       { 
        if ($_ eq "\""){$inbetweener 
++;} 
        if($_ eq "\," && $inbetweener 
% 2 == 1){$_ =~ s/\,/\;/;} 
        $new_line .= $_; 
       } 
        
       @csv_line = split(/\,/, $new_line); 
        
       #remove chr from chromosome field 
and quotation marks from fields. 
       $csv_line[15] =~ s/chr//i; 
       $csv_line[1] =~ s/\"//g; 
       $csv_line[2] =~ s/\"//g; 
       $csv_line[20] =~ s/\"//g; 
       $csv_line[21] =~ s/\"//g; 
       $csv_line[23] =~ s/\"//g; 
       $csv_line[24] =~ s/\"//g; 
       $csv_line[27] =~ s/\"//g; 
        
       #create a 'hash key' and alternate 
allele 'value' which you can use to check against the hash of your SNPs. 
       #the key is the chromosome number 
and chr. position. 
       #do not use $csv_line[16] for pos for 
deletions, as the pos will be +1 base away from the corresponding position given by my VCF 
output. 
       #The ref and variant bases from the 
CSV file. Push them into the hash of hashes of hashes of hashes of arrays. 
       if ($variant_type eq "snp") 
       { 
        $csv_chr_pos = 
$csv_line[15]."\_".$csv_line[16]; 
         
        $csv_AC = $csv_line[20]; 
         
        #sets the genotype for the 
SNP called by BGI 
        #AC=0 won't ever be used for 
BGI SNP data. 
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        if ($csv_AC =~ /\=0/) 
        { 
         $csv_ref = 
$csv_line[18]; 
         $csv_alt = 
$csv_line[18]; 
        } 
         
         if ($csv_AC eq "het") 
        { 
         $csv_ref = 
$csv_line[18]; 
         $csv_alt = 
$csv_line[19]; 
        } 
         
         if ($csv_AC eq "hom") 
        { 
         $csv_ref = 
$csv_line[19]; 
         $csv_alt = 
$csv_line[19]; 
        } 
         
        $csv_ref = $csv_line[18]; 
        $csv_alt = $csv_line[19]; 
         
        if ($csv_line[21] =~ 
/dbSNP\=\d\;/i){$their_rsID = $csv_line[9].$&;} 
       } 
        
       else #the variant is an indel 
       { 
        $csv_chr_pos = 
$csv_line[15]."\_".$csv_line[21]; 
         
        $csv_AC = $csv_line[27]; 
        $csv_AC =~ s/\;.+$//; 
         
        #set the genotype for the indel 
detected by BGI. 
        #AC=0 should never be 
encountered in the BGI indel data 
        if ($csv_AC =~ /\=0/) 
        { 
         $csv_ref = 
$csv_line[23]; 
         $csv_alt = 
$csv_line[23]; 
        } 
         
         if ($csv_AC =~ /\=1/) 
        { 
         $csv_ref = 
$csv_line[23]; 
         $csv_alt = 
$csv_line[24]; 
        } 
         
         if ($csv_AC =~ /\=2/) 
 261 
 
        { 
         $csv_ref = 
$csv_line[24]; 
         $csv_alt = 
$csv_line[24]; 
        } 
         
        $csv_ref = $csv_line[23]; 
        $csv_alt = $csv_line[24]; 
         
        $their_rsID = $csv_line[9]; 
       } 
        
       $gene_name = $csv_line[1]; 
       $their_var_effect = $csv_line[2]; 
        
       #use this line to only look at particular 
genes (specified at top of script). 
       #next unless grep {$gene_name eq 
$_} @genes; 
        
       #use this line to only look at novel 
variants (i.e. have no rsID). 
       #next if $their_rsID =~ /^rs\d+/i; 
        
       push 
(@{$their_calls{$centre}{$sample}{$variant_type}{$csv_chr_pos}}, $csv_ref, $csv_alt, 
$their_rsID, $their_var_effect); 
        
      }#end of BGIx10 CSV file 
     } 
    }#end of variant types 
     
    print "\n"; 
     
   }#end of each bgix10 samples 
  }#end of bgix10  
   
  if ($centre eq "UNC") 
  { 
   foreach (@variant_types) 
   { 
    #adds an 's' to the end of the variant, to match the directory 
path in the Chapel Hill folders. 
    $variant_type = $_; 
    $variant_types = $variant_type."s"; 
     
    opendir UNC_samples, "$vaDirs{$centre}/$variant_types 
unzipped" or die "$vaDirs{$centre}/$variant_types unzipped cannot be found. Is the drive 
mounted?\n"; 
     
    #read in files from snps/indels unzipped, use raw.vcf files as 
indels don't have filtered.vcf files (only difference is 'pass' column anyway). 
    @unc_sample_read = grep {-f 
"$vaDirs{$centre}/$variant_types unzipped/$_" && /raw\.vcf$/i} readdir UNC_samples; 
     
    #adds full filepath to each sample name and adds to 
@unc_samples. 
    foreach $sample (sort @unc_sample_read){$sample = 
"$vaDirs{$centre}/$variant_types unzipped/$sample";push (@unc_samples, $sample);} 
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   } 
    
   foreach (@unc_samples) 
   { 
    #get the type of variant (SNP/InDel) for the sample. 
    $variant_type = $_; 
    $variant_type =~ s/s.{1}unzipped.+//i; 
    $variant_type =~ s/.+\///g; 
     
    #the sample ID, just the number (eg. 042031_02136_s_6). 
    $sample = $_; 
    $sample =~ s/.+\///g; 
    $sample =~ s/\..+//; 
     
    #counts how many samples there are from North Carolina. 
    if ($variant_type eq "snp"){$sample_no++;} 
     
    print "Sample $sample_no: $sample\tVariants: 
$variant_type\n"; 
 
    #opens the VCF file to read in variants. 
    open VCF, "$_" or die "$_ file could not be opened\n"; 
       
    while ($vcf_line = <VCF>) 
    { 
     #ignores header lines. 
     next if $vcf_line =~ /^\#/; 
       
     @vcf_line = split (/\s/, $vcf_line); 
     $line_size = scalar @vcf_line; 
       
     $vcf_chr_pos = $vcf_line[0]."\_".$vcf_line[1]; 
      
     #checks whether the variant is hom ref, het or hom 
mut. since UNC have been awkward and made it so 
     #their indel VCF files do not contain the normal AC=\d 
format, use the GT 0/1 at the end of the line to get the allele count. 
     if ($vcf_line[$line_size-1] =~ /^\d\/\d/) 
     { 
      $vcf_AC = $&; 
       
       @ac = split (/\//, $vcf_AC); 
      
      #set the genotype for the variant detected by 
UNC. 
       #if variant is hom ref, ref and alt alleles are 
both the reference allele. 
      if ($ac[0] == 0) 
      { 
       $vcf_ref = $vcf_line[4]; 
       $vcf_alt = $vcf_line[4]; 
      } 
       
       #if variant is het, ref and alt alleles are ref and 
alt. 
      elsif ($ac[0] == 1 && $ac[1] == 1) 
      { 
       $vcf_ref = $vcf_line[3]; 
       $vcf_alt = $vcf_line[4]; 
      } 
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      #if variant is hom mut, ref and alt alleles are 
both the alternate allele. 
      else 
      { 
       $vcf_ref = $vcf_line[3]; 
       $vcf_alt = $vcf_line[3]; 
      } 
     } 
      
     $vcf_ref = $vcf_line[3]; 
     $vcf_alt = $vcf_line[4]; 
      
     $their_rsID = $vcf_line[2]; 
      
     #used for getting the gene name from the CCDS file. 
Not needed unless looking only at particular genes. 
     # for $coordinates (sort keys 
%{$gene_coordinates{$vcf_line[0]}}) 
     # { 
      # @coordinates = split (/\_/, $coordinates); 
      # if ($vcf_line[1] >= $coordinates[0] & 
$vcf_line[1] <= $coordinates[1]) 
      # { 
       # $gene_name = 
${$gene_coordinates{$vcf_line[0]}{$coordinates}}; 
      # } 
     # } 
      
     #use this line to only look at particular genes (specified 
at top of script). 
     #next unless grep {$gene_name eq $_} @genes; 
      
     #use this line to only look at novel variants (i.e. have no 
rsID). 
     #next if $their_rsID =~ /^rs\d+/i; 
       
     #push the reference and mutated alleles into the hash 
of hashes of hashes of hashes of arrays. 
     push 
(@{$their_calls{$centre}{$sample}{$variant_type}{$vcf_chr_pos}}, $vcf_ref, $vcf_alt, 
$their_rsID); 
    }#end of file loop. 
      
    #$variant_type .= "s"; 
     
   }#end of samples. 
  }#end of UNC. 
   
  #count the total number of samples stored in the hashes. 
  $total_samples += scalar (keys %{$their_calls{$centre}}); 
   
 }#end of all sequencing centres   
 
 %yoDirs = ( BGIx10 => "/media/Triceratops/Exomes/BGI 
output/19_GATK_variantannotator", 
   BGIx13 => "/media/Triceratops/Exomes/BGIx13 
output/19_GATK_variantannotator", 
   BGIx18 => "/media/Triceratops/Exomes/BGIx18 
output/19_GATK_variantannotator", 
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   UNC => "/media/Triceratops/Exomes/UNC 
output/19_GATK_variantannotator"); 
 
 for $my_dir (keys %yoDirs) 
 { 
  opendir YoDirs, $yoDirs{$my_dir} or die "$yoDirs{$my_dir} cannot be found, did 
you mount the drive?\n"; 
   
  @my_files = grep {-f "$yoDirs{$my_dir}/$_" && /variants\_annotated\.vcf$/} 
readdir YoDirs; 
   
  foreach $my_file (@my_files) 
  { 
   $my_sample_no++; 
    
   #open VCF must be before changes to $my_file. 
   open VCF, "$yoDirs{$my_dir}/$my_file" or die 
"$yoDirs{$my_dir}/$my_file cannot be opened, did you mount the drive?"; 
    
   $my_file =~ s/\_variants\_annotated\.vcf$//; 
    
   #if you have a bgix10 sample, change the $my_file value into the 
sample ID fom the barcode. 
   %rev_bgi = reverse %bgi_exomes; 
   if (grep {$my_file eq $_} keys %rev_bgi){$my_file = $rev_bgi{$my_file};} 
    
   print "Gathering data on my sample $my_sample_no: $my_file\n"; 
    
   while ($my_line = <VCF>) 
   { 
    #ignore header lines. 
    next if $my_line =~ /^\#/; 
     
    @my_line = split (/\s/, $my_line); 
     
    #gets a key for the hash (chromosome_position) and reference 
and alternate alleles (as well as length of these alleles, so we know if its a SNP or InDel). 
    $my_chr_pos = $my_line[0]."\_".$my_line[1]; 
     
    #checks whether the variant is hom ref, het or hom mut. 
    $my_AC = $my_line[7]; 
    $my_AC =~ s/\;.+$//; 
     
    #set the genotype for the variant I called. 
    #if variant is hom ref, ref and alt alleles are both the reference 
allele. 
    if ($my_AC =~ /\=0/) 
    { 
     $my_ref = $my_line[3]; $my_ref_length = length 
$my_ref; 
     $my_alt = $my_line[3]; $my_alt_length = length 
$my_alt; 
    } 
     
     #if variant is het, ref and alt alleles are ref and alt. 
    if ($my_AC =~ /\=1/) 
    { 
     $my_ref = $my_line[3]; $my_ref_length = length 
$my_ref; 
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     $my_alt = $my_line[4]; $my_alt_length = length 
$my_alt; 
    } 
     
     #if variant is hom mut, ref and alt alleles are both the alternate 
allele. 
    if ($my_AC =~ /\=2/) 
    { 
     $my_ref = $my_line[4]; $my_ref_length = length 
$my_ref; 
     $my_alt = $my_line[4]; $my_alt_length = length 
$my_alt; 
    } 
     
    $my_ref = $my_line[3]; $my_ref_length = length $my_ref; 
    $my_alt = $my_line[4]; $my_alt_length = length $my_alt; 
     
    $my_rsID = $my_line[2]; 
     
     
    #get gene name from line (not needed unless only comparing 
certain genes). 
    if ($my_line[7] =~ /SNPEFF_GENE_NAME=[A-Z0-9\_\-
\.]+\;/i){$gene_name = $&;} 
    $gene_name =~ s/SNPEFF_GENE_NAME\=//i; 
    $gene_name =~ s/\;//i; 
     
    #use this line to only look at particular genes (specified at top 
of script). 
    #next unless grep {$gene_name eq $_} @genes; 
     
    #use this line to only look at novel variants (i.e. have no rsID). 
    #next if $my_rsID =~ /^rs\d+/i; 
     
    if ($my_line =~ /snpeff\_effect\=[a-z0-9\_]+\;/i) 
    { 
     $my_var_effect = $&; 
     $my_var_effect =~ s/snpeff\_effect\=//i; 
     $my_var_effect =~ s/\;//i; 
    } 
     
    #checks whether the variant is a SNP or indel, and pushes it 
into a hash of hashes of hashes of arrays. 
    #Also pushes in the rsID and effect the variant has (e.g. 
synonymous, frameshift, stopgain, etc.). 
    if ($my_ref_length < 2 && $my_alt_length < 2) 
    { 
     $my_variant_type = "snp"; 
     push 
(@{$my_calls{$my_file}{$my_variant_type}{$my_chr_pos}}, $my_ref, $my_alt, $my_rsID, 
$my_var_effect); 
    } 
    else #variant is an indel 
    { 
     $my_variant_type = "indel"; 
     push 
(@{$my_calls{$my_file}{$my_variant_type}{$my_chr_pos}}, $my_ref, $my_alt, $my_rsID, 
$my_var_effect); 
    } 
   } 
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   close VCF; 
  } 
   
  closedir YoDirs; 
 } 
  
 #calculate the total number of samples analysed (actually counts the number of 
sequencing read files input). 
 $total_samples += scalar (keys %my_calls); 
 print "Total samples: $total_samples\n\n"; 
 
} 
############################################################################
############################################################################
############ 
#end of reader subroutine 
############################################################################
############################################################################
############ 
 
############################################################################
############################################################################
############ 
#sub routine to check concordance between datasets 
#loop over your hash, count totals for all samples and gather totals of the effects of each 
variant. 
#Do the same for their hash, and compare each of their samples with yours to calculate 
concordance. 
############################################################################
############################################################################
############ 
sub concordance 
{ 
 %sequencing_centres = (BGIx10 => "Beijing Genomics Institute", UNC => "University 
of North Carolina"); 
  
 print "Calculating concordance between Marc's pipeline and the sequencing centres.\n"; 
 
 #count of how many samples have been analysed. 
 $my_sample_no = 0; 
 $their_sample_no = 0; 
  
 #my hash layout (hash of hashes of hashes of arrays / hash of hashes of arrays. 
Inception eat your heart out). 
 # %my_calls = { %sample 1 .. n  = (%snp/indel   = (@chr_pos   = [ref 
allele, alt allele, rsID, effect type])) 
 #    = (%my_effect_types  = (@effect of variant  = 
[count])) 
 #    = (@sample n_stats = [my_total_variants, 
my_novel_total, my_novel_snp, my_total_snp, my_total_indel, my_novel_indel]) 
 #       } 
  
 #loop over the samples in Marc's hash. 
 for $sample (sort keys %my_calls) 
 { 
  #ignore the my_effect_types hash, only look at the samples. 
  next if $sample =~ /my\_effect\_types/; 
   
  #create name of sample stats array 
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  $sample_stats = $sample."\_stats"; 
 
  #for the 2 variant kinds, SNP and InDel. 
  for $variant_type (sort keys %{$my_calls{$sample}}) 
  { 
   #look only at the snp and indel hashes. 
   next if $variant_type eq "$sample\_stats"; 
    
   #count how many SNPs/InDels/total variants I have for this sample (ie. 
counts the number of arrays [the chr-pos combos] for each variant types, but not the array 
values) 
   ${$my_calls{$sample}{$sample_stats}}[0]+= scalar (keys 
%{$my_calls{$sample}{$variant_type}}); #$my_total_variants = ... 
    
   #count how many SNPs i found for this sample. 
   if ($variant_type eq "snp") 
   { 
    ${$my_calls{$sample}{$sample_stats}}[2] = scalar (keys 
%{$my_calls{$sample}{$variant_type}}); #$my_total_snp = ... 
   }  
    
   #count how many indels I found for this sample. 
   else 
   { 
    ${$my_calls{$sample}{$sample_stats}}[4] = scalar (keys 
%{$my_calls{$sample}{$variant_type}}); #$my_total_indel = ... 
   } 
    
   #for each variant (ie. every SNP or indel in the sample). 
   for $variant (sort keys %{$my_calls{$sample}{$variant_type}}) 
   { 
    #if the variant doesn't have an rsID (ie. isn't in the version of 
dbSNP I used for the pipeline). 
    unless (${$my_calls{$sample}{$variant_type}{$variant}}[2] =~ 
m/rs\d+/i) 
    { 
     #count how many novel variants I have. 
     ${$my_calls{$sample}{$sample_stats}}[1]++; 
#$my_novel++; 
      
     #count how many novel SNPs I have. 
     if ($variant_type eq 
"snp"){${$my_calls{$sample}{$sample_stats}}[3]++;} #$my_novel_snp++; 
      
     #count how many novel InDels I have. 
     else {${$my_calls{$sample}{$sample_stats}}[5]++;} 
#$my_novel_indel++; 
    } 
     
    #Find out what kind of variant it is ('SNPEFF_EFFECT=' 
annotations) in my data, 
    $my_effect_type = 
${$my_calls{$sample}{$variant_type}{$variant}}[3]; 
 
    #Count how many times this kind of variant appears in my 
data. 
    #each sample could have only a range of effect types, so some 
samples wont contain effect types seen in others. 
    #therefore storing my effect types in the $my_calls{$sample} 
hash means all types are acounted for. 
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 ${$my_calls{$sample}{'my_effect_types'}{$my_effect_type}}[0]++; 
   } 
  } 
   
   
   
  #push my effect types into an array, which can be looped over later for file 
printing. 
  for $my_effect_type (sort keys %{$my_calls{$sample}{'my_effect_types'}}) 
  { 
   unless (grep {$my_effect_type eq $_} @all_effect_types) 
   { 
    push (@all_effect_types, $my_effect_type); 
   } 
  } 
 } 
  
 #their hash layout (hash of hashes of hashes of hashes of arrays / hash of hashes of 
hashes of arrays. Inception eat your heart out!!). 
 # %their_calls = {%seq centre = (%sample 1 .. n = (%snp/indel   = (@chr_pos 
  = [ref allele, alt allele, rsID, effect type])) 
 #          = (%their_effect_types  = (@effect of 
variant  = [count])) 
 #      = (@sample n_stats = 
[their_total_variants, their_total_snp, their_total_indel, their_novel_total, their_novel_snp, 
their_novel_indel]) 
 #      = (@sample concordance = 
[percent of mine they found, % snps of mine they found, % indels of mine they found, percent of 
theirs I found, % snps of theirs I found, % indels of theirs I found]) 
 #    )} 
  
 #loop over the sequencing centres in their hash (BGIx10, BGIx18, UNC). 
 for $centre (sort keys %their_calls) 
 { 
  print "Calculating concordance between $centre and exomeExpress.pl.\n"; 
   
  #loop over each sample they analysed. 
  for $sample (sort keys %{$their_calls{$centre}}) 
  { 
   $total_match = 0; 
   $snp_match = 0; 
   $indel_match = 0; 
   $novel_in_theirs_match_total = 0; 
   $novel_in_theirs_match_snp = 0; 
   $novel_in_theirs_match_indel = 0; 
   $novel_in_mine_match_total = 0; 
   $novel_in_mine_match_snp = 0; 
   $novel_in_mine_match_indel = 0; 
    
   #create the name of the sample stats/concordance array. 
   $sample_stats = $sample."\_stats"; 
   $sample_concordance = $sample."\_concordance"; 
    
   #count how many samples they have analysed. 
   $their_sample_no++; 
 
   print "Sample $sample\n"; 
    
   #for every variant (ie. every single SNP and InDel). 
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   for $variant_type (sort keys %{$their_calls{$centre}{$sample}}) 
   { 
    #ignore the effect types hash, only look at samples. 
    next if $sample =~ /their_effect_types/; 
    
    #look only at the snp and indel hashes. 
    next if ($variant_type eq "$sample\_stats" || $variant_type eq 
"$sample\_concordance"); 
    
    #count how many SNPs/InDels/total variants I have for this 
sample (ie. counts the number of arrays [the chr-pos combos] for each variant types, but not the 
array values) 
    ${$their_calls{$centre}{$sample}{$sample_stats}}[0]+= scalar 
(keys %{$their_calls{$centre}{$sample}{$variant_type}}); #$their_total_variants = ... 
 
    #count how many SNPs/InDels they have for this sample (ie. 
counts the number of arrays for each variant types, but not the array values) 
    if ($variant_type eq "snp") 
    { 
     ${$their_calls{$centre}{$sample}{$sample_stats}}[2] = 
scalar (keys %{$their_calls{$centre}{$sample}{$variant_type}}); #$their_total_snp = ... 
    }  
    
    else 
    { 
     ${$their_calls{$centre}{$sample}{$sample_stats}}[4] = 
scalar (keys %{$their_calls{$centre}{$sample}{$variant_type}}); #$their_total_indel = ... 
    } 
 
    #Loop over their variants for matching. It doesn't matter 
whether you loop over their variants or Marc's, you'll be making a direct comparison to the other 
group so will effectively 
    #be looking at both anyway (i.e. all matches will be found). 
    for $variant (sort keys 
%{$their_calls{$centre}{$sample}{$variant_type}}) 
    { 
     #counts how many variants are shared between their 
data and Marc's. Also counts how many of these are SNPs/InDels. 
     $my_variant = 
${$my_calls{$sample}{$variant_type}{$variant}}[0]."\_".${$my_calls{$sample}{$variant_type}{$v
ariant}}[1]; 
     $their_variant = 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[0]."\_".${$their_calls{$centre}{$sampl
e}{$variant_type}{$variant}}[1]; 
     if ($my_variant eq $their_variant) 
     { 
      # $sample_variant_type_count = 
$sample.$variant_type; 
      # $$sample_variant_type_count++; 
      # print "matching $centre $sample 
$variant_type $$sample_variant_type_count\n$my_variant\n$their_variant\n"; 
 
      $total_match++; 
      unless 
(${$my_calls{$sample}{$variant_type}{$variant}}[2] =~ 
/^rs\d+/i){$novel_in_mine_match_total++;} 
      unless 
(${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /dbSNP\=1/i || 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /rs\d+/i) 
      { 
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       $novel_in_theirs_match_total++; 
       print "$centre $sample variant: 
$their_variant ($my_variant)\nrsID: 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2]\tmy rsID: 
${$my_calls{$sample}{$variant_type}{$variant}}[2]\n\n"; 
       
      } 
       
      if ($variant_type eq "snp") 
      { 
       $snp_match++; 
       unless 
(${$my_calls{$sample}{$variant_type}{$variant}}[2] =~ 
/^rs\d+/i){$novel_in_mine_match_snp++;} 
       unless 
(${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /dbSNP\=1/i || 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /rs\d+/i) 
       { 
       
 $novel_in_theirs_match_snp++; 
       } 
      } 
       
      else 
      { 
       $indel_match++; 
       unless 
(${$my_calls{$sample}{$variant_type}{$variant}}[2] =~ 
/^rs\d+/i){$novel_in_mine_match_indel++;} 
       unless 
(${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ 
/^rs\d+/i){$novel_in_theirs_match_indel++;} 
      } 
     } 
      
     unless 
(${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /dbSNP\=1/i || 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[2] =~ /^rs\d+/i) 
     { 
     
 ${$their_calls{$centre}{$sample}{$sample_stats}}[1]++; #$their_novel++; 
       
      if ($variant_type eq 
"snp"){${$their_calls{$centre}{$sample}{$sample_stats}}[3]++;} #$their_novel_snp++; 
       
      else 
{${$their_calls{$centre}{$sample}{$sample_stats}}[5]++;} #$their_novel_indel++; 
     } 
      
     #Find out what kind of variant it is (CSV file or 
'SNPEFF_EFFECT=' annotations in VCF) in their data, 
     $their_effect_type = 
${$their_calls{$centre}{$sample}{$variant_type}{$variant}}[3]; 
     if ($their_effect_type eq ""){$their_effect_type = "Effect 
unclassified in $centre";} 
 
     #Count how many times this kind of variant appears in 
their's data. 
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 ${$their_calls{$centre}{$sample}{'their_effect_types'}{$their_effect_type}}[0]++; 
#$their_effect_type++ 
    } 
   } 
    
   #push their effect types into an array, which can be looped over later 
for file printing. 
   for $their_effect_type (sort keys 
%{$their_calls{$centre}{$sample}{'their_effect_types'}}) 
   { 
    unless (grep {$their_effect_type eq $_} @all_effect_types) 
    { 
     push (@all_effect_types, $their_effect_type); 
    } 
   } 
    
   #the percent of my calls that they have called. 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[0] = 
$total_match / ${$my_calls{$sample}{$sample_stats}}[0] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[2] = 
$snp_match / ${$my_calls{$sample}{$sample_stats}}[2] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[4] = 
$indel_match / ${$my_calls{$sample}{$sample_stats}}[4] * 100; 
    
   #the percent my novel calls that they found. 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[1] = 
$novel_in_mine_match_total / ${$my_calls{$sample}{$sample_stats}}[1] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[3] = 
$novel_in_mine_match_snp / ${$my_calls{$sample}{$sample_stats}}[3] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[5] = 
$novel_in_mine_match_indel / ${$my_calls{$sample}{$sample_stats}}[5] * 100; 
    
   #the percent of their calls that I found. 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[6] = 
$total_match / ${$their_calls{$centre}{$sample}{$sample_stats}}[0] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[8] = 
$snp_match / ${$their_calls{$centre}{$sample}{$sample_stats}}[2] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[10] = 
$indel_match / ${$their_calls{$centre}{$sample}{$sample_stats}}[4] * 100; 
    
   #the percent their novel calls that I found. 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[7] = 
$novel_in_theirs_match_total / ${$their_calls{$centre}{$sample}{$sample_stats}}[1] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[9] = 
$novel_in_theirs_match_snp / ${$their_calls{$centre}{$sample}{$sample_stats}}[3] * 100; 
   ${$their_calls{$centre}{$sample}{$sample_concordance}}[11] = 
$novel_in_theirs_match_indel / ${$their_calls{$centre}{$sample}{$sample_stats}}[5] * 100; 
  } 
 } 
} 
############################################################################
############################################################################
############ 
#end of concordance subroutine 
############################################################################
############################################################################
############ 
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############################################################################
############################################################################
############ 
#printer 
#print header/column titles: sample, my tot var, % in other pipeline, novel var, my SNPs, % in 
other pipeline, novel SNPs, my InDels, % in other pipeline, novel InDels, their var, % in mine, 
novel var, their SNPs... their InDels... 
#also for headers, loop over the array of effect types and print each type. 
# 
############################################################################
############################################################################
############ 
sub printer 
{ 
 #name of file to print to. 
 $stats_file = "/home/marc/Documents/work/exome 
analysis/Output/Pipeline_comparisons_updated.csv"; 
  
 print "Now printing to $stats_file\n"; 
  
 open STATS, ">$stats_file" or die "output file $stats_file cannot be opened"; 
  
 #print the header line to the file (my totals, their totals, concordance and effect types). 
 print STATS "Sample,Marc's total variants,Novel variants,Marc's SNPs,Novel 
SNPs,Marc's InDels,Novel InDels,BGI/UNC total variants,Novel variants,BGI/UNC's 
SNPs,Novel SNPs,BGI/UNC's InDels,Novel InDels,"; 
 print STATS "Percent (all) they found in Marc's pipeline,Novel,Percentage (SNP) they 
found in Marc's pipeline,Novel,Percent (InDel) they found in Marc's pipeline,Novel,Percent (all) 
Marc found in their pipeline,Novel,Percentage (SNP) Marc found in their pipeline,Novel,Percent 
(InDel) Marc found in their pipeline,Novel"; 
 foreach (@all_effect_types){print STATS ",$_";} 
  
 #Loop over my hash and print the totals. If the sample is also in their hash, print their 
totals and the percents. then print the effect types. 
 for $sample (sort keys %my_calls) 
 { 
  #Used to decide whether or not one of the sequencing centres has also done 
some analysis on the sample. 
  $sample_match = 0; 
   
  $print_sample = "House\_$sample"; 
   
  #Builds a sample name, consisting of the sequencing centre and the sample. 
This is used to keep the samples together by centre when printing to a file (alphabetically). 
  for $centre (sort keys %their_calls) 
  { 
   if (grep {$sample eq $_} sort keys %{$their_calls{$centre}}) 
   { 
    $print_sample = "$centre\_$sample"; 
    last; 
   } 
  } 
   
  #start building the line to print to file. Start with a new line character and the 
centre/sample name combo. 
  $stats = "\n$print_sample"; 
   
  #foreach sample, gather stats on the total number of variants, SNPs, etc that I 
called and each of the seq centres called where applicable. 
  for $sample_stats (sort keys %{$my_calls{$sample}}) 
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  { 
   #looping over the sample_stats array in my hash, ignore the other keys 
at this level. 
   next unless $sample_stats =~ /stats$/i; 
    
   #Add each of the statistics array values to the printing line. 
   foreach $total (@{$my_calls{$sample}{$sample_stats}}){$stats .= 
",$total";} 
    
   #find the corresponding sample in the seq centres hash and add their 
statistics to the printing line as well. 
   for $centre_loop (sort keys %their_calls) 
   { 
    $centre = $centre_loop; 
    if (grep {$sample eq $_} sort keys %{$their_calls{$centre}}) 
    { 
     $sample_match = 1; 
      
     foreach $total 
(@{$their_calls{$centre}{$sample}{$sample_stats}}){$stats .= ",$total";} 
    } 
     
    #saves time by not searching rest of their hash if you have 
found the sample. 
    last if $sample_match == 1; 
   } 
  } 
 
  #find the corresponding sample in their hash and gather concordance data for 
printing. 
  for $sample_concordance (sort keys %{$their_calls{$centre}{$sample}}) 
  { 
   next unless $sample_concordance =~ /concordance$/i; 
 
   if (grep {$sample eq $_} sort keys %{$their_calls{$centre}}) 
   { 
    foreach $concordance 
(@{$their_calls{$centre}{$sample}{$sample_concordance}}){$stats .= ",$concordance";} 
   } 
  } 
   
  #if the sample isnt in their calls, then there will be 6 empty fields where their 
totals and percents should be.  
  #printing 12 commas will keep the rest of the line aligned. 
  unless ($sample_match == 1){$stats .= ",,,,,,,,,,,,,,,,,,";} 
   
  #print effect types 
  foreach $effect_type (@all_effect_types) 
  { 
   $stats .= ","; 
    
   #if the sample has a variant which causes this effect type 
   if (grep {$effect_type eq $_} sort keys 
%{$my_calls{$sample}{'my_effect_types'}}) 
   { 
    #print the number of times this effect types appears in this 
sample. 
    $stats .= 
"${$my_calls{$sample}{'my_effect_types'}{$effect_type}}[0]"; 
   } 
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   #if the sample has a variant which causes this effect type 
   if (grep {$effect_type eq $_} sort keys 
%{$their_calls{$centre}{$sample}{'their_effect_types'}}) 
   { 
    #print the number of times this effect types appears in this 
sample. 
    $stats .= 
"${$their_calls{$centre}{$sample}{'their_effect_types'}{$effect_type}}[0]"; 
   } 
  } 
   
  #push the final assembled printing line to an array. 
  push (@stats, $stats); 
 } 
 
 #loop over each of the printing lines in the array and print each line alphabetically.  
 #You will print each sample on a new line, grouped alphabetically into their sequencing 
centres. 
 foreach (sort @stats){print STATS "$_";} 
  
 close STATS; 
} 
############################################################################
############################################################################
############ 
#end of printer 
############################################################################
############################################################################
############ 
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Custom Script 5 
 
(note: There are proabably more comment lines than actual lines of code...) 
#This script is designed to compare genotypes emitted from GATK (determined by reading in 
from the final VCF files) with genotyping data from Illumina's GoldenGate assay. 
#The script has to convert GATK GT's to Illumina's top/bottom stranded convention, which is 
where things get very tricky indeed. 
 
#Illumination - comparison of GATK genotype calls with Illumina genotype calls. 
#Illumina's strand designation system make this very difficult and complex (from a 
bioinformatician's viewpoint, anyway). 
#This script functions based on the assumptions that: 
# A GATK genotype is a dinucleotide, which depending on the allele count (AC=n), 
consists of either: 
#  2 reference bases (AC=0),    e.g. AA 
#  1 reference base and 1 variant base (AC=1),  e.g. AG 
#  2 variant bases (AC=2),    e.g. GG. 
# The Illumina genotype is a dinucleotide which has been converted to Illumina's 
strand/allele designation convention. 
#  Top stranded heterozygote genotypes are: AC, AG, AT and CG. Every other 
heterozygote genotype is bottom stranded. 
#  For homozygote genotypes, strand is determined by seeing whether the ref/alt 
dinucleotide is top or bottom stranded. 
#   If top stranded then the GATK genotype does not need converting. 
#   If bottom stranded and the ref/alt dinucleotide is not top stranded, use 
the (reverse) complement of the homozygote genotype. 
#   e.g. if GATK calls hom variant AA (with ref = G), ref/alt = GA, which 
reversed is AG (top stranded) so the genotype remains AA. 
#   e.g. but if GATK hom call = TT (with ref = C), ref/alt = CT, which is the 
rev. complement of AG, so the genotype is complemented to AA. 
#  If homozygous and the ref/alt nucleotides are homozygous, you're going to 
need a bigger boat. 
 
#There is a known flaw in the comparisons, but fortunately the situation in which it arises never 
occurs when comparing my data with Chris's 153 SNPs. 
#If dealing with a multi-allelic SNP, and the call from the VCF file is homozygous reference, then 
you cannot know which SNP Illumina detected if their call is also homozygous. 
#To find the alt allele, you would have to look at the strand in which SNP occurs, which is 
possible to do by looking up the strand from %strands if the ref and alt bases are not 
complementary. 
#If the ref and alt are complementary, then you would have to look at the ref genome to 
determine strand. 
#If Illumina call a het multiallelic SNP, then you can look up their call in the %strands keys and 
then look for a value beginning with the ref allele in the values for that keys to find the alt allele. 
 
 
#Hash of BGI exomes, where sample name (key) is associated with sequencing reads name 
(value) 
%bgi_exomes = ( x => "110926_I174_FCC0343ACXX_L3_HUMvejXAAAAAPEI-9", x => 
"110930_I810_FCC02KFACXX_L6_HUMvejXABAAAPEI-12", 
  x => "110926_I174_FCC0343ACXX_L3_HUMvejXACAAAPEI-1", x => 
"110926_I174_FCC0343ACXX_L3_HUMvejXADAAAPEI-2", 
  x => "110930_I810_FCC0335ACXX_L5_HUMvejXAEAAAPEI-3", x => 
"110930_I810_FCC02KFACXX_L6_HUMvejXAFAAAPEI-4", 
  x => "110930_I810_FCC02KFACXX_L6_HUMvejXAGAAAPEI-5", x => 
"110930_I810_FCC0335ACXX_L5_HUMvejXAHAAAPEI-7", 
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  x => "110930_I810_FCC0335ACXX_L5_HUMvejXAIAAAPEI-8", x => 
"110926_I174_FCC0343ACXX_L4_HUMvejXAJAAAPEI-9"); 
 
 
#Input from the command line lets the user choose the depth to filter out genotype calls from the 
GATK data.   
print "Please enter the minimum depth threshold for filtering out genotype calls.\n"; 
while ($dp_filter !~ /^\d+$/){chomp ($dp_filter = <>);} 
 
#first sub routine, get the illumina data into a hash. 
illuminate(); 
 
#second sub routine, get my data into a hash 
enlighten(); 
 
 
############################################################################
######################################## 
#print output to a table 
############################################################################
######################################## 
open TABLE, ">/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/genotype_comparisons_table_".$dp_filter."\.csv"; 
 
print TABLE "Illumina vs Marc's genotype for sample:"; 
for $sample (sort keys %percent_matches){next if ($sample == 71021);print TABLE 
",,$sample";} 
print TABLE "\n"; 
 
for $sample (sort keys %percent_matches){next if ($sample == 71021);print TABLE 
",Illumina,Marc";} 
print TABLE "\n"; 
 
for $rsID (sort keys %table) 
{  
 print TABLE "$rsID"; 
  
 for $sample (sort keys %percent_matches) 
 { 
  if (grep {$sample eq $_} sort keys %{$table{$rsID}}) 
  { 
   print TABLE 
",${$table{$rsID}{$sample}}[0]\,${$table{$rsID}{$sample}}[1]"; 
  } 
   
  else {print TABLE ",,";} 
 } 
  
 print TABLE "\n"; 
} 
 
#prints the percent of match for each sample 
for $sample (sort keys %percent_matches) 
{ 
 print TABLE ",,${$percent_matches{$sample}}[0]"; 
 $average_concordance += ${$percent_matches{$sample}}[0]; 
} 
 
print TABLE "\n"; 
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for $sample (sort keys %percent_matches) 
{ 
  print TABLE 
",${$percent_matches{$sample}}[2],${$percent_matches{$sample}}[1]"; 
} 
 
print TABLE "\n\n"; 
 
#print a table of x/n calls, y% concordance for each sample vertically. 
for $sample (sort keys %percent_matches) 
{ 
  print TABLE 
"$sample,${$percent_matches{$sample}}[2]\/${$percent_matches{$sample}}[1],${$percent_mat
ches{$sample}}[0]\n"; 
} 
 
 
$average_concordance /= scalar keys %percent_matches; 
$total_percent = $total_matches / $total_genotypes * 100; 
print TABLE "Total:matches:percent,$total_genotypes\/$total_matches,$total_percent"; 
############################################################################
######################################## 
 
############################################################################
################################## 
#sub routine illumination. 
#Loads the data in the illumina genotypes file into a hash of hashes of hashes of arrays,  
#%genotypes = (%samples = (%genes => {@snps => [$genotype]})) 
#Necessary information from the file: 
#first line contain sample names, so use these to figure out what columns the actual genotypes 
are in  
#(split into array, note the element number of samples - they're the only purely numerical 
values). 
#From other lines, gather gene name, chromosome, rsID and position (from dbSNP file?) 
############################################################################
################################## 
sub illuminate 
{ 
 #The output file that the chromosome positions for each rsID will be written. 
 #The region file will be used to parse to GATK UnifiedGenotyper. Each line contains the 
chromosome:position-position of a SNP. 
 #The interval file is a copy of the region file with rsIDs and ref. and alt. alleles from 
dbSNP at the end of each line 
 $interval_list = "/home/marc/Documents/work/exome 
analysis/Output/Illumina_genotype_regions_rsID.interval_list"; 
 $region_file = "/home/marc/Documents/work/exome 
analysis/Output/illumina_genotype_regions.interval_list"; 
   
 #Users decides whether or not to call GATK's unified genotyper to produce the 
necessary VCF files. 
 #Cannot use VCF files from Marc's pipeline as you need to call reference sites as well, 
which haven't been called in the pipeline. 
 while ($call_gatk ne "y" && $call_gatk ne "n") 
 { 
  print "Would you like to call GATK's Unified Genotyper to produce VCF files for 
each of the variants in the Illumina data?\n"; 
  print "Please enter 'y' or 'n'.\n"; 
   
  #remove any new line characters from the input. 
  chomp ($call_gatk = <STDIN>); 
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  #ensure the input is lower case. 
  $call_gatk =~ tr/[A-Z]/[a-z]/; 
   
  #ensure input is either 'y' or 'n'. 
  if ($call_gatk ne "y" && $call_gatk ne "n") 
  { 
   $call_gatk = ""; 
   print "Please enter 'y' or 'n'\n"; 
  } 
 } 
  
 #Unless an interval list has already been created, read in data from dbSNP to a hash 
(rsID = chr:pos-pos). Some entries in this will be printed later. 
 unless (-f $interval_list){get_regions();} 
  
 #load the file created by get_regions subroutine and create the hash (rsID = chr:pos-
pos). 
 #the if statement is necessary as if the file hasn't been created then &get_regions will 
have already loaded the necessary data (plus more!) into memory. 
 #Could perhaps modify this so that the file is printed by &get_regions, and the file will 
be loaded into memory then. 
 if (-f $interval_list) 
 { 
  #open the file. 
  open INTERVAL, $interval_list or die "$interval_list exists but cannot be 
opened. You can't explain that!\n"; 
   
  #load data in from the intervals list and store the data in a hash. 
  #line format: chr:pos-pos rsID alleles 
  while ($int_line = <INTERVAL>) 
  { 
   chomp $int_line; 
    
   #split the line into an array 
   @int_line = split (/\s/, $int_line); 
    
   $chr_pos = $int_line[0]; 
   $rsID = $int_line[1]; 
   $alleles = $int_line[2]; 
    
   if ($chr_pos =~ /^[XY\d]{1,2}/i){$chr = $&;} 
   if ($chr_pos =~ /\d+$/){$pos = $&;} 
   $position_key = $chr."\_".$pos; 
    
   #skips if there is more than 1 allele for the SNP. Multiple alleles are 
fine, it is possible to 'reverse engineer' the Illumina genotype to find which allele they detected. 
   #therefore these lines should be ignored (but left in just in case!). 
   #$multi_alleles = length ($alleles); 
   #next if $multi_alleles > 2; 
    
   #this hash contains the chromosomeal position for each rsID. 
   $dbSNP{$rsID} = $chr_pos; 
   $rsIDs{$position_key} = $rsID; 
    
   #this hash contains the alt alleles for each SNP. 
   $alt_alleles{$rsID} = $alleles; 
  } 
   
  close INTERVAL; 
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  #print the data in the dbSNP hash out to a new file for parsing to the GATK 
genotyper. This file is identical to the interval file but without the rsIDs. 
  unless (-f $region_file) 
  { 
   open REGION, ">$region_file" or die "$region_file could not be 
created.\n"; 
   for $rsID (sort keys %dbSNP){print REGION "$dbSNP{$rsID}\n";} 
   close REGION; 
  } 
 } 
  
 #open the illumina file containing the Illumina genotyping data. 
 $illumina_file = "/home/marc/Documents/work/exome analysis/Miscellaneous/illumina 
genotypes 153.csv"; 
 open illumina, "$illumina_file" or die "the illumina file ($illumina_file) could not be 
opened.\n"; 
  
 #read in the lines of the illumina file and capture the relevant information. 
 while ($illumina_line = <illumina>) 
 { 
  #the counter of columns in the first line, set to 0. The first line contains sample 
names, etc. 
  $column_count = 0; 
   
  #split the line into an array. 
  @illumina_line = split (/\,/, $illumina_line); 
   
  #if the line is the first line of the file. 
  if ($illumina_line =~ /^Gene\_Name/i) 
  { 
   #loop over the line array. 
   foreach $column (@illumina_line) 
   { 
    #if the element is only numerical (or is, eg. 103006B, 
103010B...) (i.e. a sample name). 
    if ($column =~ /^\d+B?$/i) 
    { 
     #tie the sample name to its column number. the 
column number will be necessary to tell which genotypes belong to which sample later. 
     $column_sample = $column_count."\_".$column; 
      
     #push the column number/sample into an array. 
     push (@column_samples, $column_sample); 
    } 
     
    #count what column the current element is in. Must be done 
after pushing samples into array or the column number they contain will be +1 of their actual 
column. 
    $column_count++; 
   } 
    
   #NECESSARY! move past the first line of the file. Necessary! 
   next; 
  } 
   
  #capture some useful (~ essential) data from the illumina line. Note that rsID 
won't always be an rsID but some other thing which is meaningless. 
  #the chromosome positions will almost certainly not match dbSNP, my data or 
anyone else's data (Illumina data produced using an older ref genome??). 
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  $gene = $illumina_line[0]; 
  #$chr = $illumina_line[1]; 
  $rsID = $illumina_line[3]; 
   
  #the chromosome and position are set by looking in the dbSNP hash, using the 
rsID as a reference. 
  #Therefore only genotypes with a valid rsID can be processed. 
  #chromsome will actually be the chr:pos-pos, but will be modified soon. 
  $chromosome = $dbSNP{$rsID}; 
   
  #get the position of the SNP. 
  #gets the '-pos' from the chromosome, and removes '-'. 
  if ($chromosome =~ /\-[0-9]+/){$position = $&;$position =~ s/\-//;} 
  else {$position = "unknown";} 
   
  #set the chromosome number (the first numbers/letter from chr:pos-pos). 
  if ($chromosome =~ /^[0-9a-z]+/i){$chromosome = $&;} 
  else {$chromosome = "unknown";} 
   
  #the key used for a hash later. Key contains the chr, pos and rsID. 
  $hash_key = "$chromosome\_$position\_$rsID"; 
   
  #push each rsID into an array, if the rsID is in dbSNP. Will ensure only valid 
rsIDs are stored in the array. 
  if ($dbSNP{$rsID}) 
  { 
   #count the number of variants/rsIDs in the Illumina file. 
   $illumina_rsID_count++; 
   
   #also ensures no duplicate rsIDs are stored. probably not necessary. 
   unless (grep {$rsID eq $_} sort @rsID){push (@rsID, $rsID);} 
   print "$illumina_rsID_count $rsID\n"; 
  } 
 
  #look in Illumina's genotype file and store the genotype for each SNP in each 
sample into a hash. 
  foreach $column_sample (@column_samples) 
  { 
   #split the columnNumber_sample into an array (@sample = [number, 
sample]) 
   @sample = split (/\_/, $column_sample); 
    
   #set the column and sample. 
   $column = $sample[0]; 
   $sample = $sample[1]; 
    
   #get the genotype for the sample from the illumina line. 
   #Because column number was attached to sample name earlier, 
$column points to the correct column number of the @illumina_line array. 
   $genotype = $illumina_line[$column]; 
    
   #load the hash of hashes of hashes of arrays with all the (useful, i.e. 
only actual GT calls) genotype data with a valid rsID. 
   #genotype is a dinucleotide (e.g. AT, CC, GA). 
   if ($genotype =~ /^[a-z]{2}$/i) 
   { 
    if ($dbSNP{$rsID}) 
    { 
     #remember hash key = chr_pos_rsID. 
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 ${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0] = $genotype; 
    } 
   } 
  } 
 } 
  
 #Prints the interval list here if it hasn't been already. I.e. will only be printed if reading in 
from the actual dbSNP file for the first time. 
 unless (-f $interval_list) 
 { 
  #open the output file for printing the region for each rsID in Illumina's list. 
  open INTERVAL, ">$interval_list" or die "the interval list ($interval_list) could 
not be opened.\n"; 
  open REGION, ">$region_file" or die "$region_file could not be created.\n"; 
   
  #print each of the rsID regions to the output files. 
  foreach $rsID (sort {$a <=> $b} @rsID) 
  { 
   #count how many rsIDs are in the array 
   $illumina_rsIDs++; 
    
   #set the region and interval (both will = chr:pos-pos rsID alleles for 
now). 
   $region = $dbSNP{$rsID}; 
   $interval = $dbSNP{$rsID}; 
    
   chomp $region; 
   chomp $interval; 
    
   #remove the space, rsID and alleles from the end of the region line. 
   #What's left is chr:pos-pos. This will be printed to a file used by Unified 
Genotyper. 
   $region =~ s/\s.+//i; 
 
   #Store the rsID for each SNP in %alt_alleled. The alt_alleles hash will 
be used in &enlighten to get the alternate allele. 
   $alt_alleles{$rsID} = $dbSNP{$rsID}; 
    
   print "printing out $illumina_rsIDs\t$illumina_rsIDs\t$rsID 
$alt_alleles{$rsID}\n"; 
    
   #print the full line (chr:pos-pos rsID alleles) to the interval file. 
   print INTERVAL "$interval\n"; 
    
   #print the data in the dbSNP hash out to a new file for parsing to the 
GATK genotyper. This file is identical to the interval file but without the rsIDs or SNP bases. 
   print REGION "$region\n"; 
  } 
   
  #close INTERVAL and REGION. 
  close INTERVAL; 
  close REGION; 
 } 
  
 #clear the dbSNP hash and rsID array to save memory. 
 %dbSNP = (); 
 @rsID = (); 
  
} 
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############################################################################
################################## 
#End of illumination sub routine 
############################################################################
################################## 
 
############################################################################
################################## 
#sub routine get_regions 
#reads in the variants in a downloaded dbSNP file, and extracts the chromosome ID and 
position for each 
#rsID in the Illumina genotype's file. Will take an hour or more to run since the dbSNP file is 
large (>4.6 GB for v132, subsequent versions are a lot bigger!!) 
#will use a lot of memory, so maybe find a way to improve this? 
############################################################################
################################## 
sub get_regions 
{ 
 #Open up the dbSNP VCF file so that the chromosomal positions of all rsIDs/SNPs can 
be obtained. 
 #alt. alleles are necessary when specifying regions to GATK's UnifiedGenotyper tool, 
which will be used to call genotypes in Marc's data at sites that have no variants detected. 
 #Searching dbSNP for these regions will take up to an hour. The output is a file 
containing the regions, and this step will only have to be done once, 
 #unless the output file is lost. 
 $dbSNP_file = "/media/Brachiosaur/Exomes/database resources/dbsnp_135.b37.vcf"; 
 
 #In all fairness I could make this part a lot less computationally demanding. I'm not sure 
why it was so expensive in the first place. I'll put it on my 'to do... eventually' list, but for now if it 
ain't broke, don't fix it! 
 print "Getting regions from dbSNP database. This could take over an hour and will use 
a LOT of memory (>12 GB). This is going to hurt in the morning.\n"; 
  
 #loop over the dbSNP file. 
 open dbSNP, "$dbSNP_file" or die "the dbSNP file ($dbSNP_file) could not be 
opened.\n"; 
 while ($dbSNP = <dbSNP>) 
 { 
  #ignore header lines. 
  next if $dbSNP =~ /^\#/; 
   
  #split the line into an array. 
  @dbSNP = split (/\s/, $dbSNP); 
   
  #under construction - use to build a string of variants for each chromosome, will 
save memory when reading in from dbSNP. 
  #will also need to heavily edit &illuminate subroutine to account for the 
changes. 
  # #When a new chromsome is encountered... 
  # unless ($dbSNP[0] == $chr) 
  # { 
   # Push the last chromosome's string of variants into %dbsnp. 
   # if ($chr){$dbsnp{$chr} =  $chromosome_variants;} 
   #  
   # Clear the last chromosome's string, ready to build up for the new 
chromosome. 
   # $chromosome_variants = ""; 
  # } 
   
  #the rsID from the dbSNP line. 
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  $rsID = $dbSNP[2]; 
   
  #get the data for the 3 missing SNPs from Chris' list of 153 SNPs. 3 SNPs were 
merged to new rsIDs, so search dbSNP using these updated rsIDs. 
  #next unless ($rsID eq "rs1130222" || $rsID eq "rs10511" || $rsID eq 
"rs2228612"); 
   
  #the chromosome and position of the variant. 
  $chr = $dbSNP[0]; 
  $pos = $dbSNP[1]; 
   
  #the reference and alternate (variant) allele. 
  $ref = $dbSNP[3]; 
  $alt = $dbSNP[4]; 
   
  #Store the region in a hash, using the rsID as the key. 
  $dbSNP{$rsID} = "$chr:$pos-$pos\t$rsID\t$ref$alt\n"; 
   
  #$chromosome_variants .= "$chr:$pos-$pos\t$rsID\t$ref$alt\n"; 
 } 
  
 close dbSNP; 
} 
############################################################################
################################## 
#End of get_regions sub routine 
############################################################################
################################## 
 
############################################################################
################################## 
#sub routine elighten. 
#Loads the data in my variant call format (VCF) files into a hash. 
#information useful (~necessary) for capture includes the chromosome, position, rsID, ref and 
alt alleles, and the 'AC=n;' field. 
#illumina have a strangely awkward (also ingenious, but mainly awkward) way of expressing 
their genotypes based on a 'strand' basis; 
#they always express the genotype on the 'top' strand. This means to compare my GTs against 
theirs, I have to convert mine to the top 
#strand format as well. Tool up boys, we're going shopping...  
############################################################################
################################## 
sub enlighten 
{ 
 #a list of the sequencing centres, useful for finding vcf directories. 
 @sequencing_centres = qw(BGI BGIx13 BGIx18 UNC); 
  
 #The Illumina strand system. If you have a change between an A and a G (A-G) for 
example, then you would use AG (for hets) or AA/GG (for homs, depending on which base is 
now homozygous). 
 #If the change is between the complementary base pairs of these (i.e. between T-C) 
then you would still use AG (for hets). 
 #The hash table below contains all the 'top' strand bases as values and the 'bottom' 
strand bases as keys, so you can search with my data and convert the GTs to the Illumina style 
 #top strand format. 
 %strands = (AG => ["AG", "GA", "CT", "TC"], AC => ["AC", "CA", "GT", "TG"], AT => 
["AT", "TA"], CG => ["CG", "GC"]); 
 %reverse_strands = reverse %strands; 
  
 #This hash contains the bases of DNA and their complementary bases. 
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 %complementary_bases = (A => 'T', T => 'A', C => 'G', G => 'C'); 
  
 #Get the reference sequence for each chromosome and store it in a hash. The 
sequences will be stored line by line (not base by base), and prefixed with the line number and 
"_". 
 open REF, "/media/Brachiosaur/Exomes/reference genome/human_g1k_v37.fasta"; 
 while ($ref_line = <REF>) 
 { 
  chomp $ref_line; 
   
  #The header line for each chromosome (>1 ...other info). 
  if ($ref_line =~ /^\>[a-z0-9]+/i) 
  { 
    
    
   #Print the length of each chromosome (will actually be printed at the 
start of the next chromosome, therefore the last chromosome length will not be printed. 
   unless ($ref_chromosome eq "") 
   { 
    print "Chromosome: $ref_chromosome\tLength: $chr_length\n"; 
     
    #Store the line and number (lineNumber_lineSequence) in the 
hash, with the chromosome as the key. 
    push (@{$reference_genome{$ref_chromosome}}, $chr_seq); 
   } 
    
   $chr_seq = ""; 
    
   #Reset the number of lines and length for each chromosome. 
   $line_number = 0; 
   $chr_length = 0; 
    
   #Set the chromosome ID (eg. 1, 5, 19, X, Y, MT) 
   $ref_chromosome = $&; 
   $ref_chromosome =~ s/\>//; 
  } 
   
  #the line contains nucleotide sequence. 
  elsif ($ref_line =~ /^[ACGTN]/i) 
  { 
   #add the length of the line to the total chromosome length. The b37 
build uses FASTA format (so 60 bases per line), although the final line may be shorter. 
   $chr_length += length $ref_line; 
       
   #Store the chromosome sequence as a string, with lines starting with 
the line number and ending with a colon. 
   $chr_seq .= "$line_number\_$ref_line\n"; 
    
   #Increase line number. Since this is done after storage in the hash, the 
first line stored for each chromosome is line 0. 
   $line_number++; 
  } 
 } 
  
 close REF; 
  
 #Prepare to read in data from Marc's VCF files. 
 foreach $centre (@sequencing_centres) 
 { 
  #set the vcf directory. 
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  $recal_dir = "/media/Triceratops/Exomes/$centre 
output/12_GATK_tablerecalibration"; 
   
  #The directory the VCF files from the GATK are found. 
  $vcf_dir = "/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper MBQ 10"; 
   
  #open the VCF directory and read in the VCF files if they are 
'variants_annotated.vcf' files. Also reads in recalibrated .bam files in case the user wanted to 
call the GATK. 
  opendir VCF_DIR, $vcf_dir or die "could not open $vcf_dir. Did you mount the 
drive?\n"; 
  opendir RECAL_DIR, $recal_dir or die "could not open $recal_dir. Did you 
mount the drive?\n"; 
   
  #store the names of the .bam files in an array. These will be the input for the 
Unified Genotyper call. 
  @recal_files = grep {-f "$recal_dir/$_" && $_ =~ /recalibrated\.bam$/i} readdir 
RECAL_DIR; 
   
  #If the user specified yes, prepare the call to the GATK UG and store them in 
an array. 
  if ($call_gatk eq "y") 
  { 
   #for every recalibrated BAM file. 
   foreach $recal_file (@recal_files) 
   { 
    #set the sample name. 
    $sample = $recal_file; 
    $sample =~ s/\_recalibrated\.bam$//i; 
     
    #set the sample name if it is a BGIx10 exome. 
    for $exomes (sort keys %bgi_exomes) 
    { 
     #gets the sample name from the barcode thing that 
BGI insisted on calling some of their FASTQ files. 
     if ($bgi_exomes{$exomes} eq $sample){$sample = 
$exomes;} 
    } 
     
    #the command line string used to call GATK. 
    #delete/add these switches -baq 
CALCULATE_AS_NECESSARY -MBQ 17 -stand_call_conf 30 -stand_emit_conf 10 
    $gatk_call = "java -jar \"/home/marc/Documents/bioinformatics 
software/GenomeAnalysisTK/GenomeAnalysisTK.jar\" -T UnifiedGenotyper -R 
\"/media/Brachiosaur/Exomes/reference genome/human_g1k_v37.fasta\" -L \"$region_file\" -glm 
both -mbq 10 -stand_call_conf 30 -stand_emit_conf 10 -D 
\"/media/Brachiosaur/Exomes/database resources/dbsnp_135.b37.vcf\" -I 
\"$recal_dir\/$recal_file\" -o \"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper MBQ 10/$centre\-$sample\.vcf\" -out_mode 
EMIT_ALL_SITES -metrics \"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper MBQ 10/$sample\_metrics\.txt\""; 
     
    #VQSR on such a small amount of sites is apparently not 
feasible. Was only added to see if it enhanced concordance. Looking at the pipeline's VQSR 
files, it makes no difference. 
    # $var_recal_call = "java -jar 
\"/home/marc/Documents/bioinformatics software/GenomeAnalysisTK/GenomeAnalysisTK.jar\" 
-T VariantRecalibrator -R \"/media/Brachiosaur/Exomes/reference 
genome/human_g1k_v37.fasta\" -input \"/home/marc/Documents/work/exome 
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analysis/Output/illumina genotype_comparisons/unified_genotyper/$centre\-$sample\.vcf\" -
recalFile \"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper/$centre\-$sample\_recal\.csv\" -tranchesFile 
\"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper/$centre\-$sample\_tranches\.tranches\" -mode SNP -
an HaplotypeScore -an MQRankSum -an ReadPosRankSum -an MQ -an DP -
resource:hapmap,VCF,known=false,training=true,truth=true,prior=15.0 
\"/media/Brachiosaur/Exomes/database resources/hapmap_3.3.b37.sites.vcf\" -
resource:omni,known=false,training=true,truth=false,prior=12.0 
\"/media/Brachiosaur/Exomes/database resources/1000G_omni2.5.b37.sites.vcf\" -
resource:dbsnp,VCF,known=true,training=false,truth=false,prior=8.0 
\"/media/Brachiosaur/Exomes/database resources/dbsnp_135.b37.vcf\" -mG 4 -percentBad 
0.05"; 
    # $apply_recal_call = "java -jar 
\"/home/marc/Documents/bioinformatics software/GenomeAnalysisTK/GenomeAnalysisTK.jar\" 
-T ApplyRecalibration -R \"/media/Brachiosaur/Exomes/reference 
genome/human_g1k_v37.fasta\" -input \"/home/marc/Documents/work/exome 
analysis/Output/illumina genotype_comparisons/unified_genotyper/$centre\-$sample\.vcf\" -
recalFile \"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper/$centre\-$sample\_recal\.csv\" -tranchesFile 
\"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper/$centre\-$sample\_tranches\.tranches\" -o 
\"/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/unified_genotyper/$centre\-$sample\.vcf\""; 
     
    #push the GATK call into an array (providing it is not already in, 
which it shouldn't be). 
    unless (grep {$gatk_call eq $_} @gatk_calls) 
    { 
     push (@gatk_calls, $gatk_call); 
      
     #not needed unless using VQSR. 
     #push @{$system_calls{$sample}}, $gatk_call, 
$var_recal_call, $apply_recal_call; 
    } 
   } 
  } 
 } 
  
 #if the user specified yes, call the GATK UG for each sample. 
 unless ($call_gatk eq "n") 
 { 
  #Call the GATK. 
  foreach $call (@gatk_calls) 
  { 
   $call_number++; 
   print "\nNow calling Unified Genotyper on sample number 
$call_number\n"; 
   system ($call); 
  } 
   
  #Again, only used for VQSR. 
  # foreach $call (@{$system_calls{$sample}}) 
  # { 
   # $call_number++; 
   # print "\nNow calling GATK on sample number $call_number\n"; 
   # print "\n$call\n"; 
   # system ($call); 
  # } 
 } 
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 #get the names of the VCF output files from the GATK UG step. 
 @vcf_files = grep {-f "$vcf_dir/$_" && $_ =~ /\.vcf$/i} readdir VCF_DIR; 
  
 #for each of the VCF files in the directory (i.e. for each sample); 
 foreach $vcf_file (@vcf_files) 
 { 
  #resets the number of (published and novel) variants in the VCF file to 0, along 
with the number of Illumina and my genotypes per sample, and the number of matches. 
  $variant_count = 0; 
  $illumina_genotypes_total = 0; 
  $my_genotypes_total = 0; 
  $my_count = 0; 
  $genotype_matches = 0; 
   
  $depth_filtered = 0; 
  $q_filtered = 0; 
  $no_GT_filtered = 0; 
  $no_comparison_possible = 0; 
  $info = 0; 
   
  #This array is used to skip chromosomes when searching the VCF files to 
decrease run time. 
  @chromosomes = (); 
   
  #set the centre and sample name. More work is executed below for bgix10 
samples. 
  $centre = $vcf_file; 
  $centre =~ s/\-.+$//; 
   
  $sample = $vcf_file; 
  $sample =~ s/\.vcf$//i; 
  $sample =~ s/$centre\-//; 
  $sample =~ s/\_pe$//i; 
   
  #ignores the duplicate samples from the BGIx18, in which BGI sent 2 copies of 
2 samples (the second copy had 'extra' sequencing information in to reach a depth threshold). 
  #this script will ignore the second copy and only use the first copy, as the 
second copies are unlikely to contain new genotype data. 
  if ($sample =~ /B\d$/i) 
  { 
   if ($sample =~ /2$/){next;} 
   else {$sample =~ s/\d$//;} 
  } 
   
  #This sample was accidentally mistaken somewhere for 71012. As a result, 
71012 was sequenced again instead of 71021. 
  #Therefore 71021 contains the same genotypes as 71012. Not useful for this 
script, but it means 71012 has twice as much sequencing coverage. 
  next if $sample =~ /71021/; 
   
  #If the sample is an UNC sample, only use the first bit of the sample name, and 
remove the zeros (eg. 042031_02136_s_6 becomes 42031). 
  #This is to match the illumina sample names found in the illumina file. 
  if ($centre eq "UNC" && $sample =~ /\_.+/i){$sample =~ s/$&//;} 
  if ($centre eq "UNC" && $sample =~ /^0+/){$sample =~ s/$&//;} 
   
  #set the sample name if it is a BGIx10 exome - convert from BGI's barcode 
style name. 
  for $exomes (sort keys %bgi_exomes) 
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  { 
   #gets the sample name from the barcode thing that BGI insisted on 
calling their FASTQ files. 
   if ($bgi_exomes{$exomes} eq $sample){$sample = $exomes;} 
  } 
   
  print "Now reading in information from $sample\n"; 
   
  #open the VCF file. 
  open VCF, "$vcf_dir/$vcf_file" or die "$vcf_file could not be opened. Why not? 
Your guess is as good as mine.\n"; 
   
  #Loop over Marc's VCF file. 
  while ($vcf_line = <VCF>) 
  { 
   #ignore the header lines and chromosomes that aren't 1-22, X or Y. 
   next unless $vcf_line =~ /^[0-9xy]+/i; 
    
   #used for printing if the variant is a complementary homozygote. 
   $hom_comp = 0; 
    
   #reset the strand for every variant in the file. Ensures all SNPs are 
labelled correctly. 
   $strand_designation = ""; 
    
   #Counts the number of variants per sample. 
   $variant_count++; 
    
   #split the line into an array. 
   @vcf_line = split (/\s/, $vcf_line); 
    
   #capture the useful (~essential) info from each line. 
   $chromosome = $vcf_line[0]; 
   $position = $vcf_line[1]; 
   $rsID = $vcf_line[2]; 
   $ref_allele = $vcf_line[3]; 
   $alt_allele = $vcf_line[4]; 
   $filter = $vcf_line[6]; 
   $info = $vcf_line[7]; 
   $depth = $vcf_line[7]; 
   $chr_pos = $chromosome."\_".$position; 
    
   #filter out low quality calls or sites with low sequencing coverage. 
   if ($filter eq "LowQual") 
   { 
    $q_filtered++; 
     
    print "FILTER: LowQual 
$q_filtered\t$chromosome\t$position\t$rsID\t$ref_allele $alt_allele\n"; 
     
    #next is essential or else the SNP won't be filtered. 
    next; 
   } 
 
   #Used to determine whether the call is wild type homozygous (AC=0), 
heterozygous (AC=1) or mutant homozygous (AC=2). 
   if ($info =~ /^AC\=[0-9]\;/i){$info = $&;} 
    
   #the info field could be empty, due to the fact there is no sequencing 
coverage at this site. 
 289 
 
   else{$no_GT_filtered++;print "FILTER: no_GT 
$no_GT_filtered\t$chromosome\t$position\t$rsID\t$ref_allele $alt_allele\n";next;} 
    
   #check the sequencing depth and filter out if lower than a user 
specified threshold. 
   #Defined is defined in the VCF file by 'DP=n' - is the depth for that 
specific SNP. 
   if ($depth =~ /DP\=\d+/i) 
   { 
    $depth = $&; 
    $depth =~ s/DP\=//i; 
     
    #Filter out if lower than the threshold. 
    if ($depth < $dp_filter) 
    { 
     $depth_filtered++; 
     print "FILTER: low depth 
$depth_filtered\t$chromosome\t$position\t$rsID\t$ref_allele $alt_allele\n"; 
      
     #Again, the next is necessary to filter out the SNP. 
     next; 
    } 
   } 
    
   #create a variable used to check for entries in the illumina data. 
   #rsIDs can't be used as novel SNPs or reference sites won't be found. 
   $chr_pos = $chromosome."\_".$position; 
    
   #The lines in the VCF files contain only rsIDs of SNPs containing non-
reference alleles, so if the rsID in Marc's VCF file is '.' then the genotype must be a homozygous 
wild type. 
   #Look in the Illumina hash (which has position info and the rsID 
together), and using the VCF's position retrieve Illumina's rsID. 
   #Not all of Illumina's genotype have a valid rsID, and so proabably 
won't give an rsXXXXX number. Also, there are some SNPs which failed genotyping, these will 
not have 
   #an entry in Marc's VCF, or in the genotypes comparison file for the 
output (counted as 'missing'). 
   if (grep {$chr_pos eq $_} sort keys %rsIDs) 
   { 
    $rsID = $rsIDs{$chr_pos}; 
   } 
    #Loop over the genes for illumina's data for the current sample. 
    # for $gene (sort keys (%{$illumina_genotypes{$sample}})) 
    # { 
     # #look at each SNP in the illumina data. 
     # #the hash key = chr_pos_rsID. 
     # for $hash_key (sort keys 
(%{$illumina_genotypes{$sample}{$gene}})) 
     # { 
      # #set the rsID by removing the chr and pos 
text. 
      # if ($hash_key =~ /^$chr_pos\_/i) 
      # { 
       # $rsID = $hash_key; 
       # $rsID =~ s/$&//i; 
       #  
       # #once the rsID has been found for 
the SNP, stop searching the Illumina data (stop looping over SNPs). 
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       # last;    
     
      # } 
      #  
     # } 
     #  
     # #once the rsID has been found for the SNP, stop 
searching the Illumina data (stop looping over genes). 
     # #unless ($rsID eq "\."){last;} 
    # } 
    
   #if the rsID is not present in the VCF file or Illumina data, then no 
comparison is possible. 
   if ($rsID eq "\.") 
   { 
    $no_comparison_possible++; 
    print "FILTER: no_comparison 
$no_comparison_possible\t$chromosome\t$position\t$rsID\t$ref_allele $alt_allele\n"; 
    #skip this SNP if no comparison is possible. 
    next; 
   } 
    
  
 #####################################################################
######################################## 
   #THE BIG BAD ILLUMINA CONVERSION - ABANDON HOPE ALL YE 
WHO ENTER HERE 
   #Even if you can't figure out how this works, it works. Just trust me on 
this! 
  
 #####################################################################
######################################## 
   #There are 2 critical assumptions to be made: 
   # Assume that Illumina always call all their genotypes by the top 
stranded conversion. 
   # Assume that Illumina detected the same genotype as the 
GATK before converting it. 
   #  At multi-alleleic sites in which the GATK called hom 
reference, if Illumina don't call these sites  
   #  homozygous reference then it is not possible to choose 
an alternate allele or strand with complete confidence, 
   #  therefore the resulting converted genotype may not 
match the Illumina call. 
    
   #When dealing with heterozygous genotypes, Illumina gave definitions 
to define top stranded SNPs (where a SNP is in ref/alt base format).  
   #Top stranded SNPs can be used as keys in a hash, with values 
including the SNP itself and the bottom stranded combinations of reverse,  
   #complementary and reverse complementary SNPs: 
   #  - AC -> AC, CA, GT, TG 
   #  - AG -> AG, GA, CT, TC 
   #  - AT -> AT, TA 
   #  - CG -> CG, GC 
   #Using this table it is possible to decide that an A/C heterozygous SNP 
at any site is top stranded, and that C/A, G/T and T/G are bottom stranded. 
   #Although A/C is also a value in the hash, it is top stranded since it is 
also a key. Under the assumption Illumina emit only top stranded genotypes, 
   #you simply convert the heterozygous bottom stranded SNP to its top 
stranded key (so GATK genotypes CA, GT and TG would be converted to genotype AC). 
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   #For designating strands when dealing with homozygotes, more 
information is needed to make some logical rules. 
   #Looking at the calls at sites which have known alternate alleles, I 
conclude that: 
   # - If the SNP is top stranded: 
   #  - homozygous reference genotypes will be a 
dinucleotide of the reference allele. 
   #  - homozygous alternate genotypes will be a 
dinucleotide of the alternate allele. 
   # - If the SNP is bottom stranded: 
   #  - homozygous reference genotypes will be a 
dinucleotide of the complementary reference allele. 
   #  - homozygous alternate genotypes will be a 
dinucleotide of the complementary alternate allele. 
   # - In cases where the reference and alternate allele are 
complementary,then the strand must be determined by looking 
   #   at the sequence surrounding the SNP site in the reference 
genome. 
   #  - this relies on comparing the sites immediately 
upstream (site n+1) and downstream (site n-1) of the SNP (site n). 
   #  - If n+1 is an A or T and n-1 is a C or G, then the strand 
is designated top. 
   #  - If n-1 is an A or T and n+1 is a C or G, then the strand 
is designated bottom. 
   #  - If both n+1 and n-1 are a A/T or both are a C/G, then 
look at the sites next to those (n+2 and n-2). Keep going until a comparison is possible 
   #    between an A/T and a G/C. 
   #From this we can say that if a site containing an A/C SNP is 
homozygous variant, the genotype emitted would be CC. If a C/A SNP site was homozygous 
variant, 
   #the genotype would be TT. 
    
   #If GATK calls a homozygous reference SNP, then there is an issue 
which requires logic to resolve. Since the GATK will not emit an alternate allele for homozygous 
reference 
   #(normally it will not emit these sites, but is an option which has been 
turned on for use in this script), you must look in dbSNP to find the alternate allele (GATK will 
not emit rsIDs 
   #either at these sites so query dbSNP using the chromosome and 
position of the SNP). Once you have the alternate allele, you know the SNP (i.e. ref/alt) and can 
designate the strand as above. 
   #The problem arises when dbSNP contains multiple alleles at a site: 
   # - It is not always possible to say which allele Illumina detected 
if the Illumina call is homozygous reference (you don't even know that their call IS hom ref, you 
must assume it is because the 
   #   GATK call is). All you can do in this case, is designate a 
strand based on the Illumina call. 
   #  - If their call contains the reference allele, then you 
know the SNP is top stranded. If their call is complementary to the reference allele, then you 
know the SNP is bottom stranded. 
   # - Once the strand has been designated, you can follow the 
rules for homozygous reference SNPs (above) to convert the GATK genotype to suit Illumina's 
convention! 
    
    
   #if the GATK call is homozygous reference, then look up the alternate 
SNP. 
   if ($info =~ /0/) 
   { 
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    #get the alternate nucleotides from the hash of SNPs from 
dbSNP (read in from the file created earlier). 
    $alt_allele = $alt_alleles{$rsID}; 
     
    #remove the reference base from the alleles so that just the alt 
alleles at this site are left. 
    if ($alt_allele =~ /[a-z\,]+$/i){$alt_allele = $&;$alt_allele =~ 
s/^.//;} 
     
    #if the SNP has multiple alleles (eg. A -> C,G,T), then split the 
allele into an array and try to figure out from the illumina genotype which allele to use. 
    if ($alt_allele =~ /\,/) 
    { 
     #splits the alleles into an array (eg. so C,G,T would 
become @multi_allelic = (C, G, T) 
     @multi_allelic = split (/\,/, $alt_allele); 
      
     #Look through the genes in Illumina's genotypes to find 
the SNP identified by the rsID. 
     for $gene (sort keys 
(%{$illumina_genotypes{$sample}})) 
     { 
      #Loop over Illumina's rsIDs - each genotype 
call should have one. 
      for $illumina_rsID (sort keys 
%{$illumina_genotypes{$sample}{$gene}}) 
      { 
       #look at the entry in the Illumina hash 
for the specific SNP in Marc's VCF file. 
       if ($illumina_rsID =~ /$rsID$/i) 
       {    
     
        #foreach of the dbSNP alleles 
at this SNP. 
        foreach $allele (@multi_allelic) 
        { 
         #set the (temporary) 
mutation dinucleotide. 
         $mutation = 
$ref_allele.$allele; 
         $rev_mutation = 
reverse $mutation; 
          
         #If there are multiple 
alleles which form a top stranded genotype with the reference allele, (eg. ref = A, alleles = G, C, 
T, top GTs = AG, AC, AT) 
         #then you do not have 
to detect which specific allele Illumina found, all we need to know is that it is top stranded. 
Assuming the call is reference  
         #and the genotype is 
top stranded, then the genotype formed by converting to Illumina's convention will be a dinuc of 
the ref allele. 
         #eg. whether Illumina 
detected G,C or T does not matter, all will result in an AA genotype. 
         if 
(${$illumina_genotypes{$sample}{$gene}{$illumina_rsID}}[0] =~ /^$ref_allele/i) 
         { 
          #if the 
mutation is on the top strand (ie. a key in the %strands hash). 
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          if ((grep 
{$mutation eq $_} sort keys %strands) || (grep {$rev_mutation eq $_} sort keys %strands)) 
          { 
          
 #assign the alt allele and stop looping over the possible alleles. 
          
 $alt_allele = $allele; 
            
          
 $strand_designation = "top"; 
          
 $strand_designations{$chr_pos} = $strand_designation; 
            
           last; 
          } 
         } 
         
         #Illumina's genotype is 
the dinucleotide of the complementary ref allele. 
         elsif 
(${$illumina_genotypes{$sample}{$gene}{$illumina_rsID}}[0] =~ 
/^$complementary_bases{$ref_allele}/i) 
         { 
          #loop over the 
keys in the strands hash. 
          for $strand 
(sort keys %strands) 
          { 
           #if the 
mutation is a bottom stranded dinucleotide, set the allele and stop looping over the other 
possible alleles. 
           if 
(grep {$mutation eq $_} sort @{$strands{$strand}}) 
           { 
           
 $alt_allele = $allele; 
           
  
           
 $strand_designation = "bottom"; 
           
 $strand_designations{$chr_pos} = $strand_designation; 
           
  
           
 last; 
           } 
          } 
         } 
          
         #assign the strand 
here now so that if the ref and alt alleles are complementary the strand for this SNP is not 
reassigned later. 
        
 $strand_designations{$chr_pos} = $strand_designation; 
        } 
       } 
      } 
     } 
    } 
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   } 
    
   #The ref and alt alleles, used later to determine which strand should be 
used when converting to Illumina format. 
   $mutation = $ref_allele.$alt_allele; 
   $rev_mutation = reverse $mutation; 
    
   #sample is homozygous at this position. 
   if ($info =~ /2/ || $info =~ /0/) 
   { 
    #if the ref and alt alleles are not complementary (eg. are not 
A/T or G/C). 
    if ($alt_allele ne $complementary_bases{$ref_allele}) 
    { 
     #if the mutation (ref/alt) or reverse mutation (alt/ref) is a 
key in the strands hash (i.e. is on the top strand) 
     if (grep {$mutation eq $_} sort keys %strands || grep 
{$rev_mutation eq $_} sort keys %strands) 
     { 
      #if the genotype is a reference homozygote 
then it will consist of a dinucleotide of the ref allele. 
      if ($info =~ /0/){$genotype = 
$ref_allele.$ref_allele;}#print "$ref_allele is not complementary to $alt_allele and is on the top 
strand\t$genotype\n";} 
      else{$genotype = $alt_allele.$alt_allele;} 
     } 
 
     #the mutation is on the bottom strand, so convert to the 
top stranded genotype by complementing the observed genotype. 
     else 
     { 
      for $strand (sort keys %strands) 
      { 
       #if the mutation is a value in the 
strands hash array 
       if (grep {$mutation eq $_} sort 
@{$strands{$strand}}) 
       { 
        #if the VCF call is 
homozygous reference, the Illumina genotype is the dinucleotide of the base complementary to 
the reference allele 
        if ($info =~ /0/){$genotype = 
$complementary_bases{$ref_allele}.$complementary_bases{$ref_allele};}#print "$ref_allele is 
not complementary to $alt_allele and is on the bottom strand\t$genotype\n";} 
         
        #if the VCF call is 
homozygous variant, then the genotype is a dinucleotide of the base complementary to the alt 
allele. 
        else{$genotype = 
$complementary_bases{$alt_allele}.$complementary_bases{$alt_allele};} 
       } 
      } 
     } 
    } 
     
    #the mutation is homozygous and complementary. 
    else 
    {  
     #this is used to store strands for checked SNPS - 
strands determined by looking at the reference genome 
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     #are stored in here. Doing this speeds up the 
computation as it does not have to check the reference genome for each comparison. 
     if 
($strand_designations{$chr_pos}){$strand_designation = $strand_designations{$chr_pos};} 
      
     #Since Illumina's strand rules cannot be applied to 
homozygous complementary SNPs, look in the reference genome to determine the strand 
     #by comparing the bases immediately upstream and 
downstream of the SNP site. 
     else 
     { 
      #in this case, you need to determine whether 
the genotype you called is on the 'top' or 'bottom' strand. These are not the actual top or bottom 
strands, 
      #but those according to Illumina. A top strand 
is determined if the base 5' to the variant is an A or T and the base 3' to the variant is a C or G. 
If it is vice versa then 
      #the strand is designated bottom strand. If both 
neighbour bases are A/T or C/G, then compare the bases next to those (i.e. variant pos +2 vs. 
pos -2). Repeat this process 
      #until the strand has been designated. 
       
      #reset the necessary counters and strings to 
the starting values. 
      $neighbourhood = ""; 
      $strand_designation = ""; 
      $n = 1; 
      $hom_comp = 1; 
       
      #for each chromosome encountered in the ref 
file, reset the number of lines it takes up  
      #and the sum of the length of the lines to the 
variant position to 0.  
      #This, along with the next 'for loop' will ensure 
that when encountering a variant on the same chromosome as the prev. variant, 
      #you do not have to search from the 
begginning of the chromosome. 
      unless (grep {$chromosome eq $_} sort 
(@chromosomes)) 
      { 
       $i = 0; 
       $i_plus = 0; 
       $len_to_pos = 0; 
       push (@chromosomes, 
$chromosome); 
      } 
       
      @chr_seq = split (/\n/, 
${$reference_genome{$chromosome}}[0]); 
      
      #This loop counts initially from the first line of 
the ref chromosome (line 0), 
      #and then for each variant only from the line 
the prev. variant was on (for each chromosome). 
      for $i ($i_plus .. scalar (@chr_seq)) 
      { 
       #line count increments with i, and 
i_plus is always +1 more than i so that when looped, the last ref line will not be counted again. 
       $line_count = $i; 
       $i_plus = $i + 1; 
 296 
 
        
       #The DNA sequence of the reference 
line. 
       $line = $chr_seq[$line_count]; 
        
       #remove line number from the ref line 
(which I added when storing in the hash). 
       if ($line =~ /^\d+\_/){$line =~ s/$&//;} 
        
       #sum of the length of the lines upto 
and including the line which the variant is on. 
       $len_to_pos += length ($line); 
        
       #stop when the length of the lines is 
bigger than the variant's position 
       #eg. pos = 12, len_to_pos = 60, so 
stop (line_count would == 0) 
       if ($len_to_pos >= $position){last;} 
      } 
       
      #the line number of the prev and next 
reference lines. 
      $line_minus = $line_count - 1; 
      $line_plus = $line_count + 1; 
       
      #Build a string containing the ref line that the 
variant is on, along with the prev and next lines. 
      #This will be used for 'walking' when 
determining the strand. It ensures that there is always a line of sequence on either side 
      #of the variant (unless it is very close to the 
start or end of the chromosome). The length of this 'neighbourhood' can be increased if needed. 
      for $j ($line_minus .. $line_plus) 
      { 
       #the reference line (i.e. the DNA 
sequence). Remove the line numbers from the start. 
       $ref_line = $chr_seq[$j]; 
       if ($ref_line =~ /\d+\_/){$ref_line =~ 
s/$&//;} 
        
       #add the line to the neighbourhood. 
The neighbourhood will eventually contain the prev line, variant line and next line in a continual 
DNA sequence. 
       $neighbourhood .= $ref_line; 
        
       #Count the position in the 
neighbourhood that the variant is at. 
       #equation 1: length (prev line) + lengh 
(var line) - (length_to_pos - var pos) - 1. 
       if ($j == 
$line_minus){$neighbourhood_pos = length ($ref_line);} 
       elsif ($j == 
$line_count){$neighbourhood_pos += length ($ref_line);} 
       else {$neighbourhood_pos -= 
($len_to_pos - $position) +1;}#notice the +1 at the end, not a -1 as it would be a double -ve. 
      } 
       
      #split the neighbourhood into an array for 
looping. 
      @neighbourhood = split (//, $neighbourhood); 
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      while (($neighbourhood_pos - $n) >= 0 && 
($neighbourhood_pos + $n) <= scalar (@neighbourhood)) 
      { 
       if 
($neighbourhood[$neighbourhood_pos - $n] =~ /[AT]/i && 
$neighbourhood[$neighbourhood_pos + $n] =~ /[CG]/i){if ($strand_designation eq 
""){$strand_designation = "top";}} 
       if 
($neighbourhood[$neighbourhood_pos - $n] =~ /[CG]/i && 
$neighbourhood[$neighbourhood_pos + $n] =~ /[AT]/i){if ($strand_designation eq 
""){$strand_designation = "bottom";}} 
        
       last unless $strand_designation eq ""; 
       $n++; 
      } 
       
      $strand_designations{$chr_pos} = 
$strand_designation; 
     } 
      
     if ($strand_designation eq "top") 
     { 
      if ($info =~ /0/){$genotype = 
$ref_allele.$ref_allele;}#print "$rsID $ref_allele is complementary to $alt_allele and is on the top 
strand\t$genotype\n"} 
      else{$genotype = $alt_allele.$alt_allele;} 
     } 
      
     if ($strand_designation eq "bottom") 
     { 
      if ($info =~ /0/){$genotype = 
$alt_allele.$alt_allele;}#print "$rsID $ref_allele is complementary to $alt_allele and is on the 
bottom strand\t$genotype\n"} 
      else{$genotype = $ref_allele.$ref_allele;} 
     } 
      
     #if ($info =~ /0/){$genotype = $ref_allele.$ref_allele;} 
     if ($vcf_line[4] eq "\."){$strand_designation .= "\_WT";} 
      
     #print "$sample $chromosome $position $rsID 
$ref_allele \-\> $alt_allele $info $strand_designation $genotype\n"; 
    } 
   } 
    
   else #sample is heterozygous at this position. 
   { 
    #loop through the top stranded genotypes in %strands. 
    for $top_genotype (sort keys %strands) 
    { 
     #loop through all the possible heterozygous genotypes 
for the ref and alt allele dinucleotide (inc. reverse and rev. complement) 
     #and if a match is found to the observed heterozygous 
genotype then the Illumina formatted genotype will be the top stranded %strands key. 
     if (grep {$mutation eq $_} sort 
@{$strands{$top_genotype}}){$genotype = $top_genotype;} 
    } 
   } 
    
   #push data into hash. 
   ${$marc_genotypes{$sample}{$rsID}}[0] = $genotype; 
 298 
 
   ${$marc_genotypes{$sample}{$rsID}}[1] = $position; 
    
   #unless ($hom_comp == 1){print "$sample $chromosome $position 
$rsID $ref_allele \-\> $alt_allele $info $genotype\n\n";} 
  } 
   
  $sample_genotypes = 0; 
   
  deer_in_the_headlights(); 
 } 
 
} 
############################################################################
################################## 
#End of enlighten sub routine 
############################################################################
################################## 
 
############################################################################
################################## 
#sub routine deer_in_the_headlights. 
#compares the data in the illumina hash with the data in Marc's hash 
#calculate the total number of genotypes Illumina called, and see what percentage of them are 
shared in Marc's data. 
# 
############################################################################
################################## 
sub deer_in_the_headlights 
{ 
 $print_file = "/home/marc/Documents/work/exome analysis/Output/illumina 
genotype_comparisons/$sample Illumina genotypes comparison.txt"; 
 open OUT, ">$print_file" or die "Could not open $print_file. Don't ask me why, nobody 
tells me nothing.\n"; 
  
 for $rsID (sort keys %{$marc_genotypes{$sample}}) 
 { 
  #signal used later to stop searching once a hash key is found. 
  $end = 0; 
   
  $print_position = ${$marc_genotypes{$sample}{$rsID}}[1]; 
   
  for $gene (sort keys %{$illumina_genotypes{$sample}}) 
  { 
   for $hash_key (sort keys %{$illumina_genotypes{$sample}{$gene}}) 
   { 
    #cut the chr and pos from $rs. 
    $rs = $rsID; 
    $rs =~ s/.+\_//gi; 
     
    if ($hash_key =~ /$rsID$/) 
    { 
     push (@{$table{$rsID}{$sample}}, 
${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0], 
${$marc_genotypes{$sample}{$rsID}}[0]); 
      
     if 
(${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0] =~ /^[a-
z]{2}/i){$my_count++;$my_genotypes_total = scalar keys %{$marc_genotypes{$sample}};} 
      
     #Not sure where this should go... 
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     #$illumina_genotypes_total += scalar keys 
%{$illumina_genotypes{$sample}{$gene}}; 
      
     if 
(${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0] eq 
${$marc_genotypes{$sample}{$rsID}}[0]) 
     { 
      #the total number of genotypes and total 
number of matches for all samples. 
      $total_genotypes++; 
      $total_matches++; 
       
      #The number of genotypes and matches for 
the sample 
      $sample_genotypes++; 
      $genotype_matches++; 
       
      print OUT 
"${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0]\t${$marc_genotypes{$sample}{$rsID}}
[0]\t$strand_designations{$chr_pos}\tMatch\t\t$sample\t$gene\t$rsID\t$print_position\n"; 
     } 
      
     else 
     { 
      $total_genotypes++; 
      $sample_genotypes++; 
      print OUT 
"${$illumina_genotypes{$sample}{$gene}{$hash_key}}[0]\t${$marc_genotypes{$sample}{$rsID}}
[0]\t$strand_designations{$chr_pos}\tNot a match\t$sample\t$gene\t$rsID\n"; 
       
      print 
"$sample\t$gene\t$rsID\t$strand_designation${$illumina_genotypes{$sample}{$gene}{$hash_k
ey}}[0]\t${$marc_genotypes{$sample}{$rsID}}[0]\n"; 
     } 
      
     $end = 1; 
     last; 
    } 
   } 
    
   if ($end == 1){last;} 
  } 
 } 
    
 %{$marc_genotypes{$sample}} = (); 
  
 if ($my_genotypes_total == 0){$percent_match = 0;} 
 else{$percent_match = $genotype_matches / $my_count * 100;} 
  
 push (@{$percent_matches{$sample}}, $percent_match, $genotype_matches, 
$sample_genotypes); 
  
 print "total Illumina genotypes matched: $genotype_matches ($percent_match %)\nMy 
total = $my_count\n$depth_filtered with a depth lower than $dp_filter\n$q_filtered which are 
classed as low quality\n$no_GT_filtered which had no genotype data called by the 
GATK\n$no_comparison_possible which could not be compared\n\n"; 
 print OUT "total Illumina genotypes matched: $genotype_matches ($percent_match 
%)\nMy total = $my_count\nIllumina total = $illumina_genotypes_total\n"; 
  
 close OUT; 
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} 
############################################################################
################################## 
#End of deer_in_the_headlights sub routine 
############################################################################
################################## 
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Custom Script 6 
 
#Given a list of amplicon regions within a targeted resequencing panel, extract reads from a 
BAM file that map within the outer coordinates of an amplicon. 
#Reads that are contaminating reads from another panel (whose amplicons don't overlap with 
the exact amplicon regions from the first panel) that map outside 
#of the amplicons will be excluded. 
#Misaligned reads (even those that aren't contaminating) will also be excluded.  
#Input requirements: A CSV file of amplicon coordinates, sorted by chr and left-most position, 
with at least the following information per line: 
# chromosome ID, amplicon start and amplicon end coordinates. 
 
#Subroutines: 
#Read in sample BAM files. 
#Read in amplicon coord's 
#Use SAMtools view to isolate reads mapping within targeted amplicon regions. Print these 
reads to a new SAM file and convert back to BAM (may need to resort based on chr coord). 
 
use Term::ANSIColor; 
 
#CSV files containing sequencing target coordinates for a particular NGS panel. 
$amplicon_coords_file = "/home/marc/Documents/work/reseq analysis/non responder 
project/Miscellaneous/DesignStudio amplicons.csv"; 
# $amplicon_coords_file = "/home/marc/Documents/work/reseq analysis/pilot 
project/Miscellaneous/DesignStudio amplicons.csv"; 
$contig_bed_file = "/home/marc/Documents/work/reseq analysis/non responder 
project/Miscellaneous/NR project amplicon contigs.bed"; 
# $contig_bed_file = "/home/marc/Documents/work/reseq analysis/pilot 
project/Miscellaneous/pilot project amplicon contigs.bed"; 
 
$sam_dir = "/media/marc/Triceratops/Exomes/Pilot project output/WT (HD) 
output/09_GATK_indelrealigner/isolated amplicons"; 
$alien_dir = "/media/marc/Triceratops/Exomes/Non responder 
output/09_GATK_indelrealigner/alien amplicons"; 
$bam_dir = "/media/marc/Triceratops/Exomes/Pilot project output/WT (HD) 
output/09_GATK_indelrealigner"; 
$pilot_isolated_dir = "/media/marc/Triceratops/Exomes/Non responder 
output/09_GATK_indelrealigner/pilot isolated amplicons"; 
$pattern = "realigned\\.bam\$"; 
 
#Make necessary directories for output files. 
unless (-d $sam_dir){ 
 print "mkdir \"$sam_dir\"\n"; 
  
 `mkdir "$sam_dir"`; 
} 
 
unless (-d $alien_dir){ 
 print "mkdir \"$alien_dir\"\n"; 
  
 `mkdir "$alien_dir"`; 
} 
 
unless (-d $pilot_isolated_dir){ 
 print "mkdir \"$pilot_isolated_dir\"\n"; 
  
 `mkdir "$pilot_isolated_dir"`; 
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} 
 
#Read in CSV file containing sequencing target coordinates. 
$coords = get_coords($amplicon_coords_file, $contig_bed_file); 
 
#Get an array containing BAM filepaths. $pattern is used in a regex to search for particular files.  
($filepaths, $bam_files) = read_dir($bam_dir, $pattern); 
 
#Using target coord's, isolate target amplicons and print them to a new BAM file. 
#This subroutine can also isolate off-target ('alien') reads and print those to a separate BAM. 
isolate_amplicons($bam_files, $contig_bed_file, $pilot_isolated_dir, $coords); 
 
#Read dir to get BAM files. 
sub read_dir{ 
 #get the directory. 
 my ($dir, $pattern, $files) = @_; 
  
 my @files = @$files; 
  
 #open the directory. 
 opendir DIR, "$dir" or die "cannot open $dir!\n"; 
 
 #Read in all files from the directory (excluding the "." and ".." files which may be 
present), and store the full filepaths in an array. 
 my @filepaths = map{$dir."/".$_} grep {"$dir/$_" && !/^\.{1,2}$/} readdir DIR; 
  
 closedir DIR; 
 
 #foreach file and sub directory within the current directory. 
 foreach my $filepath (sort {$a <=> $b} @filepaths){ 
  #If the current file matches a certain criteria ('-f' specifies a file). 
  if (-f "$filepath" && $filepath =~ /$pattern/){ 
   push @files, $filepath; 
  } 
   
  #if the directory contains sub directories, store them in the array and call this 
sub routine on them. 
  #the result is each sub directory within a directory will be searched before 
moving onto the next directory; 
  #e.g. a/1/i and a/1/ii will be searched before a/2/i, etc. 
  if (-d $filepath){ 
   my ($returned_array, $files) = read_dir($filepath, $pattern, \@files); 
    
   @files = @$files; 
    
   my @returned_array = @$returned_array; 
    
   push @filepaths, @returned_array; 
  } 
   
 } 
  
 return (\@filepaths, \@files); 
} 
 
#Read in a CSV of target coordinates and store them in a hash table. Each target is stored in a 
F and R direction, to allow for rapid searching downstream: 
#Briefly, the start coord of a sequencing read (the left-most or right most coord for reads on the 
F and R strand, respectively) will be used to search the target coordinate hash keys. 
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#If the read start coord is a key in the hash, then the read maps to a target amplicon. End 
coords cannot be used for searching, as read length is variable between runs and so would not 
always match targeted amplicon length. 
#Therefore end coord's may not be present in the hash even though the start coord is present. 
#This subroutine also prints target coord's to a BED file for use with samtools. The BED file 
contains contigs of target amplicons, where overlapping targets are merged to avoid 
redundancy when calling samtools. 
sub get_coords{ 
 my ($amplicon_coords_file, $contig_bed_file) = @_; 
  
 my %coords; 
  
 open BED, ">$contig_bed_file" or die $!; 
  
 open AMP, "$amplicon_coords_file" or die $!; 
  
 while (my $line = <AMP>){ 
  chomp $line; 
   
  next if $line =~ /^#/; 
   
  my @fields = split (/,/, $line); 
   
  my ($chr, $start_coord, $end_coord) = @fields; 
   
  #Store the target coordinates in a hash (...of hashes of arrays...). For each left-
most coordinate, push the right-most coordinate into an array and vice versa. 
  #The sequencing read's strand will determine which of these hash keys is used 
for searching. e.g. for searchin 
  unless (grep {$end_coord eq $_} sort {"\L$a" cmp "\L$b"} 
@{$coords{"amplicons F"}{$chr}{$start_coord}}){push @{$coords{"amplicons 
F"}{$chr}{$start_coord}}, $end_coord;} 
  unless (grep {$start_coord eq $_} sort {"\L$a" cmp "\L$b"} 
@{$coords{"amplicons R"}{$chr}{$end_coord}}){push @{$coords{"amplicons 
R"}{$chr}{$end_coord}}, $start_coord;} 
 } 
  
 close AMP; 
  
 #Create a hash of contigs read for printing to the BED file. 
 for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$coords{"amplicons F"}}){ 
  my @amp_starts = sort {$a <=> $b} keys %{$coords{"amplicons F"}{$chr}}; 
  my $contig_start = $amp_starts[0]; 
  my $contig_end = $contig_start; 
   
  for my $amp_start (sort {$a <=> $b} keys %{$coords{"amplicons F"}{$chr}}){ 
   my @amp_ends = sort {$a <=> $b} @{$coords{"amplicons 
F"}{$chr}{$amp_start}}; 
    
   #The biggest entry in @amp_ends. 
   my $amp_end = $amp_ends[-1]; 
    
   #If the amplicon start is overlapping or immediately next to the current 
end of the contig, merge the amplicon into the contig. 
   if ($amp_start <= ($contig_end + 1)){ 
    if ($amp_end > $contig_end){$contig_end = $amp_end;} 
    $coords{"contigs"}{$chr}{$contig_start} = $contig_end; 
   } 
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   #The amplicon has at least a 1 nucleotide gap between itself and the 
contig end, so start a new contig. 
   else{ 
    $contig_start = $amp_start; 
     
    #This should aways be true. 
    if ($amp_end > $contig_end){$contig_end = $amp_end;} 
     
    $coords{"contigs"}{$chr}{$contig_start} = $contig_end; 
   } 
  } 
 } 
  
 for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$coords{"contigs"}}){ 
  for my $contig_start (sort {$a <=> $b} keys %{$coords{"contigs"}{$chr}}){ 
   my $contig_end = $coords{"contigs"}{$chr}{$contig_start}; 
    
   print BED "$chr\t$contig_start\t$contig_end\n"; 
  } 
 } 
  
 close BED; 
   
 return \%coords; 
} 
 
 
#For each BAM file, use samtools to extract reads to a new SAM file. Each mapped read is then 
assessed and determined whether or not its start coordinate (left-most or right-most coord for F 
and R strand reads, respectively) matches an amplicon start/end in the %coords hash. 
#Reads mapping to target amplicons are isolated and printed in a new sample-specific SAM file. 
A SAM file can also be created for printing off-target ('alien') reads if desired. 
sub isolate_amplicons{ 
 my ($bam_files, $contig_bed_file, $sam_dir, $coords) = @_; 
  
 my @bam_files = @$bam_files; 
  
 my %coords = %{$coords}; 
  
 my %flag_data; 
  
 foreach my $bam_file (sort {"\L$b" cmp "\L$a"} @bam_files){ 
  my %mapped_reads; 
   
  #Create filenames for new SAM/BAM files to be printed. 
  my $sam_file = $bam_file; 
  $sam_file =~ s/indelrealigner\//indelrealigner\/isolated amplicons\//i; 
  $sam_file =~ s/realigned\.bam$/isolated_amplicons\.sam/i; 
   
  my $alien_file = $bam_file; 
  $alien_file =~ s/indelrealigner\//indelrealigner\/alien amplicons\//i; 
  $alien_file =~ s/realigned\.bam$/alien_amplicons\.sam/i; 
   
  my $new_bam_file = $sam_file; 
  $new_bam_file =~ s/\.sam//i; 
   
  my $new_bam_file_sorted = $new_bam_file; 
  $new_bam_file_sorted .= "\_sorted"; 
   
  my $new_alien_file = $alien_file; 
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  $new_alien_file =~ s/\.sam//i; 
   
  my $new_alien_file_sorted = $new_alien_file; 
  $new_alien_file_sorted .= "\_sorted"; 
   
  my $sample = $bam_file; 
   
  $sample =~ s/^.+\///g; 
   
  my @sample = split (/-/, $sample); 
   
  my ($run, $coin, $tissue) = @sample; 
   
  $tissue =~ s/\_.+$//; 
   
  # next unless $tissue eq "e"; 
  # next unless $run =~ /NR3/i; 
  # next unless $coin =~ /26004/; 
   
  print color ("blue"), "Current sample: $run-$coin-$tissue.\n"; 
   
  #Get the unmapped reads and print to the new SAM file. Can also print these to 
the alien file. 
  print color ("green"), "Printing header and unmapped reads for "; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "samtools view "; 
  print color 'reset'; 
  print "-h -f4 \"$bam_file\" > \"$sam_file\"\n"; 
  `samtools view -h -f4 "$bam_file" > "$sam_file"`; 
  # `samtools view -h -f4 "$bam_file" > "$alien_file"`; 
   
  print color ("yellow"), "Complete!\n"; 
  print color 'reset'; 
   
  #Get the mapped reads that overlap with targeted coordinates (can get all 
mapped reads instead, which is necessary for getting alien reads, but this takes longer). 
  print color ("green"), "Gathering mapped reads overlapping amplicon regions in 
"; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "samtools view "; 
  print color 'reset'; 
  print "-h \"$bam_file\" -L \"$contig_bed_file\"\n"; 
  my @mapped_reads = `samtools view -F4 "$bam_file" -L "$contig_bed_file"`; 
#This script is capable of looking at a given set of targets (specified in a BED file)... 
  # my @mapped_reads = `samtools view -F4 "$bam_file"`;  
   #or the whole genome. 
   
  print color ("yellow"), "Complete!\n"; 
  print color ("red"), "Isolating reads mapping to the designed amplicons.\n"; 
   
  #Loop over mapped reads and store each in a hash. 
  foreach my $line (@mapped_reads){ 
   chomp $line; 
   my @fields = split (/\s+/, $line); 
    
   my ($read_name, $flag, $chr, $read_start) = @fields; 
    
   my $sequence = $fields[9]; 
    
   my $read_len = length $sequence; 
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   my $read_end = $read_start + ($read_len - 1); 
    
   unless (exists $flag_data{$flag}){ 
    $flag_data = flagstat($flag, \%flag_data); 
     
    %flag_data = %{$flag_data}; 
   } 
    
   #If the read is on the reverse strand. 
   if ($flag_data{$flag}{"SEQ is reverse complemented"} == 0){ 
    push @{$mapped_reads{"F strand 
reads"}{$chr}{$read_start}{$read_end}}, $line; 
   } 
    
   #The read is on the F strand. 
   else{ 
    push @{$mapped_reads{"R strand 
reads"}{$chr}{$read_end}{$read_start}}, $line; 
   } 
  } 
   
  print color ("yellow"), "Complete!\n"; 
  print color 'reset'; 
   
  open SAM, ">>$sam_file" or die $!; 
  open ALIEN, ">>$alien_file" or die $!; 
   
  #For each targeted amplicon starting coordinate, check if there are any mapped 
reads that map to the same coordinate. 
  #Such reads will be isolated by printing to a new SAM file.  
  #By searching in a strand specific manner, you guarantee that matching reads 
map within the target amplicon and not an adjacent one (plus it saves time). 
  for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$coords{"amplicons F"}}){ 
   for my $amplicon_start (sort {$a <=> $b} keys %{$coords{"amplicons 
F"}{$chr}}){ 
    if (exists $mapped_reads{"F strand reads"}{$chr} && exists 
$mapped_reads{"F strand reads"}{$chr}{$amplicon_start}){ 
     for my $read_end (sort {$a <=> $b} keys 
%{$mapped_reads{"F strand reads"}{$chr}{$amplicon_start}}){ 
      foreach my $read (sort {"\L$a" cmp "\L$b"} 
@{$mapped_reads{"F strand reads"}{$chr}{$amplicon_start}{$read_end}}){ 
       print SAM "$read\n"; 
      } 
     } 
    } 
     
    #This is not strictly necessary, but deletes on-target reads from 
the hash. They need to be removed if you want to print only off-target reads later. 
    delete $mapped_reads{"F strand 
reads"}{$chr}{$amplicon_start}; 
   } 
  } 
 
  #Once reads mapping to target amplicons have been isolated, anything 
remaining must be off-target.  
  #Admittedly this method will include any reads that are misaligned, but should 
definitely include amplicons that don't match target amplicons. 
  for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$mapped_reads{"F strand 
reads"}}){ 
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   for my $off_target_start (sort {$a <=> $b} keys %{$mapped_reads{"F 
strand reads"}{$chr}}){ 
    for my $read_end (sort {$a <=> $b} keys %{$mapped_reads{"F 
strand reads"}{$chr}{$off_target_start}}){ 
     foreach my $read (sort {"\L$a" cmp "\L$b"} 
@{$mapped_reads{"F strand reads"}{$chr}{$off_target_start}{$read_end}}){ 
      print ALIEN "$read\n"; 
     } 
    } 
   }  
  } 
   
  #Do the same as above, but for the reverse strand. 
  for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$coords{"amplicons R"}}){ 
   for my $amplicon_end (sort {$a <=> $b} keys %{$coords{"amplicons 
R"}{$chr}}){ 
    if (exists $mapped_reads{"R strand reads"}{$chr} && exists 
$mapped_reads{"R strand reads"}{$chr}{$amplicon_end}){ 
     for my $read_start (sort {$a <=> $b} keys 
%{$mapped_reads{"R strand reads"}{$chr}{$amplicon_end}}){ 
      foreach my $read (sort {"\L$a" cmp "\L$b"} 
@{$mapped_reads{"R strand reads"}{$chr}{$amplicon_end}{$read_start}}){ 
       print SAM "$read\n"; 
      } 
     } 
    } 
     
    delete $mapped_reads{"R strand 
reads"}{$chr}{$amplicon_end}; 
   } 
  } 
 
  for my $chr (sort {"\L$a" cmp "\L$b"} keys %{$mapped_reads{"R strand 
reads"}}){ 
   for my $off_target_end (sort {$a <=> $b} keys %{$mapped_reads{"R 
strand reads"}{$chr}}){ 
    for my $read_start (sort {$a <=> $b} keys 
%{$mapped_reads{"R strand reads"}{$chr}{$off_target_end}}){ 
     foreach my $read (sort {"\L$a" cmp "\L$b"} 
@{$mapped_reads{"R strand reads"}{$chr}{$off_target_end}{$read_start}}){ 
      print ALIEN "$read\n"; 
     } 
    } 
   } 
  } 
   
  close SAM; 
  close ALIEN; 
   
  #Convert the new SAM file(s) to BAM file(s). 
  print color ("green"), "Converting SAM file to BAM for sample "; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "samtools view "; 
  print color 'reset'; 
  print "-bSh \"$sam_file\" > \"$new_bam_file\"\n"; 
  `samtools view -bSh "$sam_file" > "$new_bam_file\.bam"`; 
  # `samtools view -bSh "$sam_file" > "$new_alien_file\.bam"`; 
   
  print color ("yellow"), "Conversion complete!\n"; 
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  #Sort the BAM files. 
  print color ("green"), "Sorting new SAM file for sample "; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "samtools sort "; 
  print color 'reset'; 
  print "\"$new_bam_file.bam\" \"$new_bam_file_sorted\"\n"; 
  `samtools sort "$new_bam_file.bam" "$new_bam_file_sorted"`; 
  # `samtools sort "$new_bam_file.bam" "$new_alien_file_sorted"`; 
   
  print color ("yellow"), "Sorting complete!\n\n"; 
   
  #Index the new sorted BAM file(s) 
  print color ("green"), "Indexing BAM file for sample "; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "samtools index "; 
  print color 'reset'; 
  print "\"$new_bam_file_sorted.bam\"\n"; 
  `samtools index "$new_bam_file_sorted.bam"`; 
  # `samtools index "$new_alien_file_sorted.bam"`; 
   
  print color ("yellow"), "Complete!\n"; 
   
  #Remove the SAM file(s) and unsorted BAM file(s) as these are no longer 
needed. 
  print color ("green"), "Removing SAM file and unsorted BAM file for sample "; 
  print color ("blue"), "$run-$coin-$tissue\n"; 
  print color ("red"), "rm"; 
  print color 'reset'; 
  print "\"$sam_file\"\n"; 
   
  `rm "$sam_file"`; 
  `rm "$alien_file"`; 
   
  print color ("red"), "rm"; 
  print color 'reset'; 
  print "\"$new_bam_file\"\n"; 
   
  `rm "$new_bam_file.bam"`; 
  `rm "$new_alien_file.bam"`; 
   
  print color ("bright_yellow"), "Isolation of amplicons is complete for sample "; 
  print color ("blue"), "$run-$coin-$tissue"; 
  print color ("bright_yellow"), ".\n"; 
  print color 'reset'; 
   
  undef %mapped_reads; 
 } 
} 
 
#Use the flag field to determine sequencing data about the read. See the flag description in the 
SAMtools documentation for further info. 
#In brief, uses a decimal integer to represent a binary string. Each digit in this string represents 
a different aspect of the read (e.g. is mapped or not, is mapped to the F or R strand, is a PCR 
duplicate, etc). 
#This subroutine converts the decimal integer to its binary string (there is only 1 possible string 
for each decimal) and stores the inferred information in a hash. 
#If the particular flag has been encountered before, then the hash key should already exist and 
this subroutine does not have to be performed again. 
sub flagstat{ 
 my ($flag, $flag_data) = @_; 
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 my %flag_data = %{$flag_data}; 
  
 my $power_sum = 0; 
  
 my $binary; 
  
 for (my $i = 11; $i >= 0; $i--){ 
  my $power = 2 ** $i; 
   
  if (($power_sum + $power) <= $flag){ 
   $power_sum += $power; 
   $binary .= "1"; 
  } 
   
  else {$binary .= "0";} 
 } 
  
 $binary = reverse $binary; 
  
 my @binary = split (//, $binary); 
  
 $flag_data{$flag}{"binary string"} = $binary; 
  
 $flag_data{$flag}{"multiple template segments"} = $binary[0]; 
 $flag_data{$flag}{"segment properly aligned"} = $binary[1]; 
 $flag_data{$flag}{"segment unmapped"} = $binary[2]; 
 $flag_data{$flag}{"next segment unmapped"} = $binary[3]; 
 $flag_data{$flag}{"SEQ is reverse complemented"} = $binary[4]; 
 $flag_data{$flag}{"SEQ of next segment is reversed"} = $binary[5]; 
 $flag_data{$flag}{"first segment in template"} = $binary[6]; 
 $flag_data{$flag}{"last segment in template"} = $binary[7]; 
 $flag_data{$flag}{"secondary alignment"} = $binary[8]; 
 $flag_data{$flag}{"failed quality controls"} = $binary[9]; 
 $flag_data{$flag}{"PCR duplicate"} = $binary[10]; 
 $flag_data{$flag}{"supplementary alignment"} = $binary[11]; 
  
 return \%flag_data; 
} 
 
